{"id": "DDI-DrugBank.d570.s0-0", "sentence_id": "DDI-DrugBank.d570.s0", "sentence": "Drug/ Laboratory Test Interactions Certain endocrine and liver function tests may be affected by estrogen-containing oral contraceptives.", "arg1": {"span": [[97, 105]], "type": "group", "id": "DDI-DrugBank.d570.s0.e0"}, "arg2": {"span": [[122, 136]], "type": "group", "id": "DDI-DrugBank.d570.s0.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d485.s2-0", "sentence_id": "DDI-DrugBank.d485.s2", "sentence": "Acetaminophen: May increase plasma concentration of synthetic estrogens, possibly by inhibiting conjugation.", "arg1": {"span": [[0, 13]], "type": "drug", "id": "DDI-DrugBank.d485.s2.e0"}, "arg2": {"span": [[52, 71]], "type": "group", "id": "DDI-DrugBank.d485.s2.e1"}, "ddi_label": 1, "ddi_type": "mechanism"}
{"id": "DDI-DrugBank.d485.s3-0", "sentence_id": "DDI-DrugBank.d485.s3", "sentence": "Combination hormonal contraceptives may also decrease the plasma concentration of acetaminophen.", "arg1": {"span": [[12, 35]], "type": "group", "id": "DDI-DrugBank.d485.s3.e0"}, "arg2": {"span": [[82, 95]], "type": "drug", "id": "DDI-DrugBank.d485.s3.e1"}, "ddi_label": 1, "ddi_type": "mechanism"}
{"id": "DDI-DrugBank.d485.s4-0", "sentence_id": "DDI-DrugBank.d485.s4", "sentence": "Acitretin: Interferes with the contraceptive effect of microdosed progestin-containing minipill preparations.", "arg1": {"span": [[0, 9]], "type": "drug", "id": "DDI-DrugBank.d485.s4.e0"}, "arg2": {"span": [[66, 75]], "type": "group", "id": "DDI-DrugBank.d485.s4.e1"}, "ddi_label": 1, "ddi_type": "effect"}
{"id": "DDI-DrugBank.d485.s6-0", "sentence_id": "DDI-DrugBank.d485.s6", "sentence": "Aminoglutethimide: May increase CYP metabolism of progestins leading to possible decrease in contraceptive effectiveness.", "arg1": {"span": [[0, 17]], "type": "drug", "id": "DDI-DrugBank.d485.s6.e0"}, "arg2": {"span": [[50, 60]], "type": "group", "id": "DDI-DrugBank.d485.s6.e1"}, "ddi_label": 1, "ddi_type": "mechanism"}
{"id": "DDI-DrugBank.d485.s8-0", "sentence_id": "DDI-DrugBank.d485.s8", "sentence": "Antibiotics (ampicillin, tetracycline): Pregnancy has been reported following concomitant use, however, pharmacokinetic studies have not shown consistent effects with these antibiotics on plasma concentrations of synthetic steroids.", "arg1": {"span": [[0, 11]], "type": "group", "id": "DDI-DrugBank.d485.s8.e0"}, "arg2": {"span": [[13, 23]], "type": "drug", "id": "DDI-DrugBank.d485.s8.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d485.s8-1", "sentence_id": "DDI-DrugBank.d485.s8", "sentence": "Antibiotics (ampicillin, tetracycline): Pregnancy has been reported following concomitant use, however, pharmacokinetic studies have not shown consistent effects with these antibiotics on plasma concentrations of synthetic steroids.", "arg1": {"span": [[0, 11]], "type": "group", "id": "DDI-DrugBank.d485.s8.e0"}, "arg2": {"span": [[25, 37]], "type": "drug", "id": "DDI-DrugBank.d485.s8.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d485.s8-2", "sentence_id": "DDI-DrugBank.d485.s8", "sentence": "Antibiotics (ampicillin, tetracycline): Pregnancy has been reported following concomitant use, however, pharmacokinetic studies have not shown consistent effects with these antibiotics on plasma concentrations of synthetic steroids.", "arg1": {"span": [[0, 11]], "type": "group", "id": "DDI-DrugBank.d485.s8.e0"}, "arg2": {"span": [[173, 184]], "type": "group", "id": "DDI-DrugBank.d485.s8.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d485.s8-3", "sentence_id": "DDI-DrugBank.d485.s8", "sentence": "Antibiotics (ampicillin, tetracycline): Pregnancy has been reported following concomitant use, however, pharmacokinetic studies have not shown consistent effects with these antibiotics on plasma concentrations of synthetic steroids.", "arg1": {"span": [[0, 11]], "type": "group", "id": "DDI-DrugBank.d485.s8.e0"}, "arg2": {"span": [[213, 231]], "type": "group", "id": "DDI-DrugBank.d485.s8.e4"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d485.s8-4", "sentence_id": "DDI-DrugBank.d485.s8", "sentence": "Antibiotics (ampicillin, tetracycline): Pregnancy has been reported following concomitant use, however, pharmacokinetic studies have not shown consistent effects with these antibiotics on plasma concentrations of synthetic steroids.", "arg1": {"span": [[13, 23]], "type": "drug", "id": "DDI-DrugBank.d485.s8.e1"}, "arg2": {"span": [[25, 37]], "type": "drug", "id": "DDI-DrugBank.d485.s8.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d485.s8-5", "sentence_id": "DDI-DrugBank.d485.s8", "sentence": "Antibiotics (ampicillin, tetracycline): Pregnancy has been reported following concomitant use, however, pharmacokinetic studies have not shown consistent effects with these antibiotics on plasma concentrations of synthetic steroids.", "arg1": {"span": [[13, 23]], "type": "drug", "id": "DDI-DrugBank.d485.s8.e1"}, "arg2": {"span": [[173, 184]], "type": "group", "id": "DDI-DrugBank.d485.s8.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d485.s8-6", "sentence_id": "DDI-DrugBank.d485.s8", "sentence": "Antibiotics (ampicillin, tetracycline): Pregnancy has been reported following concomitant use, however, pharmacokinetic studies have not shown consistent effects with these antibiotics on plasma concentrations of synthetic steroids.", "arg1": {"span": [[13, 23]], "type": "drug", "id": "DDI-DrugBank.d485.s8.e1"}, "arg2": {"span": [[213, 231]], "type": "group", "id": "DDI-DrugBank.d485.s8.e4"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d485.s8-7", "sentence_id": "DDI-DrugBank.d485.s8", "sentence": "Antibiotics (ampicillin, tetracycline): Pregnancy has been reported following concomitant use, however, pharmacokinetic studies have not shown consistent effects with these antibiotics on plasma concentrations of synthetic steroids.", "arg1": {"span": [[25, 37]], "type": "drug", "id": "DDI-DrugBank.d485.s8.e2"}, "arg2": {"span": [[173, 184]], "type": "group", "id": "DDI-DrugBank.d485.s8.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d485.s8-8", "sentence_id": "DDI-DrugBank.d485.s8", "sentence": "Antibiotics (ampicillin, tetracycline): Pregnancy has been reported following concomitant use, however, pharmacokinetic studies have not shown consistent effects with these antibiotics on plasma concentrations of synthetic steroids.", "arg1": {"span": [[25, 37]], "type": "drug", "id": "DDI-DrugBank.d485.s8.e2"}, "arg2": {"span": [[213, 231]], "type": "group", "id": "DDI-DrugBank.d485.s8.e4"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d485.s8-9", "sentence_id": "DDI-DrugBank.d485.s8", "sentence": "Antibiotics (ampicillin, tetracycline): Pregnancy has been reported following concomitant use, however, pharmacokinetic studies have not shown consistent effects with these antibiotics on plasma concentrations of synthetic steroids.", "arg1": {"span": [[173, 184]], "type": "group", "id": "DDI-DrugBank.d485.s8.e3"}, "arg2": {"span": [[213, 231]], "type": "group", "id": "DDI-DrugBank.d485.s8.e4"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d485.s10-0", "sentence_id": "DDI-DrugBank.d485.s10", "sentence": "Anticoagulants: Combination hormonal contraceptives may increase or decrease the effects of coumarin derivatives.", "arg1": {"span": [[0, 14]], "type": "group", "id": "DDI-DrugBank.d485.s10.e0"}, "arg2": {"span": [[28, 51]], "type": "group", "id": "DDI-DrugBank.d485.s10.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d485.s10-1", "sentence_id": "DDI-DrugBank.d485.s10", "sentence": "Anticoagulants: Combination hormonal contraceptives may increase or decrease the effects of coumarin derivatives.", "arg1": {"span": [[0, 14]], "type": "group", "id": "DDI-DrugBank.d485.s10.e0"}, "arg2": {"span": [[92, 112]], "type": "group", "id": "DDI-DrugBank.d485.s10.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d485.s10-2", "sentence_id": "DDI-DrugBank.d485.s10", "sentence": "Anticoagulants: Combination hormonal contraceptives may increase or decrease the effects of coumarin derivatives.", "arg1": {"span": [[28, 51]], "type": "group", "id": "DDI-DrugBank.d485.s10.e1"}, "arg2": {"span": [[92, 112]], "type": "group", "id": "DDI-DrugBank.d485.s10.e2"}, "ddi_label": 1, "ddi_type": "effect"}
{"id": "DDI-DrugBank.d485.s14-0", "sentence_id": "DDI-DrugBank.d485.s14", "sentence": "Ascorbic acid: Doses of ascorbic acid (vitamin C) 1 g/day have been reported to increase plasma concentration of synthetic estrogens by ~47%, possibly by inhibiting conjugation;", "arg1": {"span": [[0, 13]], "type": "drug", "id": "DDI-DrugBank.d485.s14.e0"}, "arg2": {"span": [[24, 37]], "type": "drug", "id": "DDI-DrugBank.d485.s14.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d485.s14-1", "sentence_id": "DDI-DrugBank.d485.s14", "sentence": "Ascorbic acid: Doses of ascorbic acid (vitamin C) 1 g/day have been reported to increase plasma concentration of synthetic estrogens by ~47%, possibly by inhibiting conjugation;", "arg1": {"span": [[0, 13]], "type": "drug", "id": "DDI-DrugBank.d485.s14.e0"}, "arg2": {"span": [[39, 48]], "type": "drug", "id": "DDI-DrugBank.d485.s14.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d485.s14-2", "sentence_id": "DDI-DrugBank.d485.s14", "sentence": "Ascorbic acid: Doses of ascorbic acid (vitamin C) 1 g/day have been reported to increase plasma concentration of synthetic estrogens by ~47%, possibly by inhibiting conjugation;", "arg1": {"span": [[0, 13]], "type": "drug", "id": "DDI-DrugBank.d485.s14.e0"}, "arg2": {"span": [[113, 132]], "type": "group", "id": "DDI-DrugBank.d485.s14.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d485.s14-3", "sentence_id": "DDI-DrugBank.d485.s14", "sentence": "Ascorbic acid: Doses of ascorbic acid (vitamin C) 1 g/day have been reported to increase plasma concentration of synthetic estrogens by ~47%, possibly by inhibiting conjugation;", "arg1": {"span": [[24, 37]], "type": "drug", "id": "DDI-DrugBank.d485.s14.e1"}, "arg2": {"span": [[39, 48]], "type": "drug", "id": "DDI-DrugBank.d485.s14.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d485.s14-4", "sentence_id": "DDI-DrugBank.d485.s14", "sentence": "Ascorbic acid: Doses of ascorbic acid (vitamin C) 1 g/day have been reported to increase plasma concentration of synthetic estrogens by ~47%, possibly by inhibiting conjugation;", "arg1": {"span": [[24, 37]], "type": "drug", "id": "DDI-DrugBank.d485.s14.e1"}, "arg2": {"span": [[113, 132]], "type": "group", "id": "DDI-DrugBank.d485.s14.e3"}, "ddi_label": 1, "ddi_type": "mechanism"}
{"id": "DDI-DrugBank.d485.s14-5", "sentence_id": "DDI-DrugBank.d485.s14", "sentence": "Ascorbic acid: Doses of ascorbic acid (vitamin C) 1 g/day have been reported to increase plasma concentration of synthetic estrogens by ~47%, possibly by inhibiting conjugation;", "arg1": {"span": [[39, 48]], "type": "drug", "id": "DDI-DrugBank.d485.s14.e2"}, "arg2": {"span": [[113, 132]], "type": "group", "id": "DDI-DrugBank.d485.s14.e3"}, "ddi_label": 1, "ddi_type": "mechanism"}
{"id": "DDI-DrugBank.d485.s16-0", "sentence_id": "DDI-DrugBank.d485.s16", "sentence": "Atorvastatin: Atorvastatin increases the AUC for norethindrone and ethinyl estradiol.", "arg1": {"span": [[0, 12]], "type": "drug", "id": "DDI-DrugBank.d485.s16.e0"}, "arg2": {"span": [[14, 26]], "type": "drug", "id": "DDI-DrugBank.d485.s16.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d485.s16-1", "sentence_id": "DDI-DrugBank.d485.s16", "sentence": "Atorvastatin: Atorvastatin increases the AUC for norethindrone and ethinyl estradiol.", "arg1": {"span": [[0, 12]], "type": "drug", "id": "DDI-DrugBank.d485.s16.e0"}, "arg2": {"span": [[49, 62]], "type": "drug", "id": "DDI-DrugBank.d485.s16.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d485.s16-2", "sentence_id": "DDI-DrugBank.d485.s16", "sentence": "Atorvastatin: Atorvastatin increases the AUC for norethindrone and ethinyl estradiol.", "arg1": {"span": [[0, 12]], "type": "drug", "id": "DDI-DrugBank.d485.s16.e0"}, "arg2": {"span": [[67, 84]], "type": "drug", "id": "DDI-DrugBank.d485.s16.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d485.s16-3", "sentence_id": "DDI-DrugBank.d485.s16", "sentence": "Atorvastatin: Atorvastatin increases the AUC for norethindrone and ethinyl estradiol.", "arg1": {"span": [[14, 26]], "type": "drug", "id": "DDI-DrugBank.d485.s16.e1"}, "arg2": {"span": [[49, 62]], "type": "drug", "id": "DDI-DrugBank.d485.s16.e2"}, "ddi_label": 1, "ddi_type": "mechanism"}
{"id": "DDI-DrugBank.d485.s16-4", "sentence_id": "DDI-DrugBank.d485.s16", "sentence": "Atorvastatin: Atorvastatin increases the AUC for norethindrone and ethinyl estradiol.", "arg1": {"span": [[14, 26]], "type": "drug", "id": "DDI-DrugBank.d485.s16.e1"}, "arg2": {"span": [[67, 84]], "type": "drug", "id": "DDI-DrugBank.d485.s16.e3"}, "ddi_label": 1, "ddi_type": "mechanism"}
{"id": "DDI-DrugBank.d485.s16-5", "sentence_id": "DDI-DrugBank.d485.s16", "sentence": "Atorvastatin: Atorvastatin increases the AUC for norethindrone and ethinyl estradiol.", "arg1": {"span": [[49, 62]], "type": "drug", "id": "DDI-DrugBank.d485.s16.e2"}, "arg2": {"span": [[67, 84]], "type": "drug", "id": "DDI-DrugBank.d485.s16.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d485.s18-0", "sentence_id": "DDI-DrugBank.d485.s18", "sentence": "Clofibric acid: Combination hormonal contraceptives may increase the clearance of clofibric acid.", "arg1": {"span": [[0, 14]], "type": "drug_n", "id": "DDI-DrugBank.d485.s18.e0"}, "arg2": {"span": [[28, 51]], "type": "group", "id": "DDI-DrugBank.d485.s18.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d485.s18-1", "sentence_id": "DDI-DrugBank.d485.s18", "sentence": "Clofibric acid: Combination hormonal contraceptives may increase the clearance of clofibric acid.", "arg1": {"span": [[0, 14]], "type": "drug_n", "id": "DDI-DrugBank.d485.s18.e0"}, "arg2": {"span": [[82, 96]], "type": "drug_n", "id": "DDI-DrugBank.d485.s18.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d485.s18-2", "sentence_id": "DDI-DrugBank.d485.s18", "sentence": "Clofibric acid: Combination hormonal contraceptives may increase the clearance of clofibric acid.", "arg1": {"span": [[28, 51]], "type": "group", "id": "DDI-DrugBank.d485.s18.e1"}, "arg2": {"span": [[82, 96]], "type": "drug_n", "id": "DDI-DrugBank.d485.s18.e2"}, "ddi_label": 1, "ddi_type": "mechanism"}
{"id": "DDI-DrugBank.d485.s19-0", "sentence_id": "DDI-DrugBank.d485.s19", "sentence": "Cyclosporine: Combination hormonal contraceptives may inhibit the metabolism of cyclosporine, leading to increased plasma concentrations;", "arg1": {"span": [[0, 12]], "type": "drug", "id": "DDI-DrugBank.d485.s19.e0"}, "arg2": {"span": [[26, 49]], "type": "group", "id": "DDI-DrugBank.d485.s19.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d485.s19-1", "sentence_id": "DDI-DrugBank.d485.s19", "sentence": "Cyclosporine: Combination hormonal contraceptives may inhibit the metabolism of cyclosporine, leading to increased plasma concentrations;", "arg1": {"span": [[0, 12]], "type": "drug", "id": "DDI-DrugBank.d485.s19.e0"}, "arg2": {"span": [[80, 92]], "type": "drug", "id": "DDI-DrugBank.d485.s19.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d485.s19-2", "sentence_id": "DDI-DrugBank.d485.s19", "sentence": "Cyclosporine: Combination hormonal contraceptives may inhibit the metabolism of cyclosporine, leading to increased plasma concentrations;", "arg1": {"span": [[26, 49]], "type": "group", "id": "DDI-DrugBank.d485.s19.e1"}, "arg2": {"span": [[80, 92]], "type": "drug", "id": "DDI-DrugBank.d485.s19.e2"}, "ddi_label": 1, "ddi_type": "mechanism"}
{"id": "DDI-DrugBank.d485.s23-0", "sentence_id": "DDI-DrugBank.d485.s23", "sentence": "Griseofulvin: Griseofulvin may induce the metabolism of combination hormonal contraceptives causing menstrual changes;", "arg1": {"span": [[0, 12]], "type": "drug", "id": "DDI-DrugBank.d485.s23.e0"}, "arg2": {"span": [[14, 26]], "type": "drug", "id": "DDI-DrugBank.d485.s23.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d485.s23-1", "sentence_id": "DDI-DrugBank.d485.s23", "sentence": "Griseofulvin: Griseofulvin may induce the metabolism of combination hormonal contraceptives causing menstrual changes;", "arg1": {"span": [[0, 12]], "type": "drug", "id": "DDI-DrugBank.d485.s23.e0"}, "arg2": {"span": [[56, 91]], "type": "group", "id": "DDI-DrugBank.d485.s23.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d485.s23-2", "sentence_id": "DDI-DrugBank.d485.s23", "sentence": "Griseofulvin: Griseofulvin may induce the metabolism of combination hormonal contraceptives causing menstrual changes;", "arg1": {"span": [[14, 26]], "type": "drug", "id": "DDI-DrugBank.d485.s23.e1"}, "arg2": {"span": [[56, 91]], "type": "group", "id": "DDI-DrugBank.d485.s23.e2"}, "ddi_label": 1, "ddi_type": "mechanism"}
{"id": "DDI-DrugBank.d485.s26-0", "sentence_id": "DDI-DrugBank.d485.s26", "sentence": "Morphine: Combination hormonal contraceptives may increase the clearance of morphine.", "arg1": {"span": [[0, 8]], "type": "drug", "id": "DDI-DrugBank.d485.s26.e0"}, "arg2": {"span": [[22, 45]], "type": "group", "id": "DDI-DrugBank.d485.s26.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d485.s26-1", "sentence_id": "DDI-DrugBank.d485.s26", "sentence": "Morphine: Combination hormonal contraceptives may increase the clearance of morphine.", "arg1": {"span": [[0, 8]], "type": "drug", "id": "DDI-DrugBank.d485.s26.e0"}, "arg2": {"span": [[76, 84]], "type": "drug", "id": "DDI-DrugBank.d485.s26.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d485.s26-2", "sentence_id": "DDI-DrugBank.d485.s26", "sentence": "Morphine: Combination hormonal contraceptives may increase the clearance of morphine.", "arg1": {"span": [[22, 45]], "type": "group", "id": "DDI-DrugBank.d485.s26.e1"}, "arg2": {"span": [[76, 84]], "type": "drug", "id": "DDI-DrugBank.d485.s26.e2"}, "ddi_label": 1, "ddi_type": "mechanism"}
{"id": "DDI-DrugBank.d485.s27-0", "sentence_id": "DDI-DrugBank.d485.s27", "sentence": "Non-nucleoside reverse transcriptase inhibitors (NNRTIs): Nevirapine may decrease plasma levels of combination hormonal contraceptives;", "arg1": {"span": [[0, 47]], "type": "group", "id": "DDI-DrugBank.d485.s27.e0"}, "arg2": {"span": [[49, 55]], "type": "group", "id": "DDI-DrugBank.d485.s27.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d485.s27-1", "sentence_id": "DDI-DrugBank.d485.s27", "sentence": "Non-nucleoside reverse transcriptase inhibitors (NNRTIs): Nevirapine may decrease plasma levels of combination hormonal contraceptives;", "arg1": {"span": [[0, 47]], "type": "group", "id": "DDI-DrugBank.d485.s27.e0"}, "arg2": {"span": [[58, 68]], "type": "drug", "id": "DDI-DrugBank.d485.s27.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d485.s27-2", "sentence_id": "DDI-DrugBank.d485.s27", "sentence": "Non-nucleoside reverse transcriptase inhibitors (NNRTIs): Nevirapine may decrease plasma levels of combination hormonal contraceptives;", "arg1": {"span": [[0, 47]], "type": "group", "id": "DDI-DrugBank.d485.s27.e0"}, "arg2": {"span": [[99, 134]], "type": "group", "id": "DDI-DrugBank.d485.s27.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d485.s27-3", "sentence_id": "DDI-DrugBank.d485.s27", "sentence": "Non-nucleoside reverse transcriptase inhibitors (NNRTIs): Nevirapine may decrease plasma levels of combination hormonal contraceptives;", "arg1": {"span": [[49, 55]], "type": "group", "id": "DDI-DrugBank.d485.s27.e1"}, "arg2": {"span": [[58, 68]], "type": "drug", "id": "DDI-DrugBank.d485.s27.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d485.s27-4", "sentence_id": "DDI-DrugBank.d485.s27", "sentence": "Non-nucleoside reverse transcriptase inhibitors (NNRTIs): Nevirapine may decrease plasma levels of combination hormonal contraceptives;", "arg1": {"span": [[49, 55]], "type": "group", "id": "DDI-DrugBank.d485.s27.e1"}, "arg2": {"span": [[99, 134]], "type": "group", "id": "DDI-DrugBank.d485.s27.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d485.s27-5", "sentence_id": "DDI-DrugBank.d485.s27", "sentence": "Non-nucleoside reverse transcriptase inhibitors (NNRTIs): Nevirapine may decrease plasma levels of combination hormonal contraceptives;", "arg1": {"span": [[58, 68]], "type": "drug", "id": "DDI-DrugBank.d485.s27.e2"}, "arg2": {"span": [[99, 134]], "type": "group", "id": "DDI-DrugBank.d485.s27.e3"}, "ddi_label": 1, "ddi_type": "mechanism"}
{"id": "DDI-DrugBank.d485.s31-0", "sentence_id": "DDI-DrugBank.d485.s31", "sentence": "Prednisolone: Ethinyl estradiol may inhibit the metabolism of prednisolone, leading to increased plasma concentrations.", "arg1": {"span": [[0, 12]], "type": "drug", "id": "DDI-DrugBank.d485.s31.e0"}, "arg2": {"span": [[14, 31]], "type": "drug", "id": "DDI-DrugBank.d485.s31.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d485.s31-1", "sentence_id": "DDI-DrugBank.d485.s31", "sentence": "Prednisolone: Ethinyl estradiol may inhibit the metabolism of prednisolone, leading to increased plasma concentrations.", "arg1": {"span": [[0, 12]], "type": "drug", "id": "DDI-DrugBank.d485.s31.e0"}, "arg2": {"span": [[62, 74]], "type": "drug", "id": "DDI-DrugBank.d485.s31.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d485.s31-2", "sentence_id": "DDI-DrugBank.d485.s31", "sentence": "Prednisolone: Ethinyl estradiol may inhibit the metabolism of prednisolone, leading to increased plasma concentrations.", "arg1": {"span": [[14, 31]], "type": "drug", "id": "DDI-DrugBank.d485.s31.e1"}, "arg2": {"span": [[62, 74]], "type": "drug", "id": "DDI-DrugBank.d485.s31.e2"}, "ddi_label": 1, "ddi_type": "mechanism"}
{"id": "DDI-DrugBank.d485.s34-0", "sentence_id": "DDI-DrugBank.d485.s34", "sentence": "Indinavir has been shown to increase plasma levels of combination hormonal contraceptives.", "arg1": {"span": [[0, 9]], "type": "drug", "id": "DDI-DrugBank.d485.s34.e0"}, "arg2": {"span": [[54, 89]], "type": "group", "id": "DDI-DrugBank.d485.s34.e1"}, "ddi_label": 1, "ddi_type": "mechanism"}
{"id": "DDI-DrugBank.d485.s36-0", "sentence_id": "DDI-DrugBank.d485.s36", "sentence": "Rifampin: Rifampin increases the metabolism of ethinyl estradiol and some progestins (norethindrone) resulting in decreased contraceptive effectiveness and increased menstrual irregularities.", "arg1": {"span": [[0, 8]], "type": "drug", "id": "DDI-DrugBank.d485.s36.e0"}, "arg2": {"span": [[10, 18]], "type": "drug", "id": "DDI-DrugBank.d485.s36.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d485.s36-1", "sentence_id": "DDI-DrugBank.d485.s36", "sentence": "Rifampin: Rifampin increases the metabolism of ethinyl estradiol and some progestins (norethindrone) resulting in decreased contraceptive effectiveness and increased menstrual irregularities.", "arg1": {"span": [[0, 8]], "type": "drug", "id": "DDI-DrugBank.d485.s36.e0"}, "arg2": {"span": [[47, 64]], "type": "drug", "id": "DDI-DrugBank.d485.s36.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d485.s36-2", "sentence_id": "DDI-DrugBank.d485.s36", "sentence": "Rifampin: Rifampin increases the metabolism of ethinyl estradiol and some progestins (norethindrone) resulting in decreased contraceptive effectiveness and increased menstrual irregularities.", "arg1": {"span": [[0, 8]], "type": "drug", "id": "DDI-DrugBank.d485.s36.e0"}, "arg2": {"span": [[74, 84]], "type": "group", "id": "DDI-DrugBank.d485.s36.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d485.s36-3", "sentence_id": "DDI-DrugBank.d485.s36", "sentence": "Rifampin: Rifampin increases the metabolism of ethinyl estradiol and some progestins (norethindrone) resulting in decreased contraceptive effectiveness and increased menstrual irregularities.", "arg1": {"span": [[0, 8]], "type": "drug", "id": "DDI-DrugBank.d485.s36.e0"}, "arg2": {"span": [[86, 99]], "type": "drug", "id": "DDI-DrugBank.d485.s36.e4"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d485.s36-4", "sentence_id": "DDI-DrugBank.d485.s36", "sentence": "Rifampin: Rifampin increases the metabolism of ethinyl estradiol and some progestins (norethindrone) resulting in decreased contraceptive effectiveness and increased menstrual irregularities.", "arg1": {"span": [[10, 18]], "type": "drug", "id": "DDI-DrugBank.d485.s36.e1"}, "arg2": {"span": [[47, 64]], "type": "drug", "id": "DDI-DrugBank.d485.s36.e2"}, "ddi_label": 1, "ddi_type": "mechanism"}
{"id": "DDI-DrugBank.d485.s36-5", "sentence_id": "DDI-DrugBank.d485.s36", "sentence": "Rifampin: Rifampin increases the metabolism of ethinyl estradiol and some progestins (norethindrone) resulting in decreased contraceptive effectiveness and increased menstrual irregularities.", "arg1": {"span": [[10, 18]], "type": "drug", "id": "DDI-DrugBank.d485.s36.e1"}, "arg2": {"span": [[74, 84]], "type": "group", "id": "DDI-DrugBank.d485.s36.e3"}, "ddi_label": 1, "ddi_type": "mechanism"}
{"id": "DDI-DrugBank.d485.s36-6", "sentence_id": "DDI-DrugBank.d485.s36", "sentence": "Rifampin: Rifampin increases the metabolism of ethinyl estradiol and some progestins (norethindrone) resulting in decreased contraceptive effectiveness and increased menstrual irregularities.", "arg1": {"span": [[10, 18]], "type": "drug", "id": "DDI-DrugBank.d485.s36.e1"}, "arg2": {"span": [[86, 99]], "type": "drug", "id": "DDI-DrugBank.d485.s36.e4"}, "ddi_label": 1, "ddi_type": "mechanism"}
{"id": "DDI-DrugBank.d485.s36-7", "sentence_id": "DDI-DrugBank.d485.s36", "sentence": "Rifampin: Rifampin increases the metabolism of ethinyl estradiol and some progestins (norethindrone) resulting in decreased contraceptive effectiveness and increased menstrual irregularities.", "arg1": {"span": [[47, 64]], "type": "drug", "id": "DDI-DrugBank.d485.s36.e2"}, "arg2": {"span": [[74, 84]], "type": "group", "id": "DDI-DrugBank.d485.s36.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d485.s36-8", "sentence_id": "DDI-DrugBank.d485.s36", "sentence": "Rifampin: Rifampin increases the metabolism of ethinyl estradiol and some progestins (norethindrone) resulting in decreased contraceptive effectiveness and increased menstrual irregularities.", "arg1": {"span": [[47, 64]], "type": "drug", "id": "DDI-DrugBank.d485.s36.e2"}, "arg2": {"span": [[86, 99]], "type": "drug", "id": "DDI-DrugBank.d485.s36.e4"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d485.s36-9", "sentence_id": "DDI-DrugBank.d485.s36", "sentence": "Rifampin: Rifampin increases the metabolism of ethinyl estradiol and some progestins (norethindrone) resulting in decreased contraceptive effectiveness and increased menstrual irregularities.", "arg1": {"span": [[74, 84]], "type": "group", "id": "DDI-DrugBank.d485.s36.e3"}, "arg2": {"span": [[86, 99]], "type": "drug", "id": "DDI-DrugBank.d485.s36.e4"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d485.s38-0", "sentence_id": "DDI-DrugBank.d485.s38", "sentence": "Salicylic acid: Combination hormonal contraceptives may increase the clearance of salicylic acid.", "arg1": {"span": [[0, 14]], "type": "drug", "id": "DDI-DrugBank.d485.s38.e0"}, "arg2": {"span": [[28, 51]], "type": "group", "id": "DDI-DrugBank.d485.s38.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d485.s38-1", "sentence_id": "DDI-DrugBank.d485.s38", "sentence": "Salicylic acid: Combination hormonal contraceptives may increase the clearance of salicylic acid.", "arg1": {"span": [[0, 14]], "type": "drug", "id": "DDI-DrugBank.d485.s38.e0"}, "arg2": {"span": [[82, 96]], "type": "drug", "id": "DDI-DrugBank.d485.s38.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d485.s38-2", "sentence_id": "DDI-DrugBank.d485.s38", "sentence": "Salicylic acid: Combination hormonal contraceptives may increase the clearance of salicylic acid.", "arg1": {"span": [[28, 51]], "type": "group", "id": "DDI-DrugBank.d485.s38.e1"}, "arg2": {"span": [[82, 96]], "type": "drug", "id": "DDI-DrugBank.d485.s38.e2"}, "ddi_label": 1, "ddi_type": "mechanism"}
{"id": "DDI-DrugBank.d485.s39-0", "sentence_id": "DDI-DrugBank.d485.s39", "sentence": "Selegiline: Combination hormonal contraceptives may increase the serum concentration of selegiline.", "arg1": {"span": [[0, 10]], "type": "drug", "id": "DDI-DrugBank.d485.s39.e0"}, "arg2": {"span": [[12, 47]], "type": "group", "id": "DDI-DrugBank.d485.s39.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d485.s39-1", "sentence_id": "DDI-DrugBank.d485.s39", "sentence": "Selegiline: Combination hormonal contraceptives may increase the serum concentration of selegiline.", "arg1": {"span": [[0, 10]], "type": "drug", "id": "DDI-DrugBank.d485.s39.e0"}, "arg2": {"span": [[88, 98]], "type": "drug", "id": "DDI-DrugBank.d485.s39.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d485.s39-2", "sentence_id": "DDI-DrugBank.d485.s39", "sentence": "Selegiline: Combination hormonal contraceptives may increase the serum concentration of selegiline.", "arg1": {"span": [[12, 47]], "type": "group", "id": "DDI-DrugBank.d485.s39.e1"}, "arg2": {"span": [[88, 98]], "type": "drug", "id": "DDI-DrugBank.d485.s39.e2"}, "ddi_label": 1, "ddi_type": "mechanism"}
{"id": "DDI-DrugBank.d485.s40-0", "sentence_id": "DDI-DrugBank.d485.s40", "sentence": "Theophylline: Ethinyl estradiol may inhibit the metabolism of theophylline, leading to increased plasma concentrations.", "arg1": {"span": [[0, 12]], "type": "drug", "id": "DDI-DrugBank.d485.s40.e0"}, "arg2": {"span": [[14, 31]], "type": "drug", "id": "DDI-DrugBank.d485.s40.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d485.s40-1", "sentence_id": "DDI-DrugBank.d485.s40", "sentence": "Theophylline: Ethinyl estradiol may inhibit the metabolism of theophylline, leading to increased plasma concentrations.", "arg1": {"span": [[0, 12]], "type": "drug", "id": "DDI-DrugBank.d485.s40.e0"}, "arg2": {"span": [[62, 74]], "type": "drug", "id": "DDI-DrugBank.d485.s40.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d485.s40-2", "sentence_id": "DDI-DrugBank.d485.s40", "sentence": "Theophylline: Ethinyl estradiol may inhibit the metabolism of theophylline, leading to increased plasma concentrations.", "arg1": {"span": [[14, 31]], "type": "drug", "id": "DDI-DrugBank.d485.s40.e1"}, "arg2": {"span": [[62, 74]], "type": "drug", "id": "DDI-DrugBank.d485.s40.e2"}, "ddi_label": 1, "ddi_type": "mechanism"}
{"id": "DDI-DrugBank.d485.s43-0", "sentence_id": "DDI-DrugBank.d485.s43", "sentence": "ETHANOL / NUTRITION / HERB INTERACTIONS: Food: CNS effects of caffeine may be enhanced if combination hormonal contraceptives are used concurrently with caffeine.", "arg1": {"span": [[0, 7]], "type": "drug", "id": "DDI-DrugBank.d485.s43.e0"}, "arg2": {"span": [[62, 70]], "type": "drug", "id": "DDI-DrugBank.d485.s43.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d485.s43-1", "sentence_id": "DDI-DrugBank.d485.s43", "sentence": "ETHANOL / NUTRITION / HERB INTERACTIONS: Food: CNS effects of caffeine may be enhanced if combination hormonal contraceptives are used concurrently with caffeine.", "arg1": {"span": [[0, 7]], "type": "drug", "id": "DDI-DrugBank.d485.s43.e0"}, "arg2": {"span": [[90, 125]], "type": "group", "id": "DDI-DrugBank.d485.s43.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d485.s43-2", "sentence_id": "DDI-DrugBank.d485.s43", "sentence": "ETHANOL / NUTRITION / HERB INTERACTIONS: Food: CNS effects of caffeine may be enhanced if combination hormonal contraceptives are used concurrently with caffeine.", "arg1": {"span": [[0, 7]], "type": "drug", "id": "DDI-DrugBank.d485.s43.e0"}, "arg2": {"span": [[153, 161]], "type": "drug", "id": "DDI-DrugBank.d485.s43.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d485.s43-3", "sentence_id": "DDI-DrugBank.d485.s43", "sentence": "ETHANOL / NUTRITION / HERB INTERACTIONS: Food: CNS effects of caffeine may be enhanced if combination hormonal contraceptives are used concurrently with caffeine.", "arg1": {"span": [[62, 70]], "type": "drug", "id": "DDI-DrugBank.d485.s43.e1"}, "arg2": {"span": [[90, 125]], "type": "group", "id": "DDI-DrugBank.d485.s43.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d485.s43-4", "sentence_id": "DDI-DrugBank.d485.s43", "sentence": "ETHANOL / NUTRITION / HERB INTERACTIONS: Food: CNS effects of caffeine may be enhanced if combination hormonal contraceptives are used concurrently with caffeine.", "arg1": {"span": [[62, 70]], "type": "drug", "id": "DDI-DrugBank.d485.s43.e1"}, "arg2": {"span": [[153, 161]], "type": "drug", "id": "DDI-DrugBank.d485.s43.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d485.s43-5", "sentence_id": "DDI-DrugBank.d485.s43", "sentence": "ETHANOL / NUTRITION / HERB INTERACTIONS: Food: CNS effects of caffeine may be enhanced if combination hormonal contraceptives are used concurrently with caffeine.", "arg1": {"span": [[90, 125]], "type": "group", "id": "DDI-DrugBank.d485.s43.e2"}, "arg2": {"span": [[153, 161]], "type": "drug", "id": "DDI-DrugBank.d485.s43.e3"}, "ddi_label": 1, "ddi_type": "effect"}
{"id": "DDI-DrugBank.d485.s44-0", "sentence_id": "DDI-DrugBank.d485.s44", "sentence": "Grapefruit juice increases ethinyl estradiol concentrations and would be expected to increase progesterone serum levels as well;", "arg1": {"span": [[27, 44]], "type": "drug", "id": "DDI-DrugBank.d485.s44.e0"}, "arg2": {"span": [[94, 106]], "type": "drug", "id": "DDI-DrugBank.d485.s44.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d227.s0-0", "sentence_id": "DDI-DrugBank.d227.s0", "sentence": "Isoflurane potentiates the muscle relaxant effect of all muscle relaxants, most notably nondepolarizing muscle relaxants, and MAC (minimum alveolar concentration) is reduced by concomitant administration of N 2O.", "arg1": {"span": [[0, 10]], "type": "drug", "id": "DDI-DrugBank.d227.s0.e0"}, "arg2": {"span": [[57, 73]], "type": "group", "id": "DDI-DrugBank.d227.s0.e1"}, "ddi_label": 1, "ddi_type": "effect"}
{"id": "DDI-DrugBank.d227.s0-1", "sentence_id": "DDI-DrugBank.d227.s0", "sentence": "Isoflurane potentiates the muscle relaxant effect of all muscle relaxants, most notably nondepolarizing muscle relaxants, and MAC (minimum alveolar concentration) is reduced by concomitant administration of N 2O.", "arg1": {"span": [[0, 10]], "type": "drug", "id": "DDI-DrugBank.d227.s0.e0"}, "arg2": {"span": [[88, 120]], "type": "group", "id": "DDI-DrugBank.d227.s0.e2"}, "ddi_label": 1, "ddi_type": "effect"}
{"id": "DDI-DrugBank.d227.s0-2", "sentence_id": "DDI-DrugBank.d227.s0", "sentence": "Isoflurane potentiates the muscle relaxant effect of all muscle relaxants, most notably nondepolarizing muscle relaxants, and MAC (minimum alveolar concentration) is reduced by concomitant administration of N 2O.", "arg1": {"span": [[57, 73]], "type": "group", "id": "DDI-DrugBank.d227.s0.e1"}, "arg2": {"span": [[88, 120]], "type": "group", "id": "DDI-DrugBank.d227.s0.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d564.s0-0", "sentence_id": "DDI-DrugBank.d564.s0", "sentence": "The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors or tricyclic antidepressants may produce severe, prolonged hypertension.", "arg1": {"span": [[28, 48]], "type": "group", "id": "DDI-DrugBank.d564.s0.e0"}, "arg2": {"span": [[60, 71]], "type": "drug", "id": "DDI-DrugBank.d564.s0.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d564.s0-1", "sentence_id": "DDI-DrugBank.d564.s0", "sentence": "The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors or tricyclic antidepressants may produce severe, prolonged hypertension.", "arg1": {"span": [[28, 48]], "type": "group", "id": "DDI-DrugBank.d564.s0.e0"}, "arg2": {"span": [[75, 89]], "type": "drug", "id": "DDI-DrugBank.d564.s0.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d564.s0-2", "sentence_id": "DDI-DrugBank.d564.s0", "sentence": "The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors or tricyclic antidepressants may produce severe, prolonged hypertension.", "arg1": {"span": [[28, 48]], "type": "group", "id": "DDI-DrugBank.d564.s0.e0"}, "arg2": {"span": [[112, 140]], "type": "group", "id": "DDI-DrugBank.d564.s0.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d564.s0-3", "sentence_id": "DDI-DrugBank.d564.s0", "sentence": "The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors or tricyclic antidepressants may produce severe, prolonged hypertension.", "arg1": {"span": [[28, 48]], "type": "group", "id": "DDI-DrugBank.d564.s0.e0"}, "arg2": {"span": [[144, 169]], "type": "group", "id": "DDI-DrugBank.d564.s0.e4"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d564.s0-4", "sentence_id": "DDI-DrugBank.d564.s0", "sentence": "The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors or tricyclic antidepressants may produce severe, prolonged hypertension.", "arg1": {"span": [[60, 71]], "type": "drug", "id": "DDI-DrugBank.d564.s0.e1"}, "arg2": {"span": [[75, 89]], "type": "drug", "id": "DDI-DrugBank.d564.s0.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d564.s0-5", "sentence_id": "DDI-DrugBank.d564.s0", "sentence": "The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors or tricyclic antidepressants may produce severe, prolonged hypertension.", "arg1": {"span": [[60, 71]], "type": "drug", "id": "DDI-DrugBank.d564.s0.e1"}, "arg2": {"span": [[112, 140]], "type": "group", "id": "DDI-DrugBank.d564.s0.e3"}, "ddi_label": 1, "ddi_type": "effect"}
{"id": "DDI-DrugBank.d564.s0-6", "sentence_id": "DDI-DrugBank.d564.s0", "sentence": "The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors or tricyclic antidepressants may produce severe, prolonged hypertension.", "arg1": {"span": [[60, 71]], "type": "drug", "id": "DDI-DrugBank.d564.s0.e1"}, "arg2": {"span": [[144, 169]], "type": "group", "id": "DDI-DrugBank.d564.s0.e4"}, "ddi_label": 1, "ddi_type": "effect"}
{"id": "DDI-DrugBank.d564.s0-7", "sentence_id": "DDI-DrugBank.d564.s0", "sentence": "The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors or tricyclic antidepressants may produce severe, prolonged hypertension.", "arg1": {"span": [[75, 89]], "type": "drug", "id": "DDI-DrugBank.d564.s0.e2"}, "arg2": {"span": [[112, 140]], "type": "group", "id": "DDI-DrugBank.d564.s0.e3"}, "ddi_label": 1, "ddi_type": "effect"}
{"id": "DDI-DrugBank.d564.s0-8", "sentence_id": "DDI-DrugBank.d564.s0", "sentence": "The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors or tricyclic antidepressants may produce severe, prolonged hypertension.", "arg1": {"span": [[75, 89]], "type": "drug", "id": "DDI-DrugBank.d564.s0.e2"}, "arg2": {"span": [[144, 169]], "type": "group", "id": "DDI-DrugBank.d564.s0.e4"}, "ddi_label": 1, "ddi_type": "effect"}
{"id": "DDI-DrugBank.d564.s0-9", "sentence_id": "DDI-DrugBank.d564.s0", "sentence": "The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors or tricyclic antidepressants may produce severe, prolonged hypertension.", "arg1": {"span": [[112, 140]], "type": "group", "id": "DDI-DrugBank.d564.s0.e3"}, "arg2": {"span": [[144, 169]], "type": "group", "id": "DDI-DrugBank.d564.s0.e4"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d564.s1-0", "sentence_id": "DDI-DrugBank.d564.s1", "sentence": "Phenothiazines and butyrophenones may reduce or reverse the pressor effect of epinephrine.", "arg1": {"span": [[0, 14]], "type": "group", "id": "DDI-DrugBank.d564.s1.e0"}, "arg2": {"span": [[19, 33]], "type": "group", "id": "DDI-DrugBank.d564.s1.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d564.s1-1", "sentence_id": "DDI-DrugBank.d564.s1", "sentence": "Phenothiazines and butyrophenones may reduce or reverse the pressor effect of epinephrine.", "arg1": {"span": [[0, 14]], "type": "group", "id": "DDI-DrugBank.d564.s1.e0"}, "arg2": {"span": [[78, 89]], "type": "drug", "id": "DDI-DrugBank.d564.s1.e2"}, "ddi_label": 1, "ddi_type": "effect"}
{"id": "DDI-DrugBank.d564.s1-2", "sentence_id": "DDI-DrugBank.d564.s1", "sentence": "Phenothiazines and butyrophenones may reduce or reverse the pressor effect of epinephrine.", "arg1": {"span": [[19, 33]], "type": "group", "id": "DDI-DrugBank.d564.s1.e1"}, "arg2": {"span": [[78, 89]], "type": "drug", "id": "DDI-DrugBank.d564.s1.e2"}, "ddi_label": 1, "ddi_type": "effect"}
{"id": "DDI-DrugBank.d564.s4-0", "sentence_id": "DDI-DrugBank.d564.s4", "sentence": "Concurrent administration of vasopressor drugs (for the treatment of hypotension related to obstetric blocks) and ergot-type oxytocic drugs may cause severe, persistent hypertension or cerebrovascular accidents.", "arg1": {"span": [[29, 46]], "type": "group", "id": "DDI-DrugBank.d564.s4.e0"}, "arg2": {"span": [[114, 139]], "type": "group", "id": "DDI-DrugBank.d564.s4.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d497.s0-0", "sentence_id": "DDI-DrugBank.d497.s0", "sentence": "AZOPT (brinzolamide ophthalmic suspension) 1% contains a carbonic anhydrase inhibitor.", "arg1": {"span": [[0, 5]], "type": "brand", "id": "DDI-DrugBank.d497.s0.e0"}, "arg2": {"span": [[7, 19]], "type": "drug", "id": "DDI-DrugBank.d497.s0.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d497.s0-1", "sentence_id": "DDI-DrugBank.d497.s0", "sentence": "AZOPT (brinzolamide ophthalmic suspension) 1% contains a carbonic anhydrase inhibitor.", "arg1": {"span": [[0, 5]], "type": "brand", "id": "DDI-DrugBank.d497.s0.e0"}, "arg2": {"span": [[57, 85]], "type": "group", "id": "DDI-DrugBank.d497.s0.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d497.s0-2", "sentence_id": "DDI-DrugBank.d497.s0", "sentence": "AZOPT (brinzolamide ophthalmic suspension) 1% contains a carbonic anhydrase inhibitor.", "arg1": {"span": [[7, 19]], "type": "drug", "id": "DDI-DrugBank.d497.s0.e1"}, "arg2": {"span": [[57, 85]], "type": "group", "id": "DDI-DrugBank.d497.s0.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d497.s2-0", "sentence_id": "DDI-DrugBank.d497.s2", "sentence": "However, in patients treated with oral carbonic anhydrase inhibitors, rare instances of drug interactions have occurred with high-dose salicylate therapy.", "arg1": {"span": [[39, 68]], "type": "group", "id": "DDI-DrugBank.d497.s2.e0"}, "arg2": {"span": [[135, 145]], "type": "drug", "id": "DDI-DrugBank.d497.s2.e1"}, "ddi_label": 1, "ddi_type": "int"}
{"id": "DDI-DrugBank.d497.s3-0", "sentence_id": "DDI-DrugBank.d497.s3", "sentence": "Therefore, the potential for such drug interaction should be considered in patients receiving AZOPT (brinzolamide ophthalmic suspension) 1%.", "arg1": {"span": [[94, 99]], "type": "brand", "id": "DDI-DrugBank.d497.s3.e0"}, "arg2": {"span": [[101, 113]], "type": "drug", "id": "DDI-DrugBank.d497.s3.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d109.s0-0", "sentence_id": "DDI-DrugBank.d109.s0", "sentence": "Ketoconazole/Itraconazole, Macrolides, Including Erythromycin", "arg1": {"span": [[0, 12]], "type": "drug", "id": "DDI-DrugBank.d109.s0.e0"}, "arg2": {"span": [[13, 25]], "type": "drug", "id": "DDI-DrugBank.d109.s0.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d109.s0-1", "sentence_id": "DDI-DrugBank.d109.s0", "sentence": "Ketoconazole/Itraconazole, Macrolides, Including Erythromycin", "arg1": {"span": [[0, 12]], "type": "drug", "id": "DDI-DrugBank.d109.s0.e0"}, "arg2": {"span": [[27, 37]], "type": "group", "id": "DDI-DrugBank.d109.s0.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d109.s0-2", "sentence_id": "DDI-DrugBank.d109.s0", "sentence": "Ketoconazole/Itraconazole, Macrolides, Including Erythromycin", "arg1": {"span": [[0, 12]], "type": "drug", "id": "DDI-DrugBank.d109.s0.e0"}, "arg2": {"span": [[49, 61]], "type": "drug", "id": "DDI-DrugBank.d109.s0.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d109.s0-3", "sentence_id": "DDI-DrugBank.d109.s0", "sentence": "Ketoconazole/Itraconazole, Macrolides, Including Erythromycin", "arg1": {"span": [[13, 25]], "type": "drug", "id": "DDI-DrugBank.d109.s0.e1"}, "arg2": {"span": [[27, 37]], "type": "group", "id": "DDI-DrugBank.d109.s0.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d109.s0-4", "sentence_id": "DDI-DrugBank.d109.s0", "sentence": "Ketoconazole/Itraconazole, Macrolides, Including Erythromycin", "arg1": {"span": [[13, 25]], "type": "drug", "id": "DDI-DrugBank.d109.s0.e1"}, "arg2": {"span": [[49, 61]], "type": "drug", "id": "DDI-DrugBank.d109.s0.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d109.s0-5", "sentence_id": "DDI-DrugBank.d109.s0", "sentence": "Ketoconazole/Itraconazole, Macrolides, Including Erythromycin", "arg1": {"span": [[27, 37]], "type": "group", "id": "DDI-DrugBank.d109.s0.e2"}, "arg2": {"span": [[49, 61]], "type": "drug", "id": "DDI-DrugBank.d109.s0.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d98.s3-0", "sentence_id": "DDI-DrugBank.d98.s3", "sentence": "Since blood level of calcitriol/ergocalcitriol will be reduced, higher doses of Rocaltrol may be necessary if these drugs are administered simultaneously.", "arg1": {"span": [[21, 31]], "type": "drug", "id": "DDI-DrugBank.d98.s3.e0"}, "arg2": {"span": [[80, 89]], "type": "brand", "id": "DDI-DrugBank.d98.s3.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d98.s4-0", "sentence_id": "DDI-DrugBank.d98.s4", "sentence": "Thiazides: Thiazides are known to induce hypercalcemia by the reduction of calcium excretion in urine.", "arg1": {"span": [[0, 9]], "type": "group", "id": "DDI-DrugBank.d98.s4.e0"}, "arg2": {"span": [[11, 20]], "type": "group", "id": "DDI-DrugBank.d98.s4.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d98.s5-0", "sentence_id": "DDI-DrugBank.d98.s5", "sentence": "Some reports have shown that the concomitant administration of thiazides with vitamin D causes hypercalcemia.", "arg1": {"span": [[63, 72]], "type": "group", "id": "DDI-DrugBank.d98.s5.e0"}, "arg2": {"span": [[78, 87]], "type": "group", "id": "DDI-DrugBank.d98.s5.e1"}, "ddi_label": 1, "ddi_type": "effect"}
{"id": "DDI-DrugBank.d98.s7-0", "sentence_id": "DDI-DrugBank.d98.s7", "sentence": "Digitalis: Vitamin D dosage must be determined with care in patients undergoing treatment with digitalis, as hypercalcemia in such patients may precipitate cardiac arrhythmias.", "arg1": {"span": [[0, 9]], "type": "group", "id": "DDI-DrugBank.d98.s7.e0"}, "arg2": {"span": [[11, 20]], "type": "group", "id": "DDI-DrugBank.d98.s7.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d98.s7-1", "sentence_id": "DDI-DrugBank.d98.s7", "sentence": "Digitalis: Vitamin D dosage must be determined with care in patients undergoing treatment with digitalis, as hypercalcemia in such patients may precipitate cardiac arrhythmias.", "arg1": {"span": [[0, 9]], "type": "group", "id": "DDI-DrugBank.d98.s7.e0"}, "arg2": {"span": [[95, 104]], "type": "group", "id": "DDI-DrugBank.d98.s7.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d98.s7-2", "sentence_id": "DDI-DrugBank.d98.s7", "sentence": "Digitalis: Vitamin D dosage must be determined with care in patients undergoing treatment with digitalis, as hypercalcemia in such patients may precipitate cardiac arrhythmias.", "arg1": {"span": [[11, 20]], "type": "group", "id": "DDI-DrugBank.d98.s7.e1"}, "arg2": {"span": [[95, 104]], "type": "group", "id": "DDI-DrugBank.d98.s7.e2"}, "ddi_label": 1, "ddi_type": "advise"}
{"id": "DDI-DrugBank.d98.s8-0", "sentence_id": "DDI-DrugBank.d98.s8", "sentence": "Ketoconazole: Ketoconazole may inhibit both synthetic and catabolic enzymes of vitamin D.", "arg1": {"span": [[0, 12]], "type": "drug", "id": "DDI-DrugBank.d98.s8.e0"}, "arg2": {"span": [[14, 26]], "type": "drug", "id": "DDI-DrugBank.d98.s8.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d98.s8-1", "sentence_id": "DDI-DrugBank.d98.s8", "sentence": "Ketoconazole: Ketoconazole may inhibit both synthetic and catabolic enzymes of vitamin D.", "arg1": {"span": [[0, 12]], "type": "drug", "id": "DDI-DrugBank.d98.s8.e0"}, "arg2": {"span": [[79, 88]], "type": "group", "id": "DDI-DrugBank.d98.s8.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d98.s8-2", "sentence_id": "DDI-DrugBank.d98.s8", "sentence": "Ketoconazole: Ketoconazole may inhibit both synthetic and catabolic enzymes of vitamin D.", "arg1": {"span": [[14, 26]], "type": "drug", "id": "DDI-DrugBank.d98.s8.e1"}, "arg2": {"span": [[79, 88]], "type": "group", "id": "DDI-DrugBank.d98.s8.e2"}, "ddi_label": 1, "ddi_type": "mechanism"}
{"id": "DDI-DrugBank.d98.s10-0", "sentence_id": "DDI-DrugBank.d98.s10", "sentence": "However, in vivo drug interaction studies of ketoconazole with vitamin D have not been investigated.", "arg1": {"span": [[45, 57]], "type": "drug", "id": "DDI-DrugBank.d98.s10.e0"}, "arg2": {"span": [[63, 72]], "type": "group", "id": "DDI-DrugBank.d98.s10.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d98.s11-0", "sentence_id": "DDI-DrugBank.d98.s11", "sentence": "Corticosteroids: A relationship of functional antagonism exists between vitamin D analogues, which promote calcium absorption, and corticosteroids, which inhibit calcium absorption.", "arg1": {"span": [[0, 15]], "type": "group", "id": "DDI-DrugBank.d98.s11.e0"}, "arg2": {"span": [[72, 91]], "type": "group", "id": "DDI-DrugBank.d98.s11.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d98.s11-1", "sentence_id": "DDI-DrugBank.d98.s11", "sentence": "Corticosteroids: A relationship of functional antagonism exists between vitamin D analogues, which promote calcium absorption, and corticosteroids, which inhibit calcium absorption.", "arg1": {"span": [[0, 15]], "type": "group", "id": "DDI-DrugBank.d98.s11.e0"}, "arg2": {"span": [[131, 146]], "type": "group", "id": "DDI-DrugBank.d98.s11.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d98.s11-2", "sentence_id": "DDI-DrugBank.d98.s11", "sentence": "Corticosteroids: A relationship of functional antagonism exists between vitamin D analogues, which promote calcium absorption, and corticosteroids, which inhibit calcium absorption.", "arg1": {"span": [[72, 91]], "type": "group", "id": "DDI-DrugBank.d98.s11.e1"}, "arg2": {"span": [[131, 146]], "type": "group", "id": "DDI-DrugBank.d98.s11.e2"}, "ddi_label": 1, "ddi_type": "mechanism"}
{"id": "DDI-DrugBank.d98.s13-0", "sentence_id": "DDI-DrugBank.d98.s13", "sentence": "Vitamin D: The coadministration of any of the vitamin D analogues should be avoided as this could create possible additive effects and hypercalcemia.", "arg1": {"span": [[0, 9]], "type": "group", "id": "DDI-DrugBank.d98.s13.e0"}, "arg2": {"span": [[46, 65]], "type": "group", "id": "DDI-DrugBank.d98.s13.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d98.s14-0", "sentence_id": "DDI-DrugBank.d98.s14", "sentence": "Calcium Supplements: Uncontrolled intake of additional calcium-containing preparations should be avoided.", "arg1": {"span": [[0, 7]], "type": "drug", "id": "DDI-DrugBank.d98.s14.e0"}, "arg2": {"span": [[55, 62]], "type": "drug", "id": "DDI-DrugBank.d98.s14.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d98.s15-0", "sentence_id": "DDI-DrugBank.d98.s15", "sentence": "Magnesium: Magnesium-containing preparations (eg, antacids) may cause hypermagnesemia and should therefore not be taken during therapy with vitamin D by patients on chronic renal dialysis.", "arg1": {"span": [[0, 9]], "type": "drug", "id": "DDI-DrugBank.d98.s15.e0"}, "arg2": {"span": [[11, 20]], "type": "drug", "id": "DDI-DrugBank.d98.s15.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d98.s15-1", "sentence_id": "DDI-DrugBank.d98.s15", "sentence": "Magnesium: Magnesium-containing preparations (eg, antacids) may cause hypermagnesemia and should therefore not be taken during therapy with vitamin D by patients on chronic renal dialysis.", "arg1": {"span": [[0, 9]], "type": "drug", "id": "DDI-DrugBank.d98.s15.e0"}, "arg2": {"span": [[50, 58]], "type": "group", "id": "DDI-DrugBank.d98.s15.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d98.s15-2", "sentence_id": "DDI-DrugBank.d98.s15", "sentence": "Magnesium: Magnesium-containing preparations (eg, antacids) may cause hypermagnesemia and should therefore not be taken during therapy with vitamin D by patients on chronic renal dialysis.", "arg1": {"span": [[0, 9]], "type": "drug", "id": "DDI-DrugBank.d98.s15.e0"}, "arg2": {"span": [[140, 149]], "type": "group", "id": "DDI-DrugBank.d98.s15.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d98.s15-3", "sentence_id": "DDI-DrugBank.d98.s15", "sentence": "Magnesium: Magnesium-containing preparations (eg, antacids) may cause hypermagnesemia and should therefore not be taken during therapy with vitamin D by patients on chronic renal dialysis.", "arg1": {"span": [[11, 20]], "type": "drug", "id": "DDI-DrugBank.d98.s15.e1"}, "arg2": {"span": [[50, 58]], "type": "group", "id": "DDI-DrugBank.d98.s15.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d98.s15-4", "sentence_id": "DDI-DrugBank.d98.s15", "sentence": "Magnesium: Magnesium-containing preparations (eg, antacids) may cause hypermagnesemia and should therefore not be taken during therapy with vitamin D by patients on chronic renal dialysis.", "arg1": {"span": [[11, 20]], "type": "drug", "id": "DDI-DrugBank.d98.s15.e1"}, "arg2": {"span": [[140, 149]], "type": "group", "id": "DDI-DrugBank.d98.s15.e3"}, "ddi_label": 1, "ddi_type": "advise"}
{"id": "DDI-DrugBank.d98.s15-5", "sentence_id": "DDI-DrugBank.d98.s15", "sentence": "Magnesium: Magnesium-containing preparations (eg, antacids) may cause hypermagnesemia and should therefore not be taken during therapy with vitamin D by patients on chronic renal dialysis.", "arg1": {"span": [[50, 58]], "type": "group", "id": "DDI-DrugBank.d98.s15.e2"}, "arg2": {"span": [[140, 149]], "type": "group", "id": "DDI-DrugBank.d98.s15.e3"}, "ddi_label": 1, "ddi_type": "advise"}
{"id": "DDI-DrugBank.d281.s0-0", "sentence_id": "DDI-DrugBank.d281.s0", "sentence": "Probenecid may decrease renal tubular secretion of cephalosporins when used concurrently, resulting in increased and more prolonged cephalosporin blood levels.", "arg1": {"span": [[0, 10]], "type": "drug", "id": "DDI-DrugBank.d281.s0.e0"}, "arg2": {"span": [[51, 65]], "type": "group", "id": "DDI-DrugBank.d281.s0.e1"}, "ddi_label": 1, "ddi_type": "mechanism"}
{"id": "DDI-DrugBank.d281.s0-1", "sentence_id": "DDI-DrugBank.d281.s0", "sentence": "Probenecid may decrease renal tubular secretion of cephalosporins when used concurrently, resulting in increased and more prolonged cephalosporin blood levels.", "arg1": {"span": [[0, 10]], "type": "drug", "id": "DDI-DrugBank.d281.s0.e0"}, "arg2": {"span": [[132, 145]], "type": "group", "id": "DDI-DrugBank.d281.s0.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d281.s0-2", "sentence_id": "DDI-DrugBank.d281.s0", "sentence": "Probenecid may decrease renal tubular secretion of cephalosporins when used concurrently, resulting in increased and more prolonged cephalosporin blood levels.", "arg1": {"span": [[51, 65]], "type": "group", "id": "DDI-DrugBank.d281.s0.e1"}, "arg2": {"span": [[132, 145]], "type": "group", "id": "DDI-DrugBank.d281.s0.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d46.s1-0", "sentence_id": "DDI-DrugBank.d46.s1", "sentence": "- Alcohol, barbiturates, or narcotics: Potentiation of otthostatic hypotension may occur", "arg1": {"span": [[2, 9]], "type": "drug", "id": "DDI-DrugBank.d46.s1.e0"}, "arg2": {"span": [[11, 23]], "type": "group", "id": "DDI-DrugBank.d46.s1.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d46.s1-1", "sentence_id": "DDI-DrugBank.d46.s1", "sentence": "- Alcohol, barbiturates, or narcotics: Potentiation of otthostatic hypotension may occur", "arg1": {"span": [[2, 9]], "type": "drug", "id": "DDI-DrugBank.d46.s1.e0"}, "arg2": {"span": [[28, 37]], "type": "group", "id": "DDI-DrugBank.d46.s1.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d46.s1-2", "sentence_id": "DDI-DrugBank.d46.s1", "sentence": "- Alcohol, barbiturates, or narcotics: Potentiation of otthostatic hypotension may occur", "arg1": {"span": [[11, 23]], "type": "group", "id": "DDI-DrugBank.d46.s1.e1"}, "arg2": {"span": [[28, 37]], "type": "group", "id": "DDI-DrugBank.d46.s1.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d46.s3-0", "sentence_id": "DDI-DrugBank.d46.s3", "sentence": "- Antidiabetic drugs: (Oral agents and insulin) Dosage adjustment of the antidiabetic drug may be required", "arg1": {"span": [[2, 20]], "type": "group", "id": "DDI-DrugBank.d46.s3.e0"}, "arg2": {"span": [[39, 46]], "type": "drug", "id": "DDI-DrugBank.d46.s3.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d46.s3-1", "sentence_id": "DDI-DrugBank.d46.s3", "sentence": "- Antidiabetic drugs: (Oral agents and insulin) Dosage adjustment of the antidiabetic drug may be required", "arg1": {"span": [[2, 20]], "type": "group", "id": "DDI-DrugBank.d46.s3.e0"}, "arg2": {"span": [[73, 90]], "type": "group", "id": "DDI-DrugBank.d46.s3.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d46.s3-2", "sentence_id": "DDI-DrugBank.d46.s3", "sentence": "- Antidiabetic drugs: (Oral agents and insulin) Dosage adjustment of the antidiabetic drug may be required", "arg1": {"span": [[39, 46]], "type": "drug", "id": "DDI-DrugBank.d46.s3.e1"}, "arg2": {"span": [[73, 90]], "type": "group", "id": "DDI-DrugBank.d46.s3.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d46.s9-0", "sentence_id": "DDI-DrugBank.d46.s9", "sentence": "- Corticosteroids, ACTH: Intensified electrolyte depletion, particularly hypokalemia", "arg1": {"span": [[2, 17]], "type": "group", "id": "DDI-DrugBank.d46.s9.e0"}, "arg2": {"span": [[19, 23]], "type": "drug", "id": "DDI-DrugBank.d46.s9.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d46.s13-0", "sentence_id": "DDI-DrugBank.d46.s13", "sentence": "- Skeletal muscle relaxants, nondepolarizing (e.g., tubocurarine): Possible increased responsiveness to the muscle relaxant", "arg1": {"span": [[2, 27]], "type": "group", "id": "DDI-DrugBank.d46.s13.e0"}, "arg2": {"span": [[52, 64]], "type": "drug", "id": "DDI-DrugBank.d46.s13.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d46.s13-1", "sentence_id": "DDI-DrugBank.d46.s13", "sentence": "- Skeletal muscle relaxants, nondepolarizing (e.g., tubocurarine): Possible increased responsiveness to the muscle relaxant", "arg1": {"span": [[2, 27]], "type": "group", "id": "DDI-DrugBank.d46.s13.e0"}, "arg2": {"span": [[108, 123]], "type": "group", "id": "DDI-DrugBank.d46.s13.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d46.s13-2", "sentence_id": "DDI-DrugBank.d46.s13", "sentence": "- Skeletal muscle relaxants, nondepolarizing (e.g., tubocurarine): Possible increased responsiveness to the muscle relaxant", "arg1": {"span": [[52, 64]], "type": "drug", "id": "DDI-DrugBank.d46.s13.e1"}, "arg2": {"span": [[108, 123]], "type": "group", "id": "DDI-DrugBank.d46.s13.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d46.s15-0", "sentence_id": "DDI-DrugBank.d46.s15", "sentence": "- Lithium: Generally should not be given with diuretics.", "arg1": {"span": [[2, 9]], "type": "drug", "id": "DDI-DrugBank.d46.s15.e0"}, "arg2": {"span": [[46, 55]], "type": "group", "id": "DDI-DrugBank.d46.s15.e1"}, "ddi_label": 1, "ddi_type": "advise"}
{"id": "DDI-DrugBank.d46.s16-0", "sentence_id": "DDI-DrugBank.d46.s16", "sentence": "Diuretic agents reduce the renal clearance of lithium and add a high risk of lithium toxicity.", "arg1": {"span": [[0, 15]], "type": "group", "id": "DDI-DrugBank.d46.s16.e0"}, "arg2": {"span": [[46, 53]], "type": "drug", "id": "DDI-DrugBank.d46.s16.e1"}, "ddi_label": 1, "ddi_type": "mechanism"}
{"id": "DDI-DrugBank.d46.s16-1", "sentence_id": "DDI-DrugBank.d46.s16", "sentence": "Diuretic agents reduce the renal clearance of lithium and add a high risk of lithium toxicity.", "arg1": {"span": [[0, 15]], "type": "group", "id": "DDI-DrugBank.d46.s16.e0"}, "arg2": {"span": [[77, 84]], "type": "drug", "id": "DDI-DrugBank.d46.s16.e2"}, "ddi_label": 1, "ddi_type": "mechanism"}
{"id": "DDI-DrugBank.d46.s16-2", "sentence_id": "DDI-DrugBank.d46.s16", "sentence": "Diuretic agents reduce the renal clearance of lithium and add a high risk of lithium toxicity.", "arg1": {"span": [[46, 53]], "type": "drug", "id": "DDI-DrugBank.d46.s16.e1"}, "arg2": {"span": [[77, 84]], "type": "drug", "id": "DDI-DrugBank.d46.s16.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d46.s17-0", "sentence_id": "DDI-DrugBank.d46.s17", "sentence": "Refer to the package insert for lithium preparations before use of such preparations with chlorothiazide", "arg1": {"span": [[32, 39]], "type": "drug", "id": "DDI-DrugBank.d46.s17.e0"}, "arg2": {"span": [[90, 104]], "type": "drug", "id": "DDI-DrugBank.d46.s17.e1"}, "ddi_label": 1, "ddi_type": "advise"}
{"id": "DDI-DrugBank.d46.s19-0", "sentence_id": "DDI-DrugBank.d46.s19", "sentence": "- Non-steroidal Anti-inflammatory Drugs: In some patients, the administration of a non-steroidal anti-inflammatory agent can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium-sparing and thiazide diuretics.", "arg1": {"span": [[2, 39]], "type": "group", "id": "DDI-DrugBank.d46.s19.e0"}, "arg2": {"span": [[83, 120]], "type": "group", "id": "DDI-DrugBank.d46.s19.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d46.s19-1", "sentence_id": "DDI-DrugBank.d46.s19", "sentence": "- Non-steroidal Anti-inflammatory Drugs: In some patients, the administration of a non-steroidal anti-inflammatory agent can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium-sparing and thiazide diuretics.", "arg1": {"span": [[2, 39]], "type": "group", "id": "DDI-DrugBank.d46.s19.e0"}, "arg2": {"span": [[219, 237]], "type": "drug", "id": "DDI-DrugBank.d46.s19.e4"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d46.s19-2", "sentence_id": "DDI-DrugBank.d46.s19", "sentence": "- Non-steroidal Anti-inflammatory Drugs: In some patients, the administration of a non-steroidal anti-inflammatory agent can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium-sparing and thiazide diuretics.", "arg1": {"span": [[83, 120]], "type": "group", "id": "DDI-DrugBank.d46.s19.e1"}, "arg2": {"span": [[219, 237]], "type": "drug", "id": "DDI-DrugBank.d46.s19.e4"}, "ddi_label": 1, "ddi_type": "effect"}
{"id": "DDI-DrugBank.d46.s20-0", "sentence_id": "DDI-DrugBank.d46.s20", "sentence": "Therefore, when chlorothiazide and non-steroidal anti-inflammatory agents are used concomitantly, the patient should be observed closely to determine if the desired effect of the diuretic is obtained", "arg1": {"span": [[16, 30]], "type": "drug", "id": "DDI-DrugBank.d46.s20.e0"}, "arg2": {"span": [[35, 73]], "type": "group", "id": "DDI-DrugBank.d46.s20.e1"}, "ddi_label": 1, "ddi_type": "advise"}
{"id": "DDI-DrugBank.d46.s20-1", "sentence_id": "DDI-DrugBank.d46.s20", "sentence": "Therefore, when chlorothiazide and non-steroidal anti-inflammatory agents are used concomitantly, the patient should be observed closely to determine if the desired effect of the diuretic is obtained", "arg1": {"span": [[16, 30]], "type": "drug", "id": "DDI-DrugBank.d46.s20.e0"}, "arg2": {"span": [[179, 187]], "type": "group", "id": "DDI-DrugBank.d46.s20.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d46.s20-2", "sentence_id": "DDI-DrugBank.d46.s20", "sentence": "Therefore, when chlorothiazide and non-steroidal anti-inflammatory agents are used concomitantly, the patient should be observed closely to determine if the desired effect of the diuretic is obtained", "arg1": {"span": [[35, 73]], "type": "group", "id": "DDI-DrugBank.d46.s20.e1"}, "arg2": {"span": [[179, 187]], "type": "group", "id": "DDI-DrugBank.d46.s20.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d343.s0-0", "sentence_id": "DDI-DrugBank.d343.s0", "sentence": "Aspirin, warfarin, heparin, NSAIDs", "arg1": {"span": [[0, 7]], "type": "brand", "id": "DDI-DrugBank.d343.s0.e0"}, "arg2": {"span": [[9, 17]], "type": "drug", "id": "DDI-DrugBank.d343.s0.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d343.s0-1", "sentence_id": "DDI-DrugBank.d343.s0", "sentence": "Aspirin, warfarin, heparin, NSAIDs", "arg1": {"span": [[0, 7]], "type": "brand", "id": "DDI-DrugBank.d343.s0.e0"}, "arg2": {"span": [[19, 26]], "type": "drug", "id": "DDI-DrugBank.d343.s0.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d343.s0-2", "sentence_id": "DDI-DrugBank.d343.s0", "sentence": "Aspirin, warfarin, heparin, NSAIDs", "arg1": {"span": [[0, 7]], "type": "brand", "id": "DDI-DrugBank.d343.s0.e0"}, "arg2": {"span": [[28, 34]], "type": "group", "id": "DDI-DrugBank.d343.s0.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d343.s0-3", "sentence_id": "DDI-DrugBank.d343.s0", "sentence": "Aspirin, warfarin, heparin, NSAIDs", "arg1": {"span": [[9, 17]], "type": "drug", "id": "DDI-DrugBank.d343.s0.e1"}, "arg2": {"span": [[19, 26]], "type": "drug", "id": "DDI-DrugBank.d343.s0.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d343.s0-4", "sentence_id": "DDI-DrugBank.d343.s0", "sentence": "Aspirin, warfarin, heparin, NSAIDs", "arg1": {"span": [[9, 17]], "type": "drug", "id": "DDI-DrugBank.d343.s0.e1"}, "arg2": {"span": [[28, 34]], "type": "group", "id": "DDI-DrugBank.d343.s0.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d343.s0-5", "sentence_id": "DDI-DrugBank.d343.s0", "sentence": "Aspirin, warfarin, heparin, NSAIDs", "arg1": {"span": [[19, 26]], "type": "drug", "id": "DDI-DrugBank.d343.s0.e2"}, "arg2": {"span": [[28, 34]], "type": "group", "id": "DDI-DrugBank.d343.s0.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d439.s0-0", "sentence_id": "DDI-DrugBank.d439.s0", "sentence": "Corticotropin may accentuate the electrolyte loss associated with diuretic therapy.", "arg1": {"span": [[0, 13]], "type": "drug", "id": "DDI-DrugBank.d439.s0.e0"}, "arg2": {"span": [[66, 74]], "type": "group", "id": "DDI-DrugBank.d439.s0.e1"}, "ddi_label": 1, "ddi_type": "effect"}
{"id": "DDI-DrugBank.d386.s3-0", "sentence_id": "DDI-DrugBank.d386.s3", "sentence": "Poor metabolizers have higher than expected plasma concentrations of tricyclic antidepressants (TCAs) when given usual doses.", "arg1": {"span": [[69, 94]], "type": "group", "id": "DDI-DrugBank.d386.s3.e0"}, "arg2": {"span": [[96, 100]], "type": "group", "id": "DDI-DrugBank.d386.s3.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d386.s9-0", "sentence_id": "DDI-DrugBank.d386.s9", "sentence": "cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the Type 1C antiarrhythrnics propatenone and flecainide).", "arg1": {"span": [[0, 10]], "type": "drug", "id": "DDI-DrugBank.d386.s9.e0"}, "arg2": {"span": [[66, 81]], "type": "group", "id": "DDI-DrugBank.d386.s9.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d386.s9-1", "sentence_id": "DDI-DrugBank.d386.s9", "sentence": "cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the Type 1C antiarrhythrnics propatenone and flecainide).", "arg1": {"span": [[0, 10]], "type": "drug", "id": "DDI-DrugBank.d386.s9.e0"}, "arg2": {"span": [[83, 97]], "type": "group", "id": "DDI-DrugBank.d386.s9.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d386.s9-2", "sentence_id": "DDI-DrugBank.d386.s9", "sentence": "cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the Type 1C antiarrhythrnics propatenone and flecainide).", "arg1": {"span": [[0, 10]], "type": "drug", "id": "DDI-DrugBank.d386.s9.e0"}, "arg2": {"span": [[148, 158]], "type": "drug", "id": "DDI-DrugBank.d386.s9.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d386.s9-3", "sentence_id": "DDI-DrugBank.d386.s9", "sentence": "cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the Type 1C antiarrhythrnics propatenone and flecainide).", "arg1": {"span": [[66, 81]], "type": "group", "id": "DDI-DrugBank.d386.s9.e1"}, "arg2": {"span": [[83, 97]], "type": "group", "id": "DDI-DrugBank.d386.s9.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d386.s9-4", "sentence_id": "DDI-DrugBank.d386.s9", "sentence": "cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the Type 1C antiarrhythrnics propatenone and flecainide).", "arg1": {"span": [[66, 81]], "type": "group", "id": "DDI-DrugBank.d386.s9.e1"}, "arg2": {"span": [[148, 158]], "type": "drug", "id": "DDI-DrugBank.d386.s9.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d386.s9-5", "sentence_id": "DDI-DrugBank.d386.s9", "sentence": "cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the Type 1C antiarrhythrnics propatenone and flecainide).", "arg1": {"span": [[83, 97]], "type": "group", "id": "DDI-DrugBank.d386.s9.e2"}, "arg2": {"span": [[148, 158]], "type": "drug", "id": "DDI-DrugBank.d386.s9.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d386.s10-0", "sentence_id": "DDI-DrugBank.d386.s10", "sentence": "While all the selective serotonin reuptake inhibitors (SSRIs), e.g., fluoxetine, seriraline, and paroxetine, inhibit P450 2D6, they may vary in the extent of inhibition.", "arg1": {"span": [[14, 53]], "type": "group", "id": "DDI-DrugBank.d386.s10.e0"}, "arg2": {"span": [[55, 60]], "type": "group", "id": "DDI-DrugBank.d386.s10.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d386.s10-1", "sentence_id": "DDI-DrugBank.d386.s10", "sentence": "While all the selective serotonin reuptake inhibitors (SSRIs), e.g., fluoxetine, seriraline, and paroxetine, inhibit P450 2D6, they may vary in the extent of inhibition.", "arg1": {"span": [[14, 53]], "type": "group", "id": "DDI-DrugBank.d386.s10.e0"}, "arg2": {"span": [[69, 79]], "type": "drug", "id": "DDI-DrugBank.d386.s10.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d386.s10-2", "sentence_id": "DDI-DrugBank.d386.s10", "sentence": "While all the selective serotonin reuptake inhibitors (SSRIs), e.g., fluoxetine, seriraline, and paroxetine, inhibit P450 2D6, they may vary in the extent of inhibition.", "arg1": {"span": [[14, 53]], "type": "group", "id": "DDI-DrugBank.d386.s10.e0"}, "arg2": {"span": [[97, 107]], "type": "drug", "id": "DDI-DrugBank.d386.s10.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d386.s10-3", "sentence_id": "DDI-DrugBank.d386.s10", "sentence": "While all the selective serotonin reuptake inhibitors (SSRIs), e.g., fluoxetine, seriraline, and paroxetine, inhibit P450 2D6, they may vary in the extent of inhibition.", "arg1": {"span": [[55, 60]], "type": "group", "id": "DDI-DrugBank.d386.s10.e1"}, "arg2": {"span": [[69, 79]], "type": "drug", "id": "DDI-DrugBank.d386.s10.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d386.s10-4", "sentence_id": "DDI-DrugBank.d386.s10", "sentence": "While all the selective serotonin reuptake inhibitors (SSRIs), e.g., fluoxetine, seriraline, and paroxetine, inhibit P450 2D6, they may vary in the extent of inhibition.", "arg1": {"span": [[55, 60]], "type": "group", "id": "DDI-DrugBank.d386.s10.e1"}, "arg2": {"span": [[97, 107]], "type": "drug", "id": "DDI-DrugBank.d386.s10.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d386.s10-5", "sentence_id": "DDI-DrugBank.d386.s10", "sentence": "While all the selective serotonin reuptake inhibitors (SSRIs), e.g., fluoxetine, seriraline, and paroxetine, inhibit P450 2D6, they may vary in the extent of inhibition.", "arg1": {"span": [[69, 79]], "type": "drug", "id": "DDI-DrugBank.d386.s10.e2"}, "arg2": {"span": [[97, 107]], "type": "drug", "id": "DDI-DrugBank.d386.s10.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d386.s11-0", "sentence_id": "DDI-DrugBank.d386.s11", "sentence": "The extent to which SSRI-TCA interactions may pose clinical problems will depend on the degree of inhibition and the pharmacokinetics of the SSRI involved.", "arg1": {"span": [[20, 24]], "type": "group", "id": "DDI-DrugBank.d386.s11.e0"}, "arg2": {"span": [[25, 28]], "type": "group", "id": "DDI-DrugBank.d386.s11.e1"}, "ddi_label": 1, "ddi_type": "int"}
{"id": "DDI-DrugBank.d386.s11-1", "sentence_id": "DDI-DrugBank.d386.s11", "sentence": "The extent to which SSRI-TCA interactions may pose clinical problems will depend on the degree of inhibition and the pharmacokinetics of the SSRI involved.", "arg1": {"span": [[20, 24]], "type": "group", "id": "DDI-DrugBank.d386.s11.e0"}, "arg2": {"span": [[141, 145]], "type": "group", "id": "DDI-DrugBank.d386.s11.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d386.s11-2", "sentence_id": "DDI-DrugBank.d386.s11", "sentence": "The extent to which SSRI-TCA interactions may pose clinical problems will depend on the degree of inhibition and the pharmacokinetics of the SSRI involved.", "arg1": {"span": [[25, 28]], "type": "group", "id": "DDI-DrugBank.d386.s11.e1"}, "arg2": {"span": [[141, 145]], "type": "group", "id": "DDI-DrugBank.d386.s11.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d386.s12-0", "sentence_id": "DDI-DrugBank.d386.s12", "sentence": "Nevertheless, caution is indicated in the co-administration of T.A. with any of the SSRIs and also in switching from one class to the other.", "arg1": {"span": [[63, 67]], "type": "group", "id": "DDI-DrugBank.d386.s12.e0"}, "arg2": {"span": [[84, 89]], "type": "group", "id": "DDI-DrugBank.d386.s12.e1"}, "ddi_label": 1, "ddi_type": "advise"}
{"id": "DDI-DrugBank.d386.s14-0", "sentence_id": "DDI-DrugBank.d386.s14", "sentence": "Concomitant use of tricyclic antidepressants with drugs that can inhibit cytochrome P450 2D6 may require lower doses than usually prescribed for either the tricyclic antidepressant or the other drug.", "arg1": {"span": [[19, 44]], "type": "group", "id": "DDI-DrugBank.d386.s14.e0"}, "arg2": {"span": [[156, 180]], "type": "group", "id": "DDI-DrugBank.d386.s14.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d386.s16-0", "sentence_id": "DDI-DrugBank.d386.s16", "sentence": "It is desirable to monitor TCA plasma levels whenever a TCA is going to be co-administered with another drug known to be an inhibitor of P450 2D6.", "arg1": {"span": [[27, 30]], "type": "group", "id": "DDI-DrugBank.d386.s16.e0"}, "arg2": {"span": [[56, 59]], "type": "group", "id": "DDI-DrugBank.d386.s16.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d386.s18-0", "sentence_id": "DDI-DrugBank.d386.s18", "sentence": "Close supervision and careful adjustment of dosage are required when this drug is given concomitantly with anticholinergic or sympathomimetic drugs.", "arg1": {"span": [[107, 122]], "type": "group", "id": "DDI-DrugBank.d386.s18.e0"}, "arg2": {"span": [[126, 147]], "type": "group", "id": "DDI-DrugBank.d386.s18.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d386.s24-0", "sentence_id": "DDI-DrugBank.d386.s24", "sentence": "Both the sedative and anticholinergic effects of the major tranquilizers are also additive to those of desipramine.", "arg1": {"span": [[53, 72]], "type": "group", "id": "DDI-DrugBank.d386.s24.e0"}, "arg2": {"span": [[103, 114]], "type": "drug", "id": "DDI-DrugBank.d386.s24.e1"}, "ddi_label": 1, "ddi_type": "effect"}
{"id": "DDI-DrugBank.d386.s26-0", "sentence_id": "DDI-DrugBank.d386.s26", "sentence": "Concurrent administration of cimetidine and tricyclic antidepressants can produce clinically significant increases in the plasma levels of the tricyclic antidepressants.", "arg1": {"span": [[29, 39]], "type": "drug", "id": "DDI-DrugBank.d386.s26.e0"}, "arg2": {"span": [[44, 69]], "type": "group", "id": "DDI-DrugBank.d386.s26.e1"}, "ddi_label": 1, "ddi_type": "mechanism"}
{"id": "DDI-DrugBank.d386.s26-1", "sentence_id": "DDI-DrugBank.d386.s26", "sentence": "Concurrent administration of cimetidine and tricyclic antidepressants can produce clinically significant increases in the plasma levels of the tricyclic antidepressants.", "arg1": {"span": [[29, 39]], "type": "drug", "id": "DDI-DrugBank.d386.s26.e0"}, "arg2": {"span": [[143, 168]], "type": "group", "id": "DDI-DrugBank.d386.s26.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d386.s26-2", "sentence_id": "DDI-DrugBank.d386.s26", "sentence": "Concurrent administration of cimetidine and tricyclic antidepressants can produce clinically significant increases in the plasma levels of the tricyclic antidepressants.", "arg1": {"span": [[44, 69]], "type": "group", "id": "DDI-DrugBank.d386.s26.e1"}, "arg2": {"span": [[143, 168]], "type": "group", "id": "DDI-DrugBank.d386.s26.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d386.s27-0", "sentence_id": "DDI-DrugBank.d386.s27", "sentence": "Conversely, decreases in plasma levels of the tricyclic antidepressants have been reported upon discontinuation of cimetidine which may result in the loss of the therapeutic efficacy of the tricyclic antidepressant 6.", "arg1": {"span": [[46, 71]], "type": "group", "id": "DDI-DrugBank.d386.s27.e0"}, "arg2": {"span": [[115, 125]], "type": "drug", "id": "DDI-DrugBank.d386.s27.e1"}, "ddi_label": 1, "ddi_type": "mechanism"}
{"id": "DDI-DrugBank.d386.s27-1", "sentence_id": "DDI-DrugBank.d386.s27", "sentence": "Conversely, decreases in plasma levels of the tricyclic antidepressants have been reported upon discontinuation of cimetidine which may result in the loss of the therapeutic efficacy of the tricyclic antidepressant 6.", "arg1": {"span": [[46, 71]], "type": "group", "id": "DDI-DrugBank.d386.s27.e0"}, "arg2": {"span": [[190, 214]], "type": "group", "id": "DDI-DrugBank.d386.s27.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d386.s27-2", "sentence_id": "DDI-DrugBank.d386.s27", "sentence": "Conversely, decreases in plasma levels of the tricyclic antidepressants have been reported upon discontinuation of cimetidine which may result in the loss of the therapeutic efficacy of the tricyclic antidepressant 6.", "arg1": {"span": [[115, 125]], "type": "drug", "id": "DDI-DrugBank.d386.s27.e1"}, "arg2": {"span": [[190, 214]], "type": "group", "id": "DDI-DrugBank.d386.s27.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d386.s28-0", "sentence_id": "DDI-DrugBank.d386.s28", "sentence": "There have been greater than two-fold increases of previously stable plasma levels of tricyclic antidepressants when fluoxetine has been administered in combination with these agents.", "arg1": {"span": [[86, 111]], "type": "group", "id": "DDI-DrugBank.d386.s28.e0"}, "arg2": {"span": [[117, 127]], "type": "drug", "id": "DDI-DrugBank.d386.s28.e1"}, "ddi_label": 1, "ddi_type": "mechanism"}
{"id": "DDI-DrugBank.d166.s0-0", "sentence_id": "DDI-DrugBank.d166.s0", "sentence": "Trecator has been found to temporarily raise serum concentrations of isoniazid.", "arg1": {"span": [[0, 8]], "type": "brand", "id": "DDI-DrugBank.d166.s0.e0"}, "arg2": {"span": [[69, 78]], "type": "drug", "id": "DDI-DrugBank.d166.s0.e1"}, "ddi_label": 1, "ddi_type": "mechanism"}
{"id": "DDI-DrugBank.d166.s1-0", "sentence_id": "DDI-DrugBank.d166.s1", "sentence": "Trecator may potentiate the adverse effects of other antituberculous drugs administered concomitantly.", "arg1": {"span": [[0, 8]], "type": "brand", "id": "DDI-DrugBank.d166.s1.e0"}, "arg2": {"span": [[53, 74]], "type": "group", "id": "DDI-DrugBank.d166.s1.e1"}, "ddi_label": 1, "ddi_type": "effect"}
{"id": "DDI-DrugBank.d166.s2-0", "sentence_id": "DDI-DrugBank.d166.s2", "sentence": "In particular, convulsions have been reported when ethionamide is administered with cycloserine and special care should be taken when the treatment regimen includes both of these drugs.", "arg1": {"span": [[51, 62]], "type": "drug", "id": "DDI-DrugBank.d166.s2.e0"}, "arg2": {"span": [[84, 95]], "type": "drug", "id": "DDI-DrugBank.d166.s2.e1"}, "ddi_label": 1, "ddi_type": "effect"}
{"id": "DDI-DrugBank.d199.s0-0", "sentence_id": "DDI-DrugBank.d199.s0", "sentence": "Metoclopramide: When coadministered with MONUROL, metoclopramide, a drug which increases gastrointestinal motility, lowers the serum concentration and urinary excretion of fosfomycin.", "arg1": {"span": [[0, 14]], "type": "drug", "id": "DDI-DrugBank.d199.s0.e0"}, "arg2": {"span": [[41, 48]], "type": "brand", "id": "DDI-DrugBank.d199.s0.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d199.s0-1", "sentence_id": "DDI-DrugBank.d199.s0", "sentence": "Metoclopramide: When coadministered with MONUROL, metoclopramide, a drug which increases gastrointestinal motility, lowers the serum concentration and urinary excretion of fosfomycin.", "arg1": {"span": [[0, 14]], "type": "drug", "id": "DDI-DrugBank.d199.s0.e0"}, "arg2": {"span": [[50, 64]], "type": "drug", "id": "DDI-DrugBank.d199.s0.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d199.s0-2", "sentence_id": "DDI-DrugBank.d199.s0", "sentence": "Metoclopramide: When coadministered with MONUROL, metoclopramide, a drug which increases gastrointestinal motility, lowers the serum concentration and urinary excretion of fosfomycin.", "arg1": {"span": [[0, 14]], "type": "drug", "id": "DDI-DrugBank.d199.s0.e0"}, "arg2": {"span": [[172, 182]], "type": "drug", "id": "DDI-DrugBank.d199.s0.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d199.s0-3", "sentence_id": "DDI-DrugBank.d199.s0", "sentence": "Metoclopramide: When coadministered with MONUROL, metoclopramide, a drug which increases gastrointestinal motility, lowers the serum concentration and urinary excretion of fosfomycin.", "arg1": {"span": [[41, 48]], "type": "brand", "id": "DDI-DrugBank.d199.s0.e1"}, "arg2": {"span": [[50, 64]], "type": "drug", "id": "DDI-DrugBank.d199.s0.e2"}, "ddi_label": 1, "ddi_type": "mechanism"}
{"id": "DDI-DrugBank.d199.s0-4", "sentence_id": "DDI-DrugBank.d199.s0", "sentence": "Metoclopramide: When coadministered with MONUROL, metoclopramide, a drug which increases gastrointestinal motility, lowers the serum concentration and urinary excretion of fosfomycin.", "arg1": {"span": [[41, 48]], "type": "brand", "id": "DDI-DrugBank.d199.s0.e1"}, "arg2": {"span": [[172, 182]], "type": "drug", "id": "DDI-DrugBank.d199.s0.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d199.s0-5", "sentence_id": "DDI-DrugBank.d199.s0", "sentence": "Metoclopramide: When coadministered with MONUROL, metoclopramide, a drug which increases gastrointestinal motility, lowers the serum concentration and urinary excretion of fosfomycin.", "arg1": {"span": [[50, 64]], "type": "drug", "id": "DDI-DrugBank.d199.s0.e2"}, "arg2": {"span": [[172, 182]], "type": "drug", "id": "DDI-DrugBank.d199.s0.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d199.s2-0", "sentence_id": "DDI-DrugBank.d199.s2", "sentence": "Cimetidine: Cimetidine does not affect the pharmacokinetics of fosfomycin when coadministered with MONUROL.", "arg1": {"span": [[0, 10]], "type": "drug", "id": "DDI-DrugBank.d199.s2.e0"}, "arg2": {"span": [[12, 22]], "type": "drug", "id": "DDI-DrugBank.d199.s2.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d199.s2-1", "sentence_id": "DDI-DrugBank.d199.s2", "sentence": "Cimetidine: Cimetidine does not affect the pharmacokinetics of fosfomycin when coadministered with MONUROL.", "arg1": {"span": [[0, 10]], "type": "drug", "id": "DDI-DrugBank.d199.s2.e0"}, "arg2": {"span": [[63, 73]], "type": "drug", "id": "DDI-DrugBank.d199.s2.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d199.s2-2", "sentence_id": "DDI-DrugBank.d199.s2", "sentence": "Cimetidine: Cimetidine does not affect the pharmacokinetics of fosfomycin when coadministered with MONUROL.", "arg1": {"span": [[0, 10]], "type": "drug", "id": "DDI-DrugBank.d199.s2.e0"}, "arg2": {"span": [[99, 106]], "type": "brand", "id": "DDI-DrugBank.d199.s2.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d199.s2-3", "sentence_id": "DDI-DrugBank.d199.s2", "sentence": "Cimetidine: Cimetidine does not affect the pharmacokinetics of fosfomycin when coadministered with MONUROL.", "arg1": {"span": [[12, 22]], "type": "drug", "id": "DDI-DrugBank.d199.s2.e1"}, "arg2": {"span": [[63, 73]], "type": "drug", "id": "DDI-DrugBank.d199.s2.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d199.s2-4", "sentence_id": "DDI-DrugBank.d199.s2", "sentence": "Cimetidine: Cimetidine does not affect the pharmacokinetics of fosfomycin when coadministered with MONUROL.", "arg1": {"span": [[12, 22]], "type": "drug", "id": "DDI-DrugBank.d199.s2.e1"}, "arg2": {"span": [[99, 106]], "type": "brand", "id": "DDI-DrugBank.d199.s2.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d199.s2-5", "sentence_id": "DDI-DrugBank.d199.s2", "sentence": "Cimetidine: Cimetidine does not affect the pharmacokinetics of fosfomycin when coadministered with MONUROL.", "arg1": {"span": [[63, 73]], "type": "drug", "id": "DDI-DrugBank.d199.s2.e2"}, "arg2": {"span": [[99, 106]], "type": "brand", "id": "DDI-DrugBank.d199.s2.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d178.s7-0", "sentence_id": "DDI-DrugBank.d178.s7", "sentence": "A possible interaction between glyburide and ciprofloxacin, a fluoroquinolone antibiotic, has been reported, resulting in a potentiation of the hypoglycemic action of glyburide.", "arg1": {"span": [[31, 40]], "type": "drug", "id": "DDI-DrugBank.d178.s7.e0"}, "arg2": {"span": [[45, 58]], "type": "drug", "id": "DDI-DrugBank.d178.s7.e1"}, "ddi_label": 1, "ddi_type": "int"}
{"id": "DDI-DrugBank.d178.s7-1", "sentence_id": "DDI-DrugBank.d178.s7", "sentence": "A possible interaction between glyburide and ciprofloxacin, a fluoroquinolone antibiotic, has been reported, resulting in a potentiation of the hypoglycemic action of glyburide.", "arg1": {"span": [[31, 40]], "type": "drug", "id": "DDI-DrugBank.d178.s7.e0"}, "arg2": {"span": [[62, 88]], "type": "group", "id": "DDI-DrugBank.d178.s7.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d178.s7-2", "sentence_id": "DDI-DrugBank.d178.s7", "sentence": "A possible interaction between glyburide and ciprofloxacin, a fluoroquinolone antibiotic, has been reported, resulting in a potentiation of the hypoglycemic action of glyburide.", "arg1": {"span": [[31, 40]], "type": "drug", "id": "DDI-DrugBank.d178.s7.e0"}, "arg2": {"span": [[167, 176]], "type": "drug", "id": "DDI-DrugBank.d178.s7.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d178.s7-3", "sentence_id": "DDI-DrugBank.d178.s7", "sentence": "A possible interaction between glyburide and ciprofloxacin, a fluoroquinolone antibiotic, has been reported, resulting in a potentiation of the hypoglycemic action of glyburide.", "arg1": {"span": [[45, 58]], "type": "drug", "id": "DDI-DrugBank.d178.s7.e1"}, "arg2": {"span": [[62, 88]], "type": "group", "id": "DDI-DrugBank.d178.s7.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d178.s7-4", "sentence_id": "DDI-DrugBank.d178.s7", "sentence": "A possible interaction between glyburide and ciprofloxacin, a fluoroquinolone antibiotic, has been reported, resulting in a potentiation of the hypoglycemic action of glyburide.", "arg1": {"span": [[45, 58]], "type": "drug", "id": "DDI-DrugBank.d178.s7.e1"}, "arg2": {"span": [[167, 176]], "type": "drug", "id": "DDI-DrugBank.d178.s7.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d178.s7-5", "sentence_id": "DDI-DrugBank.d178.s7", "sentence": "A possible interaction between glyburide and ciprofloxacin, a fluoroquinolone antibiotic, has been reported, resulting in a potentiation of the hypoglycemic action of glyburide.", "arg1": {"span": [[62, 88]], "type": "group", "id": "DDI-DrugBank.d178.s7.e2"}, "arg2": {"span": [[167, 176]], "type": "drug", "id": "DDI-DrugBank.d178.s7.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d178.s9-0", "sentence_id": "DDI-DrugBank.d178.s9", "sentence": "A potential interaction between oral miconazole and oral hypoglycemic agents leading to severe hypoglycemia has been reported.", "arg1": {"span": [[37, 47]], "type": "drug", "id": "DDI-DrugBank.d178.s9.e0"}, "arg2": {"span": [[57, 76]], "type": "group", "id": "DDI-DrugBank.d178.s9.e1"}, "ddi_label": 1, "ddi_type": "effect"}
{"id": "DDI-DrugBank.d178.s11-0", "sentence_id": "DDI-DrugBank.d178.s11", "sentence": "Metformin: In a single-dose interaction study in NIDDM subjects, decreases in glyburide AUC and Cmax were observed, but were highly variable.", "arg1": {"span": [[0, 9]], "type": "drug", "id": "DDI-DrugBank.d178.s11.e0"}, "arg2": {"span": [[78, 87]], "type": "drug", "id": "DDI-DrugBank.d178.s11.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d178.s13-0", "sentence_id": "DDI-DrugBank.d178.s13", "sentence": "Coadministration of gly-buride and metformin did not result in any changes in either metformin pharmacokinetics or pharmaco-dynamics.", "arg1": {"span": [[35, 44]], "type": "drug", "id": "DDI-DrugBank.d178.s13.e0"}, "arg2": {"span": [[85, 94]], "type": "drug", "id": "DDI-DrugBank.d178.s13.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d135.s0-0", "sentence_id": "DDI-DrugBank.d135.s0", "sentence": "Effects of Lapatinib on Drug Metabolizing Enzymes and Drug Transport Systems Lapatinib inhibits CYP3A4 and CYP2C8 in vitro at clinically relevant concentrations.", "arg1": {"span": [[11, 20]], "type": "drug", "id": "DDI-DrugBank.d135.s0.e0"}, "arg2": {"span": [[77, 86]], "type": "drug", "id": "DDI-DrugBank.d135.s0.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d135.s5-0", "sentence_id": "DDI-DrugBank.d135.s5", "sentence": "Drugs that Inhibit or Induce Cytochrome P450 3A4 Enzymes Lapatinib undergoes extensive metabolism by CYP3A4, and concomitant administration of strong inhibitors or inducers of CYP3A4 alter lapatinib concentrations significantly.", "arg1": {"span": [[57, 66]], "type": "drug", "id": "DDI-DrugBank.d135.s5.e0"}, "arg2": {"span": [[189, 198]], "type": "drug", "id": "DDI-DrugBank.d135.s5.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d135.s7-0", "sentence_id": "DDI-DrugBank.d135.s7", "sentence": "Ketoconazole: In healthy subjects receiving ketoconazole, a CYP3A4 inhibitor, at 200 mg twice daily for 7 days, systemic exposure (AUC) to lapatinib was increased to approximately 3.6-fold of control and half-life increased to 1.7-fold of control.", "arg1": {"span": [[0, 12]], "type": "drug", "id": "DDI-DrugBank.d135.s7.e0"}, "arg2": {"span": [[44, 56]], "type": "drug", "id": "DDI-DrugBank.d135.s7.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d135.s7-1", "sentence_id": "DDI-DrugBank.d135.s7", "sentence": "Ketoconazole: In healthy subjects receiving ketoconazole, a CYP3A4 inhibitor, at 200 mg twice daily for 7 days, systemic exposure (AUC) to lapatinib was increased to approximately 3.6-fold of control and half-life increased to 1.7-fold of control.", "arg1": {"span": [[0, 12]], "type": "drug", "id": "DDI-DrugBank.d135.s7.e0"}, "arg2": {"span": [[139, 148]], "type": "drug", "id": "DDI-DrugBank.d135.s7.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d135.s7-2", "sentence_id": "DDI-DrugBank.d135.s7", "sentence": "Ketoconazole: In healthy subjects receiving ketoconazole, a CYP3A4 inhibitor, at 200 mg twice daily for 7 days, systemic exposure (AUC) to lapatinib was increased to approximately 3.6-fold of control and half-life increased to 1.7-fold of control.", "arg1": {"span": [[44, 56]], "type": "drug", "id": "DDI-DrugBank.d135.s7.e1"}, "arg2": {"span": [[139, 148]], "type": "drug", "id": "DDI-DrugBank.d135.s7.e2"}, "ddi_label": 1, "ddi_type": "mechanism"}
{"id": "DDI-DrugBank.d135.s8-0", "sentence_id": "DDI-DrugBank.d135.s8", "sentence": "Carbamazepine: In healthy subjects receiving the CYP3A4 inducer, carbamazepine, at 100 mg twice daily for 3 days and 200 mg twice daily for 17 days, systemic exposure (AUC) to lapatinib was decreased approximately 72%.", "arg1": {"span": [[0, 13]], "type": "drug", "id": "DDI-DrugBank.d135.s8.e0"}, "arg2": {"span": [[65, 78]], "type": "drug", "id": "DDI-DrugBank.d135.s8.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d135.s8-1", "sentence_id": "DDI-DrugBank.d135.s8", "sentence": "Carbamazepine: In healthy subjects receiving the CYP3A4 inducer, carbamazepine, at 100 mg twice daily for 3 days and 200 mg twice daily for 17 days, systemic exposure (AUC) to lapatinib was decreased approximately 72%.", "arg1": {"span": [[0, 13]], "type": "drug", "id": "DDI-DrugBank.d135.s8.e0"}, "arg2": {"span": [[176, 185]], "type": "drug", "id": "DDI-DrugBank.d135.s8.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d135.s8-2", "sentence_id": "DDI-DrugBank.d135.s8", "sentence": "Carbamazepine: In healthy subjects receiving the CYP3A4 inducer, carbamazepine, at 100 mg twice daily for 3 days and 200 mg twice daily for 17 days, systemic exposure (AUC) to lapatinib was decreased approximately 72%.", "arg1": {"span": [[65, 78]], "type": "drug", "id": "DDI-DrugBank.d135.s8.e1"}, "arg2": {"span": [[176, 185]], "type": "drug", "id": "DDI-DrugBank.d135.s8.e2"}, "ddi_label": 1, "ddi_type": "mechanism"}
{"id": "DDI-DrugBank.d135.s10-0", "sentence_id": "DDI-DrugBank.d135.s10", "sentence": "If TYKERB is administered with drugs that inhibit Pgp, increased concentrations of lapatinib are likely, and caution should be exercised.", "arg1": {"span": [[3, 9]], "type": "brand", "id": "DDI-DrugBank.d135.s10.e0"}, "arg2": {"span": [[83, 92]], "type": "drug", "id": "DDI-DrugBank.d135.s10.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d135.s11-0", "sentence_id": "DDI-DrugBank.d135.s11", "sentence": "Other Chemotherapy Agents In a separate study, concomitant administration of lapatinib with capecitabine did not meaningfully alter the pharmacokinetics of either agent (or the metabolites of capecitabine).", "arg1": {"span": [[77, 86]], "type": "drug", "id": "DDI-DrugBank.d135.s11.e0"}, "arg2": {"span": [[92, 104]], "type": "drug", "id": "DDI-DrugBank.d135.s11.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d135.s11-1", "sentence_id": "DDI-DrugBank.d135.s11", "sentence": "Other Chemotherapy Agents In a separate study, concomitant administration of lapatinib with capecitabine did not meaningfully alter the pharmacokinetics of either agent (or the metabolites of capecitabine).", "arg1": {"span": [[77, 86]], "type": "drug", "id": "DDI-DrugBank.d135.s11.e0"}, "arg2": {"span": [[192, 204]], "type": "drug", "id": "DDI-DrugBank.d135.s11.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d135.s11-2", "sentence_id": "DDI-DrugBank.d135.s11", "sentence": "Other Chemotherapy Agents In a separate study, concomitant administration of lapatinib with capecitabine did not meaningfully alter the pharmacokinetics of either agent (or the metabolites of capecitabine).", "arg1": {"span": [[92, 104]], "type": "drug", "id": "DDI-DrugBank.d135.s11.e1"}, "arg2": {"span": [[192, 204]], "type": "drug", "id": "DDI-DrugBank.d135.s11.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d261.s0-0", "sentence_id": "DDI-DrugBank.d261.s0", "sentence": "Tetracycline, a bacteriostatic antibiotic, may antagonize the bactericidal effect of penicillin and concurrent use of these drugs should be avoided.", "arg1": {"span": [[0, 12]], "type": "drug", "id": "DDI-DrugBank.d261.s0.e0"}, "arg2": {"span": [[16, 41]], "type": "group", "id": "DDI-DrugBank.d261.s0.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d261.s0-1", "sentence_id": "DDI-DrugBank.d261.s0", "sentence": "Tetracycline, a bacteriostatic antibiotic, may antagonize the bactericidal effect of penicillin and concurrent use of these drugs should be avoided.", "arg1": {"span": [[0, 12]], "type": "drug", "id": "DDI-DrugBank.d261.s0.e0"}, "arg2": {"span": [[85, 95]], "type": "drug", "id": "DDI-DrugBank.d261.s0.e2"}, "ddi_label": 1, "ddi_type": "effect"}
{"id": "DDI-DrugBank.d261.s0-2", "sentence_id": "DDI-DrugBank.d261.s0", "sentence": "Tetracycline, a bacteriostatic antibiotic, may antagonize the bactericidal effect of penicillin and concurrent use of these drugs should be avoided.", "arg1": {"span": [[16, 41]], "type": "group", "id": "DDI-DrugBank.d261.s0.e1"}, "arg2": {"span": [[85, 95]], "type": "drug", "id": "DDI-DrugBank.d261.s0.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d198.s4-0", "sentence_id": "DDI-DrugBank.d198.s4", "sentence": "Cimetidine (400 mg b.i.d.) had no effect on vardenafil bioavailability (AUC) and maximum concentration (Cmax) of vardenafil when co-administered with 20 mg Vardenafil in healthy volunteers.", "arg1": {"span": [[0, 10]], "type": "drug", "id": "DDI-DrugBank.d198.s4.e0"}, "arg2": {"span": [[44, 54]], "type": "drug", "id": "DDI-DrugBank.d198.s4.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d198.s4-1", "sentence_id": "DDI-DrugBank.d198.s4", "sentence": "Cimetidine (400 mg b.i.d.) had no effect on vardenafil bioavailability (AUC) and maximum concentration (Cmax) of vardenafil when co-administered with 20 mg Vardenafil in healthy volunteers.", "arg1": {"span": [[0, 10]], "type": "drug", "id": "DDI-DrugBank.d198.s4.e0"}, "arg2": {"span": [[113, 123]], "type": "drug", "id": "DDI-DrugBank.d198.s4.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d198.s4-2", "sentence_id": "DDI-DrugBank.d198.s4", "sentence": "Cimetidine (400 mg b.i.d.) had no effect on vardenafil bioavailability (AUC) and maximum concentration (Cmax) of vardenafil when co-administered with 20 mg Vardenafil in healthy volunteers.", "arg1": {"span": [[0, 10]], "type": "drug", "id": "DDI-DrugBank.d198.s4.e0"}, "arg2": {"span": [[156, 166]], "type": "drug", "id": "DDI-DrugBank.d198.s4.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d198.s4-3", "sentence_id": "DDI-DrugBank.d198.s4", "sentence": "Cimetidine (400 mg b.i.d.) had no effect on vardenafil bioavailability (AUC) and maximum concentration (Cmax) of vardenafil when co-administered with 20 mg Vardenafil in healthy volunteers.", "arg1": {"span": [[44, 54]], "type": "drug", "id": "DDI-DrugBank.d198.s4.e1"}, "arg2": {"span": [[113, 123]], "type": "drug", "id": "DDI-DrugBank.d198.s4.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d198.s4-4", "sentence_id": "DDI-DrugBank.d198.s4", "sentence": "Cimetidine (400 mg b.i.d.) had no effect on vardenafil bioavailability (AUC) and maximum concentration (Cmax) of vardenafil when co-administered with 20 mg Vardenafil in healthy volunteers.", "arg1": {"span": [[44, 54]], "type": "drug", "id": "DDI-DrugBank.d198.s4.e1"}, "arg2": {"span": [[156, 166]], "type": "drug", "id": "DDI-DrugBank.d198.s4.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d198.s4-5", "sentence_id": "DDI-DrugBank.d198.s4", "sentence": "Cimetidine (400 mg b.i.d.) had no effect on vardenafil bioavailability (AUC) and maximum concentration (Cmax) of vardenafil when co-administered with 20 mg Vardenafil in healthy volunteers.", "arg1": {"span": [[113, 123]], "type": "drug", "id": "DDI-DrugBank.d198.s4.e2"}, "arg2": {"span": [[156, 166]], "type": "drug", "id": "DDI-DrugBank.d198.s4.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d198.s5-0", "sentence_id": "DDI-DrugBank.d198.s5", "sentence": "Erythromycin (500 mg t.i.d) produced a 4-fold increase in vardenafil AUC and a 3-fold increase in Cmax when co-administered with Vardenafil 5 mg in healthy volunteers.", "arg1": {"span": [[0, 12]], "type": "drug", "id": "DDI-DrugBank.d198.s5.e0"}, "arg2": {"span": [[58, 68]], "type": "drug", "id": "DDI-DrugBank.d198.s5.e1"}, "ddi_label": 1, "ddi_type": "mechanism"}
{"id": "DDI-DrugBank.d198.s5-1", "sentence_id": "DDI-DrugBank.d198.s5", "sentence": "Erythromycin (500 mg t.i.d) produced a 4-fold increase in vardenafil AUC and a 3-fold increase in Cmax when co-administered with Vardenafil 5 mg in healthy volunteers.", "arg1": {"span": [[0, 12]], "type": "drug", "id": "DDI-DrugBank.d198.s5.e0"}, "arg2": {"span": [[129, 139]], "type": "drug", "id": "DDI-DrugBank.d198.s5.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d198.s5-2", "sentence_id": "DDI-DrugBank.d198.s5", "sentence": "Erythromycin (500 mg t.i.d) produced a 4-fold increase in vardenafil AUC and a 3-fold increase in Cmax when co-administered with Vardenafil 5 mg in healthy volunteers.", "arg1": {"span": [[58, 68]], "type": "drug", "id": "DDI-DrugBank.d198.s5.e1"}, "arg2": {"span": [[129, 139]], "type": "drug", "id": "DDI-DrugBank.d198.s5.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d198.s6-0", "sentence_id": "DDI-DrugBank.d198.s6", "sentence": "It is recommended not to exceed a single 5 mg dose of Vardenafil in a 24-hour period when used in combination with erythromycin.", "arg1": {"span": [[54, 64]], "type": "drug", "id": "DDI-DrugBank.d198.s6.e0"}, "arg2": {"span": [[115, 127]], "type": "drug", "id": "DDI-DrugBank.d198.s6.e1"}, "ddi_label": 1, "ddi_type": "advise"}
{"id": "DDI-DrugBank.d198.s7-0", "sentence_id": "DDI-DrugBank.d198.s7", "sentence": "Ketoconazole (200 mg once daily) produced a 10-fold increase in vardenafil AUC and a 4-fold increase in Cmax when co-administered with Vardenafil (5 mg) in healthy volunteers.", "arg1": {"span": [[0, 12]], "type": "drug", "id": "DDI-DrugBank.d198.s7.e0"}, "arg2": {"span": [[64, 74]], "type": "drug", "id": "DDI-DrugBank.d198.s7.e1"}, "ddi_label": 1, "ddi_type": "mechanism"}
{"id": "DDI-DrugBank.d198.s7-1", "sentence_id": "DDI-DrugBank.d198.s7", "sentence": "Ketoconazole (200 mg once daily) produced a 10-fold increase in vardenafil AUC and a 4-fold increase in Cmax when co-administered with Vardenafil (5 mg) in healthy volunteers.", "arg1": {"span": [[0, 12]], "type": "drug", "id": "DDI-DrugBank.d198.s7.e0"}, "arg2": {"span": [[135, 145]], "type": "drug", "id": "DDI-DrugBank.d198.s7.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d198.s7-2", "sentence_id": "DDI-DrugBank.d198.s7", "sentence": "Ketoconazole (200 mg once daily) produced a 10-fold increase in vardenafil AUC and a 4-fold increase in Cmax when co-administered with Vardenafil (5 mg) in healthy volunteers.", "arg1": {"span": [[64, 74]], "type": "drug", "id": "DDI-DrugBank.d198.s7.e1"}, "arg2": {"span": [[135, 145]], "type": "drug", "id": "DDI-DrugBank.d198.s7.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d198.s8-0", "sentence_id": "DDI-DrugBank.d198.s8", "sentence": "A 5-mg Vardenafil dose should not be exceeded when used in combination with 200 mg once daily ketoconazole.", "arg1": {"span": [[7, 17]], "type": "drug", "id": "DDI-DrugBank.d198.s8.e0"}, "arg2": {"span": [[94, 106]], "type": "drug", "id": "DDI-DrugBank.d198.s8.e1"}, "ddi_label": 1, "ddi_type": "advise"}
{"id": "DDI-DrugBank.d198.s9-0", "sentence_id": "DDI-DrugBank.d198.s9", "sentence": "Since higher doses of ketoconazole (400 mg daily) may result in higher increases in Cmax and AUC, a single 2.5 mg dose of Vardenafil should not be exceeded in a 24-hour period when used in combination with ketoconazole 400 mg daily.", "arg1": {"span": [[22, 34]], "type": "drug", "id": "DDI-DrugBank.d198.s9.e0"}, "arg2": {"span": [[122, 132]], "type": "drug", "id": "DDI-DrugBank.d198.s9.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d198.s9-1", "sentence_id": "DDI-DrugBank.d198.s9", "sentence": "Since higher doses of ketoconazole (400 mg daily) may result in higher increases in Cmax and AUC, a single 2.5 mg dose of Vardenafil should not be exceeded in a 24-hour period when used in combination with ketoconazole 400 mg daily.", "arg1": {"span": [[22, 34]], "type": "drug", "id": "DDI-DrugBank.d198.s9.e0"}, "arg2": {"span": [[206, 218]], "type": "drug", "id": "DDI-DrugBank.d198.s9.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d198.s9-2", "sentence_id": "DDI-DrugBank.d198.s9", "sentence": "Since higher doses of ketoconazole (400 mg daily) may result in higher increases in Cmax and AUC, a single 2.5 mg dose of Vardenafil should not be exceeded in a 24-hour period when used in combination with ketoconazole 400 mg daily.", "arg1": {"span": [[122, 132]], "type": "drug", "id": "DDI-DrugBank.d198.s9.e1"}, "arg2": {"span": [[206, 218]], "type": "drug", "id": "DDI-DrugBank.d198.s9.e2"}, "ddi_label": 1, "ddi_type": "advise"}
{"id": "DDI-DrugBank.d198.s11-0", "sentence_id": "DDI-DrugBank.d198.s11", "sentence": "It is recommended not to exceed a single 2.5 mg Vardenafil dose in a 24-hour period when used in combination with indinavir.", "arg1": {"span": [[48, 58]], "type": "drug", "id": "DDI-DrugBank.d198.s11.e0"}, "arg2": {"span": [[114, 123]], "type": "drug", "id": "DDI-DrugBank.d198.s11.e1"}, "ddi_label": 1, "ddi_type": "advise"}
{"id": "DDI-DrugBank.d198.s12-0", "sentence_id": "DDI-DrugBank.d198.s12", "sentence": "Ritonavir (600 mg b.i.d.) co-administered with Vardenafil 5 mg resulted in a 49-fold increase in vardenafil AUC and a 13-fold increase in vardenafil Cmax.", "arg1": {"span": [[0, 9]], "type": "drug", "id": "DDI-DrugBank.d198.s12.e0"}, "arg2": {"span": [[47, 57]], "type": "drug", "id": "DDI-DrugBank.d198.s12.e1"}, "ddi_label": 1, "ddi_type": "mechanism"}
{"id": "DDI-DrugBank.d198.s12-1", "sentence_id": "DDI-DrugBank.d198.s12", "sentence": "Ritonavir (600 mg b.i.d.) co-administered with Vardenafil 5 mg resulted in a 49-fold increase in vardenafil AUC and a 13-fold increase in vardenafil Cmax.", "arg1": {"span": [[0, 9]], "type": "drug", "id": "DDI-DrugBank.d198.s12.e0"}, "arg2": {"span": [[97, 107]], "type": "drug", "id": "DDI-DrugBank.d198.s12.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d198.s12-2", "sentence_id": "DDI-DrugBank.d198.s12", "sentence": "Ritonavir (600 mg b.i.d.) co-administered with Vardenafil 5 mg resulted in a 49-fold increase in vardenafil AUC and a 13-fold increase in vardenafil Cmax.", "arg1": {"span": [[0, 9]], "type": "drug", "id": "DDI-DrugBank.d198.s12.e0"}, "arg2": {"span": [[138, 148]], "type": "drug", "id": "DDI-DrugBank.d198.s12.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d198.s12-3", "sentence_id": "DDI-DrugBank.d198.s12", "sentence": "Ritonavir (600 mg b.i.d.) co-administered with Vardenafil 5 mg resulted in a 49-fold increase in vardenafil AUC and a 13-fold increase in vardenafil Cmax.", "arg1": {"span": [[47, 57]], "type": "drug", "id": "DDI-DrugBank.d198.s12.e1"}, "arg2": {"span": [[97, 107]], "type": "drug", "id": "DDI-DrugBank.d198.s12.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d198.s12-4", "sentence_id": "DDI-DrugBank.d198.s12", "sentence": "Ritonavir (600 mg b.i.d.) co-administered with Vardenafil 5 mg resulted in a 49-fold increase in vardenafil AUC and a 13-fold increase in vardenafil Cmax.", "arg1": {"span": [[47, 57]], "type": "drug", "id": "DDI-DrugBank.d198.s12.e1"}, "arg2": {"span": [[138, 148]], "type": "drug", "id": "DDI-DrugBank.d198.s12.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d198.s12-5", "sentence_id": "DDI-DrugBank.d198.s12", "sentence": "Ritonavir (600 mg b.i.d.) co-administered with Vardenafil 5 mg resulted in a 49-fold increase in vardenafil AUC and a 13-fold increase in vardenafil Cmax.", "arg1": {"span": [[97, 107]], "type": "drug", "id": "DDI-DrugBank.d198.s12.e2"}, "arg2": {"span": [[138, 148]], "type": "drug", "id": "DDI-DrugBank.d198.s12.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d198.s13-0", "sentence_id": "DDI-DrugBank.d198.s13", "sentence": "The interaction is a consequence of blocking hepatic metabolism of vardenafil by ritonavir, a highly potent CYP3A4 inhibitor, which also inhibits CYP2C9.", "arg1": {"span": [[67, 77]], "type": "drug", "id": "DDI-DrugBank.d198.s13.e0"}, "arg2": {"span": [[81, 90]], "type": "drug", "id": "DDI-DrugBank.d198.s13.e1"}, "ddi_label": 1, "ddi_type": "mechanism"}
{"id": "DDI-DrugBank.d198.s14-0", "sentence_id": "DDI-DrugBank.d198.s14", "sentence": "Ritonavir significantly prolonged the half-life of vardenafil to 26 hours.", "arg1": {"span": [[0, 9]], "type": "drug", "id": "DDI-DrugBank.d198.s14.e0"}, "arg2": {"span": [[51, 61]], "type": "drug", "id": "DDI-DrugBank.d198.s14.e1"}, "ddi_label": 1, "ddi_type": "mechanism"}
{"id": "DDI-DrugBank.d198.s15-0", "sentence_id": "DDI-DrugBank.d198.s15", "sentence": "Consequently, it is recommended not to exceed a single 2.5 mg Vardenafil dose in a 72-hour period when used in combination with ritonavir.", "arg1": {"span": [[62, 72]], "type": "drug", "id": "DDI-DrugBank.d198.s15.e0"}, "arg2": {"span": [[128, 137]], "type": "drug", "id": "DDI-DrugBank.d198.s15.e1"}, "ddi_label": 1, "ddi_type": "advise"}
{"id": "DDI-DrugBank.d198.s17-0", "sentence_id": "DDI-DrugBank.d198.s17", "sentence": "In the warfarin study, vardenafil had no effect on the prothrombin time or other pharmacodynamic parameters.", "arg1": {"span": [[7, 15]], "type": "drug", "id": "DDI-DrugBank.d198.s17.e0"}, "arg2": {"span": [[23, 33]], "type": "drug", "id": "DDI-DrugBank.d198.s17.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d198.s22-0", "sentence_id": "DDI-DrugBank.d198.s22", "sentence": "In vivo studies: Nitrates: The blood pressure lowering effects of sublingual nitrates (0.4 mg) taken 1 and 4 hours after vardenafil and increases in heart rate when taken at 1, 4 and 8 hours were potentiated by a 20 mg dose of Vardenafil in healthy middle-aged subjects.", "arg1": {"span": [[17, 25]], "type": "group", "id": "DDI-DrugBank.d198.s22.e0"}, "arg2": {"span": [[77, 85]], "type": "group", "id": "DDI-DrugBank.d198.s22.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d198.s22-1", "sentence_id": "DDI-DrugBank.d198.s22", "sentence": "In vivo studies: Nitrates: The blood pressure lowering effects of sublingual nitrates (0.4 mg) taken 1 and 4 hours after vardenafil and increases in heart rate when taken at 1, 4 and 8 hours were potentiated by a 20 mg dose of Vardenafil in healthy middle-aged subjects.", "arg1": {"span": [[17, 25]], "type": "group", "id": "DDI-DrugBank.d198.s22.e0"}, "arg2": {"span": [[121, 131]], "type": "drug", "id": "DDI-DrugBank.d198.s22.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d198.s22-2", "sentence_id": "DDI-DrugBank.d198.s22", "sentence": "In vivo studies: Nitrates: The blood pressure lowering effects of sublingual nitrates (0.4 mg) taken 1 and 4 hours after vardenafil and increases in heart rate when taken at 1, 4 and 8 hours were potentiated by a 20 mg dose of Vardenafil in healthy middle-aged subjects.", "arg1": {"span": [[17, 25]], "type": "group", "id": "DDI-DrugBank.d198.s22.e0"}, "arg2": {"span": [[227, 237]], "type": "drug", "id": "DDI-DrugBank.d198.s22.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d198.s22-3", "sentence_id": "DDI-DrugBank.d198.s22", "sentence": "In vivo studies: Nitrates: The blood pressure lowering effects of sublingual nitrates (0.4 mg) taken 1 and 4 hours after vardenafil and increases in heart rate when taken at 1, 4 and 8 hours were potentiated by a 20 mg dose of Vardenafil in healthy middle-aged subjects.", "arg1": {"span": [[77, 85]], "type": "group", "id": "DDI-DrugBank.d198.s22.e1"}, "arg2": {"span": [[121, 131]], "type": "drug", "id": "DDI-DrugBank.d198.s22.e2"}, "ddi_label": 1, "ddi_type": "mechanism"}
{"id": "DDI-DrugBank.d198.s22-4", "sentence_id": "DDI-DrugBank.d198.s22", "sentence": "In vivo studies: Nitrates: The blood pressure lowering effects of sublingual nitrates (0.4 mg) taken 1 and 4 hours after vardenafil and increases in heart rate when taken at 1, 4 and 8 hours were potentiated by a 20 mg dose of Vardenafil in healthy middle-aged subjects.", "arg1": {"span": [[77, 85]], "type": "group", "id": "DDI-DrugBank.d198.s22.e1"}, "arg2": {"span": [[227, 237]], "type": "drug", "id": "DDI-DrugBank.d198.s22.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d198.s22-5", "sentence_id": "DDI-DrugBank.d198.s22", "sentence": "In vivo studies: Nitrates: The blood pressure lowering effects of sublingual nitrates (0.4 mg) taken 1 and 4 hours after vardenafil and increases in heart rate when taken at 1, 4 and 8 hours were potentiated by a 20 mg dose of Vardenafil in healthy middle-aged subjects.", "arg1": {"span": [[121, 131]], "type": "drug", "id": "DDI-DrugBank.d198.s22.e2"}, "arg2": {"span": [[227, 237]], "type": "drug", "id": "DDI-DrugBank.d198.s22.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d198.s23-0", "sentence_id": "DDI-DrugBank.d198.s23", "sentence": "These effects were not observed when Vardenafil 20 mg was taken 24 hours before the NTG.", "arg1": {"span": [[37, 47]], "type": "drug", "id": "DDI-DrugBank.d198.s23.e0"}, "arg2": {"span": [[84, 87]], "type": "drug", "id": "DDI-DrugBank.d198.s23.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d198.s24-0", "sentence_id": "DDI-DrugBank.d198.s24", "sentence": "Potentiation of the hypotensive effects of nitrates for patients with ischemic heart disease has not been evaluated, and concomitant use of Vardenafil and nitrates is contraindicated.", "arg1": {"span": [[43, 51]], "type": "group", "id": "DDI-DrugBank.d198.s24.e0"}, "arg2": {"span": [[140, 150]], "type": "drug", "id": "DDI-DrugBank.d198.s24.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d198.s24-1", "sentence_id": "DDI-DrugBank.d198.s24", "sentence": "Potentiation of the hypotensive effects of nitrates for patients with ischemic heart disease has not been evaluated, and concomitant use of Vardenafil and nitrates is contraindicated.", "arg1": {"span": [[43, 51]], "type": "group", "id": "DDI-DrugBank.d198.s24.e0"}, "arg2": {"span": [[155, 163]], "type": "group", "id": "DDI-DrugBank.d198.s24.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d198.s24-2", "sentence_id": "DDI-DrugBank.d198.s24", "sentence": "Potentiation of the hypotensive effects of nitrates for patients with ischemic heart disease has not been evaluated, and concomitant use of Vardenafil and nitrates is contraindicated.", "arg1": {"span": [[140, 150]], "type": "drug", "id": "DDI-DrugBank.d198.s24.e1"}, "arg2": {"span": [[155, 163]], "type": "group", "id": "DDI-DrugBank.d198.s24.e2"}, "ddi_label": 1, "ddi_type": "advise"}
{"id": "DDI-DrugBank.d198.s25-0", "sentence_id": "DDI-DrugBank.d198.s25", "sentence": "Nifedipine: Vardenafil 20 mg, when co-administered with slow-release nifedipine 30 mg or 60 mg once daily, did not affect the relative bioavailability (AUC) or maximum concentration (Cmax) of nifedipine, a drug that is metabolized via CYP3A4.", "arg1": {"span": [[0, 10]], "type": "drug", "id": "DDI-DrugBank.d198.s25.e0"}, "arg2": {"span": [[12, 22]], "type": "drug", "id": "DDI-DrugBank.d198.s25.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d198.s25-1", "sentence_id": "DDI-DrugBank.d198.s25", "sentence": "Nifedipine: Vardenafil 20 mg, when co-administered with slow-release nifedipine 30 mg or 60 mg once daily, did not affect the relative bioavailability (AUC) or maximum concentration (Cmax) of nifedipine, a drug that is metabolized via CYP3A4.", "arg1": {"span": [[0, 10]], "type": "drug", "id": "DDI-DrugBank.d198.s25.e0"}, "arg2": {"span": [[69, 79]], "type": "drug", "id": "DDI-DrugBank.d198.s25.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d198.s25-2", "sentence_id": "DDI-DrugBank.d198.s25", "sentence": "Nifedipine: Vardenafil 20 mg, when co-administered with slow-release nifedipine 30 mg or 60 mg once daily, did not affect the relative bioavailability (AUC) or maximum concentration (Cmax) of nifedipine, a drug that is metabolized via CYP3A4.", "arg1": {"span": [[0, 10]], "type": "drug", "id": "DDI-DrugBank.d198.s25.e0"}, "arg2": {"span": [[192, 202]], "type": "drug", "id": "DDI-DrugBank.d198.s25.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d198.s25-3", "sentence_id": "DDI-DrugBank.d198.s25", "sentence": "Nifedipine: Vardenafil 20 mg, when co-administered with slow-release nifedipine 30 mg or 60 mg once daily, did not affect the relative bioavailability (AUC) or maximum concentration (Cmax) of nifedipine, a drug that is metabolized via CYP3A4.", "arg1": {"span": [[12, 22]], "type": "drug", "id": "DDI-DrugBank.d198.s25.e1"}, "arg2": {"span": [[69, 79]], "type": "drug", "id": "DDI-DrugBank.d198.s25.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d198.s25-4", "sentence_id": "DDI-DrugBank.d198.s25", "sentence": "Nifedipine: Vardenafil 20 mg, when co-administered with slow-release nifedipine 30 mg or 60 mg once daily, did not affect the relative bioavailability (AUC) or maximum concentration (Cmax) of nifedipine, a drug that is metabolized via CYP3A4.", "arg1": {"span": [[12, 22]], "type": "drug", "id": "DDI-DrugBank.d198.s25.e1"}, "arg2": {"span": [[192, 202]], "type": "drug", "id": "DDI-DrugBank.d198.s25.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d198.s25-5", "sentence_id": "DDI-DrugBank.d198.s25", "sentence": "Nifedipine: Vardenafil 20 mg, when co-administered with slow-release nifedipine 30 mg or 60 mg once daily, did not affect the relative bioavailability (AUC) or maximum concentration (Cmax) of nifedipine, a drug that is metabolized via CYP3A4.", "arg1": {"span": [[69, 79]], "type": "drug", "id": "DDI-DrugBank.d198.s25.e2"}, "arg2": {"span": [[192, 202]], "type": "drug", "id": "DDI-DrugBank.d198.s25.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d198.s26-0", "sentence_id": "DDI-DrugBank.d198.s26", "sentence": "Nifedipine did not alter the plasma levels of Vardenafil when taken in combination.", "arg1": {"span": [[0, 10]], "type": "drug", "id": "DDI-DrugBank.d198.s26.e0"}, "arg2": {"span": [[46, 56]], "type": "drug", "id": "DDI-DrugBank.d198.s26.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d198.s27-0", "sentence_id": "DDI-DrugBank.d198.s27", "sentence": "In these patients whose hypertension was controlled with nifedipine, Vardenafil 20 mg produced mean additional supine systolic/diastolic blood pressure reductions of 6/5 mm Hg compared to placebo.", "arg1": {"span": [[57, 67]], "type": "drug", "id": "DDI-DrugBank.d198.s27.e0"}, "arg2": {"span": [[69, 79]], "type": "drug", "id": "DDI-DrugBank.d198.s27.e1"}, "ddi_label": 1, "ddi_type": "effect"}
{"id": "DDI-DrugBank.d198.s28-0", "sentence_id": "DDI-DrugBank.d198.s28", "sentence": "Alpha-blockers: When Vardenafil 10 or 20 mg was given to healthy volunteers either simultaneously or 6 hours after a 10 mg dose of terazosin, significant hypotension developed in a substantial number of subjects.", "arg1": {"span": [[0, 14]], "type": "group", "id": "DDI-DrugBank.d198.s28.e0"}, "arg2": {"span": [[21, 31]], "type": "drug", "id": "DDI-DrugBank.d198.s28.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d198.s28-1", "sentence_id": "DDI-DrugBank.d198.s28", "sentence": "Alpha-blockers: When Vardenafil 10 or 20 mg was given to healthy volunteers either simultaneously or 6 hours after a 10 mg dose of terazosin, significant hypotension developed in a substantial number of subjects.", "arg1": {"span": [[0, 14]], "type": "group", "id": "DDI-DrugBank.d198.s28.e0"}, "arg2": {"span": [[131, 140]], "type": "drug", "id": "DDI-DrugBank.d198.s28.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d198.s28-2", "sentence_id": "DDI-DrugBank.d198.s28", "sentence": "Alpha-blockers: When Vardenafil 10 or 20 mg was given to healthy volunteers either simultaneously or 6 hours after a 10 mg dose of terazosin, significant hypotension developed in a substantial number of subjects.", "arg1": {"span": [[21, 31]], "type": "drug", "id": "DDI-DrugBank.d198.s28.e1"}, "arg2": {"span": [[131, 140]], "type": "drug", "id": "DDI-DrugBank.d198.s28.e2"}, "ddi_label": 1, "ddi_type": "effect"}
{"id": "DDI-DrugBank.d198.s29-0", "sentence_id": "DDI-DrugBank.d198.s29", "sentence": "With simultaneous dosing of Vardenafil 10 mg and terazosin 10 mg, 6 of 8 subjects experienced a standing systolic blood pressure of less than 85 mm Hg.", "arg1": {"span": [[28, 38]], "type": "drug", "id": "DDI-DrugBank.d198.s29.e0"}, "arg2": {"span": [[49, 58]], "type": "drug", "id": "DDI-DrugBank.d198.s29.e1"}, "ddi_label": 1, "ddi_type": "effect"}
{"id": "DDI-DrugBank.d198.s30-0", "sentence_id": "DDI-DrugBank.d198.s30", "sentence": "With simultaneous dosing of Vardenafil 20 mg and terazosin 10 mg, 2 of 9 subjects experienced a standing systolic blood pressure of less than 85 mm Hg.", "arg1": {"span": [[28, 38]], "type": "drug", "id": "DDI-DrugBank.d198.s30.e0"}, "arg2": {"span": [[49, 58]], "type": "drug", "id": "DDI-DrugBank.d198.s30.e1"}, "ddi_label": 1, "ddi_type": "effect"}
{"id": "DDI-DrugBank.d198.s31-0", "sentence_id": "DDI-DrugBank.d198.s31", "sentence": "When Vardenafil dosing was separated from terazosin 10 mg by 6 hours, 7 of 28 subjects who received 20 mg of Vardenafil experienced a decrease in standing systolic blood pressure below 85 mm Hg.", "arg1": {"span": [[5, 15]], "type": "drug", "id": "DDI-DrugBank.d198.s31.e0"}, "arg2": {"span": [[42, 51]], "type": "drug", "id": "DDI-DrugBank.d198.s31.e1"}, "ddi_label": 1, "ddi_type": "effect"}
{"id": "DDI-DrugBank.d198.s31-1", "sentence_id": "DDI-DrugBank.d198.s31", "sentence": "When Vardenafil dosing was separated from terazosin 10 mg by 6 hours, 7 of 28 subjects who received 20 mg of Vardenafil experienced a decrease in standing systolic blood pressure below 85 mm Hg.", "arg1": {"span": [[5, 15]], "type": "drug", "id": "DDI-DrugBank.d198.s31.e0"}, "arg2": {"span": [[109, 119]], "type": "drug", "id": "DDI-DrugBank.d198.s31.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d198.s31-2", "sentence_id": "DDI-DrugBank.d198.s31", "sentence": "When Vardenafil dosing was separated from terazosin 10 mg by 6 hours, 7 of 28 subjects who received 20 mg of Vardenafil experienced a decrease in standing systolic blood pressure below 85 mm Hg.", "arg1": {"span": [[42, 51]], "type": "drug", "id": "DDI-DrugBank.d198.s31.e1"}, "arg2": {"span": [[109, 119]], "type": "drug", "id": "DDI-DrugBank.d198.s31.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d198.s32-0", "sentence_id": "DDI-DrugBank.d198.s32", "sentence": "In a similar study with tamsulosin in healthy volunteers, 1 of 24 subjects dosed with Vardenafil 20 mg and tamsulosin 0.4 mg separated by 6 hours experienced a standing systolic blood pressure below 85 mm Hg.", "arg1": {"span": [[24, 34]], "type": "drug", "id": "DDI-DrugBank.d198.s32.e0"}, "arg2": {"span": [[86, 96]], "type": "drug", "id": "DDI-DrugBank.d198.s32.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d198.s32-1", "sentence_id": "DDI-DrugBank.d198.s32", "sentence": "In a similar study with tamsulosin in healthy volunteers, 1 of 24 subjects dosed with Vardenafil 20 mg and tamsulosin 0.4 mg separated by 6 hours experienced a standing systolic blood pressure below 85 mm Hg.", "arg1": {"span": [[24, 34]], "type": "drug", "id": "DDI-DrugBank.d198.s32.e0"}, "arg2": {"span": [[107, 117]], "type": "drug", "id": "DDI-DrugBank.d198.s32.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d198.s32-2", "sentence_id": "DDI-DrugBank.d198.s32", "sentence": "In a similar study with tamsulosin in healthy volunteers, 1 of 24 subjects dosed with Vardenafil 20 mg and tamsulosin 0.4 mg separated by 6 hours experienced a standing systolic blood pressure below 85 mm Hg.", "arg1": {"span": [[86, 96]], "type": "drug", "id": "DDI-DrugBank.d198.s32.e1"}, "arg2": {"span": [[107, 117]], "type": "drug", "id": "DDI-DrugBank.d198.s32.e2"}, "ddi_label": 1, "ddi_type": "effect"}
{"id": "DDI-DrugBank.d198.s33-0", "sentence_id": "DDI-DrugBank.d198.s33", "sentence": "Two of 16 subjects dosed simultaneously with Vardenafil 10 mg and tamsulosin 0.4 mg experienced a standing systolic blood pressure below 85 mm Hg.", "arg1": {"span": [[45, 55]], "type": "drug", "id": "DDI-DrugBank.d198.s33.e0"}, "arg2": {"span": [[66, 76]], "type": "drug", "id": "DDI-DrugBank.d198.s33.e1"}, "ddi_label": 1, "ddi_type": "effect"}
{"id": "DDI-DrugBank.d198.s34-0", "sentence_id": "DDI-DrugBank.d198.s34", "sentence": "The administration of lower doses of Vardenafil with alpha-blockers has not been completely evaluated to determine if they can be safely administered together.", "arg1": {"span": [[37, 47]], "type": "drug", "id": "DDI-DrugBank.d198.s34.e0"}, "arg2": {"span": [[53, 67]], "type": "group", "id": "DDI-DrugBank.d198.s34.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d198.s35-0", "sentence_id": "DDI-DrugBank.d198.s35", "sentence": "Based on these data, Vardenafil should not be used in patients on alpha-blocker therapy.", "arg1": {"span": [[21, 31]], "type": "drug", "id": "DDI-DrugBank.d198.s35.e0"}, "arg2": {"span": [[66, 79]], "type": "group", "id": "DDI-DrugBank.d198.s35.e1"}, "ddi_label": 1, "ddi_type": "advise"}
{"id": "DDI-DrugBank.d198.s36-0", "sentence_id": "DDI-DrugBank.d198.s36", "sentence": "Ritonavir and indinavir: Upon concomitant administration of 5 mg of Vardenafil with 600 mg BID ritonavir, the Cmax and AUC of ritonavir were reduced by approximately 20%.", "arg1": {"span": [[0, 9]], "type": "drug", "id": "DDI-DrugBank.d198.s36.e0"}, "arg2": {"span": [[14, 23]], "type": "drug", "id": "DDI-DrugBank.d198.s36.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d198.s36-1", "sentence_id": "DDI-DrugBank.d198.s36", "sentence": "Ritonavir and indinavir: Upon concomitant administration of 5 mg of Vardenafil with 600 mg BID ritonavir, the Cmax and AUC of ritonavir were reduced by approximately 20%.", "arg1": {"span": [[0, 9]], "type": "drug", "id": "DDI-DrugBank.d198.s36.e0"}, "arg2": {"span": [[68, 78]], "type": "drug", "id": "DDI-DrugBank.d198.s36.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d198.s36-2", "sentence_id": "DDI-DrugBank.d198.s36", "sentence": "Ritonavir and indinavir: Upon concomitant administration of 5 mg of Vardenafil with 600 mg BID ritonavir, the Cmax and AUC of ritonavir were reduced by approximately 20%.", "arg1": {"span": [[0, 9]], "type": "drug", "id": "DDI-DrugBank.d198.s36.e0"}, "arg2": {"span": [[95, 104]], "type": "drug", "id": "DDI-DrugBank.d198.s36.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d198.s36-3", "sentence_id": "DDI-DrugBank.d198.s36", "sentence": "Ritonavir and indinavir: Upon concomitant administration of 5 mg of Vardenafil with 600 mg BID ritonavir, the Cmax and AUC of ritonavir were reduced by approximately 20%.", "arg1": {"span": [[0, 9]], "type": "drug", "id": "DDI-DrugBank.d198.s36.e0"}, "arg2": {"span": [[126, 135]], "type": "drug", "id": "DDI-DrugBank.d198.s36.e4"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d198.s36-4", "sentence_id": "DDI-DrugBank.d198.s36", "sentence": "Ritonavir and indinavir: Upon concomitant administration of 5 mg of Vardenafil with 600 mg BID ritonavir, the Cmax and AUC of ritonavir were reduced by approximately 20%.", "arg1": {"span": [[14, 23]], "type": "drug", "id": "DDI-DrugBank.d198.s36.e1"}, "arg2": {"span": [[68, 78]], "type": "drug", "id": "DDI-DrugBank.d198.s36.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d198.s36-5", "sentence_id": "DDI-DrugBank.d198.s36", "sentence": "Ritonavir and indinavir: Upon concomitant administration of 5 mg of Vardenafil with 600 mg BID ritonavir, the Cmax and AUC of ritonavir were reduced by approximately 20%.", "arg1": {"span": [[14, 23]], "type": "drug", "id": "DDI-DrugBank.d198.s36.e1"}, "arg2": {"span": [[95, 104]], "type": "drug", "id": "DDI-DrugBank.d198.s36.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d198.s36-6", "sentence_id": "DDI-DrugBank.d198.s36", "sentence": "Ritonavir and indinavir: Upon concomitant administration of 5 mg of Vardenafil with 600 mg BID ritonavir, the Cmax and AUC of ritonavir were reduced by approximately 20%.", "arg1": {"span": [[14, 23]], "type": "drug", "id": "DDI-DrugBank.d198.s36.e1"}, "arg2": {"span": [[126, 135]], "type": "drug", "id": "DDI-DrugBank.d198.s36.e4"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d198.s36-7", "sentence_id": "DDI-DrugBank.d198.s36", "sentence": "Ritonavir and indinavir: Upon concomitant administration of 5 mg of Vardenafil with 600 mg BID ritonavir, the Cmax and AUC of ritonavir were reduced by approximately 20%.", "arg1": {"span": [[68, 78]], "type": "drug", "id": "DDI-DrugBank.d198.s36.e2"}, "arg2": {"span": [[95, 104]], "type": "drug", "id": "DDI-DrugBank.d198.s36.e3"}, "ddi_label": 1, "ddi_type": "mechanism"}
{"id": "DDI-DrugBank.d198.s36-8", "sentence_id": "DDI-DrugBank.d198.s36", "sentence": "Ritonavir and indinavir: Upon concomitant administration of 5 mg of Vardenafil with 600 mg BID ritonavir, the Cmax and AUC of ritonavir were reduced by approximately 20%.", "arg1": {"span": [[68, 78]], "type": "drug", "id": "DDI-DrugBank.d198.s36.e2"}, "arg2": {"span": [[126, 135]], "type": "drug", "id": "DDI-DrugBank.d198.s36.e4"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d198.s36-9", "sentence_id": "DDI-DrugBank.d198.s36", "sentence": "Ritonavir and indinavir: Upon concomitant administration of 5 mg of Vardenafil with 600 mg BID ritonavir, the Cmax and AUC of ritonavir were reduced by approximately 20%.", "arg1": {"span": [[95, 104]], "type": "drug", "id": "DDI-DrugBank.d198.s36.e3"}, "arg2": {"span": [[126, 135]], "type": "drug", "id": "DDI-DrugBank.d198.s36.e4"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d198.s37-0", "sentence_id": "DDI-DrugBank.d198.s37", "sentence": "Upon administration of 10 mg of Vardenafil with 800 mg TID indinavir, the Cmax and AUC of indinavir were reduced by 40% and 30%, respectively.", "arg1": {"span": [[32, 42]], "type": "drug", "id": "DDI-DrugBank.d198.s37.e0"}, "arg2": {"span": [[59, 68]], "type": "drug", "id": "DDI-DrugBank.d198.s37.e1"}, "ddi_label": 1, "ddi_type": "mechanism"}
{"id": "DDI-DrugBank.d198.s37-1", "sentence_id": "DDI-DrugBank.d198.s37", "sentence": "Upon administration of 10 mg of Vardenafil with 800 mg TID indinavir, the Cmax and AUC of indinavir were reduced by 40% and 30%, respectively.", "arg1": {"span": [[32, 42]], "type": "drug", "id": "DDI-DrugBank.d198.s37.e0"}, "arg2": {"span": [[90, 99]], "type": "drug", "id": "DDI-DrugBank.d198.s37.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d198.s37-2", "sentence_id": "DDI-DrugBank.d198.s37", "sentence": "Upon administration of 10 mg of Vardenafil with 800 mg TID indinavir, the Cmax and AUC of indinavir were reduced by 40% and 30%, respectively.", "arg1": {"span": [[59, 68]], "type": "drug", "id": "DDI-DrugBank.d198.s37.e1"}, "arg2": {"span": [[90, 99]], "type": "drug", "id": "DDI-DrugBank.d198.s37.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d198.s38-0", "sentence_id": "DDI-DrugBank.d198.s38", "sentence": "Alcohol: Alcohol (0.5 g/kg body weight: approximately 40 mL of absolute alcohol in a 70 kg person) and vardenafil plasma levels were not altered when dosed simultaneously.", "arg1": {"span": [[0, 7]], "type": "drug", "id": "DDI-DrugBank.d198.s38.e0"}, "arg2": {"span": [[9, 16]], "type": "drug", "id": "DDI-DrugBank.d198.s38.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d198.s38-1", "sentence_id": "DDI-DrugBank.d198.s38", "sentence": "Alcohol: Alcohol (0.5 g/kg body weight: approximately 40 mL of absolute alcohol in a 70 kg person) and vardenafil plasma levels were not altered when dosed simultaneously.", "arg1": {"span": [[0, 7]], "type": "drug", "id": "DDI-DrugBank.d198.s38.e0"}, "arg2": {"span": [[103, 113]], "type": "drug", "id": "DDI-DrugBank.d198.s38.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d198.s38-2", "sentence_id": "DDI-DrugBank.d198.s38", "sentence": "Alcohol: Alcohol (0.5 g/kg body weight: approximately 40 mL of absolute alcohol in a 70 kg person) and vardenafil plasma levels were not altered when dosed simultaneously.", "arg1": {"span": [[9, 16]], "type": "drug", "id": "DDI-DrugBank.d198.s38.e1"}, "arg2": {"span": [[103, 113]], "type": "drug", "id": "DDI-DrugBank.d198.s38.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d198.s39-0", "sentence_id": "DDI-DrugBank.d198.s39", "sentence": "Vardenafil (20 mg) did not potentiate the hypotensive effects of alcohol during the 4-hour observation period in healthy volunteers when administered with alcohol (0.5 g/kg body weight).", "arg1": {"span": [[0, 10]], "type": "drug", "id": "DDI-DrugBank.d198.s39.e0"}, "arg2": {"span": [[65, 72]], "type": "drug", "id": "DDI-DrugBank.d198.s39.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d198.s39-1", "sentence_id": "DDI-DrugBank.d198.s39", "sentence": "Vardenafil (20 mg) did not potentiate the hypotensive effects of alcohol during the 4-hour observation period in healthy volunteers when administered with alcohol (0.5 g/kg body weight).", "arg1": {"span": [[0, 10]], "type": "drug", "id": "DDI-DrugBank.d198.s39.e0"}, "arg2": {"span": [[155, 162]], "type": "drug", "id": "DDI-DrugBank.d198.s39.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d198.s39-2", "sentence_id": "DDI-DrugBank.d198.s39", "sentence": "Vardenafil (20 mg) did not potentiate the hypotensive effects of alcohol during the 4-hour observation period in healthy volunteers when administered with alcohol (0.5 g/kg body weight).", "arg1": {"span": [[65, 72]], "type": "drug", "id": "DDI-DrugBank.d198.s39.e1"}, "arg2": {"span": [[155, 162]], "type": "drug", "id": "DDI-DrugBank.d198.s39.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d198.s40-0", "sentence_id": "DDI-DrugBank.d198.s40", "sentence": "Aspirin: Vardenafil (10 mg and 20 mg) did not potentiate the increase in bleeding time caused by aspirin (two 81 mg tablets).", "arg1": {"span": [[0, 7]], "type": "brand", "id": "DDI-DrugBank.d198.s40.e0"}, "arg2": {"span": [[9, 19]], "type": "drug", "id": "DDI-DrugBank.d198.s40.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d198.s40-1", "sentence_id": "DDI-DrugBank.d198.s40", "sentence": "Aspirin: Vardenafil (10 mg and 20 mg) did not potentiate the increase in bleeding time caused by aspirin (two 81 mg tablets).", "arg1": {"span": [[0, 7]], "type": "brand", "id": "DDI-DrugBank.d198.s40.e0"}, "arg2": {"span": [[97, 104]], "type": "brand", "id": "DDI-DrugBank.d198.s40.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d198.s40-2", "sentence_id": "DDI-DrugBank.d198.s40", "sentence": "Aspirin: Vardenafil (10 mg and 20 mg) did not potentiate the increase in bleeding time caused by aspirin (two 81 mg tablets).", "arg1": {"span": [[9, 19]], "type": "drug", "id": "DDI-DrugBank.d198.s40.e1"}, "arg2": {"span": [[97, 104]], "type": "brand", "id": "DDI-DrugBank.d198.s40.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d198.s41-0", "sentence_id": "DDI-DrugBank.d198.s41", "sentence": "Other interactions: Vardenafil had no effect on the pharmacodynamics of glyburide (glucose and insulin concentrations) and warfarin (prothrombin time or other pharmacodynamic parameters).", "arg1": {"span": [[20, 30]], "type": "drug", "id": "DDI-DrugBank.d198.s41.e0"}, "arg2": {"span": [[72, 81]], "type": "drug", "id": "DDI-DrugBank.d198.s41.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d198.s41-1", "sentence_id": "DDI-DrugBank.d198.s41", "sentence": "Other interactions: Vardenafil had no effect on the pharmacodynamics of glyburide (glucose and insulin concentrations) and warfarin (prothrombin time or other pharmacodynamic parameters).", "arg1": {"span": [[20, 30]], "type": "drug", "id": "DDI-DrugBank.d198.s41.e0"}, "arg2": {"span": [[123, 131]], "type": "drug", "id": "DDI-DrugBank.d198.s41.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d198.s41-2", "sentence_id": "DDI-DrugBank.d198.s41", "sentence": "Other interactions: Vardenafil had no effect on the pharmacodynamics of glyburide (glucose and insulin concentrations) and warfarin (prothrombin time or other pharmacodynamic parameters).", "arg1": {"span": [[72, 81]], "type": "drug", "id": "DDI-DrugBank.d198.s41.e1"}, "arg2": {"span": [[123, 131]], "type": "drug", "id": "DDI-DrugBank.d198.s41.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d536.s3-0", "sentence_id": "DDI-DrugBank.d536.s3", "sentence": "When such drugs are withdrawn from patients receiving Acarbose in combination with sulfonylureas or insulin, patients should be observed closely for any evidence of hypoglycemia.", "arg1": {"span": [[54, 62]], "type": "drug", "id": "DDI-DrugBank.d536.s3.e0"}, "arg2": {"span": [[83, 96]], "type": "group", "id": "DDI-DrugBank.d536.s3.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d536.s3-1", "sentence_id": "DDI-DrugBank.d536.s3", "sentence": "When such drugs are withdrawn from patients receiving Acarbose in combination with sulfonylureas or insulin, patients should be observed closely for any evidence of hypoglycemia.", "arg1": {"span": [[54, 62]], "type": "drug", "id": "DDI-DrugBank.d536.s3.e0"}, "arg2": {"span": [[100, 107]], "type": "drug", "id": "DDI-DrugBank.d536.s3.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d536.s3-2", "sentence_id": "DDI-DrugBank.d536.s3", "sentence": "When such drugs are withdrawn from patients receiving Acarbose in combination with sulfonylureas or insulin, patients should be observed closely for any evidence of hypoglycemia.", "arg1": {"span": [[83, 96]], "type": "group", "id": "DDI-DrugBank.d536.s3.e1"}, "arg2": {"span": [[100, 107]], "type": "drug", "id": "DDI-DrugBank.d536.s3.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d536.s5-0", "sentence_id": "DDI-DrugBank.d536.s5", "sentence": "Acarbose has been shown to change the bioavailabillty digoxin when they are co-administered, which may require digoxin dose adjustment.", "arg1": {"span": [[0, 8]], "type": "drug", "id": "DDI-DrugBank.d536.s5.e0"}, "arg2": {"span": [[54, 61]], "type": "drug", "id": "DDI-DrugBank.d536.s5.e1"}, "ddi_label": 1, "ddi_type": "mechanism"}
{"id": "DDI-DrugBank.d536.s5-1", "sentence_id": "DDI-DrugBank.d536.s5", "sentence": "Acarbose has been shown to change the bioavailabillty digoxin when they are co-administered, which may require digoxin dose adjustment.", "arg1": {"span": [[0, 8]], "type": "drug", "id": "DDI-DrugBank.d536.s5.e0"}, "arg2": {"span": [[111, 118]], "type": "drug", "id": "DDI-DrugBank.d536.s5.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d536.s5-2", "sentence_id": "DDI-DrugBank.d536.s5", "sentence": "Acarbose has been shown to change the bioavailabillty digoxin when they are co-administered, which may require digoxin dose adjustment.", "arg1": {"span": [[54, 61]], "type": "drug", "id": "DDI-DrugBank.d536.s5.e1"}, "arg2": {"span": [[111, 118]], "type": "drug", "id": "DDI-DrugBank.d536.s5.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d536.s6-0", "sentence_id": "DDI-DrugBank.d536.s6", "sentence": "Studies in healthy volunteers have shown that Acarbose has no effect on either the pharmacokinetics or pharmacodynamics of digoxin, nifedipine, propranolol, or ranitidine.", "arg1": {"span": [[46, 54]], "type": "drug", "id": "DDI-DrugBank.d536.s6.e0"}, "arg2": {"span": [[123, 130]], "type": "drug", "id": "DDI-DrugBank.d536.s6.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d536.s6-1", "sentence_id": "DDI-DrugBank.d536.s6", "sentence": "Studies in healthy volunteers have shown that Acarbose has no effect on either the pharmacokinetics or pharmacodynamics of digoxin, nifedipine, propranolol, or ranitidine.", "arg1": {"span": [[46, 54]], "type": "drug", "id": "DDI-DrugBank.d536.s6.e0"}, "arg2": {"span": [[132, 142]], "type": "drug", "id": "DDI-DrugBank.d536.s6.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d536.s6-2", "sentence_id": "DDI-DrugBank.d536.s6", "sentence": "Studies in healthy volunteers have shown that Acarbose has no effect on either the pharmacokinetics or pharmacodynamics of digoxin, nifedipine, propranolol, or ranitidine.", "arg1": {"span": [[46, 54]], "type": "drug", "id": "DDI-DrugBank.d536.s6.e0"}, "arg2": {"span": [[144, 155]], "type": "drug", "id": "DDI-DrugBank.d536.s6.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d536.s6-3", "sentence_id": "DDI-DrugBank.d536.s6", "sentence": "Studies in healthy volunteers have shown that Acarbose has no effect on either the pharmacokinetics or pharmacodynamics of digoxin, nifedipine, propranolol, or ranitidine.", "arg1": {"span": [[46, 54]], "type": "drug", "id": "DDI-DrugBank.d536.s6.e0"}, "arg2": {"span": [[160, 170]], "type": "drug", "id": "DDI-DrugBank.d536.s6.e4"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d536.s6-4", "sentence_id": "DDI-DrugBank.d536.s6", "sentence": "Studies in healthy volunteers have shown that Acarbose has no effect on either the pharmacokinetics or pharmacodynamics of digoxin, nifedipine, propranolol, or ranitidine.", "arg1": {"span": [[123, 130]], "type": "drug", "id": "DDI-DrugBank.d536.s6.e1"}, "arg2": {"span": [[132, 142]], "type": "drug", "id": "DDI-DrugBank.d536.s6.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d536.s6-5", "sentence_id": "DDI-DrugBank.d536.s6", "sentence": "Studies in healthy volunteers have shown that Acarbose has no effect on either the pharmacokinetics or pharmacodynamics of digoxin, nifedipine, propranolol, or ranitidine.", "arg1": {"span": [[123, 130]], "type": "drug", "id": "DDI-DrugBank.d536.s6.e1"}, "arg2": {"span": [[144, 155]], "type": "drug", "id": "DDI-DrugBank.d536.s6.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d536.s6-6", "sentence_id": "DDI-DrugBank.d536.s6", "sentence": "Studies in healthy volunteers have shown that Acarbose has no effect on either the pharmacokinetics or pharmacodynamics of digoxin, nifedipine, propranolol, or ranitidine.", "arg1": {"span": [[123, 130]], "type": "drug", "id": "DDI-DrugBank.d536.s6.e1"}, "arg2": {"span": [[160, 170]], "type": "drug", "id": "DDI-DrugBank.d536.s6.e4"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d536.s6-7", "sentence_id": "DDI-DrugBank.d536.s6", "sentence": "Studies in healthy volunteers have shown that Acarbose has no effect on either the pharmacokinetics or pharmacodynamics of digoxin, nifedipine, propranolol, or ranitidine.", "arg1": {"span": [[132, 142]], "type": "drug", "id": "DDI-DrugBank.d536.s6.e2"}, "arg2": {"span": [[144, 155]], "type": "drug", "id": "DDI-DrugBank.d536.s6.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d536.s6-8", "sentence_id": "DDI-DrugBank.d536.s6", "sentence": "Studies in healthy volunteers have shown that Acarbose has no effect on either the pharmacokinetics or pharmacodynamics of digoxin, nifedipine, propranolol, or ranitidine.", "arg1": {"span": [[132, 142]], "type": "drug", "id": "DDI-DrugBank.d536.s6.e2"}, "arg2": {"span": [[160, 170]], "type": "drug", "id": "DDI-DrugBank.d536.s6.e4"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d536.s6-9", "sentence_id": "DDI-DrugBank.d536.s6", "sentence": "Studies in healthy volunteers have shown that Acarbose has no effect on either the pharmacokinetics or pharmacodynamics of digoxin, nifedipine, propranolol, or ranitidine.", "arg1": {"span": [[144, 155]], "type": "drug", "id": "DDI-DrugBank.d536.s6.e3"}, "arg2": {"span": [[160, 170]], "type": "drug", "id": "DDI-DrugBank.d536.s6.e4"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d536.s7-0", "sentence_id": "DDI-DrugBank.d536.s7", "sentence": "Acarbose did not interfere with the absorption or disposition of the sulfonylurea glyburide in diabetic patients.", "arg1": {"span": [[0, 8]], "type": "drug", "id": "DDI-DrugBank.d536.s7.e0"}, "arg2": {"span": [[69, 81]], "type": "drug", "id": "DDI-DrugBank.d536.s7.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d536.s7-1", "sentence_id": "DDI-DrugBank.d536.s7", "sentence": "Acarbose did not interfere with the absorption or disposition of the sulfonylurea glyburide in diabetic patients.", "arg1": {"span": [[0, 8]], "type": "drug", "id": "DDI-DrugBank.d536.s7.e0"}, "arg2": {"span": [[82, 91]], "type": "drug", "id": "DDI-DrugBank.d536.s7.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d536.s7-2", "sentence_id": "DDI-DrugBank.d536.s7", "sentence": "Acarbose did not interfere with the absorption or disposition of the sulfonylurea glyburide in diabetic patients.", "arg1": {"span": [[69, 81]], "type": "drug", "id": "DDI-DrugBank.d536.s7.e1"}, "arg2": {"span": [[82, 91]], "type": "drug", "id": "DDI-DrugBank.d536.s7.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d536.s8-0", "sentence_id": "DDI-DrugBank.d536.s8", "sentence": "Acarbose may affect digoxin bioavailabillty and may require dose adjustment of digoxin by 16% (90% confidence interval: 8-23%), decrease mean C max digoxin by 26% (90% confidence interval: 16-34%) and decrease mean trough concentrations of digoxin by 9% (90% confidence limit: 19% decrease to 2% increase).", "arg1": {"span": [[0, 8]], "type": "drug", "id": "DDI-DrugBank.d536.s8.e0"}, "arg2": {"span": [[20, 27]], "type": "drug", "id": "DDI-DrugBank.d536.s8.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d536.s8-1", "sentence_id": "DDI-DrugBank.d536.s8", "sentence": "Acarbose may affect digoxin bioavailabillty and may require dose adjustment of digoxin by 16% (90% confidence interval: 8-23%), decrease mean C max digoxin by 26% (90% confidence interval: 16-34%) and decrease mean trough concentrations of digoxin by 9% (90% confidence limit: 19% decrease to 2% increase).", "arg1": {"span": [[0, 8]], "type": "drug", "id": "DDI-DrugBank.d536.s8.e0"}, "arg2": {"span": [[79, 86]], "type": "drug", "id": "DDI-DrugBank.d536.s8.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d536.s8-2", "sentence_id": "DDI-DrugBank.d536.s8", "sentence": "Acarbose may affect digoxin bioavailabillty and may require dose adjustment of digoxin by 16% (90% confidence interval: 8-23%), decrease mean C max digoxin by 26% (90% confidence interval: 16-34%) and decrease mean trough concentrations of digoxin by 9% (90% confidence limit: 19% decrease to 2% increase).", "arg1": {"span": [[0, 8]], "type": "drug", "id": "DDI-DrugBank.d536.s8.e0"}, "arg2": {"span": [[148, 155]], "type": "drug", "id": "DDI-DrugBank.d536.s8.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d536.s8-3", "sentence_id": "DDI-DrugBank.d536.s8", "sentence": "Acarbose may affect digoxin bioavailabillty and may require dose adjustment of digoxin by 16% (90% confidence interval: 8-23%), decrease mean C max digoxin by 26% (90% confidence interval: 16-34%) and decrease mean trough concentrations of digoxin by 9% (90% confidence limit: 19% decrease to 2% increase).", "arg1": {"span": [[0, 8]], "type": "drug", "id": "DDI-DrugBank.d536.s8.e0"}, "arg2": {"span": [[240, 247]], "type": "drug", "id": "DDI-DrugBank.d536.s8.e4"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d536.s8-4", "sentence_id": "DDI-DrugBank.d536.s8", "sentence": "Acarbose may affect digoxin bioavailabillty and may require dose adjustment of digoxin by 16% (90% confidence interval: 8-23%), decrease mean C max digoxin by 26% (90% confidence interval: 16-34%) and decrease mean trough concentrations of digoxin by 9% (90% confidence limit: 19% decrease to 2% increase).", "arg1": {"span": [[20, 27]], "type": "drug", "id": "DDI-DrugBank.d536.s8.e1"}, "arg2": {"span": [[79, 86]], "type": "drug", "id": "DDI-DrugBank.d536.s8.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d536.s8-5", "sentence_id": "DDI-DrugBank.d536.s8", "sentence": "Acarbose may affect digoxin bioavailabillty and may require dose adjustment of digoxin by 16% (90% confidence interval: 8-23%), decrease mean C max digoxin by 26% (90% confidence interval: 16-34%) and decrease mean trough concentrations of digoxin by 9% (90% confidence limit: 19% decrease to 2% increase).", "arg1": {"span": [[20, 27]], "type": "drug", "id": "DDI-DrugBank.d536.s8.e1"}, "arg2": {"span": [[148, 155]], "type": "drug", "id": "DDI-DrugBank.d536.s8.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d536.s8-6", "sentence_id": "DDI-DrugBank.d536.s8", "sentence": "Acarbose may affect digoxin bioavailabillty and may require dose adjustment of digoxin by 16% (90% confidence interval: 8-23%), decrease mean C max digoxin by 26% (90% confidence interval: 16-34%) and decrease mean trough concentrations of digoxin by 9% (90% confidence limit: 19% decrease to 2% increase).", "arg1": {"span": [[20, 27]], "type": "drug", "id": "DDI-DrugBank.d536.s8.e1"}, "arg2": {"span": [[240, 247]], "type": "drug", "id": "DDI-DrugBank.d536.s8.e4"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d536.s8-7", "sentence_id": "DDI-DrugBank.d536.s8", "sentence": "Acarbose may affect digoxin bioavailabillty and may require dose adjustment of digoxin by 16% (90% confidence interval: 8-23%), decrease mean C max digoxin by 26% (90% confidence interval: 16-34%) and decrease mean trough concentrations of digoxin by 9% (90% confidence limit: 19% decrease to 2% increase).", "arg1": {"span": [[79, 86]], "type": "drug", "id": "DDI-DrugBank.d536.s8.e2"}, "arg2": {"span": [[148, 155]], "type": "drug", "id": "DDI-DrugBank.d536.s8.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d536.s8-8", "sentence_id": "DDI-DrugBank.d536.s8", "sentence": "Acarbose may affect digoxin bioavailabillty and may require dose adjustment of digoxin by 16% (90% confidence interval: 8-23%), decrease mean C max digoxin by 26% (90% confidence interval: 16-34%) and decrease mean trough concentrations of digoxin by 9% (90% confidence limit: 19% decrease to 2% increase).", "arg1": {"span": [[79, 86]], "type": "drug", "id": "DDI-DrugBank.d536.s8.e2"}, "arg2": {"span": [[240, 247]], "type": "drug", "id": "DDI-DrugBank.d536.s8.e4"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d536.s8-9", "sentence_id": "DDI-DrugBank.d536.s8", "sentence": "Acarbose may affect digoxin bioavailabillty and may require dose adjustment of digoxin by 16% (90% confidence interval: 8-23%), decrease mean C max digoxin by 26% (90% confidence interval: 16-34%) and decrease mean trough concentrations of digoxin by 9% (90% confidence limit: 19% decrease to 2% increase).", "arg1": {"span": [[148, 155]], "type": "drug", "id": "DDI-DrugBank.d536.s8.e3"}, "arg2": {"span": [[240, 247]], "type": "drug", "id": "DDI-DrugBank.d536.s8.e4"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d536.s9-0", "sentence_id": "DDI-DrugBank.d536.s9", "sentence": "The amount of metformin absorbed while taking Acarbose was bioequivalent to the amount absorbed when taking placebo, as indicated by the plasma AUC values.", "arg1": {"span": [[14, 23]], "type": "drug", "id": "DDI-DrugBank.d536.s9.e0"}, "arg2": {"span": [[46, 54]], "type": "drug", "id": "DDI-DrugBank.d536.s9.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d536.s10-0", "sentence_id": "DDI-DrugBank.d536.s10", "sentence": "However, the peak plasma level of metformin was reduced by approximately 20% when taking Acarbose due to a slight delay in the absorption of metformin.", "arg1": {"span": [[34, 43]], "type": "drug", "id": "DDI-DrugBank.d536.s10.e0"}, "arg2": {"span": [[89, 97]], "type": "drug", "id": "DDI-DrugBank.d536.s10.e1"}, "ddi_label": 1, "ddi_type": "mechanism"}
{"id": "DDI-DrugBank.d536.s10-1", "sentence_id": "DDI-DrugBank.d536.s10", "sentence": "However, the peak plasma level of metformin was reduced by approximately 20% when taking Acarbose due to a slight delay in the absorption of metformin.", "arg1": {"span": [[34, 43]], "type": "drug", "id": "DDI-DrugBank.d536.s10.e0"}, "arg2": {"span": [[141, 150]], "type": "drug", "id": "DDI-DrugBank.d536.s10.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d536.s10-2", "sentence_id": "DDI-DrugBank.d536.s10", "sentence": "However, the peak plasma level of metformin was reduced by approximately 20% when taking Acarbose due to a slight delay in the absorption of metformin.", "arg1": {"span": [[89, 97]], "type": "drug", "id": "DDI-DrugBank.d536.s10.e1"}, "arg2": {"span": [[141, 150]], "type": "drug", "id": "DDI-DrugBank.d536.s10.e2"}, "ddi_label": 1, "ddi_type": "mechanism"}
{"id": "DDI-DrugBank.d536.s11-0", "sentence_id": "DDI-DrugBank.d536.s11", "sentence": "There is little if any clinically significant interaction between Acarbose and metformin.", "arg1": {"span": [[66, 74]], "type": "drug", "id": "DDI-DrugBank.d536.s11.e0"}, "arg2": {"span": [[79, 88]], "type": "drug", "id": "DDI-DrugBank.d536.s11.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d197.s2-0", "sentence_id": "DDI-DrugBank.d197.s2", "sentence": "Specific studies have confirmed these effects with sevoflurane, isoflurane, propofol, alfentanil, and midazolam.", "arg1": {"span": [[51, 62]], "type": "drug", "id": "DDI-DrugBank.d197.s2.e0"}, "arg2": {"span": [[64, 74]], "type": "drug", "id": "DDI-DrugBank.d197.s2.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d197.s2-1", "sentence_id": "DDI-DrugBank.d197.s2", "sentence": "Specific studies have confirmed these effects with sevoflurane, isoflurane, propofol, alfentanil, and midazolam.", "arg1": {"span": [[51, 62]], "type": "drug", "id": "DDI-DrugBank.d197.s2.e0"}, "arg2": {"span": [[76, 84]], "type": "drug", "id": "DDI-DrugBank.d197.s2.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d197.s2-2", "sentence_id": "DDI-DrugBank.d197.s2", "sentence": "Specific studies have confirmed these effects with sevoflurane, isoflurane, propofol, alfentanil, and midazolam.", "arg1": {"span": [[51, 62]], "type": "drug", "id": "DDI-DrugBank.d197.s2.e0"}, "arg2": {"span": [[86, 96]], "type": "drug", "id": "DDI-DrugBank.d197.s2.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d197.s2-3", "sentence_id": "DDI-DrugBank.d197.s2", "sentence": "Specific studies have confirmed these effects with sevoflurane, isoflurane, propofol, alfentanil, and midazolam.", "arg1": {"span": [[51, 62]], "type": "drug", "id": "DDI-DrugBank.d197.s2.e0"}, "arg2": {"span": [[102, 111]], "type": "drug", "id": "DDI-DrugBank.d197.s2.e4"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d197.s2-4", "sentence_id": "DDI-DrugBank.d197.s2", "sentence": "Specific studies have confirmed these effects with sevoflurane, isoflurane, propofol, alfentanil, and midazolam.", "arg1": {"span": [[64, 74]], "type": "drug", "id": "DDI-DrugBank.d197.s2.e1"}, "arg2": {"span": [[76, 84]], "type": "drug", "id": "DDI-DrugBank.d197.s2.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d197.s2-5", "sentence_id": "DDI-DrugBank.d197.s2", "sentence": "Specific studies have confirmed these effects with sevoflurane, isoflurane, propofol, alfentanil, and midazolam.", "arg1": {"span": [[64, 74]], "type": "drug", "id": "DDI-DrugBank.d197.s2.e1"}, "arg2": {"span": [[86, 96]], "type": "drug", "id": "DDI-DrugBank.d197.s2.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d197.s2-6", "sentence_id": "DDI-DrugBank.d197.s2", "sentence": "Specific studies have confirmed these effects with sevoflurane, isoflurane, propofol, alfentanil, and midazolam.", "arg1": {"span": [[64, 74]], "type": "drug", "id": "DDI-DrugBank.d197.s2.e1"}, "arg2": {"span": [[102, 111]], "type": "drug", "id": "DDI-DrugBank.d197.s2.e4"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d197.s2-7", "sentence_id": "DDI-DrugBank.d197.s2", "sentence": "Specific studies have confirmed these effects with sevoflurane, isoflurane, propofol, alfentanil, and midazolam.", "arg1": {"span": [[76, 84]], "type": "drug", "id": "DDI-DrugBank.d197.s2.e2"}, "arg2": {"span": [[86, 96]], "type": "drug", "id": "DDI-DrugBank.d197.s2.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d197.s2-8", "sentence_id": "DDI-DrugBank.d197.s2", "sentence": "Specific studies have confirmed these effects with sevoflurane, isoflurane, propofol, alfentanil, and midazolam.", "arg1": {"span": [[76, 84]], "type": "drug", "id": "DDI-DrugBank.d197.s2.e2"}, "arg2": {"span": [[102, 111]], "type": "drug", "id": "DDI-DrugBank.d197.s2.e4"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d197.s2-9", "sentence_id": "DDI-DrugBank.d197.s2", "sentence": "Specific studies have confirmed these effects with sevoflurane, isoflurane, propofol, alfentanil, and midazolam.", "arg1": {"span": [[86, 96]], "type": "drug", "id": "DDI-DrugBank.d197.s2.e3"}, "arg2": {"span": [[102, 111]], "type": "drug", "id": "DDI-DrugBank.d197.s2.e4"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d197.s3-0", "sentence_id": "DDI-DrugBank.d197.s3", "sentence": "No pharmacokinetic interactions between dexmedetomidine and isoflurane, propofol, alfentanil, and midazolam have been demonstrated.", "arg1": {"span": [[40, 55]], "type": "drug", "id": "DDI-DrugBank.d197.s3.e0"}, "arg2": {"span": [[60, 70]], "type": "drug", "id": "DDI-DrugBank.d197.s3.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d197.s3-1", "sentence_id": "DDI-DrugBank.d197.s3", "sentence": "No pharmacokinetic interactions between dexmedetomidine and isoflurane, propofol, alfentanil, and midazolam have been demonstrated.", "arg1": {"span": [[40, 55]], "type": "drug", "id": "DDI-DrugBank.d197.s3.e0"}, "arg2": {"span": [[72, 80]], "type": "drug", "id": "DDI-DrugBank.d197.s3.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d197.s3-2", "sentence_id": "DDI-DrugBank.d197.s3", "sentence": "No pharmacokinetic interactions between dexmedetomidine and isoflurane, propofol, alfentanil, and midazolam have been demonstrated.", "arg1": {"span": [[40, 55]], "type": "drug", "id": "DDI-DrugBank.d197.s3.e0"}, "arg2": {"span": [[82, 92]], "type": "drug", "id": "DDI-DrugBank.d197.s3.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d197.s3-3", "sentence_id": "DDI-DrugBank.d197.s3", "sentence": "No pharmacokinetic interactions between dexmedetomidine and isoflurane, propofol, alfentanil, and midazolam have been demonstrated.", "arg1": {"span": [[40, 55]], "type": "drug", "id": "DDI-DrugBank.d197.s3.e0"}, "arg2": {"span": [[98, 107]], "type": "drug", "id": "DDI-DrugBank.d197.s3.e4"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d197.s3-4", "sentence_id": "DDI-DrugBank.d197.s3", "sentence": "No pharmacokinetic interactions between dexmedetomidine and isoflurane, propofol, alfentanil, and midazolam have been demonstrated.", "arg1": {"span": [[60, 70]], "type": "drug", "id": "DDI-DrugBank.d197.s3.e1"}, "arg2": {"span": [[72, 80]], "type": "drug", "id": "DDI-DrugBank.d197.s3.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d197.s3-5", "sentence_id": "DDI-DrugBank.d197.s3", "sentence": "No pharmacokinetic interactions between dexmedetomidine and isoflurane, propofol, alfentanil, and midazolam have been demonstrated.", "arg1": {"span": [[60, 70]], "type": "drug", "id": "DDI-DrugBank.d197.s3.e1"}, "arg2": {"span": [[82, 92]], "type": "drug", "id": "DDI-DrugBank.d197.s3.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d197.s3-6", "sentence_id": "DDI-DrugBank.d197.s3", "sentence": "No pharmacokinetic interactions between dexmedetomidine and isoflurane, propofol, alfentanil, and midazolam have been demonstrated.", "arg1": {"span": [[60, 70]], "type": "drug", "id": "DDI-DrugBank.d197.s3.e1"}, "arg2": {"span": [[98, 107]], "type": "drug", "id": "DDI-DrugBank.d197.s3.e4"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d197.s3-7", "sentence_id": "DDI-DrugBank.d197.s3", "sentence": "No pharmacokinetic interactions between dexmedetomidine and isoflurane, propofol, alfentanil, and midazolam have been demonstrated.", "arg1": {"span": [[72, 80]], "type": "drug", "id": "DDI-DrugBank.d197.s3.e2"}, "arg2": {"span": [[82, 92]], "type": "drug", "id": "DDI-DrugBank.d197.s3.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d197.s3-8", "sentence_id": "DDI-DrugBank.d197.s3", "sentence": "No pharmacokinetic interactions between dexmedetomidine and isoflurane, propofol, alfentanil, and midazolam have been demonstrated.", "arg1": {"span": [[72, 80]], "type": "drug", "id": "DDI-DrugBank.d197.s3.e2"}, "arg2": {"span": [[98, 107]], "type": "drug", "id": "DDI-DrugBank.d197.s3.e4"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d197.s3-9", "sentence_id": "DDI-DrugBank.d197.s3", "sentence": "No pharmacokinetic interactions between dexmedetomidine and isoflurane, propofol, alfentanil, and midazolam have been demonstrated.", "arg1": {"span": [[82, 92]], "type": "drug", "id": "DDI-DrugBank.d197.s3.e3"}, "arg2": {"span": [[98, 107]], "type": "drug", "id": "DDI-DrugBank.d197.s3.e4"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d197.s5-0", "sentence_id": "DDI-DrugBank.d197.s5", "sentence": "Neuromuscular Blockers: In one study of 10 healthy volunteers, administration of PRECEDEX for 45 minutes at a plasma concentration of 1 (one) ng/mL resulted in no clinically meaningful increases in the magnitude or neuromuscular blockade associated with rocuronium administration.", "arg1": {"span": [[0, 22]], "type": "group", "id": "DDI-DrugBank.d197.s5.e0"}, "arg2": {"span": [[81, 89]], "type": "brand", "id": "DDI-DrugBank.d197.s5.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d197.s5-1", "sentence_id": "DDI-DrugBank.d197.s5", "sentence": "Neuromuscular Blockers: In one study of 10 healthy volunteers, administration of PRECEDEX for 45 minutes at a plasma concentration of 1 (one) ng/mL resulted in no clinically meaningful increases in the magnitude or neuromuscular blockade associated with rocuronium administration.", "arg1": {"span": [[0, 22]], "type": "group", "id": "DDI-DrugBank.d197.s5.e0"}, "arg2": {"span": [[254, 264]], "type": "drug", "id": "DDI-DrugBank.d197.s5.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d197.s5-2", "sentence_id": "DDI-DrugBank.d197.s5", "sentence": "Neuromuscular Blockers: In one study of 10 healthy volunteers, administration of PRECEDEX for 45 minutes at a plasma concentration of 1 (one) ng/mL resulted in no clinically meaningful increases in the magnitude or neuromuscular blockade associated with rocuronium administration.", "arg1": {"span": [[81, 89]], "type": "brand", "id": "DDI-DrugBank.d197.s5.e1"}, "arg2": {"span": [[254, 264]], "type": "drug", "id": "DDI-DrugBank.d197.s5.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d153.s0-0", "sentence_id": "DDI-DrugBank.d153.s0", "sentence": "The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors or tricyclic antidepressants may produce severe, prolonged hypertension.", "arg1": {"span": [[28, 48]], "type": "group", "id": "DDI-DrugBank.d153.s0.e0"}, "arg2": {"span": [[60, 71]], "type": "drug", "id": "DDI-DrugBank.d153.s0.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d153.s0-1", "sentence_id": "DDI-DrugBank.d153.s0", "sentence": "The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors or tricyclic antidepressants may produce severe, prolonged hypertension.", "arg1": {"span": [[28, 48]], "type": "group", "id": "DDI-DrugBank.d153.s0.e0"}, "arg2": {"span": [[75, 89]], "type": "drug", "id": "DDI-DrugBank.d153.s0.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d153.s0-2", "sentence_id": "DDI-DrugBank.d153.s0", "sentence": "The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors or tricyclic antidepressants may produce severe, prolonged hypertension.", "arg1": {"span": [[28, 48]], "type": "group", "id": "DDI-DrugBank.d153.s0.e0"}, "arg2": {"span": [[112, 140]], "type": "group", "id": "DDI-DrugBank.d153.s0.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d153.s0-3", "sentence_id": "DDI-DrugBank.d153.s0", "sentence": "The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors or tricyclic antidepressants may produce severe, prolonged hypertension.", "arg1": {"span": [[28, 48]], "type": "group", "id": "DDI-DrugBank.d153.s0.e0"}, "arg2": {"span": [[144, 169]], "type": "group", "id": "DDI-DrugBank.d153.s0.e4"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d153.s0-4", "sentence_id": "DDI-DrugBank.d153.s0", "sentence": "The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors or tricyclic antidepressants may produce severe, prolonged hypertension.", "arg1": {"span": [[60, 71]], "type": "drug", "id": "DDI-DrugBank.d153.s0.e1"}, "arg2": {"span": [[75, 89]], "type": "drug", "id": "DDI-DrugBank.d153.s0.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d153.s0-5", "sentence_id": "DDI-DrugBank.d153.s0", "sentence": "The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors or tricyclic antidepressants may produce severe, prolonged hypertension.", "arg1": {"span": [[60, 71]], "type": "drug", "id": "DDI-DrugBank.d153.s0.e1"}, "arg2": {"span": [[112, 140]], "type": "group", "id": "DDI-DrugBank.d153.s0.e3"}, "ddi_label": 1, "ddi_type": "effect"}
{"id": "DDI-DrugBank.d153.s0-6", "sentence_id": "DDI-DrugBank.d153.s0", "sentence": "The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors or tricyclic antidepressants may produce severe, prolonged hypertension.", "arg1": {"span": [[60, 71]], "type": "drug", "id": "DDI-DrugBank.d153.s0.e1"}, "arg2": {"span": [[144, 169]], "type": "group", "id": "DDI-DrugBank.d153.s0.e4"}, "ddi_label": 1, "ddi_type": "effect"}
{"id": "DDI-DrugBank.d153.s0-7", "sentence_id": "DDI-DrugBank.d153.s0", "sentence": "The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors or tricyclic antidepressants may produce severe, prolonged hypertension.", "arg1": {"span": [[75, 89]], "type": "drug", "id": "DDI-DrugBank.d153.s0.e2"}, "arg2": {"span": [[112, 140]], "type": "group", "id": "DDI-DrugBank.d153.s0.e3"}, "ddi_label": 1, "ddi_type": "effect"}
{"id": "DDI-DrugBank.d153.s0-8", "sentence_id": "DDI-DrugBank.d153.s0", "sentence": "The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors or tricyclic antidepressants may produce severe, prolonged hypertension.", "arg1": {"span": [[75, 89]], "type": "drug", "id": "DDI-DrugBank.d153.s0.e2"}, "arg2": {"span": [[144, 169]], "type": "group", "id": "DDI-DrugBank.d153.s0.e4"}, "ddi_label": 1, "ddi_type": "effect"}
{"id": "DDI-DrugBank.d153.s0-9", "sentence_id": "DDI-DrugBank.d153.s0", "sentence": "The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors or tricyclic antidepressants may produce severe, prolonged hypertension.", "arg1": {"span": [[112, 140]], "type": "group", "id": "DDI-DrugBank.d153.s0.e3"}, "arg2": {"span": [[144, 169]], "type": "group", "id": "DDI-DrugBank.d153.s0.e4"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d153.s3-0", "sentence_id": "DDI-DrugBank.d153.s3", "sentence": "Concurrent administration of vasopressor drugs and of ergot-type oxytocic drugs may cause severe, persistent hypertension or cerebrovascular accidents.", "arg1": {"span": [[29, 46]], "type": "group", "id": "DDI-DrugBank.d153.s3.e0"}, "arg2": {"span": [[54, 79]], "type": "group", "id": "DDI-DrugBank.d153.s3.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d153.s4-0", "sentence_id": "DDI-DrugBank.d153.s4", "sentence": "Phenothiazines and butyrophenones may reduce or reverse the pressor effect of epinephrine.", "arg1": {"span": [[0, 14]], "type": "group", "id": "DDI-DrugBank.d153.s4.e0"}, "arg2": {"span": [[19, 33]], "type": "group", "id": "DDI-DrugBank.d153.s4.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d153.s4-1", "sentence_id": "DDI-DrugBank.d153.s4", "sentence": "Phenothiazines and butyrophenones may reduce or reverse the pressor effect of epinephrine.", "arg1": {"span": [[0, 14]], "type": "group", "id": "DDI-DrugBank.d153.s4.e0"}, "arg2": {"span": [[78, 89]], "type": "drug", "id": "DDI-DrugBank.d153.s4.e2"}, "ddi_label": 1, "ddi_type": "effect"}
{"id": "DDI-DrugBank.d153.s4-2", "sentence_id": "DDI-DrugBank.d153.s4", "sentence": "Phenothiazines and butyrophenones may reduce or reverse the pressor effect of epinephrine.", "arg1": {"span": [[19, 33]], "type": "group", "id": "DDI-DrugBank.d153.s4.e1"}, "arg2": {"span": [[78, 89]], "type": "drug", "id": "DDI-DrugBank.d153.s4.e2"}, "ddi_label": 1, "ddi_type": "effect"}
{"id": "DDI-DrugBank.d325.s0-0", "sentence_id": "DDI-DrugBank.d325.s0", "sentence": "Because dopamine is metabolized by monoamine oxidase (MAO), inhibition of this enzyme prolongs and potentiates the effect of dopamine.", "arg1": {"span": [[8, 16]], "type": "drug", "id": "DDI-DrugBank.d325.s0.e0"}, "arg2": {"span": [[125, 133]], "type": "drug", "id": "DDI-DrugBank.d325.s0.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d325.s1-0", "sentence_id": "DDI-DrugBank.d325.s1", "sentence": "Patients who have been treated with MAO inhibitors within two to three weeks prior to the administration of dopamine HCl should receive initial doses of dopamine HCl no greater than one-tenth (1/10) of the usual dose.", "arg1": {"span": [[36, 50]], "type": "group", "id": "DDI-DrugBank.d325.s1.e0"}, "arg2": {"span": [[108, 120]], "type": "drug", "id": "DDI-DrugBank.d325.s1.e1"}, "ddi_label": 1, "ddi_type": "advise"}
{"id": "DDI-DrugBank.d325.s1-1", "sentence_id": "DDI-DrugBank.d325.s1", "sentence": "Patients who have been treated with MAO inhibitors within two to three weeks prior to the administration of dopamine HCl should receive initial doses of dopamine HCl no greater than one-tenth (1/10) of the usual dose.", "arg1": {"span": [[36, 50]], "type": "group", "id": "DDI-DrugBank.d325.s1.e0"}, "arg2": {"span": [[153, 165]], "type": "drug", "id": "DDI-DrugBank.d325.s1.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d325.s1-2", "sentence_id": "DDI-DrugBank.d325.s1", "sentence": "Patients who have been treated with MAO inhibitors within two to three weeks prior to the administration of dopamine HCl should receive initial doses of dopamine HCl no greater than one-tenth (1/10) of the usual dose.", "arg1": {"span": [[108, 120]], "type": "drug", "id": "DDI-DrugBank.d325.s1.e1"}, "arg2": {"span": [[153, 165]], "type": "drug", "id": "DDI-DrugBank.d325.s1.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d325.s2-0", "sentence_id": "DDI-DrugBank.d325.s2", "sentence": "Concurrent administration of low-dose dopamine HCl and diuretic agents may produce an additive or potentiating effect on urine flow.", "arg1": {"span": [[38, 50]], "type": "drug", "id": "DDI-DrugBank.d325.s2.e0"}, "arg2": {"span": [[55, 70]], "type": "group", "id": "DDI-DrugBank.d325.s2.e1"}, "ddi_label": 1, "ddi_type": "effect"}
{"id": "DDI-DrugBank.d325.s4-0", "sentence_id": "DDI-DrugBank.d325.s4", "sentence": "Cardiac effects of dopamine are antagonized by beta-adrenergic blocking agents, such as propranolol and metoprolol.", "arg1": {"span": [[19, 27]], "type": "drug", "id": "DDI-DrugBank.d325.s4.e0"}, "arg2": {"span": [[47, 78]], "type": "group", "id": "DDI-DrugBank.d325.s4.e1"}, "ddi_label": 1, "ddi_type": "effect"}
{"id": "DDI-DrugBank.d325.s4-1", "sentence_id": "DDI-DrugBank.d325.s4", "sentence": "Cardiac effects of dopamine are antagonized by beta-adrenergic blocking agents, such as propranolol and metoprolol.", "arg1": {"span": [[19, 27]], "type": "drug", "id": "DDI-DrugBank.d325.s4.e0"}, "arg2": {"span": [[88, 99]], "type": "drug", "id": "DDI-DrugBank.d325.s4.e2"}, "ddi_label": 1, "ddi_type": "effect"}
{"id": "DDI-DrugBank.d325.s4-2", "sentence_id": "DDI-DrugBank.d325.s4", "sentence": "Cardiac effects of dopamine are antagonized by beta-adrenergic blocking agents, such as propranolol and metoprolol.", "arg1": {"span": [[19, 27]], "type": "drug", "id": "DDI-DrugBank.d325.s4.e0"}, "arg2": {"span": [[104, 114]], "type": "drug", "id": "DDI-DrugBank.d325.s4.e3"}, "ddi_label": 1, "ddi_type": "effect"}
{"id": "DDI-DrugBank.d325.s4-3", "sentence_id": "DDI-DrugBank.d325.s4", "sentence": "Cardiac effects of dopamine are antagonized by beta-adrenergic blocking agents, such as propranolol and metoprolol.", "arg1": {"span": [[47, 78]], "type": "group", "id": "DDI-DrugBank.d325.s4.e1"}, "arg2": {"span": [[88, 99]], "type": "drug", "id": "DDI-DrugBank.d325.s4.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d325.s4-4", "sentence_id": "DDI-DrugBank.d325.s4", "sentence": "Cardiac effects of dopamine are antagonized by beta-adrenergic blocking agents, such as propranolol and metoprolol.", "arg1": {"span": [[47, 78]], "type": "group", "id": "DDI-DrugBank.d325.s4.e1"}, "arg2": {"span": [[104, 114]], "type": "drug", "id": "DDI-DrugBank.d325.s4.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d325.s4-5", "sentence_id": "DDI-DrugBank.d325.s4", "sentence": "Cardiac effects of dopamine are antagonized by beta-adrenergic blocking agents, such as propranolol and metoprolol.", "arg1": {"span": [[88, 99]], "type": "drug", "id": "DDI-DrugBank.d325.s4.e2"}, "arg2": {"span": [[104, 114]], "type": "drug", "id": "DDI-DrugBank.d325.s4.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d325.s5-0", "sentence_id": "DDI-DrugBank.d325.s5", "sentence": "The peripheral vasoconstriction caused by high doses of dopamine HCl is antagonized by alpha-adrenergic blocking agents.", "arg1": {"span": [[56, 68]], "type": "drug", "id": "DDI-DrugBank.d325.s5.e0"}, "arg2": {"span": [[87, 119]], "type": "group", "id": "DDI-DrugBank.d325.s5.e1"}, "ddi_label": 1, "ddi_type": "effect"}
{"id": "DDI-DrugBank.d325.s6-0", "sentence_id": "DDI-DrugBank.d325.s6", "sentence": "Dopamine-induced renal and mesenteric vasodilation is not antagonized by either alpha- or beta-adrenergic blocking agents.", "arg1": {"span": [[0, 8]], "type": "drug", "id": "DDI-DrugBank.d325.s6.e0"}, "arg2": {"span": [[90, 121]], "type": "drug", "id": "DDI-DrugBank.d325.s6.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d325.s7-0", "sentence_id": "DDI-DrugBank.d325.s7", "sentence": "Butyrophenones (such as haloperidol) and phenothiazines can suppress the dopaminergic renal and mesenteric vasodilation induced with low dose dopamine infusion.", "arg1": {"span": [[0, 14]], "type": "group", "id": "DDI-DrugBank.d325.s7.e0"}, "arg2": {"span": [[24, 35]], "type": "drug", "id": "DDI-DrugBank.d325.s7.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d325.s7-1", "sentence_id": "DDI-DrugBank.d325.s7", "sentence": "Butyrophenones (such as haloperidol) and phenothiazines can suppress the dopaminergic renal and mesenteric vasodilation induced with low dose dopamine infusion.", "arg1": {"span": [[0, 14]], "type": "group", "id": "DDI-DrugBank.d325.s7.e0"}, "arg2": {"span": [[41, 55]], "type": "group", "id": "DDI-DrugBank.d325.s7.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d325.s7-2", "sentence_id": "DDI-DrugBank.d325.s7", "sentence": "Butyrophenones (such as haloperidol) and phenothiazines can suppress the dopaminergic renal and mesenteric vasodilation induced with low dose dopamine infusion.", "arg1": {"span": [[0, 14]], "type": "group", "id": "DDI-DrugBank.d325.s7.e0"}, "arg2": {"span": [[73, 81]], "type": "drug", "id": "DDI-DrugBank.d325.s7.e3"}, "ddi_label": 1, "ddi_type": "effect"}
{"id": "DDI-DrugBank.d325.s7-3", "sentence_id": "DDI-DrugBank.d325.s7", "sentence": "Butyrophenones (such as haloperidol) and phenothiazines can suppress the dopaminergic renal and mesenteric vasodilation induced with low dose dopamine infusion.", "arg1": {"span": [[24, 35]], "type": "drug", "id": "DDI-DrugBank.d325.s7.e1"}, "arg2": {"span": [[41, 55]], "type": "group", "id": "DDI-DrugBank.d325.s7.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d325.s7-4", "sentence_id": "DDI-DrugBank.d325.s7", "sentence": "Butyrophenones (such as haloperidol) and phenothiazines can suppress the dopaminergic renal and mesenteric vasodilation induced with low dose dopamine infusion.", "arg1": {"span": [[24, 35]], "type": "drug", "id": "DDI-DrugBank.d325.s7.e1"}, "arg2": {"span": [[73, 81]], "type": "drug", "id": "DDI-DrugBank.d325.s7.e3"}, "ddi_label": 1, "ddi_type": "effect"}
{"id": "DDI-DrugBank.d325.s7-5", "sentence_id": "DDI-DrugBank.d325.s7", "sentence": "Butyrophenones (such as haloperidol) and phenothiazines can suppress the dopaminergic renal and mesenteric vasodilation induced with low dose dopamine infusion.", "arg1": {"span": [[41, 55]], "type": "group", "id": "DDI-DrugBank.d325.s7.e2"}, "arg2": {"span": [[73, 81]], "type": "drug", "id": "DDI-DrugBank.d325.s7.e3"}, "ddi_label": 1, "ddi_type": "effect"}
{"id": "DDI-DrugBank.d325.s8-0", "sentence_id": "DDI-DrugBank.d325.s8", "sentence": "Cyclopropane or halogenated hydrocarbon anesthetics increase cardiac autonomic irritability and may sensitize the myocardium to the action of certain intravenously administered catecholamines, such as dopamine.", "arg1": {"span": [[0, 12]], "type": "drug", "id": "DDI-DrugBank.d325.s8.e0"}, "arg2": {"span": [[16, 51]], "type": "group", "id": "DDI-DrugBank.d325.s8.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d325.s8-1", "sentence_id": "DDI-DrugBank.d325.s8", "sentence": "Cyclopropane or halogenated hydrocarbon anesthetics increase cardiac autonomic irritability and may sensitize the myocardium to the action of certain intravenously administered catecholamines, such as dopamine.", "arg1": {"span": [[0, 12]], "type": "drug", "id": "DDI-DrugBank.d325.s8.e0"}, "arg2": {"span": [[177, 191]], "type": "group", "id": "DDI-DrugBank.d325.s8.e2"}, "ddi_label": 1, "ddi_type": "effect"}
{"id": "DDI-DrugBank.d325.s8-2", "sentence_id": "DDI-DrugBank.d325.s8", "sentence": "Cyclopropane or halogenated hydrocarbon anesthetics increase cardiac autonomic irritability and may sensitize the myocardium to the action of certain intravenously administered catecholamines, such as dopamine.", "arg1": {"span": [[0, 12]], "type": "drug", "id": "DDI-DrugBank.d325.s8.e0"}, "arg2": {"span": [[201, 209]], "type": "drug", "id": "DDI-DrugBank.d325.s8.e3"}, "ddi_label": 1, "ddi_type": "effect"}
{"id": "DDI-DrugBank.d325.s8-3", "sentence_id": "DDI-DrugBank.d325.s8", "sentence": "Cyclopropane or halogenated hydrocarbon anesthetics increase cardiac autonomic irritability and may sensitize the myocardium to the action of certain intravenously administered catecholamines, such as dopamine.", "arg1": {"span": [[16, 51]], "type": "group", "id": "DDI-DrugBank.d325.s8.e1"}, "arg2": {"span": [[177, 191]], "type": "group", "id": "DDI-DrugBank.d325.s8.e2"}, "ddi_label": 1, "ddi_type": "effect"}
{"id": "DDI-DrugBank.d325.s8-4", "sentence_id": "DDI-DrugBank.d325.s8", "sentence": "Cyclopropane or halogenated hydrocarbon anesthetics increase cardiac autonomic irritability and may sensitize the myocardium to the action of certain intravenously administered catecholamines, such as dopamine.", "arg1": {"span": [[16, 51]], "type": "group", "id": "DDI-DrugBank.d325.s8.e1"}, "arg2": {"span": [[201, 209]], "type": "drug", "id": "DDI-DrugBank.d325.s8.e3"}, "ddi_label": 1, "ddi_type": "effect"}
{"id": "DDI-DrugBank.d325.s8-5", "sentence_id": "DDI-DrugBank.d325.s8", "sentence": "Cyclopropane or halogenated hydrocarbon anesthetics increase cardiac autonomic irritability and may sensitize the myocardium to the action of certain intravenously administered catecholamines, such as dopamine.", "arg1": {"span": [[177, 191]], "type": "group", "id": "DDI-DrugBank.d325.s8.e2"}, "arg2": {"span": [[201, 209]], "type": "drug", "id": "DDI-DrugBank.d325.s8.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d325.s10-0", "sentence_id": "DDI-DrugBank.d325.s10", "sentence": "Therefore, EXTREME CAUTION should be exercised when administering dopamine HCl to patients receiving cyclopropane or halogenated hydrocarbon anesthetics.", "arg1": {"span": [[66, 78]], "type": "drug", "id": "DDI-DrugBank.d325.s10.e0"}, "arg2": {"span": [[101, 113]], "type": "drug", "id": "DDI-DrugBank.d325.s10.e1"}, "ddi_label": 1, "ddi_type": "advise"}
{"id": "DDI-DrugBank.d325.s10-1", "sentence_id": "DDI-DrugBank.d325.s10", "sentence": "Therefore, EXTREME CAUTION should be exercised when administering dopamine HCl to patients receiving cyclopropane or halogenated hydrocarbon anesthetics.", "arg1": {"span": [[66, 78]], "type": "drug", "id": "DDI-DrugBank.d325.s10.e0"}, "arg2": {"span": [[117, 152]], "type": "group", "id": "DDI-DrugBank.d325.s10.e2"}, "ddi_label": 1, "ddi_type": "advise"}
{"id": "DDI-DrugBank.d325.s10-2", "sentence_id": "DDI-DrugBank.d325.s10", "sentence": "Therefore, EXTREME CAUTION should be exercised when administering dopamine HCl to patients receiving cyclopropane or halogenated hydrocarbon anesthetics.", "arg1": {"span": [[101, 113]], "type": "drug", "id": "DDI-DrugBank.d325.s10.e1"}, "arg2": {"span": [[117, 152]], "type": "group", "id": "DDI-DrugBank.d325.s10.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d325.s11-0", "sentence_id": "DDI-DrugBank.d325.s11", "sentence": "It has been reported that results of studies in animals indicate that dopamine-induced ventricular arrhythmias during anesthesia can be reversed by propranolol.", "arg1": {"span": [[70, 78]], "type": "drug", "id": "DDI-DrugBank.d325.s11.e0"}, "arg2": {"span": [[148, 159]], "type": "drug", "id": "DDI-DrugBank.d325.s11.e1"}, "ddi_label": 1, "ddi_type": "effect"}
{"id": "DDI-DrugBank.d325.s12-0", "sentence_id": "DDI-DrugBank.d325.s12", "sentence": "The concomitant use of vasopressors, vasoconstricting agents (such as ergonovine) and some oxytocic drugs may result in severe hypertension.", "arg1": {"span": [[23, 34]], "type": "group", "id": "DDI-DrugBank.d325.s12.e0"}, "arg2": {"span": [[70, 80]], "type": "drug", "id": "DDI-DrugBank.d325.s12.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d325.s12-1", "sentence_id": "DDI-DrugBank.d325.s12", "sentence": "The concomitant use of vasopressors, vasoconstricting agents (such as ergonovine) and some oxytocic drugs may result in severe hypertension.", "arg1": {"span": [[23, 34]], "type": "group", "id": "DDI-DrugBank.d325.s12.e0"}, "arg2": {"span": [[91, 105]], "type": "group", "id": "DDI-DrugBank.d325.s12.e2"}, "ddi_label": 1, "ddi_type": "effect"}
{"id": "DDI-DrugBank.d325.s12-2", "sentence_id": "DDI-DrugBank.d325.s12", "sentence": "The concomitant use of vasopressors, vasoconstricting agents (such as ergonovine) and some oxytocic drugs may result in severe hypertension.", "arg1": {"span": [[70, 80]], "type": "drug", "id": "DDI-DrugBank.d325.s12.e1"}, "arg2": {"span": [[91, 105]], "type": "group", "id": "DDI-DrugBank.d325.s12.e2"}, "ddi_label": 1, "ddi_type": "effect"}
{"id": "DDI-DrugBank.d325.s13-0", "sentence_id": "DDI-DrugBank.d325.s13", "sentence": "Administration of phenytoin to patients receiving dopamine HCl has been reported to lead to hypotension and bradycardia.", "arg1": {"span": [[18, 27]], "type": "drug", "id": "DDI-DrugBank.d325.s13.e0"}, "arg2": {"span": [[50, 62]], "type": "drug", "id": "DDI-DrugBank.d325.s13.e1"}, "ddi_label": 1, "ddi_type": "effect"}
{"id": "DDI-DrugBank.d325.s14-0", "sentence_id": "DDI-DrugBank.d325.s14", "sentence": "It is suggested that in patients receiving dopamine HCl, alternatives to phenytoin should be used if anticonvulsant therapy is needed.", "arg1": {"span": [[43, 55]], "type": "drug", "id": "DDI-DrugBank.d325.s14.e0"}, "arg2": {"span": [[73, 82]], "type": "drug", "id": "DDI-DrugBank.d325.s14.e1"}, "ddi_label": 1, "ddi_type": "advise"}
{"id": "DDI-DrugBank.d325.s14-1", "sentence_id": "DDI-DrugBank.d325.s14", "sentence": "It is suggested that in patients receiving dopamine HCl, alternatives to phenytoin should be used if anticonvulsant therapy is needed.", "arg1": {"span": [[43, 55]], "type": "drug", "id": "DDI-DrugBank.d325.s14.e0"}, "arg2": {"span": [[101, 115]], "type": "group", "id": "DDI-DrugBank.d325.s14.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d325.s14-2", "sentence_id": "DDI-DrugBank.d325.s14", "sentence": "It is suggested that in patients receiving dopamine HCl, alternatives to phenytoin should be used if anticonvulsant therapy is needed.", "arg1": {"span": [[73, 82]], "type": "drug", "id": "DDI-DrugBank.d325.s14.e1"}, "arg2": {"span": [[101, 115]], "type": "group", "id": "DDI-DrugBank.d325.s14.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d375.s0-0", "sentence_id": "DDI-DrugBank.d375.s0", "sentence": "The potential for drug interactions with EMTRIVA has been studied in combination with indinavir, stavudine, famciclovir, and tenofovir disoproxil fumarate.", "arg1": {"span": [[41, 48]], "type": "brand", "id": "DDI-DrugBank.d375.s0.e0"}, "arg2": {"span": [[86, 95]], "type": "drug", "id": "DDI-DrugBank.d375.s0.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d375.s0-1", "sentence_id": "DDI-DrugBank.d375.s0", "sentence": "The potential for drug interactions with EMTRIVA has been studied in combination with indinavir, stavudine, famciclovir, and tenofovir disoproxil fumarate.", "arg1": {"span": [[41, 48]], "type": "brand", "id": "DDI-DrugBank.d375.s0.e0"}, "arg2": {"span": [[97, 106]], "type": "drug", "id": "DDI-DrugBank.d375.s0.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d375.s0-2", "sentence_id": "DDI-DrugBank.d375.s0", "sentence": "The potential for drug interactions with EMTRIVA has been studied in combination with indinavir, stavudine, famciclovir, and tenofovir disoproxil fumarate.", "arg1": {"span": [[41, 48]], "type": "brand", "id": "DDI-DrugBank.d375.s0.e0"}, "arg2": {"span": [[108, 119]], "type": "drug", "id": "DDI-DrugBank.d375.s0.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d375.s0-3", "sentence_id": "DDI-DrugBank.d375.s0", "sentence": "The potential for drug interactions with EMTRIVA has been studied in combination with indinavir, stavudine, famciclovir, and tenofovir disoproxil fumarate.", "arg1": {"span": [[41, 48]], "type": "brand", "id": "DDI-DrugBank.d375.s0.e0"}, "arg2": {"span": [[125, 154]], "type": "drug", "id": "DDI-DrugBank.d375.s0.e4"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d375.s0-4", "sentence_id": "DDI-DrugBank.d375.s0", "sentence": "The potential for drug interactions with EMTRIVA has been studied in combination with indinavir, stavudine, famciclovir, and tenofovir disoproxil fumarate.", "arg1": {"span": [[86, 95]], "type": "drug", "id": "DDI-DrugBank.d375.s0.e1"}, "arg2": {"span": [[97, 106]], "type": "drug", "id": "DDI-DrugBank.d375.s0.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d375.s0-5", "sentence_id": "DDI-DrugBank.d375.s0", "sentence": "The potential for drug interactions with EMTRIVA has been studied in combination with indinavir, stavudine, famciclovir, and tenofovir disoproxil fumarate.", "arg1": {"span": [[86, 95]], "type": "drug", "id": "DDI-DrugBank.d375.s0.e1"}, "arg2": {"span": [[108, 119]], "type": "drug", "id": "DDI-DrugBank.d375.s0.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d375.s0-6", "sentence_id": "DDI-DrugBank.d375.s0", "sentence": "The potential for drug interactions with EMTRIVA has been studied in combination with indinavir, stavudine, famciclovir, and tenofovir disoproxil fumarate.", "arg1": {"span": [[86, 95]], "type": "drug", "id": "DDI-DrugBank.d375.s0.e1"}, "arg2": {"span": [[125, 154]], "type": "drug", "id": "DDI-DrugBank.d375.s0.e4"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d375.s0-7", "sentence_id": "DDI-DrugBank.d375.s0", "sentence": "The potential for drug interactions with EMTRIVA has been studied in combination with indinavir, stavudine, famciclovir, and tenofovir disoproxil fumarate.", "arg1": {"span": [[97, 106]], "type": "drug", "id": "DDI-DrugBank.d375.s0.e2"}, "arg2": {"span": [[108, 119]], "type": "drug", "id": "DDI-DrugBank.d375.s0.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d375.s0-8", "sentence_id": "DDI-DrugBank.d375.s0", "sentence": "The potential for drug interactions with EMTRIVA has been studied in combination with indinavir, stavudine, famciclovir, and tenofovir disoproxil fumarate.", "arg1": {"span": [[97, 106]], "type": "drug", "id": "DDI-DrugBank.d375.s0.e2"}, "arg2": {"span": [[125, 154]], "type": "drug", "id": "DDI-DrugBank.d375.s0.e4"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d375.s0-9", "sentence_id": "DDI-DrugBank.d375.s0", "sentence": "The potential for drug interactions with EMTRIVA has been studied in combination with indinavir, stavudine, famciclovir, and tenofovir disoproxil fumarate.", "arg1": {"span": [[108, 119]], "type": "drug", "id": "DDI-DrugBank.d375.s0.e3"}, "arg2": {"span": [[125, 154]], "type": "drug", "id": "DDI-DrugBank.d375.s0.e4"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d535.s1-0", "sentence_id": "DDI-DrugBank.d535.s1", "sentence": "Antiretroviral Agents: No drug interactions with other antiretroviral medications have been identified that would warrant alteration of either the enfuvirtide dose or the dose of the other antiretroviral medication.", "arg1": {"span": [[0, 21]], "type": "group", "id": "DDI-DrugBank.d535.s1.e0"}, "arg2": {"span": [[55, 81]], "type": "group", "id": "DDI-DrugBank.d535.s1.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d535.s1-1", "sentence_id": "DDI-DrugBank.d535.s1", "sentence": "Antiretroviral Agents: No drug interactions with other antiretroviral medications have been identified that would warrant alteration of either the enfuvirtide dose or the dose of the other antiretroviral medication.", "arg1": {"span": [[0, 21]], "type": "group", "id": "DDI-DrugBank.d535.s1.e0"}, "arg2": {"span": [[147, 158]], "type": "drug", "id": "DDI-DrugBank.d535.s1.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d535.s1-2", "sentence_id": "DDI-DrugBank.d535.s1", "sentence": "Antiretroviral Agents: No drug interactions with other antiretroviral medications have been identified that would warrant alteration of either the enfuvirtide dose or the dose of the other antiretroviral medication.", "arg1": {"span": [[0, 21]], "type": "group", "id": "DDI-DrugBank.d535.s1.e0"}, "arg2": {"span": [[189, 214]], "type": "group", "id": "DDI-DrugBank.d535.s1.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d535.s1-3", "sentence_id": "DDI-DrugBank.d535.s1", "sentence": "Antiretroviral Agents: No drug interactions with other antiretroviral medications have been identified that would warrant alteration of either the enfuvirtide dose or the dose of the other antiretroviral medication.", "arg1": {"span": [[55, 81]], "type": "group", "id": "DDI-DrugBank.d535.s1.e1"}, "arg2": {"span": [[147, 158]], "type": "drug", "id": "DDI-DrugBank.d535.s1.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d535.s1-4", "sentence_id": "DDI-DrugBank.d535.s1", "sentence": "Antiretroviral Agents: No drug interactions with other antiretroviral medications have been identified that would warrant alteration of either the enfuvirtide dose or the dose of the other antiretroviral medication.", "arg1": {"span": [[55, 81]], "type": "group", "id": "DDI-DrugBank.d535.s1.e1"}, "arg2": {"span": [[189, 214]], "type": "group", "id": "DDI-DrugBank.d535.s1.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d535.s1-5", "sentence_id": "DDI-DrugBank.d535.s1", "sentence": "Antiretroviral Agents: No drug interactions with other antiretroviral medications have been identified that would warrant alteration of either the enfuvirtide dose or the dose of the other antiretroviral medication.", "arg1": {"span": [[147, 158]], "type": "drug", "id": "DDI-DrugBank.d535.s1.e2"}, "arg2": {"span": [[189, 214]], "type": "group", "id": "DDI-DrugBank.d535.s1.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d397.s0-0", "sentence_id": "DDI-DrugBank.d397.s0", "sentence": "Erythromycin use in patients who are receiving high doses of theophylline may be associated with an increase in serum theophylline levels and potential theophylline toxicity.", "arg1": {"span": [[0, 12]], "type": "drug", "id": "DDI-DrugBank.d397.s0.e0"}, "arg2": {"span": [[61, 73]], "type": "drug", "id": "DDI-DrugBank.d397.s0.e1"}, "ddi_label": 1, "ddi_type": "effect"}
{"id": "DDI-DrugBank.d397.s0-1", "sentence_id": "DDI-DrugBank.d397.s0", "sentence": "Erythromycin use in patients who are receiving high doses of theophylline may be associated with an increase in serum theophylline levels and potential theophylline toxicity.", "arg1": {"span": [[0, 12]], "type": "drug", "id": "DDI-DrugBank.d397.s0.e0"}, "arg2": {"span": [[118, 130]], "type": "drug", "id": "DDI-DrugBank.d397.s0.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d397.s0-2", "sentence_id": "DDI-DrugBank.d397.s0", "sentence": "Erythromycin use in patients who are receiving high doses of theophylline may be associated with an increase in serum theophylline levels and potential theophylline toxicity.", "arg1": {"span": [[0, 12]], "type": "drug", "id": "DDI-DrugBank.d397.s0.e0"}, "arg2": {"span": [[152, 164]], "type": "drug", "id": "DDI-DrugBank.d397.s0.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d397.s0-3", "sentence_id": "DDI-DrugBank.d397.s0", "sentence": "Erythromycin use in patients who are receiving high doses of theophylline may be associated with an increase in serum theophylline levels and potential theophylline toxicity.", "arg1": {"span": [[61, 73]], "type": "drug", "id": "DDI-DrugBank.d397.s0.e1"}, "arg2": {"span": [[118, 130]], "type": "drug", "id": "DDI-DrugBank.d397.s0.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d397.s0-4", "sentence_id": "DDI-DrugBank.d397.s0", "sentence": "Erythromycin use in patients who are receiving high doses of theophylline may be associated with an increase in serum theophylline levels and potential theophylline toxicity.", "arg1": {"span": [[61, 73]], "type": "drug", "id": "DDI-DrugBank.d397.s0.e1"}, "arg2": {"span": [[152, 164]], "type": "drug", "id": "DDI-DrugBank.d397.s0.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d397.s0-5", "sentence_id": "DDI-DrugBank.d397.s0", "sentence": "Erythromycin use in patients who are receiving high doses of theophylline may be associated with an increase in serum theophylline levels and potential theophylline toxicity.", "arg1": {"span": [[118, 130]], "type": "drug", "id": "DDI-DrugBank.d397.s0.e2"}, "arg2": {"span": [[152, 164]], "type": "drug", "id": "DDI-DrugBank.d397.s0.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d397.s1-0", "sentence_id": "DDI-DrugBank.d397.s1", "sentence": "In case of theophylline toxicity and/or elevated serum theophylline levels, the dose of theophylline should be reduced while the patient is receiving concomitant erythromycin therapy.", "arg1": {"span": [[11, 23]], "type": "drug", "id": "DDI-DrugBank.d397.s1.e0"}, "arg2": {"span": [[55, 67]], "type": "drug", "id": "DDI-DrugBank.d397.s1.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d397.s1-1", "sentence_id": "DDI-DrugBank.d397.s1", "sentence": "In case of theophylline toxicity and/or elevated serum theophylline levels, the dose of theophylline should be reduced while the patient is receiving concomitant erythromycin therapy.", "arg1": {"span": [[11, 23]], "type": "drug", "id": "DDI-DrugBank.d397.s1.e0"}, "arg2": {"span": [[88, 100]], "type": "drug", "id": "DDI-DrugBank.d397.s1.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d397.s1-2", "sentence_id": "DDI-DrugBank.d397.s1", "sentence": "In case of theophylline toxicity and/or elevated serum theophylline levels, the dose of theophylline should be reduced while the patient is receiving concomitant erythromycin therapy.", "arg1": {"span": [[11, 23]], "type": "drug", "id": "DDI-DrugBank.d397.s1.e0"}, "arg2": {"span": [[162, 174]], "type": "drug", "id": "DDI-DrugBank.d397.s1.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d397.s1-3", "sentence_id": "DDI-DrugBank.d397.s1", "sentence": "In case of theophylline toxicity and/or elevated serum theophylline levels, the dose of theophylline should be reduced while the patient is receiving concomitant erythromycin therapy.", "arg1": {"span": [[55, 67]], "type": "drug", "id": "DDI-DrugBank.d397.s1.e1"}, "arg2": {"span": [[88, 100]], "type": "drug", "id": "DDI-DrugBank.d397.s1.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d397.s1-4", "sentence_id": "DDI-DrugBank.d397.s1", "sentence": "In case of theophylline toxicity and/or elevated serum theophylline levels, the dose of theophylline should be reduced while the patient is receiving concomitant erythromycin therapy.", "arg1": {"span": [[55, 67]], "type": "drug", "id": "DDI-DrugBank.d397.s1.e1"}, "arg2": {"span": [[162, 174]], "type": "drug", "id": "DDI-DrugBank.d397.s1.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d397.s1-5", "sentence_id": "DDI-DrugBank.d397.s1", "sentence": "In case of theophylline toxicity and/or elevated serum theophylline levels, the dose of theophylline should be reduced while the patient is receiving concomitant erythromycin therapy.", "arg1": {"span": [[88, 100]], "type": "drug", "id": "DDI-DrugBank.d397.s1.e2"}, "arg2": {"span": [[162, 174]], "type": "drug", "id": "DDI-DrugBank.d397.s1.e3"}, "ddi_label": 1, "ddi_type": "advise"}
{"id": "DDI-DrugBank.d397.s2-0", "sentence_id": "DDI-DrugBank.d397.s2", "sentence": "Concomitant administration of erythromycin and digoxin has been reported to result in elevated digoxin serum levels.", "arg1": {"span": [[30, 42]], "type": "drug", "id": "DDI-DrugBank.d397.s2.e0"}, "arg2": {"span": [[47, 54]], "type": "drug", "id": "DDI-DrugBank.d397.s2.e1"}, "ddi_label": 1, "ddi_type": "mechanism"}
{"id": "DDI-DrugBank.d397.s2-1", "sentence_id": "DDI-DrugBank.d397.s2", "sentence": "Concomitant administration of erythromycin and digoxin has been reported to result in elevated digoxin serum levels.", "arg1": {"span": [[30, 42]], "type": "drug", "id": "DDI-DrugBank.d397.s2.e0"}, "arg2": {"span": [[95, 102]], "type": "drug", "id": "DDI-DrugBank.d397.s2.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d397.s2-2", "sentence_id": "DDI-DrugBank.d397.s2", "sentence": "Concomitant administration of erythromycin and digoxin has been reported to result in elevated digoxin serum levels.", "arg1": {"span": [[47, 54]], "type": "drug", "id": "DDI-DrugBank.d397.s2.e1"}, "arg2": {"span": [[95, 102]], "type": "drug", "id": "DDI-DrugBank.d397.s2.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d397.s3-0", "sentence_id": "DDI-DrugBank.d397.s3", "sentence": "There have been reports of increased anticoagulant effects when erythromycin and oral anticoagulants were used concomitantly.", "arg1": {"span": [[64, 76]], "type": "drug", "id": "DDI-DrugBank.d397.s3.e0"}, "arg2": {"span": [[86, 100]], "type": "group", "id": "DDI-DrugBank.d397.s3.e1"}, "ddi_label": 1, "ddi_type": "effect"}
{"id": "DDI-DrugBank.d397.s5-0", "sentence_id": "DDI-DrugBank.d397.s5", "sentence": "Concurrent use of erythromycin and ergotamine or dihydroergotamine has been associated in some patients with acute ergot toxicity characterized by severe peripheral vasospasm and dysesthesia.", "arg1": {"span": [[18, 30]], "type": "drug", "id": "DDI-DrugBank.d397.s5.e0"}, "arg2": {"span": [[35, 45]], "type": "drug", "id": "DDI-DrugBank.d397.s5.e1"}, "ddi_label": 1, "ddi_type": "effect"}
{"id": "DDI-DrugBank.d397.s5-1", "sentence_id": "DDI-DrugBank.d397.s5", "sentence": "Concurrent use of erythromycin and ergotamine or dihydroergotamine has been associated in some patients with acute ergot toxicity characterized by severe peripheral vasospasm and dysesthesia.", "arg1": {"span": [[18, 30]], "type": "drug", "id": "DDI-DrugBank.d397.s5.e0"}, "arg2": {"span": [[49, 66]], "type": "drug", "id": "DDI-DrugBank.d397.s5.e2"}, "ddi_label": 1, "ddi_type": "effect"}
{"id": "DDI-DrugBank.d397.s5-2", "sentence_id": "DDI-DrugBank.d397.s5", "sentence": "Concurrent use of erythromycin and ergotamine or dihydroergotamine has been associated in some patients with acute ergot toxicity characterized by severe peripheral vasospasm and dysesthesia.", "arg1": {"span": [[35, 45]], "type": "drug", "id": "DDI-DrugBank.d397.s5.e1"}, "arg2": {"span": [[49, 66]], "type": "drug", "id": "DDI-DrugBank.d397.s5.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d397.s6-0", "sentence_id": "DDI-DrugBank.d397.s6", "sentence": "Erythromycin has been reported to decrease the clearance of triazolam and midazolam and thus may increase the pharmacologic effect of these benzodiazepines.", "arg1": {"span": [[0, 12]], "type": "drug", "id": "DDI-DrugBank.d397.s6.e0"}, "arg2": {"span": [[60, 69]], "type": "drug", "id": "DDI-DrugBank.d397.s6.e1"}, "ddi_label": 1, "ddi_type": "mechanism"}
{"id": "DDI-DrugBank.d397.s6-1", "sentence_id": "DDI-DrugBank.d397.s6", "sentence": "Erythromycin has been reported to decrease the clearance of triazolam and midazolam and thus may increase the pharmacologic effect of these benzodiazepines.", "arg1": {"span": [[0, 12]], "type": "drug", "id": "DDI-DrugBank.d397.s6.e0"}, "arg2": {"span": [[74, 83]], "type": "drug", "id": "DDI-DrugBank.d397.s6.e2"}, "ddi_label": 1, "ddi_type": "mechanism"}
{"id": "DDI-DrugBank.d397.s6-2", "sentence_id": "DDI-DrugBank.d397.s6", "sentence": "Erythromycin has been reported to decrease the clearance of triazolam and midazolam and thus may increase the pharmacologic effect of these benzodiazepines.", "arg1": {"span": [[0, 12]], "type": "drug", "id": "DDI-DrugBank.d397.s6.e0"}, "arg2": {"span": [[140, 155]], "type": "group", "id": "DDI-DrugBank.d397.s6.e3"}, "ddi_label": 1, "ddi_type": "effect"}
{"id": "DDI-DrugBank.d397.s6-3", "sentence_id": "DDI-DrugBank.d397.s6", "sentence": "Erythromycin has been reported to decrease the clearance of triazolam and midazolam and thus may increase the pharmacologic effect of these benzodiazepines.", "arg1": {"span": [[60, 69]], "type": "drug", "id": "DDI-DrugBank.d397.s6.e1"}, "arg2": {"span": [[74, 83]], "type": "drug", "id": "DDI-DrugBank.d397.s6.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d397.s6-4", "sentence_id": "DDI-DrugBank.d397.s6", "sentence": "Erythromycin has been reported to decrease the clearance of triazolam and midazolam and thus may increase the pharmacologic effect of these benzodiazepines.", "arg1": {"span": [[60, 69]], "type": "drug", "id": "DDI-DrugBank.d397.s6.e1"}, "arg2": {"span": [[140, 155]], "type": "group", "id": "DDI-DrugBank.d397.s6.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d397.s6-5", "sentence_id": "DDI-DrugBank.d397.s6", "sentence": "Erythromycin has been reported to decrease the clearance of triazolam and midazolam and thus may increase the pharmacologic effect of these benzodiazepines.", "arg1": {"span": [[74, 83]], "type": "drug", "id": "DDI-DrugBank.d397.s6.e2"}, "arg2": {"span": [[140, 155]], "type": "group", "id": "DDI-DrugBank.d397.s6.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d397.s10-0", "sentence_id": "DDI-DrugBank.d397.s10", "sentence": "Erythromycin has been reported to significantly alter the metabolism of nonsedating antihistamines terfenadine and astemizole when taken concomitantly.", "arg1": {"span": [[0, 12]], "type": "drug", "id": "DDI-DrugBank.d397.s10.e0"}, "arg2": {"span": [[84, 98]], "type": "group", "id": "DDI-DrugBank.d397.s10.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d397.s10-1", "sentence_id": "DDI-DrugBank.d397.s10", "sentence": "Erythromycin has been reported to significantly alter the metabolism of nonsedating antihistamines terfenadine and astemizole when taken concomitantly.", "arg1": {"span": [[0, 12]], "type": "drug", "id": "DDI-DrugBank.d397.s10.e0"}, "arg2": {"span": [[99, 110]], "type": "drug", "id": "DDI-DrugBank.d397.s10.e2"}, "ddi_label": 1, "ddi_type": "mechanism"}
{"id": "DDI-DrugBank.d397.s10-2", "sentence_id": "DDI-DrugBank.d397.s10", "sentence": "Erythromycin has been reported to significantly alter the metabolism of nonsedating antihistamines terfenadine and astemizole when taken concomitantly.", "arg1": {"span": [[0, 12]], "type": "drug", "id": "DDI-DrugBank.d397.s10.e0"}, "arg2": {"span": [[115, 125]], "type": "drug", "id": "DDI-DrugBank.d397.s10.e3"}, "ddi_label": 1, "ddi_type": "mechanism"}
{"id": "DDI-DrugBank.d397.s10-3", "sentence_id": "DDI-DrugBank.d397.s10", "sentence": "Erythromycin has been reported to significantly alter the metabolism of nonsedating antihistamines terfenadine and astemizole when taken concomitantly.", "arg1": {"span": [[84, 98]], "type": "group", "id": "DDI-DrugBank.d397.s10.e1"}, "arg2": {"span": [[99, 110]], "type": "drug", "id": "DDI-DrugBank.d397.s10.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d397.s10-4", "sentence_id": "DDI-DrugBank.d397.s10", "sentence": "Erythromycin has been reported to significantly alter the metabolism of nonsedating antihistamines terfenadine and astemizole when taken concomitantly.", "arg1": {"span": [[84, 98]], "type": "group", "id": "DDI-DrugBank.d397.s10.e1"}, "arg2": {"span": [[115, 125]], "type": "drug", "id": "DDI-DrugBank.d397.s10.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d397.s10-5", "sentence_id": "DDI-DrugBank.d397.s10", "sentence": "Erythromycin has been reported to significantly alter the metabolism of nonsedating antihistamines terfenadine and astemizole when taken concomitantly.", "arg1": {"span": [[99, 110]], "type": "drug", "id": "DDI-DrugBank.d397.s10.e2"}, "arg2": {"span": [[115, 125]], "type": "drug", "id": "DDI-DrugBank.d397.s10.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d397.s12-0", "sentence_id": "DDI-DrugBank.d397.s12", "sentence": "In addition, deaths have been reported rarely with concomitant administration of terfenadine and erythromycin.", "arg1": {"span": [[81, 92]], "type": "drug", "id": "DDI-DrugBank.d397.s12.e0"}, "arg2": {"span": [[97, 109]], "type": "drug", "id": "DDI-DrugBank.d397.s12.e1"}, "ddi_label": 1, "ddi_type": "effect"}
{"id": "DDI-DrugBank.d397.s13-0", "sentence_id": "DDI-DrugBank.d397.s13", "sentence": "There have been postmarketing reports of drug interactions when erythromycin is coadministered with cisapride, resulting in QT prolongation, cardiac arrythmias, ventricular tachycardia, ventricular fibrulation, and torsades de pointes, most like due to inhibition of hepatic metabolism of cisapride by erythromycin.", "arg1": {"span": [[64, 76]], "type": "drug", "id": "DDI-DrugBank.d397.s13.e0"}, "arg2": {"span": [[100, 109]], "type": "drug", "id": "DDI-DrugBank.d397.s13.e1"}, "ddi_label": 1, "ddi_type": "effect"}
{"id": "DDI-DrugBank.d397.s13-1", "sentence_id": "DDI-DrugBank.d397.s13", "sentence": "There have been postmarketing reports of drug interactions when erythromycin is coadministered with cisapride, resulting in QT prolongation, cardiac arrythmias, ventricular tachycardia, ventricular fibrulation, and torsades de pointes, most like due to inhibition of hepatic metabolism of cisapride by erythromycin.", "arg1": {"span": [[64, 76]], "type": "drug", "id": "DDI-DrugBank.d397.s13.e0"}, "arg2": {"span": [[289, 298]], "type": "drug", "id": "DDI-DrugBank.d397.s13.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d397.s13-2", "sentence_id": "DDI-DrugBank.d397.s13", "sentence": "There have been postmarketing reports of drug interactions when erythromycin is coadministered with cisapride, resulting in QT prolongation, cardiac arrythmias, ventricular tachycardia, ventricular fibrulation, and torsades de pointes, most like due to inhibition of hepatic metabolism of cisapride by erythromycin.", "arg1": {"span": [[64, 76]], "type": "drug", "id": "DDI-DrugBank.d397.s13.e0"}, "arg2": {"span": [[302, 314]], "type": "drug", "id": "DDI-DrugBank.d397.s13.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d397.s13-3", "sentence_id": "DDI-DrugBank.d397.s13", "sentence": "There have been postmarketing reports of drug interactions when erythromycin is coadministered with cisapride, resulting in QT prolongation, cardiac arrythmias, ventricular tachycardia, ventricular fibrulation, and torsades de pointes, most like due to inhibition of hepatic metabolism of cisapride by erythromycin.", "arg1": {"span": [[100, 109]], "type": "drug", "id": "DDI-DrugBank.d397.s13.e1"}, "arg2": {"span": [[289, 298]], "type": "drug", "id": "DDI-DrugBank.d397.s13.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d397.s13-4", "sentence_id": "DDI-DrugBank.d397.s13", "sentence": "There have been postmarketing reports of drug interactions when erythromycin is coadministered with cisapride, resulting in QT prolongation, cardiac arrythmias, ventricular tachycardia, ventricular fibrulation, and torsades de pointes, most like due to inhibition of hepatic metabolism of cisapride by erythromycin.", "arg1": {"span": [[100, 109]], "type": "drug", "id": "DDI-DrugBank.d397.s13.e1"}, "arg2": {"span": [[302, 314]], "type": "drug", "id": "DDI-DrugBank.d397.s13.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d397.s13-5", "sentence_id": "DDI-DrugBank.d397.s13", "sentence": "There have been postmarketing reports of drug interactions when erythromycin is coadministered with cisapride, resulting in QT prolongation, cardiac arrythmias, ventricular tachycardia, ventricular fibrulation, and torsades de pointes, most like due to inhibition of hepatic metabolism of cisapride by erythromycin.", "arg1": {"span": [[289, 298]], "type": "drug", "id": "DDI-DrugBank.d397.s13.e2"}, "arg2": {"span": [[302, 314]], "type": "drug", "id": "DDI-DrugBank.d397.s13.e3"}, "ddi_label": 1, "ddi_type": "mechanism"}
{"id": "DDI-DrugBank.d397.s15-0", "sentence_id": "DDI-DrugBank.d397.s15", "sentence": "Patients receiving concomitant lovastatin and erythromycin should be carefully monitored;", "arg1": {"span": [[31, 41]], "type": "drug", "id": "DDI-DrugBank.d397.s15.e0"}, "arg2": {"span": [[46, 58]], "type": "drug", "id": "DDI-DrugBank.d397.s15.e1"}, "ddi_label": 1, "ddi_type": "advise"}
{"id": "DDI-DrugBank.d369.s1-0", "sentence_id": "DDI-DrugBank.d369.s1", "sentence": "These would include a variety of preparations which contain androgens, estrogens, progestins, or glucocorticoids.", "arg1": {"span": [[60, 69]], "type": "group", "id": "DDI-DrugBank.d369.s1.e0"}, "arg2": {"span": [[71, 80]], "type": "group", "id": "DDI-DrugBank.d369.s1.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d369.s1-1", "sentence_id": "DDI-DrugBank.d369.s1", "sentence": "These would include a variety of preparations which contain androgens, estrogens, progestins, or glucocorticoids.", "arg1": {"span": [[60, 69]], "type": "group", "id": "DDI-DrugBank.d369.s1.e0"}, "arg2": {"span": [[82, 92]], "type": "group", "id": "DDI-DrugBank.d369.s1.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d369.s1-2", "sentence_id": "DDI-DrugBank.d369.s1", "sentence": "These would include a variety of preparations which contain androgens, estrogens, progestins, or glucocorticoids.", "arg1": {"span": [[60, 69]], "type": "group", "id": "DDI-DrugBank.d369.s1.e0"}, "arg2": {"span": [[97, 112]], "type": "group", "id": "DDI-DrugBank.d369.s1.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d369.s1-3", "sentence_id": "DDI-DrugBank.d369.s1", "sentence": "These would include a variety of preparations which contain androgens, estrogens, progestins, or glucocorticoids.", "arg1": {"span": [[71, 80]], "type": "group", "id": "DDI-DrugBank.d369.s1.e1"}, "arg2": {"span": [[82, 92]], "type": "group", "id": "DDI-DrugBank.d369.s1.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d369.s1-4", "sentence_id": "DDI-DrugBank.d369.s1", "sentence": "These would include a variety of preparations which contain androgens, estrogens, progestins, or glucocorticoids.", "arg1": {"span": [[71, 80]], "type": "group", "id": "DDI-DrugBank.d369.s1.e1"}, "arg2": {"span": [[97, 112]], "type": "group", "id": "DDI-DrugBank.d369.s1.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d369.s1-5", "sentence_id": "DDI-DrugBank.d369.s1", "sentence": "These would include a variety of preparations which contain androgens, estrogens, progestins, or glucocorticoids.", "arg1": {"span": [[82, 92]], "type": "group", "id": "DDI-DrugBank.d369.s1.e2"}, "arg2": {"span": [[97, 112]], "type": "group", "id": "DDI-DrugBank.d369.s1.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d369.s2-0", "sentence_id": "DDI-DrugBank.d369.s2", "sentence": "The gonadotropin levels may be transiently elevated by spironolactone, minimally elevated by levodopa, and suppressed by oral contraceptives and digoxin.", "arg1": {"span": [[55, 69]], "type": "drug", "id": "DDI-DrugBank.d369.s2.e0"}, "arg2": {"span": [[93, 101]], "type": "drug", "id": "DDI-DrugBank.d369.s2.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d369.s2-1", "sentence_id": "DDI-DrugBank.d369.s2", "sentence": "The gonadotropin levels may be transiently elevated by spironolactone, minimally elevated by levodopa, and suppressed by oral contraceptives and digoxin.", "arg1": {"span": [[55, 69]], "type": "drug", "id": "DDI-DrugBank.d369.s2.e0"}, "arg2": {"span": [[126, 140]], "type": "group", "id": "DDI-DrugBank.d369.s2.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d369.s2-2", "sentence_id": "DDI-DrugBank.d369.s2", "sentence": "The gonadotropin levels may be transiently elevated by spironolactone, minimally elevated by levodopa, and suppressed by oral contraceptives and digoxin.", "arg1": {"span": [[55, 69]], "type": "drug", "id": "DDI-DrugBank.d369.s2.e0"}, "arg2": {"span": [[145, 152]], "type": "drug", "id": "DDI-DrugBank.d369.s2.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d369.s2-3", "sentence_id": "DDI-DrugBank.d369.s2", "sentence": "The gonadotropin levels may be transiently elevated by spironolactone, minimally elevated by levodopa, and suppressed by oral contraceptives and digoxin.", "arg1": {"span": [[93, 101]], "type": "drug", "id": "DDI-DrugBank.d369.s2.e1"}, "arg2": {"span": [[126, 140]], "type": "group", "id": "DDI-DrugBank.d369.s2.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d369.s2-4", "sentence_id": "DDI-DrugBank.d369.s2", "sentence": "The gonadotropin levels may be transiently elevated by spironolactone, minimally elevated by levodopa, and suppressed by oral contraceptives and digoxin.", "arg1": {"span": [[93, 101]], "type": "drug", "id": "DDI-DrugBank.d369.s2.e1"}, "arg2": {"span": [[145, 152]], "type": "drug", "id": "DDI-DrugBank.d369.s2.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d369.s2-5", "sentence_id": "DDI-DrugBank.d369.s2", "sentence": "The gonadotropin levels may be transiently elevated by spironolactone, minimally elevated by levodopa, and suppressed by oral contraceptives and digoxin.", "arg1": {"span": [[126, 140]], "type": "group", "id": "DDI-DrugBank.d369.s2.e2"}, "arg2": {"span": [[145, 152]], "type": "drug", "id": "DDI-DrugBank.d369.s2.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d369.s3-0", "sentence_id": "DDI-DrugBank.d369.s3", "sentence": "The response to Factrel may be blunted by phenothiazines and dopamine antagonists which cause a rise in prolactin.", "arg1": {"span": [[16, 23]], "type": "brand", "id": "DDI-DrugBank.d369.s3.e0"}, "arg2": {"span": [[42, 56]], "type": "group", "id": "DDI-DrugBank.d369.s3.e1"}, "ddi_label": 1, "ddi_type": "effect"}
{"id": "DDI-DrugBank.d369.s3-1", "sentence_id": "DDI-DrugBank.d369.s3", "sentence": "The response to Factrel may be blunted by phenothiazines and dopamine antagonists which cause a rise in prolactin.", "arg1": {"span": [[16, 23]], "type": "brand", "id": "DDI-DrugBank.d369.s3.e0"}, "arg2": {"span": [[61, 81]], "type": "group", "id": "DDI-DrugBank.d369.s3.e2"}, "ddi_label": 1, "ddi_type": "effect"}
{"id": "DDI-DrugBank.d369.s3-2", "sentence_id": "DDI-DrugBank.d369.s3", "sentence": "The response to Factrel may be blunted by phenothiazines and dopamine antagonists which cause a rise in prolactin.", "arg1": {"span": [[42, 56]], "type": "group", "id": "DDI-DrugBank.d369.s3.e1"}, "arg2": {"span": [[61, 81]], "type": "group", "id": "DDI-DrugBank.d369.s3.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d320.s0-0", "sentence_id": "DDI-DrugBank.d320.s0", "sentence": "Chirocaine   should be used with caution in patients receiving other local anesthetics or agents structurally related to amide-type local anesthetics since the toxic effects of these drugs could be additive.", "arg1": {"span": [[0, 10]], "type": "brand", "id": "DDI-DrugBank.d320.s0.e0"}, "arg2": {"span": [[75, 86]], "type": "group", "id": "DDI-DrugBank.d320.s0.e1"}, "ddi_label": 1, "ddi_type": "advise"}
{"id": "DDI-DrugBank.d320.s1-0", "sentence_id": "DDI-DrugBank.d320.s1", "sentence": "In vitro studies indicate CYP3A4 isoform and CYP1A2 isoform mediate the metabolism of levobupivacaine to desbutyl levobupivacaine and 3-hydroxy levobupivacaine, respectively.", "arg1": {"span": [[86, 101]], "type": "drug", "id": "DDI-DrugBank.d320.s1.e0"}, "arg2": {"span": [[105, 129]], "type": "drug_n", "id": "DDI-DrugBank.d320.s1.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d320.s1-1", "sentence_id": "DDI-DrugBank.d320.s1", "sentence": "In vitro studies indicate CYP3A4 isoform and CYP1A2 isoform mediate the metabolism of levobupivacaine to desbutyl levobupivacaine and 3-hydroxy levobupivacaine, respectively.", "arg1": {"span": [[86, 101]], "type": "drug", "id": "DDI-DrugBank.d320.s1.e0"}, "arg2": {"span": [[134, 159]], "type": "drug_n", "id": "DDI-DrugBank.d320.s1.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d320.s1-2", "sentence_id": "DDI-DrugBank.d320.s1", "sentence": "In vitro studies indicate CYP3A4 isoform and CYP1A2 isoform mediate the metabolism of levobupivacaine to desbutyl levobupivacaine and 3-hydroxy levobupivacaine, respectively.", "arg1": {"span": [[105, 129]], "type": "drug_n", "id": "DDI-DrugBank.d320.s1.e1"}, "arg2": {"span": [[134, 159]], "type": "drug_n", "id": "DDI-DrugBank.d320.s1.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d320.s2-0", "sentence_id": "DDI-DrugBank.d320.s2", "sentence": "Thus agents likely to be concomitantly administered with Chirocaine that are metabolized by this isoenzyme family may potentially interact with Chirocaine.", "arg1": {"span": [[57, 67]], "type": "brand", "id": "DDI-DrugBank.d320.s2.e0"}, "arg2": {"span": [[144, 154]], "type": "brand", "id": "DDI-DrugBank.d320.s2.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d320.s3-0", "sentence_id": "DDI-DrugBank.d320.s3", "sentence": "Although no clinical studies have been conducted, it is likely that the metabolism of levobupivacaine may be affected by the known CYP3A4 inducers (such as phenytoin, phenobarbital, rifampin), CYP3A4 inhibitors (azole antimycotics e.g., ketoconazole;", "arg1": {"span": [[86, 101]], "type": "drug", "id": "DDI-DrugBank.d320.s3.e0"}, "arg2": {"span": [[156, 165]], "type": "drug", "id": "DDI-DrugBank.d320.s3.e1"}, "ddi_label": 1, "ddi_type": "mechanism"}
{"id": "DDI-DrugBank.d320.s3-1", "sentence_id": "DDI-DrugBank.d320.s3", "sentence": "Although no clinical studies have been conducted, it is likely that the metabolism of levobupivacaine may be affected by the known CYP3A4 inducers (such as phenytoin, phenobarbital, rifampin), CYP3A4 inhibitors (azole antimycotics e.g., ketoconazole;", "arg1": {"span": [[86, 101]], "type": "drug", "id": "DDI-DrugBank.d320.s3.e0"}, "arg2": {"span": [[167, 180]], "type": "drug", "id": "DDI-DrugBank.d320.s3.e2"}, "ddi_label": 1, "ddi_type": "mechanism"}
{"id": "DDI-DrugBank.d320.s3-2", "sentence_id": "DDI-DrugBank.d320.s3", "sentence": "Although no clinical studies have been conducted, it is likely that the metabolism of levobupivacaine may be affected by the known CYP3A4 inducers (such as phenytoin, phenobarbital, rifampin), CYP3A4 inhibitors (azole antimycotics e.g., ketoconazole;", "arg1": {"span": [[86, 101]], "type": "drug", "id": "DDI-DrugBank.d320.s3.e0"}, "arg2": {"span": [[182, 190]], "type": "drug", "id": "DDI-DrugBank.d320.s3.e3"}, "ddi_label": 1, "ddi_type": "mechanism"}
{"id": "DDI-DrugBank.d320.s3-3", "sentence_id": "DDI-DrugBank.d320.s3", "sentence": "Although no clinical studies have been conducted, it is likely that the metabolism of levobupivacaine may be affected by the known CYP3A4 inducers (such as phenytoin, phenobarbital, rifampin), CYP3A4 inhibitors (azole antimycotics e.g., ketoconazole;", "arg1": {"span": [[86, 101]], "type": "drug", "id": "DDI-DrugBank.d320.s3.e0"}, "arg2": {"span": [[237, 249]], "type": "drug", "id": "DDI-DrugBank.d320.s3.e4"}, "ddi_label": 1, "ddi_type": "mechanism"}
{"id": "DDI-DrugBank.d320.s3-4", "sentence_id": "DDI-DrugBank.d320.s3", "sentence": "Although no clinical studies have been conducted, it is likely that the metabolism of levobupivacaine may be affected by the known CYP3A4 inducers (such as phenytoin, phenobarbital, rifampin), CYP3A4 inhibitors (azole antimycotics e.g., ketoconazole;", "arg1": {"span": [[156, 165]], "type": "drug", "id": "DDI-DrugBank.d320.s3.e1"}, "arg2": {"span": [[167, 180]], "type": "drug", "id": "DDI-DrugBank.d320.s3.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d320.s3-5", "sentence_id": "DDI-DrugBank.d320.s3", "sentence": "Although no clinical studies have been conducted, it is likely that the metabolism of levobupivacaine may be affected by the known CYP3A4 inducers (such as phenytoin, phenobarbital, rifampin), CYP3A4 inhibitors (azole antimycotics e.g., ketoconazole;", "arg1": {"span": [[156, 165]], "type": "drug", "id": "DDI-DrugBank.d320.s3.e1"}, "arg2": {"span": [[182, 190]], "type": "drug", "id": "DDI-DrugBank.d320.s3.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d320.s3-6", "sentence_id": "DDI-DrugBank.d320.s3", "sentence": "Although no clinical studies have been conducted, it is likely that the metabolism of levobupivacaine may be affected by the known CYP3A4 inducers (such as phenytoin, phenobarbital, rifampin), CYP3A4 inhibitors (azole antimycotics e.g., ketoconazole;", "arg1": {"span": [[156, 165]], "type": "drug", "id": "DDI-DrugBank.d320.s3.e1"}, "arg2": {"span": [[237, 249]], "type": "drug", "id": "DDI-DrugBank.d320.s3.e4"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d320.s3-7", "sentence_id": "DDI-DrugBank.d320.s3", "sentence": "Although no clinical studies have been conducted, it is likely that the metabolism of levobupivacaine may be affected by the known CYP3A4 inducers (such as phenytoin, phenobarbital, rifampin), CYP3A4 inhibitors (azole antimycotics e.g., ketoconazole;", "arg1": {"span": [[167, 180]], "type": "drug", "id": "DDI-DrugBank.d320.s3.e2"}, "arg2": {"span": [[182, 190]], "type": "drug", "id": "DDI-DrugBank.d320.s3.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d320.s3-8", "sentence_id": "DDI-DrugBank.d320.s3", "sentence": "Although no clinical studies have been conducted, it is likely that the metabolism of levobupivacaine may be affected by the known CYP3A4 inducers (such as phenytoin, phenobarbital, rifampin), CYP3A4 inhibitors (azole antimycotics e.g., ketoconazole;", "arg1": {"span": [[167, 180]], "type": "drug", "id": "DDI-DrugBank.d320.s3.e2"}, "arg2": {"span": [[237, 249]], "type": "drug", "id": "DDI-DrugBank.d320.s3.e4"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d320.s3-9", "sentence_id": "DDI-DrugBank.d320.s3", "sentence": "Although no clinical studies have been conducted, it is likely that the metabolism of levobupivacaine may be affected by the known CYP3A4 inducers (such as phenytoin, phenobarbital, rifampin), CYP3A4 inhibitors (azole antimycotics e.g., ketoconazole;", "arg1": {"span": [[182, 190]], "type": "drug", "id": "DDI-DrugBank.d320.s3.e3"}, "arg2": {"span": [[237, 249]], "type": "drug", "id": "DDI-DrugBank.d320.s3.e4"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d320.s5-0", "sentence_id": "DDI-DrugBank.d320.s5", "sentence": "macrolide antibiotics e.g., erythromycin;", "arg1": {"span": [[0, 21]], "type": "group", "id": "DDI-DrugBank.d320.s5.e0"}, "arg2": {"span": [[28, 40]], "type": "drug", "id": "DDI-DrugBank.d320.s5.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d320.s6-0", "sentence_id": "DDI-DrugBank.d320.s6", "sentence": "and calcium channel antagonists e.g., verapamil), CYP1A2 inducers (omeprazole) and CYP1A2 inhibitors (furafylline and clarithromycin).", "arg1": {"span": [[4, 31]], "type": "group", "id": "DDI-DrugBank.d320.s6.e0"}, "arg2": {"span": [[38, 47]], "type": "drug", "id": "DDI-DrugBank.d320.s6.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d320.s6-1", "sentence_id": "DDI-DrugBank.d320.s6", "sentence": "and calcium channel antagonists e.g., verapamil), CYP1A2 inducers (omeprazole) and CYP1A2 inhibitors (furafylline and clarithromycin).", "arg1": {"span": [[4, 31]], "type": "group", "id": "DDI-DrugBank.d320.s6.e0"}, "arg2": {"span": [[67, 77]], "type": "drug", "id": "DDI-DrugBank.d320.s6.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d320.s6-2", "sentence_id": "DDI-DrugBank.d320.s6", "sentence": "and calcium channel antagonists e.g., verapamil), CYP1A2 inducers (omeprazole) and CYP1A2 inhibitors (furafylline and clarithromycin).", "arg1": {"span": [[4, 31]], "type": "group", "id": "DDI-DrugBank.d320.s6.e0"}, "arg2": {"span": [[102, 113]], "type": "drug", "id": "DDI-DrugBank.d320.s6.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d320.s6-3", "sentence_id": "DDI-DrugBank.d320.s6", "sentence": "and calcium channel antagonists e.g., verapamil), CYP1A2 inducers (omeprazole) and CYP1A2 inhibitors (furafylline and clarithromycin).", "arg1": {"span": [[4, 31]], "type": "group", "id": "DDI-DrugBank.d320.s6.e0"}, "arg2": {"span": [[118, 132]], "type": "drug", "id": "DDI-DrugBank.d320.s6.e4"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d320.s6-4", "sentence_id": "DDI-DrugBank.d320.s6", "sentence": "and calcium channel antagonists e.g., verapamil), CYP1A2 inducers (omeprazole) and CYP1A2 inhibitors (furafylline and clarithromycin).", "arg1": {"span": [[38, 47]], "type": "drug", "id": "DDI-DrugBank.d320.s6.e1"}, "arg2": {"span": [[67, 77]], "type": "drug", "id": "DDI-DrugBank.d320.s6.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d320.s6-5", "sentence_id": "DDI-DrugBank.d320.s6", "sentence": "and calcium channel antagonists e.g., verapamil), CYP1A2 inducers (omeprazole) and CYP1A2 inhibitors (furafylline and clarithromycin).", "arg1": {"span": [[38, 47]], "type": "drug", "id": "DDI-DrugBank.d320.s6.e1"}, "arg2": {"span": [[102, 113]], "type": "drug", "id": "DDI-DrugBank.d320.s6.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d320.s6-6", "sentence_id": "DDI-DrugBank.d320.s6", "sentence": "and calcium channel antagonists e.g., verapamil), CYP1A2 inducers (omeprazole) and CYP1A2 inhibitors (furafylline and clarithromycin).", "arg1": {"span": [[38, 47]], "type": "drug", "id": "DDI-DrugBank.d320.s6.e1"}, "arg2": {"span": [[118, 132]], "type": "drug", "id": "DDI-DrugBank.d320.s6.e4"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d320.s6-7", "sentence_id": "DDI-DrugBank.d320.s6", "sentence": "and calcium channel antagonists e.g., verapamil), CYP1A2 inducers (omeprazole) and CYP1A2 inhibitors (furafylline and clarithromycin).", "arg1": {"span": [[67, 77]], "type": "drug", "id": "DDI-DrugBank.d320.s6.e2"}, "arg2": {"span": [[102, 113]], "type": "drug", "id": "DDI-DrugBank.d320.s6.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d320.s6-8", "sentence_id": "DDI-DrugBank.d320.s6", "sentence": "and calcium channel antagonists e.g., verapamil), CYP1A2 inducers (omeprazole) and CYP1A2 inhibitors (furafylline and clarithromycin).", "arg1": {"span": [[67, 77]], "type": "drug", "id": "DDI-DrugBank.d320.s6.e2"}, "arg2": {"span": [[118, 132]], "type": "drug", "id": "DDI-DrugBank.d320.s6.e4"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d320.s6-9", "sentence_id": "DDI-DrugBank.d320.s6", "sentence": "and calcium channel antagonists e.g., verapamil), CYP1A2 inducers (omeprazole) and CYP1A2 inhibitors (furafylline and clarithromycin).", "arg1": {"span": [[102, 113]], "type": "drug", "id": "DDI-DrugBank.d320.s6.e3"}, "arg2": {"span": [[118, 132]], "type": "drug", "id": "DDI-DrugBank.d320.s6.e4"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d320.s7-0", "sentence_id": "DDI-DrugBank.d320.s7", "sentence": "Dosage adjustment may be warranted when levobupivacaine is concurrently administered with CYP3A4 inhibitors and CYP1A2 inhibitors as systemic levobupivacaine levels may rise resulting in toxicity.", "arg1": {"span": [[40, 55]], "type": "drug", "id": "DDI-DrugBank.d320.s7.e0"}, "arg2": {"span": [[142, 157]], "type": "drug", "id": "DDI-DrugBank.d320.s7.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d330.s1-0", "sentence_id": "DDI-DrugBank.d330.s1", "sentence": "Caution should also be taken in concurrent or serial use of other aminoglycosides and polymyxins because they may enhance neomycin s nephrotoxicity and/or ototoxicity and potentiate neomycin sulfate neuromuscular blocking effects.", "arg1": {"span": [[66, 81]], "type": "group", "id": "DDI-DrugBank.d330.s1.e0"}, "arg2": {"span": [[86, 96]], "type": "group", "id": "DDI-DrugBank.d330.s1.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d330.s1-1", "sentence_id": "DDI-DrugBank.d330.s1", "sentence": "Caution should also be taken in concurrent or serial use of other aminoglycosides and polymyxins because they may enhance neomycin s nephrotoxicity and/or ototoxicity and potentiate neomycin sulfate neuromuscular blocking effects.", "arg1": {"span": [[66, 81]], "type": "group", "id": "DDI-DrugBank.d330.s1.e0"}, "arg2": {"span": [[182, 198]], "type": "drug", "id": "DDI-DrugBank.d330.s1.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d330.s1-2", "sentence_id": "DDI-DrugBank.d330.s1", "sentence": "Caution should also be taken in concurrent or serial use of other aminoglycosides and polymyxins because they may enhance neomycin s nephrotoxicity and/or ototoxicity and potentiate neomycin sulfate neuromuscular blocking effects.", "arg1": {"span": [[86, 96]], "type": "group", "id": "DDI-DrugBank.d330.s1.e1"}, "arg2": {"span": [[182, 198]], "type": "drug", "id": "DDI-DrugBank.d330.s1.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d330.s2-0", "sentence_id": "DDI-DrugBank.d330.s2", "sentence": "Oral neomycin inhibits the gastrointestinal absorption of penicillin V, oral vitamin B-12, methotrexate and 5-fluorouracil.", "arg1": {"span": [[5, 13]], "type": "drug", "id": "DDI-DrugBank.d330.s2.e0"}, "arg2": {"span": [[58, 70]], "type": "drug", "id": "DDI-DrugBank.d330.s2.e1"}, "ddi_label": 1, "ddi_type": "mechanism"}
{"id": "DDI-DrugBank.d330.s2-1", "sentence_id": "DDI-DrugBank.d330.s2", "sentence": "Oral neomycin inhibits the gastrointestinal absorption of penicillin V, oral vitamin B-12, methotrexate and 5-fluorouracil.", "arg1": {"span": [[5, 13]], "type": "drug", "id": "DDI-DrugBank.d330.s2.e0"}, "arg2": {"span": [[77, 89]], "type": "drug", "id": "DDI-DrugBank.d330.s2.e2"}, "ddi_label": 1, "ddi_type": "mechanism"}
{"id": "DDI-DrugBank.d330.s2-2", "sentence_id": "DDI-DrugBank.d330.s2", "sentence": "Oral neomycin inhibits the gastrointestinal absorption of penicillin V, oral vitamin B-12, methotrexate and 5-fluorouracil.", "arg1": {"span": [[5, 13]], "type": "drug", "id": "DDI-DrugBank.d330.s2.e0"}, "arg2": {"span": [[91, 103]], "type": "drug", "id": "DDI-DrugBank.d330.s2.e3"}, "ddi_label": 1, "ddi_type": "mechanism"}
{"id": "DDI-DrugBank.d330.s2-3", "sentence_id": "DDI-DrugBank.d330.s2", "sentence": "Oral neomycin inhibits the gastrointestinal absorption of penicillin V, oral vitamin B-12, methotrexate and 5-fluorouracil.", "arg1": {"span": [[5, 13]], "type": "drug", "id": "DDI-DrugBank.d330.s2.e0"}, "arg2": {"span": [[108, 122]], "type": "drug", "id": "DDI-DrugBank.d330.s2.e4"}, "ddi_label": 1, "ddi_type": "mechanism"}
{"id": "DDI-DrugBank.d330.s2-4", "sentence_id": "DDI-DrugBank.d330.s2", "sentence": "Oral neomycin inhibits the gastrointestinal absorption of penicillin V, oral vitamin B-12, methotrexate and 5-fluorouracil.", "arg1": {"span": [[58, 70]], "type": "drug", "id": "DDI-DrugBank.d330.s2.e1"}, "arg2": {"span": [[77, 89]], "type": "drug", "id": "DDI-DrugBank.d330.s2.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d330.s2-5", "sentence_id": "DDI-DrugBank.d330.s2", "sentence": "Oral neomycin inhibits the gastrointestinal absorption of penicillin V, oral vitamin B-12, methotrexate and 5-fluorouracil.", "arg1": {"span": [[58, 70]], "type": "drug", "id": "DDI-DrugBank.d330.s2.e1"}, "arg2": {"span": [[91, 103]], "type": "drug", "id": "DDI-DrugBank.d330.s2.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d330.s2-6", "sentence_id": "DDI-DrugBank.d330.s2", "sentence": "Oral neomycin inhibits the gastrointestinal absorption of penicillin V, oral vitamin B-12, methotrexate and 5-fluorouracil.", "arg1": {"span": [[58, 70]], "type": "drug", "id": "DDI-DrugBank.d330.s2.e1"}, "arg2": {"span": [[108, 122]], "type": "drug", "id": "DDI-DrugBank.d330.s2.e4"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d330.s2-7", "sentence_id": "DDI-DrugBank.d330.s2", "sentence": "Oral neomycin inhibits the gastrointestinal absorption of penicillin V, oral vitamin B-12, methotrexate and 5-fluorouracil.", "arg1": {"span": [[77, 89]], "type": "drug", "id": "DDI-DrugBank.d330.s2.e2"}, "arg2": {"span": [[91, 103]], "type": "drug", "id": "DDI-DrugBank.d330.s2.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d330.s2-8", "sentence_id": "DDI-DrugBank.d330.s2", "sentence": "Oral neomycin inhibits the gastrointestinal absorption of penicillin V, oral vitamin B-12, methotrexate and 5-fluorouracil.", "arg1": {"span": [[77, 89]], "type": "drug", "id": "DDI-DrugBank.d330.s2.e2"}, "arg2": {"span": [[108, 122]], "type": "drug", "id": "DDI-DrugBank.d330.s2.e4"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d330.s2-9", "sentence_id": "DDI-DrugBank.d330.s2", "sentence": "Oral neomycin inhibits the gastrointestinal absorption of penicillin V, oral vitamin B-12, methotrexate and 5-fluorouracil.", "arg1": {"span": [[91, 103]], "type": "drug", "id": "DDI-DrugBank.d330.s2.e3"}, "arg2": {"span": [[108, 122]], "type": "drug", "id": "DDI-DrugBank.d330.s2.e4"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d330.s5-0", "sentence_id": "DDI-DrugBank.d330.s5", "sentence": "Oral neomycin sulfate may enhance the effect of coumarin in anticoagulants by decreasing vitamin K availability.", "arg1": {"span": [[5, 21]], "type": "drug", "id": "DDI-DrugBank.d330.s5.e0"}, "arg2": {"span": [[48, 56]], "type": "group", "id": "DDI-DrugBank.d330.s5.e1"}, "ddi_label": 1, "ddi_type": "effect"}
{"id": "DDI-DrugBank.d330.s5-1", "sentence_id": "DDI-DrugBank.d330.s5", "sentence": "Oral neomycin sulfate may enhance the effect of coumarin in anticoagulants by decreasing vitamin K availability.", "arg1": {"span": [[5, 21]], "type": "drug", "id": "DDI-DrugBank.d330.s5.e0"}, "arg2": {"span": [[60, 74]], "type": "group", "id": "DDI-DrugBank.d330.s5.e2"}, "ddi_label": 1, "ddi_type": "effect"}
{"id": "DDI-DrugBank.d330.s5-2", "sentence_id": "DDI-DrugBank.d330.s5", "sentence": "Oral neomycin sulfate may enhance the effect of coumarin in anticoagulants by decreasing vitamin K availability.", "arg1": {"span": [[48, 56]], "type": "group", "id": "DDI-DrugBank.d330.s5.e1"}, "arg2": {"span": [[60, 74]], "type": "group", "id": "DDI-DrugBank.d330.s5.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d14.s0-0", "sentence_id": "DDI-DrugBank.d14.s0", "sentence": "The vasodilating effects of nitroglycerin may be additive with those of other vasodilators.", "arg1": {"span": [[28, 41]], "type": "drug", "id": "DDI-DrugBank.d14.s0.e0"}, "arg2": {"span": [[78, 90]], "type": "group", "id": "DDI-DrugBank.d14.s0.e1"}, "ddi_label": 1, "ddi_type": "effect"}
{"id": "DDI-DrugBank.d14.s2-0", "sentence_id": "DDI-DrugBank.d14.s2", "sentence": "Marked symptomatic orthostatic hypotension has been reported when calcium channel blockers and organic nitrates were used in combination.", "arg1": {"span": [[66, 90]], "type": "group", "id": "DDI-DrugBank.d14.s2.e0"}, "arg2": {"span": [[103, 111]], "type": "group", "id": "DDI-DrugBank.d14.s2.e1"}, "ddi_label": 1, "ddi_type": "effect"}
{"id": "DDI-DrugBank.d336.s0-0", "sentence_id": "DDI-DrugBank.d336.s0", "sentence": "Although clinical studies have not established a cause and effect relationship, physicians should be aware that variable effects an blood coagulation have been reported very rarely in patients receiving oral anticoagulants and chlordiazepoxide.", "arg1": {"span": [[208, 222]], "type": "group", "id": "DDI-DrugBank.d336.s0.e0"}, "arg2": {"span": [[227, 243]], "type": "drug", "id": "DDI-DrugBank.d336.s0.e1"}, "ddi_label": 1, "ddi_type": "effect"}
{"id": "DDI-DrugBank.d336.s1-0", "sentence_id": "DDI-DrugBank.d336.s1", "sentence": "The concomitant use of alcohol or other central nervous system depressants may have an additive effect.", "arg1": {"span": [[23, 30]], "type": "drug", "id": "DDI-DrugBank.d336.s1.e0"}, "arg2": {"span": [[40, 74]], "type": "group", "id": "DDI-DrugBank.d336.s1.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d378.s0-0", "sentence_id": "DDI-DrugBank.d378.s0", "sentence": "Renal function should be monitored carefully if high doses of aminoglycosides are to be administered with MAXIPIME because of the increased potential of nephrotoxicity and ototoxicity of aminoglycoside antibiotics.", "arg1": {"span": [[62, 77]], "type": "group", "id": "DDI-DrugBank.d378.s0.e0"}, "arg2": {"span": [[106, 114]], "type": "brand", "id": "DDI-DrugBank.d378.s0.e1"}, "ddi_label": 1, "ddi_type": "advise"}
{"id": "DDI-DrugBank.d378.s0-1", "sentence_id": "DDI-DrugBank.d378.s0", "sentence": "Renal function should be monitored carefully if high doses of aminoglycosides are to be administered with MAXIPIME because of the increased potential of nephrotoxicity and ototoxicity of aminoglycoside antibiotics.", "arg1": {"span": [[62, 77]], "type": "group", "id": "DDI-DrugBank.d378.s0.e0"}, "arg2": {"span": [[187, 213]], "type": "group", "id": "DDI-DrugBank.d378.s0.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d378.s0-2", "sentence_id": "DDI-DrugBank.d378.s0", "sentence": "Renal function should be monitored carefully if high doses of aminoglycosides are to be administered with MAXIPIME because of the increased potential of nephrotoxicity and ototoxicity of aminoglycoside antibiotics.", "arg1": {"span": [[106, 114]], "type": "brand", "id": "DDI-DrugBank.d378.s0.e1"}, "arg2": {"span": [[187, 213]], "type": "group", "id": "DDI-DrugBank.d378.s0.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d378.s1-0", "sentence_id": "DDI-DrugBank.d378.s1", "sentence": "Nephrotoxicity has been reported following concomitant administration of other cephalosporins with potent diuretics such as furosemide.", "arg1": {"span": [[79, 93]], "type": "group", "id": "DDI-DrugBank.d378.s1.e0"}, "arg2": {"span": [[106, 115]], "type": "group", "id": "DDI-DrugBank.d378.s1.e1"}, "ddi_label": 1, "ddi_type": "effect"}
{"id": "DDI-DrugBank.d378.s1-1", "sentence_id": "DDI-DrugBank.d378.s1", "sentence": "Nephrotoxicity has been reported following concomitant administration of other cephalosporins with potent diuretics such as furosemide.", "arg1": {"span": [[79, 93]], "type": "group", "id": "DDI-DrugBank.d378.s1.e0"}, "arg2": {"span": [[124, 134]], "type": "drug", "id": "DDI-DrugBank.d378.s1.e2"}, "ddi_label": 1, "ddi_type": "effect"}
{"id": "DDI-DrugBank.d378.s1-2", "sentence_id": "DDI-DrugBank.d378.s1", "sentence": "Nephrotoxicity has been reported following concomitant administration of other cephalosporins with potent diuretics such as furosemide.", "arg1": {"span": [[106, 115]], "type": "group", "id": "DDI-DrugBank.d378.s1.e1"}, "arg2": {"span": [[124, 134]], "type": "drug", "id": "DDI-DrugBank.d378.s1.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d19.s1-0", "sentence_id": "DDI-DrugBank.d19.s1", "sentence": "DISULFIRAM SHOULD BE USED WITH CAUTION IN THOSE PATIENTS REVEIVING PHENYTOIN AND ITS CONGENERS.", "arg1": {"span": [[0, 10]], "type": "drug", "id": "DDI-DrugBank.d19.s1.e0"}, "arg2": {"span": [[67, 76]], "type": "drug", "id": "DDI-DrugBank.d19.s1.e1"}, "ddi_label": 1, "ddi_type": "advise"}
{"id": "DDI-DrugBank.d19.s2-0", "sentence_id": "DDI-DrugBank.d19.s2", "sentence": "SINCE THE CONCOMITANT ADMINISTRATION OF THESE TWO DRUGS CAN LEAD TO PHENYTOIN INTOXICATION, PRIOR TO ADMINISTERING DISULFIRAM TO A PATIENT ON PHENYTOIN THERAPY, A BASELINE PHENYTOIN SERUM LEVEL SHOULD BE OBTAINED.", "arg1": {"span": [[68, 77]], "type": "drug", "id": "DDI-DrugBank.d19.s2.e0"}, "arg2": {"span": [[115, 125]], "type": "drug", "id": "DDI-DrugBank.d19.s2.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d19.s2-1", "sentence_id": "DDI-DrugBank.d19.s2", "sentence": "SINCE THE CONCOMITANT ADMINISTRATION OF THESE TWO DRUGS CAN LEAD TO PHENYTOIN INTOXICATION, PRIOR TO ADMINISTERING DISULFIRAM TO A PATIENT ON PHENYTOIN THERAPY, A BASELINE PHENYTOIN SERUM LEVEL SHOULD BE OBTAINED.", "arg1": {"span": [[68, 77]], "type": "drug", "id": "DDI-DrugBank.d19.s2.e0"}, "arg2": {"span": [[142, 151]], "type": "drug", "id": "DDI-DrugBank.d19.s2.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d19.s2-2", "sentence_id": "DDI-DrugBank.d19.s2", "sentence": "SINCE THE CONCOMITANT ADMINISTRATION OF THESE TWO DRUGS CAN LEAD TO PHENYTOIN INTOXICATION, PRIOR TO ADMINISTERING DISULFIRAM TO A PATIENT ON PHENYTOIN THERAPY, A BASELINE PHENYTOIN SERUM LEVEL SHOULD BE OBTAINED.", "arg1": {"span": [[68, 77]], "type": "drug", "id": "DDI-DrugBank.d19.s2.e0"}, "arg2": {"span": [[172, 181]], "type": "drug", "id": "DDI-DrugBank.d19.s2.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d19.s2-3", "sentence_id": "DDI-DrugBank.d19.s2", "sentence": "SINCE THE CONCOMITANT ADMINISTRATION OF THESE TWO DRUGS CAN LEAD TO PHENYTOIN INTOXICATION, PRIOR TO ADMINISTERING DISULFIRAM TO A PATIENT ON PHENYTOIN THERAPY, A BASELINE PHENYTOIN SERUM LEVEL SHOULD BE OBTAINED.", "arg1": {"span": [[115, 125]], "type": "drug", "id": "DDI-DrugBank.d19.s2.e1"}, "arg2": {"span": [[142, 151]], "type": "drug", "id": "DDI-DrugBank.d19.s2.e2"}, "ddi_label": 1, "ddi_type": "effect"}
{"id": "DDI-DrugBank.d19.s2-4", "sentence_id": "DDI-DrugBank.d19.s2", "sentence": "SINCE THE CONCOMITANT ADMINISTRATION OF THESE TWO DRUGS CAN LEAD TO PHENYTOIN INTOXICATION, PRIOR TO ADMINISTERING DISULFIRAM TO A PATIENT ON PHENYTOIN THERAPY, A BASELINE PHENYTOIN SERUM LEVEL SHOULD BE OBTAINED.", "arg1": {"span": [[115, 125]], "type": "drug", "id": "DDI-DrugBank.d19.s2.e1"}, "arg2": {"span": [[172, 181]], "type": "drug", "id": "DDI-DrugBank.d19.s2.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d19.s2-5", "sentence_id": "DDI-DrugBank.d19.s2", "sentence": "SINCE THE CONCOMITANT ADMINISTRATION OF THESE TWO DRUGS CAN LEAD TO PHENYTOIN INTOXICATION, PRIOR TO ADMINISTERING DISULFIRAM TO A PATIENT ON PHENYTOIN THERAPY, A BASELINE PHENYTOIN SERUM LEVEL SHOULD BE OBTAINED.", "arg1": {"span": [[142, 151]], "type": "drug", "id": "DDI-DrugBank.d19.s2.e2"}, "arg2": {"span": [[172, 181]], "type": "drug", "id": "DDI-DrugBank.d19.s2.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d19.s6-0", "sentence_id": "DDI-DrugBank.d19.s6", "sentence": "It may be necessary to adjust the dosage of oral anticoagulants upon beginning or stopping disulfiram. since disulfiram may prolong prothrombin time.", "arg1": {"span": [[49, 63]], "type": "group", "id": "DDI-DrugBank.d19.s6.e0"}, "arg2": {"span": [[91, 101]], "type": "drug", "id": "DDI-DrugBank.d19.s6.e1"}, "ddi_label": 1, "ddi_type": "advise"}
{"id": "DDI-DrugBank.d19.s6-1", "sentence_id": "DDI-DrugBank.d19.s6", "sentence": "It may be necessary to adjust the dosage of oral anticoagulants upon beginning or stopping disulfiram. since disulfiram may prolong prothrombin time.", "arg1": {"span": [[49, 63]], "type": "group", "id": "DDI-DrugBank.d19.s6.e0"}, "arg2": {"span": [[109, 119]], "type": "drug", "id": "DDI-DrugBank.d19.s6.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d19.s6-2", "sentence_id": "DDI-DrugBank.d19.s6", "sentence": "It may be necessary to adjust the dosage of oral anticoagulants upon beginning or stopping disulfiram. since disulfiram may prolong prothrombin time.", "arg1": {"span": [[91, 101]], "type": "drug", "id": "DDI-DrugBank.d19.s6.e1"}, "arg2": {"span": [[109, 119]], "type": "drug", "id": "DDI-DrugBank.d19.s6.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d19.s7-0", "sentence_id": "DDI-DrugBank.d19.s7", "sentence": "Patients taking isoniazid when disulfiram is given should be observed for the appearance of unsteady gait or marked changes in mental status;", "arg1": {"span": [[16, 25]], "type": "drug", "id": "DDI-DrugBank.d19.s7.e0"}, "arg2": {"span": [[31, 41]], "type": "drug", "id": "DDI-DrugBank.d19.s7.e1"}, "ddi_label": 1, "ddi_type": "advise"}
{"id": "DDI-DrugBank.d19.s9-0", "sentence_id": "DDI-DrugBank.d19.s9", "sentence": "In rats, simultaneous ingestion of disulfiram and nitrite in the diet for 78 weeks has been reported to cause tumors, and it has been suggested that disulfiram may react with nitrites in the rat stomach to form a nitrosamine, which is tumorigenic.", "arg1": {"span": [[35, 45]], "type": "drug", "id": "DDI-DrugBank.d19.s9.e0"}, "arg2": {"span": [[50, 57]], "type": "drug", "id": "DDI-DrugBank.d19.s9.e1"}, "ddi_label": 1, "ddi_type": "effect"}
{"id": "DDI-DrugBank.d19.s9-1", "sentence_id": "DDI-DrugBank.d19.s9", "sentence": "In rats, simultaneous ingestion of disulfiram and nitrite in the diet for 78 weeks has been reported to cause tumors, and it has been suggested that disulfiram may react with nitrites in the rat stomach to form a nitrosamine, which is tumorigenic.", "arg1": {"span": [[35, 45]], "type": "drug", "id": "DDI-DrugBank.d19.s9.e0"}, "arg2": {"span": [[149, 159]], "type": "drug", "id": "DDI-DrugBank.d19.s9.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d19.s9-2", "sentence_id": "DDI-DrugBank.d19.s9", "sentence": "In rats, simultaneous ingestion of disulfiram and nitrite in the diet for 78 weeks has been reported to cause tumors, and it has been suggested that disulfiram may react with nitrites in the rat stomach to form a nitrosamine, which is tumorigenic.", "arg1": {"span": [[35, 45]], "type": "drug", "id": "DDI-DrugBank.d19.s9.e0"}, "arg2": {"span": [[175, 183]], "type": "group", "id": "DDI-DrugBank.d19.s9.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d19.s9-3", "sentence_id": "DDI-DrugBank.d19.s9", "sentence": "In rats, simultaneous ingestion of disulfiram and nitrite in the diet for 78 weeks has been reported to cause tumors, and it has been suggested that disulfiram may react with nitrites in the rat stomach to form a nitrosamine, which is tumorigenic.", "arg1": {"span": [[50, 57]], "type": "drug", "id": "DDI-DrugBank.d19.s9.e1"}, "arg2": {"span": [[149, 159]], "type": "drug", "id": "DDI-DrugBank.d19.s9.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d19.s9-4", "sentence_id": "DDI-DrugBank.d19.s9", "sentence": "In rats, simultaneous ingestion of disulfiram and nitrite in the diet for 78 weeks has been reported to cause tumors, and it has been suggested that disulfiram may react with nitrites in the rat stomach to form a nitrosamine, which is tumorigenic.", "arg1": {"span": [[50, 57]], "type": "drug", "id": "DDI-DrugBank.d19.s9.e1"}, "arg2": {"span": [[175, 183]], "type": "group", "id": "DDI-DrugBank.d19.s9.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d19.s9-5", "sentence_id": "DDI-DrugBank.d19.s9", "sentence": "In rats, simultaneous ingestion of disulfiram and nitrite in the diet for 78 weeks has been reported to cause tumors, and it has been suggested that disulfiram may react with nitrites in the rat stomach to form a nitrosamine, which is tumorigenic.", "arg1": {"span": [[149, 159]], "type": "drug", "id": "DDI-DrugBank.d19.s9.e2"}, "arg2": {"span": [[175, 183]], "type": "group", "id": "DDI-DrugBank.d19.s9.e3"}, "ddi_label": 1, "ddi_type": "effect"}
{"id": "DDI-DrugBank.d71.s3-0", "sentence_id": "DDI-DrugBank.d71.s3", "sentence": "There is no information regarding the effect on lamivudine pharmacokinetics of higher doses of TMP/SMX such as those used to treat Pneumocystis carinii pneumonia.", "arg1": {"span": [[48, 58]], "type": "drug", "id": "DDI-DrugBank.d71.s3.e0"}, "arg2": {"span": [[95, 98]], "type": "drug", "id": "DDI-DrugBank.d71.s3.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d71.s3-1", "sentence_id": "DDI-DrugBank.d71.s3", "sentence": "There is no information regarding the effect on lamivudine pharmacokinetics of higher doses of TMP/SMX such as those used to treat Pneumocystis carinii pneumonia.", "arg1": {"span": [[48, 58]], "type": "drug", "id": "DDI-DrugBank.d71.s3.e0"}, "arg2": {"span": [[99, 102]], "type": "drug", "id": "DDI-DrugBank.d71.s3.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d71.s3-2", "sentence_id": "DDI-DrugBank.d71.s3", "sentence": "There is no information regarding the effect on lamivudine pharmacokinetics of higher doses of TMP/SMX such as those used to treat Pneumocystis carinii pneumonia.", "arg1": {"span": [[95, 98]], "type": "drug", "id": "DDI-DrugBank.d71.s3.e1"}, "arg2": {"span": [[99, 102]], "type": "drug", "id": "DDI-DrugBank.d71.s3.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d71.s5-0", "sentence_id": "DDI-DrugBank.d71.s5", "sentence": "Lamivudine and zalcitabine may inhibit the intracellular phosphorylation of one another.", "arg1": {"span": [[0, 10]], "type": "drug", "id": "DDI-DrugBank.d71.s5.e0"}, "arg2": {"span": [[15, 26]], "type": "drug", "id": "DDI-DrugBank.d71.s5.e1"}, "ddi_label": 1, "ddi_type": "effect"}
{"id": "DDI-DrugBank.d71.s6-0", "sentence_id": "DDI-DrugBank.d71.s6", "sentence": "Therefore, use of lamivudine in combination with zalcitabine is not recommended", "arg1": {"span": [[18, 28]], "type": "drug", "id": "DDI-DrugBank.d71.s6.e0"}, "arg2": {"span": [[49, 60]], "type": "drug", "id": "DDI-DrugBank.d71.s6.e1"}, "ddi_label": 1, "ddi_type": "advise"}
{"id": "DDI-DrugBank.d475.s3-0", "sentence_id": "DDI-DrugBank.d475.s3", "sentence": "In patients given very high doses (3900 mg) of aspirin daily, increases in serum salicylate levels were seen when nizatidine, 150 mg b.i.d., was administered concurrently.", "arg1": {"span": [[47, 54]], "type": "brand", "id": "DDI-DrugBank.d475.s3.e0"}, "arg2": {"span": [[81, 91]], "type": "group", "id": "DDI-DrugBank.d475.s3.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d475.s3-1", "sentence_id": "DDI-DrugBank.d475.s3", "sentence": "In patients given very high doses (3900 mg) of aspirin daily, increases in serum salicylate levels were seen when nizatidine, 150 mg b.i.d., was administered concurrently.", "arg1": {"span": [[47, 54]], "type": "brand", "id": "DDI-DrugBank.d475.s3.e0"}, "arg2": {"span": [[114, 124]], "type": "drug", "id": "DDI-DrugBank.d475.s3.e2"}, "ddi_label": 1, "ddi_type": "mechanism"}
{"id": "DDI-DrugBank.d475.s3-2", "sentence_id": "DDI-DrugBank.d475.s3", "sentence": "In patients given very high doses (3900 mg) of aspirin daily, increases in serum salicylate levels were seen when nizatidine, 150 mg b.i.d., was administered concurrently.", "arg1": {"span": [[81, 91]], "type": "group", "id": "DDI-DrugBank.d475.s3.e1"}, "arg2": {"span": [[114, 124]], "type": "drug", "id": "DDI-DrugBank.d475.s3.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d395.s0-0", "sentence_id": "DDI-DrugBank.d395.s0", "sentence": "Bismuth: Bismuth subsalicylate, given concomitantly with enoxacin or 60 minutes following enoxacin administration, decreased enoxacin bioavailability by approximately 25%.", "arg1": {"span": [[0, 7]], "type": "drug", "id": "DDI-DrugBank.d395.s0.e0"}, "arg2": {"span": [[9, 30]], "type": "drug", "id": "DDI-DrugBank.d395.s0.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d395.s0-1", "sentence_id": "DDI-DrugBank.d395.s0", "sentence": "Bismuth: Bismuth subsalicylate, given concomitantly with enoxacin or 60 minutes following enoxacin administration, decreased enoxacin bioavailability by approximately 25%.", "arg1": {"span": [[0, 7]], "type": "drug", "id": "DDI-DrugBank.d395.s0.e0"}, "arg2": {"span": [[57, 65]], "type": "drug", "id": "DDI-DrugBank.d395.s0.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d395.s0-2", "sentence_id": "DDI-DrugBank.d395.s0", "sentence": "Bismuth: Bismuth subsalicylate, given concomitantly with enoxacin or 60 minutes following enoxacin administration, decreased enoxacin bioavailability by approximately 25%.", "arg1": {"span": [[0, 7]], "type": "drug", "id": "DDI-DrugBank.d395.s0.e0"}, "arg2": {"span": [[90, 98]], "type": "drug", "id": "DDI-DrugBank.d395.s0.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d395.s0-3", "sentence_id": "DDI-DrugBank.d395.s0", "sentence": "Bismuth: Bismuth subsalicylate, given concomitantly with enoxacin or 60 minutes following enoxacin administration, decreased enoxacin bioavailability by approximately 25%.", "arg1": {"span": [[0, 7]], "type": "drug", "id": "DDI-DrugBank.d395.s0.e0"}, "arg2": {"span": [[125, 133]], "type": "drug", "id": "DDI-DrugBank.d395.s0.e4"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d395.s0-4", "sentence_id": "DDI-DrugBank.d395.s0", "sentence": "Bismuth: Bismuth subsalicylate, given concomitantly with enoxacin or 60 minutes following enoxacin administration, decreased enoxacin bioavailability by approximately 25%.", "arg1": {"span": [[9, 30]], "type": "drug", "id": "DDI-DrugBank.d395.s0.e1"}, "arg2": {"span": [[57, 65]], "type": "drug", "id": "DDI-DrugBank.d395.s0.e2"}, "ddi_label": 1, "ddi_type": "mechanism"}
{"id": "DDI-DrugBank.d395.s0-5", "sentence_id": "DDI-DrugBank.d395.s0", "sentence": "Bismuth: Bismuth subsalicylate, given concomitantly with enoxacin or 60 minutes following enoxacin administration, decreased enoxacin bioavailability by approximately 25%.", "arg1": {"span": [[9, 30]], "type": "drug", "id": "DDI-DrugBank.d395.s0.e1"}, "arg2": {"span": [[90, 98]], "type": "drug", "id": "DDI-DrugBank.d395.s0.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d395.s0-6", "sentence_id": "DDI-DrugBank.d395.s0", "sentence": "Bismuth: Bismuth subsalicylate, given concomitantly with enoxacin or 60 minutes following enoxacin administration, decreased enoxacin bioavailability by approximately 25%.", "arg1": {"span": [[9, 30]], "type": "drug", "id": "DDI-DrugBank.d395.s0.e1"}, "arg2": {"span": [[125, 133]], "type": "drug", "id": "DDI-DrugBank.d395.s0.e4"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d395.s0-7", "sentence_id": "DDI-DrugBank.d395.s0", "sentence": "Bismuth: Bismuth subsalicylate, given concomitantly with enoxacin or 60 minutes following enoxacin administration, decreased enoxacin bioavailability by approximately 25%.", "arg1": {"span": [[57, 65]], "type": "drug", "id": "DDI-DrugBank.d395.s0.e2"}, "arg2": {"span": [[90, 98]], "type": "drug", "id": "DDI-DrugBank.d395.s0.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d395.s0-8", "sentence_id": "DDI-DrugBank.d395.s0", "sentence": "Bismuth: Bismuth subsalicylate, given concomitantly with enoxacin or 60 minutes following enoxacin administration, decreased enoxacin bioavailability by approximately 25%.", "arg1": {"span": [[57, 65]], "type": "drug", "id": "DDI-DrugBank.d395.s0.e2"}, "arg2": {"span": [[125, 133]], "type": "drug", "id": "DDI-DrugBank.d395.s0.e4"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d395.s0-9", "sentence_id": "DDI-DrugBank.d395.s0", "sentence": "Bismuth: Bismuth subsalicylate, given concomitantly with enoxacin or 60 minutes following enoxacin administration, decreased enoxacin bioavailability by approximately 25%.", "arg1": {"span": [[90, 98]], "type": "drug", "id": "DDI-DrugBank.d395.s0.e3"}, "arg2": {"span": [[125, 133]], "type": "drug", "id": "DDI-DrugBank.d395.s0.e4"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d395.s1-0", "sentence_id": "DDI-DrugBank.d395.s1", "sentence": "Thus, concomitant administration of enoxacin and bismuth subsalicylate should be avoided.", "arg1": {"span": [[36, 44]], "type": "drug", "id": "DDI-DrugBank.d395.s1.e0"}, "arg2": {"span": [[49, 70]], "type": "drug", "id": "DDI-DrugBank.d395.s1.e1"}, "ddi_label": 1, "ddi_type": "advise"}
{"id": "DDI-DrugBank.d395.s2-0", "sentence_id": "DDI-DrugBank.d395.s2", "sentence": "Caffeine: Enoxacin is a potent inhibitor of the cytochrome P-450 isozymes responsible for the metabolism of methylxanthines.", "arg1": {"span": [[0, 8]], "type": "drug", "id": "DDI-DrugBank.d395.s2.e0"}, "arg2": {"span": [[10, 18]], "type": "drug", "id": "DDI-DrugBank.d395.s2.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d395.s2-1", "sentence_id": "DDI-DrugBank.d395.s2", "sentence": "Caffeine: Enoxacin is a potent inhibitor of the cytochrome P-450 isozymes responsible for the metabolism of methylxanthines.", "arg1": {"span": [[0, 8]], "type": "drug", "id": "DDI-DrugBank.d395.s2.e0"}, "arg2": {"span": [[108, 123]], "type": "group", "id": "DDI-DrugBank.d395.s2.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d395.s2-2", "sentence_id": "DDI-DrugBank.d395.s2", "sentence": "Caffeine: Enoxacin is a potent inhibitor of the cytochrome P-450 isozymes responsible for the metabolism of methylxanthines.", "arg1": {"span": [[10, 18]], "type": "drug", "id": "DDI-DrugBank.d395.s2.e1"}, "arg2": {"span": [[108, 123]], "type": "group", "id": "DDI-DrugBank.d395.s2.e2"}, "ddi_label": 1, "ddi_type": "mechanism"}
{"id": "DDI-DrugBank.d395.s3-0", "sentence_id": "DDI-DrugBank.d395.s3", "sentence": "In a multiple-dose study, enoxacin caused a dose-related increase in the mean elimination half-life of caffeine, thereby decreasing the clearance of caffeine by up to 80% and leading to a five-fold increase in the AUC and the half-life of caffeine.", "arg1": {"span": [[26, 34]], "type": "drug", "id": "DDI-DrugBank.d395.s3.e0"}, "arg2": {"span": [[103, 111]], "type": "drug", "id": "DDI-DrugBank.d395.s3.e1"}, "ddi_label": 1, "ddi_type": "mechanism"}
{"id": "DDI-DrugBank.d395.s3-1", "sentence_id": "DDI-DrugBank.d395.s3", "sentence": "In a multiple-dose study, enoxacin caused a dose-related increase in the mean elimination half-life of caffeine, thereby decreasing the clearance of caffeine by up to 80% and leading to a five-fold increase in the AUC and the half-life of caffeine.", "arg1": {"span": [[26, 34]], "type": "drug", "id": "DDI-DrugBank.d395.s3.e0"}, "arg2": {"span": [[149, 157]], "type": "drug", "id": "DDI-DrugBank.d395.s3.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d395.s3-2", "sentence_id": "DDI-DrugBank.d395.s3", "sentence": "In a multiple-dose study, enoxacin caused a dose-related increase in the mean elimination half-life of caffeine, thereby decreasing the clearance of caffeine by up to 80% and leading to a five-fold increase in the AUC and the half-life of caffeine.", "arg1": {"span": [[26, 34]], "type": "drug", "id": "DDI-DrugBank.d395.s3.e0"}, "arg2": {"span": [[239, 247]], "type": "drug", "id": "DDI-DrugBank.d395.s3.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d395.s3-3", "sentence_id": "DDI-DrugBank.d395.s3", "sentence": "In a multiple-dose study, enoxacin caused a dose-related increase in the mean elimination half-life of caffeine, thereby decreasing the clearance of caffeine by up to 80% and leading to a five-fold increase in the AUC and the half-life of caffeine.", "arg1": {"span": [[103, 111]], "type": "drug", "id": "DDI-DrugBank.d395.s3.e1"}, "arg2": {"span": [[149, 157]], "type": "drug", "id": "DDI-DrugBank.d395.s3.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d395.s3-4", "sentence_id": "DDI-DrugBank.d395.s3", "sentence": "In a multiple-dose study, enoxacin caused a dose-related increase in the mean elimination half-life of caffeine, thereby decreasing the clearance of caffeine by up to 80% and leading to a five-fold increase in the AUC and the half-life of caffeine.", "arg1": {"span": [[103, 111]], "type": "drug", "id": "DDI-DrugBank.d395.s3.e1"}, "arg2": {"span": [[239, 247]], "type": "drug", "id": "DDI-DrugBank.d395.s3.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d395.s3-5", "sentence_id": "DDI-DrugBank.d395.s3", "sentence": "In a multiple-dose study, enoxacin caused a dose-related increase in the mean elimination half-life of caffeine, thereby decreasing the clearance of caffeine by up to 80% and leading to a five-fold increase in the AUC and the half-life of caffeine.", "arg1": {"span": [[149, 157]], "type": "drug", "id": "DDI-DrugBank.d395.s3.e2"}, "arg2": {"span": [[239, 247]], "type": "drug", "id": "DDI-DrugBank.d395.s3.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d395.s4-0", "sentence_id": "DDI-DrugBank.d395.s4", "sentence": "Trough plasma enoxacin levels were also 20% higher when caffeine and enoxacin were administered concomitantly.", "arg1": {"span": [[14, 22]], "type": "drug", "id": "DDI-DrugBank.d395.s4.e0"}, "arg2": {"span": [[56, 64]], "type": "drug", "id": "DDI-DrugBank.d395.s4.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d395.s4-1", "sentence_id": "DDI-DrugBank.d395.s4", "sentence": "Trough plasma enoxacin levels were also 20% higher when caffeine and enoxacin were administered concomitantly.", "arg1": {"span": [[14, 22]], "type": "drug", "id": "DDI-DrugBank.d395.s4.e0"}, "arg2": {"span": [[69, 77]], "type": "drug", "id": "DDI-DrugBank.d395.s4.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d395.s4-2", "sentence_id": "DDI-DrugBank.d395.s4", "sentence": "Trough plasma enoxacin levels were also 20% higher when caffeine and enoxacin were administered concomitantly.", "arg1": {"span": [[56, 64]], "type": "drug", "id": "DDI-DrugBank.d395.s4.e1"}, "arg2": {"span": [[69, 77]], "type": "drug", "id": "DDI-DrugBank.d395.s4.e2"}, "ddi_label": 1, "ddi_type": "mechanism"}
{"id": "DDI-DrugBank.d395.s5-0", "sentence_id": "DDI-DrugBank.d395.s5", "sentence": "Caffeine-related adverse effects have occurred in patients consuming caffeine while on therapy with enoxacin.", "arg1": {"span": [[0, 8]], "type": "drug", "id": "DDI-DrugBank.d395.s5.e0"}, "arg2": {"span": [[69, 77]], "type": "drug", "id": "DDI-DrugBank.d395.s5.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d395.s5-1", "sentence_id": "DDI-DrugBank.d395.s5", "sentence": "Caffeine-related adverse effects have occurred in patients consuming caffeine while on therapy with enoxacin.", "arg1": {"span": [[0, 8]], "type": "drug", "id": "DDI-DrugBank.d395.s5.e0"}, "arg2": {"span": [[100, 108]], "type": "drug", "id": "DDI-DrugBank.d395.s5.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d395.s5-2", "sentence_id": "DDI-DrugBank.d395.s5", "sentence": "Caffeine-related adverse effects have occurred in patients consuming caffeine while on therapy with enoxacin.", "arg1": {"span": [[69, 77]], "type": "drug", "id": "DDI-DrugBank.d395.s5.e1"}, "arg2": {"span": [[100, 108]], "type": "drug", "id": "DDI-DrugBank.d395.s5.e2"}, "ddi_label": 1, "ddi_type": "effect"}
{"id": "DDI-DrugBank.d395.s6-0", "sentence_id": "DDI-DrugBank.d395.s6", "sentence": "Cyclosporine: Elevated serum levels of cyclosporine have been reported with concomitant use of cyclosporine with other members of the quinolone class.", "arg1": {"span": [[0, 12]], "type": "drug", "id": "DDI-DrugBank.d395.s6.e0"}, "arg2": {"span": [[39, 51]], "type": "drug", "id": "DDI-DrugBank.d395.s6.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d395.s6-1", "sentence_id": "DDI-DrugBank.d395.s6", "sentence": "Cyclosporine: Elevated serum levels of cyclosporine have been reported with concomitant use of cyclosporine with other members of the quinolone class.", "arg1": {"span": [[0, 12]], "type": "drug", "id": "DDI-DrugBank.d395.s6.e0"}, "arg2": {"span": [[95, 107]], "type": "drug", "id": "DDI-DrugBank.d395.s6.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d395.s6-2", "sentence_id": "DDI-DrugBank.d395.s6", "sentence": "Cyclosporine: Elevated serum levels of cyclosporine have been reported with concomitant use of cyclosporine with other members of the quinolone class.", "arg1": {"span": [[0, 12]], "type": "drug", "id": "DDI-DrugBank.d395.s6.e0"}, "arg2": {"span": [[134, 149]], "type": "group", "id": "DDI-DrugBank.d395.s6.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d395.s6-3", "sentence_id": "DDI-DrugBank.d395.s6", "sentence": "Cyclosporine: Elevated serum levels of cyclosporine have been reported with concomitant use of cyclosporine with other members of the quinolone class.", "arg1": {"span": [[39, 51]], "type": "drug", "id": "DDI-DrugBank.d395.s6.e1"}, "arg2": {"span": [[95, 107]], "type": "drug", "id": "DDI-DrugBank.d395.s6.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d395.s6-4", "sentence_id": "DDI-DrugBank.d395.s6", "sentence": "Cyclosporine: Elevated serum levels of cyclosporine have been reported with concomitant use of cyclosporine with other members of the quinolone class.", "arg1": {"span": [[39, 51]], "type": "drug", "id": "DDI-DrugBank.d395.s6.e1"}, "arg2": {"span": [[134, 149]], "type": "group", "id": "DDI-DrugBank.d395.s6.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d395.s6-5", "sentence_id": "DDI-DrugBank.d395.s6", "sentence": "Cyclosporine: Elevated serum levels of cyclosporine have been reported with concomitant use of cyclosporine with other members of the quinolone class.", "arg1": {"span": [[95, 107]], "type": "drug", "id": "DDI-DrugBank.d395.s6.e2"}, "arg2": {"span": [[134, 149]], "type": "group", "id": "DDI-DrugBank.d395.s6.e3"}, "ddi_label": 1, "ddi_type": "mechanism"}
{"id": "DDI-DrugBank.d395.s7-0", "sentence_id": "DDI-DrugBank.d395.s7", "sentence": "Digoxin: Enoxacin may raise serum digoxin levels in some individuals.", "arg1": {"span": [[0, 7]], "type": "drug", "id": "DDI-DrugBank.d395.s7.e0"}, "arg2": {"span": [[9, 17]], "type": "drug", "id": "DDI-DrugBank.d395.s7.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d395.s7-1", "sentence_id": "DDI-DrugBank.d395.s7", "sentence": "Digoxin: Enoxacin may raise serum digoxin levels in some individuals.", "arg1": {"span": [[0, 7]], "type": "drug", "id": "DDI-DrugBank.d395.s7.e0"}, "arg2": {"span": [[34, 41]], "type": "drug", "id": "DDI-DrugBank.d395.s7.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d395.s7-2", "sentence_id": "DDI-DrugBank.d395.s7", "sentence": "Digoxin: Enoxacin may raise serum digoxin levels in some individuals.", "arg1": {"span": [[9, 17]], "type": "drug", "id": "DDI-DrugBank.d395.s7.e1"}, "arg2": {"span": [[34, 41]], "type": "drug", "id": "DDI-DrugBank.d395.s7.e2"}, "ddi_label": 1, "ddi_type": "mechanism"}
{"id": "DDI-DrugBank.d395.s8-0", "sentence_id": "DDI-DrugBank.d395.s8", "sentence": "If signs and symptoms suggestive of digoxin toxicity occur when enoxacin and digoxin are given concomitantly, physicians are advised to obtain serum digoxin levels and adjust digoxin doses appropriately.", "arg1": {"span": [[36, 43]], "type": "drug", "id": "DDI-DrugBank.d395.s8.e0"}, "arg2": {"span": [[64, 72]], "type": "drug", "id": "DDI-DrugBank.d395.s8.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d395.s8-1", "sentence_id": "DDI-DrugBank.d395.s8", "sentence": "If signs and symptoms suggestive of digoxin toxicity occur when enoxacin and digoxin are given concomitantly, physicians are advised to obtain serum digoxin levels and adjust digoxin doses appropriately.", "arg1": {"span": [[36, 43]], "type": "drug", "id": "DDI-DrugBank.d395.s8.e0"}, "arg2": {"span": [[77, 84]], "type": "drug", "id": "DDI-DrugBank.d395.s8.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d395.s8-2", "sentence_id": "DDI-DrugBank.d395.s8", "sentence": "If signs and symptoms suggestive of digoxin toxicity occur when enoxacin and digoxin are given concomitantly, physicians are advised to obtain serum digoxin levels and adjust digoxin doses appropriately.", "arg1": {"span": [[36, 43]], "type": "drug", "id": "DDI-DrugBank.d395.s8.e0"}, "arg2": {"span": [[149, 156]], "type": "drug", "id": "DDI-DrugBank.d395.s8.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d395.s8-3", "sentence_id": "DDI-DrugBank.d395.s8", "sentence": "If signs and symptoms suggestive of digoxin toxicity occur when enoxacin and digoxin are given concomitantly, physicians are advised to obtain serum digoxin levels and adjust digoxin doses appropriately.", "arg1": {"span": [[36, 43]], "type": "drug", "id": "DDI-DrugBank.d395.s8.e0"}, "arg2": {"span": [[175, 182]], "type": "drug", "id": "DDI-DrugBank.d395.s8.e4"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d395.s8-4", "sentence_id": "DDI-DrugBank.d395.s8", "sentence": "If signs and symptoms suggestive of digoxin toxicity occur when enoxacin and digoxin are given concomitantly, physicians are advised to obtain serum digoxin levels and adjust digoxin doses appropriately.", "arg1": {"span": [[64, 72]], "type": "drug", "id": "DDI-DrugBank.d395.s8.e1"}, "arg2": {"span": [[77, 84]], "type": "drug", "id": "DDI-DrugBank.d395.s8.e2"}, "ddi_label": 1, "ddi_type": "effect"}
{"id": "DDI-DrugBank.d395.s8-5", "sentence_id": "DDI-DrugBank.d395.s8", "sentence": "If signs and symptoms suggestive of digoxin toxicity occur when enoxacin and digoxin are given concomitantly, physicians are advised to obtain serum digoxin levels and adjust digoxin doses appropriately.", "arg1": {"span": [[64, 72]], "type": "drug", "id": "DDI-DrugBank.d395.s8.e1"}, "arg2": {"span": [[149, 156]], "type": "drug", "id": "DDI-DrugBank.d395.s8.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d395.s8-6", "sentence_id": "DDI-DrugBank.d395.s8", "sentence": "If signs and symptoms suggestive of digoxin toxicity occur when enoxacin and digoxin are given concomitantly, physicians are advised to obtain serum digoxin levels and adjust digoxin doses appropriately.", "arg1": {"span": [[64, 72]], "type": "drug", "id": "DDI-DrugBank.d395.s8.e1"}, "arg2": {"span": [[175, 182]], "type": "drug", "id": "DDI-DrugBank.d395.s8.e4"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d395.s8-7", "sentence_id": "DDI-DrugBank.d395.s8", "sentence": "If signs and symptoms suggestive of digoxin toxicity occur when enoxacin and digoxin are given concomitantly, physicians are advised to obtain serum digoxin levels and adjust digoxin doses appropriately.", "arg1": {"span": [[77, 84]], "type": "drug", "id": "DDI-DrugBank.d395.s8.e2"}, "arg2": {"span": [[149, 156]], "type": "drug", "id": "DDI-DrugBank.d395.s8.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d395.s8-8", "sentence_id": "DDI-DrugBank.d395.s8", "sentence": "If signs and symptoms suggestive of digoxin toxicity occur when enoxacin and digoxin are given concomitantly, physicians are advised to obtain serum digoxin levels and adjust digoxin doses appropriately.", "arg1": {"span": [[77, 84]], "type": "drug", "id": "DDI-DrugBank.d395.s8.e2"}, "arg2": {"span": [[175, 182]], "type": "drug", "id": "DDI-DrugBank.d395.s8.e4"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d395.s8-9", "sentence_id": "DDI-DrugBank.d395.s8", "sentence": "If signs and symptoms suggestive of digoxin toxicity occur when enoxacin and digoxin are given concomitantly, physicians are advised to obtain serum digoxin levels and adjust digoxin doses appropriately.", "arg1": {"span": [[149, 156]], "type": "drug", "id": "DDI-DrugBank.d395.s8.e3"}, "arg2": {"span": [[175, 182]], "type": "drug", "id": "DDI-DrugBank.d395.s8.e4"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d395.s9-0", "sentence_id": "DDI-DrugBank.d395.s9", "sentence": "Non-steroidal anti-inflammatory agents: Seizures have been reported in patients taking enoxacin concomitantly with the nonsteroidal anti-inflammatory drug fenbufen.", "arg1": {"span": [[0, 38]], "type": "group", "id": "DDI-DrugBank.d395.s9.e0"}, "arg2": {"span": [[87, 95]], "type": "drug", "id": "DDI-DrugBank.d395.s9.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d395.s9-1", "sentence_id": "DDI-DrugBank.d395.s9", "sentence": "Non-steroidal anti-inflammatory agents: Seizures have been reported in patients taking enoxacin concomitantly with the nonsteroidal anti-inflammatory drug fenbufen.", "arg1": {"span": [[0, 38]], "type": "group", "id": "DDI-DrugBank.d395.s9.e0"}, "arg2": {"span": [[119, 154]], "type": "group", "id": "DDI-DrugBank.d395.s9.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d395.s9-2", "sentence_id": "DDI-DrugBank.d395.s9", "sentence": "Non-steroidal anti-inflammatory agents: Seizures have been reported in patients taking enoxacin concomitantly with the nonsteroidal anti-inflammatory drug fenbufen.", "arg1": {"span": [[0, 38]], "type": "group", "id": "DDI-DrugBank.d395.s9.e0"}, "arg2": {"span": [[155, 163]], "type": "drug", "id": "DDI-DrugBank.d395.s9.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d395.s9-3", "sentence_id": "DDI-DrugBank.d395.s9", "sentence": "Non-steroidal anti-inflammatory agents: Seizures have been reported in patients taking enoxacin concomitantly with the nonsteroidal anti-inflammatory drug fenbufen.", "arg1": {"span": [[87, 95]], "type": "drug", "id": "DDI-DrugBank.d395.s9.e1"}, "arg2": {"span": [[119, 154]], "type": "group", "id": "DDI-DrugBank.d395.s9.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d395.s9-4", "sentence_id": "DDI-DrugBank.d395.s9", "sentence": "Non-steroidal anti-inflammatory agents: Seizures have been reported in patients taking enoxacin concomitantly with the nonsteroidal anti-inflammatory drug fenbufen.", "arg1": {"span": [[87, 95]], "type": "drug", "id": "DDI-DrugBank.d395.s9.e1"}, "arg2": {"span": [[155, 163]], "type": "drug", "id": "DDI-DrugBank.d395.s9.e3"}, "ddi_label": 1, "ddi_type": "effect"}
{"id": "DDI-DrugBank.d395.s9-5", "sentence_id": "DDI-DrugBank.d395.s9", "sentence": "Non-steroidal anti-inflammatory agents: Seizures have been reported in patients taking enoxacin concomitantly with the nonsteroidal anti-inflammatory drug fenbufen.", "arg1": {"span": [[119, 154]], "type": "group", "id": "DDI-DrugBank.d395.s9.e2"}, "arg2": {"span": [[155, 163]], "type": "drug", "id": "DDI-DrugBank.d395.s9.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d395.s12-0", "sentence_id": "DDI-DrugBank.d395.s12", "sentence": "Sucralfate and antacids: Quinolones form chelates with metal cations.", "arg1": {"span": [[0, 10]], "type": "drug", "id": "DDI-DrugBank.d395.s12.e0"}, "arg2": {"span": [[15, 23]], "type": "group", "id": "DDI-DrugBank.d395.s12.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d395.s12-1", "sentence_id": "DDI-DrugBank.d395.s12", "sentence": "Sucralfate and antacids: Quinolones form chelates with metal cations.", "arg1": {"span": [[0, 10]], "type": "drug", "id": "DDI-DrugBank.d395.s12.e0"}, "arg2": {"span": [[25, 35]], "type": "group", "id": "DDI-DrugBank.d395.s12.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d395.s12-2", "sentence_id": "DDI-DrugBank.d395.s12", "sentence": "Sucralfate and antacids: Quinolones form chelates with metal cations.", "arg1": {"span": [[15, 23]], "type": "group", "id": "DDI-DrugBank.d395.s12.e1"}, "arg2": {"span": [[25, 35]], "type": "group", "id": "DDI-DrugBank.d395.s12.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d395.s13-0", "sentence_id": "DDI-DrugBank.d395.s13", "sentence": "Therefore, administration of quinolones with antacids containing calcium, magnesium, or aluminum;", "arg1": {"span": [[29, 39]], "type": "group", "id": "DDI-DrugBank.d395.s13.e0"}, "arg2": {"span": [[45, 53]], "type": "group", "id": "DDI-DrugBank.d395.s13.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d395.s13-1", "sentence_id": "DDI-DrugBank.d395.s13", "sentence": "Therefore, administration of quinolones with antacids containing calcium, magnesium, or aluminum;", "arg1": {"span": [[29, 39]], "type": "group", "id": "DDI-DrugBank.d395.s13.e0"}, "arg2": {"span": [[65, 72]], "type": "drug", "id": "DDI-DrugBank.d395.s13.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d395.s13-2", "sentence_id": "DDI-DrugBank.d395.s13", "sentence": "Therefore, administration of quinolones with antacids containing calcium, magnesium, or aluminum;", "arg1": {"span": [[29, 39]], "type": "group", "id": "DDI-DrugBank.d395.s13.e0"}, "arg2": {"span": [[74, 83]], "type": "drug", "id": "DDI-DrugBank.d395.s13.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d395.s13-3", "sentence_id": "DDI-DrugBank.d395.s13", "sentence": "Therefore, administration of quinolones with antacids containing calcium, magnesium, or aluminum;", "arg1": {"span": [[29, 39]], "type": "group", "id": "DDI-DrugBank.d395.s13.e0"}, "arg2": {"span": [[88, 96]], "type": "drug", "id": "DDI-DrugBank.d395.s13.e4"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d395.s13-4", "sentence_id": "DDI-DrugBank.d395.s13", "sentence": "Therefore, administration of quinolones with antacids containing calcium, magnesium, or aluminum;", "arg1": {"span": [[45, 53]], "type": "group", "id": "DDI-DrugBank.d395.s13.e1"}, "arg2": {"span": [[65, 72]], "type": "drug", "id": "DDI-DrugBank.d395.s13.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d395.s13-5", "sentence_id": "DDI-DrugBank.d395.s13", "sentence": "Therefore, administration of quinolones with antacids containing calcium, magnesium, or aluminum;", "arg1": {"span": [[45, 53]], "type": "group", "id": "DDI-DrugBank.d395.s13.e1"}, "arg2": {"span": [[74, 83]], "type": "drug", "id": "DDI-DrugBank.d395.s13.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d395.s13-6", "sentence_id": "DDI-DrugBank.d395.s13", "sentence": "Therefore, administration of quinolones with antacids containing calcium, magnesium, or aluminum;", "arg1": {"span": [[45, 53]], "type": "group", "id": "DDI-DrugBank.d395.s13.e1"}, "arg2": {"span": [[88, 96]], "type": "drug", "id": "DDI-DrugBank.d395.s13.e4"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d395.s13-7", "sentence_id": "DDI-DrugBank.d395.s13", "sentence": "Therefore, administration of quinolones with antacids containing calcium, magnesium, or aluminum;", "arg1": {"span": [[65, 72]], "type": "drug", "id": "DDI-DrugBank.d395.s13.e2"}, "arg2": {"span": [[74, 83]], "type": "drug", "id": "DDI-DrugBank.d395.s13.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d395.s13-8", "sentence_id": "DDI-DrugBank.d395.s13", "sentence": "Therefore, administration of quinolones with antacids containing calcium, magnesium, or aluminum;", "arg1": {"span": [[65, 72]], "type": "drug", "id": "DDI-DrugBank.d395.s13.e2"}, "arg2": {"span": [[88, 96]], "type": "drug", "id": "DDI-DrugBank.d395.s13.e4"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d395.s13-9", "sentence_id": "DDI-DrugBank.d395.s13", "sentence": "Therefore, administration of quinolones with antacids containing calcium, magnesium, or aluminum;", "arg1": {"span": [[74, 83]], "type": "drug", "id": "DDI-DrugBank.d395.s13.e3"}, "arg2": {"span": [[88, 96]], "type": "drug", "id": "DDI-DrugBank.d395.s13.e4"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d395.s16-0", "sentence_id": "DDI-DrugBank.d395.s16", "sentence": "or with multivitamins containing zinc may substantially interfere with drug absorption and result in insufficient plasma and tissue quinolone concentrations.", "arg1": {"span": [[8, 21]], "type": "group", "id": "DDI-DrugBank.d395.s16.e0"}, "arg2": {"span": [[33, 37]], "type": "drug", "id": "DDI-DrugBank.d395.s16.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d395.s16-1", "sentence_id": "DDI-DrugBank.d395.s16", "sentence": "or with multivitamins containing zinc may substantially interfere with drug absorption and result in insufficient plasma and tissue quinolone concentrations.", "arg1": {"span": [[8, 21]], "type": "group", "id": "DDI-DrugBank.d395.s16.e0"}, "arg2": {"span": [[132, 141]], "type": "group", "id": "DDI-DrugBank.d395.s16.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d395.s16-2", "sentence_id": "DDI-DrugBank.d395.s16", "sentence": "or with multivitamins containing zinc may substantially interfere with drug absorption and result in insufficient plasma and tissue quinolone concentrations.", "arg1": {"span": [[33, 37]], "type": "drug", "id": "DDI-DrugBank.d395.s16.e1"}, "arg2": {"span": [[132, 141]], "type": "group", "id": "DDI-DrugBank.d395.s16.e2"}, "ddi_label": 1, "ddi_type": "mechanism"}
{"id": "DDI-DrugBank.d395.s17-0", "sentence_id": "DDI-DrugBank.d395.s17", "sentence": "Antacids containing aluminum hydroxide and magnesium hydroxide reduce the oral absorption of enoxacin by 75%.", "arg1": {"span": [[0, 8]], "type": "group", "id": "DDI-DrugBank.d395.s17.e0"}, "arg2": {"span": [[20, 38]], "type": "drug", "id": "DDI-DrugBank.d395.s17.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d395.s17-1", "sentence_id": "DDI-DrugBank.d395.s17", "sentence": "Antacids containing aluminum hydroxide and magnesium hydroxide reduce the oral absorption of enoxacin by 75%.", "arg1": {"span": [[0, 8]], "type": "group", "id": "DDI-DrugBank.d395.s17.e0"}, "arg2": {"span": [[43, 62]], "type": "drug", "id": "DDI-DrugBank.d395.s17.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d395.s17-2", "sentence_id": "DDI-DrugBank.d395.s17", "sentence": "Antacids containing aluminum hydroxide and magnesium hydroxide reduce the oral absorption of enoxacin by 75%.", "arg1": {"span": [[0, 8]], "type": "group", "id": "DDI-DrugBank.d395.s17.e0"}, "arg2": {"span": [[93, 101]], "type": "drug", "id": "DDI-DrugBank.d395.s17.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d395.s17-3", "sentence_id": "DDI-DrugBank.d395.s17", "sentence": "Antacids containing aluminum hydroxide and magnesium hydroxide reduce the oral absorption of enoxacin by 75%.", "arg1": {"span": [[20, 38]], "type": "drug", "id": "DDI-DrugBank.d395.s17.e1"}, "arg2": {"span": [[43, 62]], "type": "drug", "id": "DDI-DrugBank.d395.s17.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d395.s17-4", "sentence_id": "DDI-DrugBank.d395.s17", "sentence": "Antacids containing aluminum hydroxide and magnesium hydroxide reduce the oral absorption of enoxacin by 75%.", "arg1": {"span": [[20, 38]], "type": "drug", "id": "DDI-DrugBank.d395.s17.e1"}, "arg2": {"span": [[93, 101]], "type": "drug", "id": "DDI-DrugBank.d395.s17.e3"}, "ddi_label": 1, "ddi_type": "mechanism"}
{"id": "DDI-DrugBank.d395.s17-5", "sentence_id": "DDI-DrugBank.d395.s17", "sentence": "Antacids containing aluminum hydroxide and magnesium hydroxide reduce the oral absorption of enoxacin by 75%.", "arg1": {"span": [[43, 62]], "type": "drug", "id": "DDI-DrugBank.d395.s17.e2"}, "arg2": {"span": [[93, 101]], "type": "drug", "id": "DDI-DrugBank.d395.s17.e3"}, "ddi_label": 1, "ddi_type": "mechanism"}
{"id": "DDI-DrugBank.d395.s18-0", "sentence_id": "DDI-DrugBank.d395.s18", "sentence": "The oral bioavailability of enoxacin is reduced by 60% with coadministration of ranitidine.", "arg1": {"span": [[28, 36]], "type": "drug", "id": "DDI-DrugBank.d395.s18.e0"}, "arg2": {"span": [[80, 90]], "type": "drug", "id": "DDI-DrugBank.d395.s18.e1"}, "ddi_label": 1, "ddi_type": "mechanism"}
{"id": "DDI-DrugBank.d395.s20-0", "sentence_id": "DDI-DrugBank.d395.s20", "sentence": "Theophylline: Enoxacin is a potent inhibitor of the cytochrome P-450 isozymes responsible for the metabolism of methylxanthines.", "arg1": {"span": [[0, 12]], "type": "drug", "id": "DDI-DrugBank.d395.s20.e0"}, "arg2": {"span": [[14, 22]], "type": "drug", "id": "DDI-DrugBank.d395.s20.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d395.s20-1", "sentence_id": "DDI-DrugBank.d395.s20", "sentence": "Theophylline: Enoxacin is a potent inhibitor of the cytochrome P-450 isozymes responsible for the metabolism of methylxanthines.", "arg1": {"span": [[0, 12]], "type": "drug", "id": "DDI-DrugBank.d395.s20.e0"}, "arg2": {"span": [[112, 127]], "type": "group", "id": "DDI-DrugBank.d395.s20.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d395.s20-2", "sentence_id": "DDI-DrugBank.d395.s20", "sentence": "Theophylline: Enoxacin is a potent inhibitor of the cytochrome P-450 isozymes responsible for the metabolism of methylxanthines.", "arg1": {"span": [[14, 22]], "type": "drug", "id": "DDI-DrugBank.d395.s20.e1"}, "arg2": {"span": [[112, 127]], "type": "group", "id": "DDI-DrugBank.d395.s20.e2"}, "ddi_label": 1, "ddi_type": "mechanism"}
{"id": "DDI-DrugBank.d395.s21-0", "sentence_id": "DDI-DrugBank.d395.s21", "sentence": "Enoxacin interferes with the metabolism of theophylline resulting in a 42% to 74% dose-related decrease in theophylline clearance and a subsequent 260% to 350% increase in serum theophylline levels.", "arg1": {"span": [[0, 8]], "type": "drug", "id": "DDI-DrugBank.d395.s21.e0"}, "arg2": {"span": [[43, 55]], "type": "drug", "id": "DDI-DrugBank.d395.s21.e1"}, "ddi_label": 1, "ddi_type": "mechanism"}
{"id": "DDI-DrugBank.d395.s21-1", "sentence_id": "DDI-DrugBank.d395.s21", "sentence": "Enoxacin interferes with the metabolism of theophylline resulting in a 42% to 74% dose-related decrease in theophylline clearance and a subsequent 260% to 350% increase in serum theophylline levels.", "arg1": {"span": [[0, 8]], "type": "drug", "id": "DDI-DrugBank.d395.s21.e0"}, "arg2": {"span": [[107, 119]], "type": "drug", "id": "DDI-DrugBank.d395.s21.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d395.s21-2", "sentence_id": "DDI-DrugBank.d395.s21", "sentence": "Enoxacin interferes with the metabolism of theophylline resulting in a 42% to 74% dose-related decrease in theophylline clearance and a subsequent 260% to 350% increase in serum theophylline levels.", "arg1": {"span": [[43, 55]], "type": "drug", "id": "DDI-DrugBank.d395.s21.e1"}, "arg2": {"span": [[107, 119]], "type": "drug", "id": "DDI-DrugBank.d395.s21.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d395.s22-0", "sentence_id": "DDI-DrugBank.d395.s22", "sentence": "Theophylline-related adverse effects have occurred in patients when theophylline and enoxacin were coadministered.", "arg1": {"span": [[0, 12]], "type": "drug", "id": "DDI-DrugBank.d395.s22.e0"}, "arg2": {"span": [[68, 80]], "type": "drug", "id": "DDI-DrugBank.d395.s22.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d395.s22-1", "sentence_id": "DDI-DrugBank.d395.s22", "sentence": "Theophylline-related adverse effects have occurred in patients when theophylline and enoxacin were coadministered.", "arg1": {"span": [[0, 12]], "type": "drug", "id": "DDI-DrugBank.d395.s22.e0"}, "arg2": {"span": [[85, 93]], "type": "drug", "id": "DDI-DrugBank.d395.s22.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d395.s22-2", "sentence_id": "DDI-DrugBank.d395.s22", "sentence": "Theophylline-related adverse effects have occurred in patients when theophylline and enoxacin were coadministered.", "arg1": {"span": [[68, 80]], "type": "drug", "id": "DDI-DrugBank.d395.s22.e1"}, "arg2": {"span": [[85, 93]], "type": "drug", "id": "DDI-DrugBank.d395.s22.e2"}, "ddi_label": 1, "ddi_type": "effect"}
{"id": "DDI-DrugBank.d395.s23-0", "sentence_id": "DDI-DrugBank.d395.s23", "sentence": "Warfarin: Quinolones, including enoxacin, decrease the clearance of R-warfarin, the less active isomer of racemic warfarin.", "arg1": {"span": [[0, 8]], "type": "drug", "id": "DDI-DrugBank.d395.s23.e0"}, "arg2": {"span": [[10, 20]], "type": "group", "id": "DDI-DrugBank.d395.s23.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d395.s23-1", "sentence_id": "DDI-DrugBank.d395.s23", "sentence": "Warfarin: Quinolones, including enoxacin, decrease the clearance of R-warfarin, the less active isomer of racemic warfarin.", "arg1": {"span": [[0, 8]], "type": "drug", "id": "DDI-DrugBank.d395.s23.e0"}, "arg2": {"span": [[32, 40]], "type": "drug", "id": "DDI-DrugBank.d395.s23.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d395.s23-2", "sentence_id": "DDI-DrugBank.d395.s23", "sentence": "Warfarin: Quinolones, including enoxacin, decrease the clearance of R-warfarin, the less active isomer of racemic warfarin.", "arg1": {"span": [[0, 8]], "type": "drug", "id": "DDI-DrugBank.d395.s23.e0"}, "arg2": {"span": [[68, 78]], "type": "drug", "id": "DDI-DrugBank.d395.s23.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d395.s23-3", "sentence_id": "DDI-DrugBank.d395.s23", "sentence": "Warfarin: Quinolones, including enoxacin, decrease the clearance of R-warfarin, the less active isomer of racemic warfarin.", "arg1": {"span": [[0, 8]], "type": "drug", "id": "DDI-DrugBank.d395.s23.e0"}, "arg2": {"span": [[114, 122]], "type": "drug", "id": "DDI-DrugBank.d395.s23.e4"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d395.s23-4", "sentence_id": "DDI-DrugBank.d395.s23", "sentence": "Warfarin: Quinolones, including enoxacin, decrease the clearance of R-warfarin, the less active isomer of racemic warfarin.", "arg1": {"span": [[10, 20]], "type": "group", "id": "DDI-DrugBank.d395.s23.e1"}, "arg2": {"span": [[32, 40]], "type": "drug", "id": "DDI-DrugBank.d395.s23.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d395.s23-5", "sentence_id": "DDI-DrugBank.d395.s23", "sentence": "Warfarin: Quinolones, including enoxacin, decrease the clearance of R-warfarin, the less active isomer of racemic warfarin.", "arg1": {"span": [[10, 20]], "type": "group", "id": "DDI-DrugBank.d395.s23.e1"}, "arg2": {"span": [[68, 78]], "type": "drug", "id": "DDI-DrugBank.d395.s23.e3"}, "ddi_label": 1, "ddi_type": "mechanism"}
{"id": "DDI-DrugBank.d395.s23-6", "sentence_id": "DDI-DrugBank.d395.s23", "sentence": "Warfarin: Quinolones, including enoxacin, decrease the clearance of R-warfarin, the less active isomer of racemic warfarin.", "arg1": {"span": [[10, 20]], "type": "group", "id": "DDI-DrugBank.d395.s23.e1"}, "arg2": {"span": [[114, 122]], "type": "drug", "id": "DDI-DrugBank.d395.s23.e4"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d395.s23-7", "sentence_id": "DDI-DrugBank.d395.s23", "sentence": "Warfarin: Quinolones, including enoxacin, decrease the clearance of R-warfarin, the less active isomer of racemic warfarin.", "arg1": {"span": [[32, 40]], "type": "drug", "id": "DDI-DrugBank.d395.s23.e2"}, "arg2": {"span": [[68, 78]], "type": "drug", "id": "DDI-DrugBank.d395.s23.e3"}, "ddi_label": 1, "ddi_type": "mechanism"}
{"id": "DDI-DrugBank.d395.s23-8", "sentence_id": "DDI-DrugBank.d395.s23", "sentence": "Warfarin: Quinolones, including enoxacin, decrease the clearance of R-warfarin, the less active isomer of racemic warfarin.", "arg1": {"span": [[32, 40]], "type": "drug", "id": "DDI-DrugBank.d395.s23.e2"}, "arg2": {"span": [[114, 122]], "type": "drug", "id": "DDI-DrugBank.d395.s23.e4"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d395.s23-9", "sentence_id": "DDI-DrugBank.d395.s23", "sentence": "Warfarin: Quinolones, including enoxacin, decrease the clearance of R-warfarin, the less active isomer of racemic warfarin.", "arg1": {"span": [[68, 78]], "type": "drug", "id": "DDI-DrugBank.d395.s23.e3"}, "arg2": {"span": [[114, 122]], "type": "drug", "id": "DDI-DrugBank.d395.s23.e4"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d395.s24-0", "sentence_id": "DDI-DrugBank.d395.s24", "sentence": "Enoxacin does not affect the clearance of the active S-isomer, and changes in clotting time have not been observed when enoxacin and warfarin were coadministered.", "arg1": {"span": [[0, 8]], "type": "drug", "id": "DDI-DrugBank.d395.s24.e0"}, "arg2": {"span": [[120, 128]], "type": "drug", "id": "DDI-DrugBank.d395.s24.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d395.s24-1", "sentence_id": "DDI-DrugBank.d395.s24", "sentence": "Enoxacin does not affect the clearance of the active S-isomer, and changes in clotting time have not been observed when enoxacin and warfarin were coadministered.", "arg1": {"span": [[0, 8]], "type": "drug", "id": "DDI-DrugBank.d395.s24.e0"}, "arg2": {"span": [[133, 141]], "type": "drug", "id": "DDI-DrugBank.d395.s24.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d395.s24-2", "sentence_id": "DDI-DrugBank.d395.s24", "sentence": "Enoxacin does not affect the clearance of the active S-isomer, and changes in clotting time have not been observed when enoxacin and warfarin were coadministered.", "arg1": {"span": [[120, 128]], "type": "drug", "id": "DDI-DrugBank.d395.s24.e1"}, "arg2": {"span": [[133, 141]], "type": "drug", "id": "DDI-DrugBank.d395.s24.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d395.s25-0", "sentence_id": "DDI-DrugBank.d395.s25", "sentence": "Nevertheless, the prothrombin time or other suitable coagulation test should be monitored when warfarin or its derivatives and enoxacin are given concomitantly.", "arg1": {"span": [[95, 103]], "type": "drug", "id": "DDI-DrugBank.d395.s25.e0"}, "arg2": {"span": [[127, 135]], "type": "drug", "id": "DDI-DrugBank.d395.s25.e1"}, "ddi_label": 1, "ddi_type": "advise"}
{"id": "DDI-DrugBank.d16.s2-0", "sentence_id": "DDI-DrugBank.d16.s2", "sentence": "Since hydroxyurea may raise the serum uric acid level, dosage adjustment of uricosuric medication may be necessary", "arg1": {"span": [[6, 17]], "type": "drug", "id": "DDI-DrugBank.d16.s2.e0"}, "arg2": {"span": [[76, 97]], "type": "group", "id": "DDI-DrugBank.d16.s2.e1"}, "ddi_label": 1, "ddi_type": "effect"}
{"id": "DDI-DrugBank.d245.s7-0", "sentence_id": "DDI-DrugBank.d245.s7", "sentence": "Since animal studies suggest that the action of barbiturates may be prolonged by therapy with chlorpropamide, barbiturates should be employed with caution.", "arg1": {"span": [[48, 60]], "type": "group", "id": "DDI-DrugBank.d245.s7.e0"}, "arg2": {"span": [[94, 108]], "type": "drug", "id": "DDI-DrugBank.d245.s7.e1"}, "ddi_label": 1, "ddi_type": "effect"}
{"id": "DDI-DrugBank.d245.s7-1", "sentence_id": "DDI-DrugBank.d245.s7", "sentence": "Since animal studies suggest that the action of barbiturates may be prolonged by therapy with chlorpropamide, barbiturates should be employed with caution.", "arg1": {"span": [[48, 60]], "type": "group", "id": "DDI-DrugBank.d245.s7.e0"}, "arg2": {"span": [[110, 122]], "type": "group", "id": "DDI-DrugBank.d245.s7.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d245.s7-2", "sentence_id": "DDI-DrugBank.d245.s7", "sentence": "Since animal studies suggest that the action of barbiturates may be prolonged by therapy with chlorpropamide, barbiturates should be employed with caution.", "arg1": {"span": [[94, 108]], "type": "drug", "id": "DDI-DrugBank.d245.s7.e1"}, "arg2": {"span": [[110, 122]], "type": "group", "id": "DDI-DrugBank.d245.s7.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d245.s8-0", "sentence_id": "DDI-DrugBank.d245.s8", "sentence": "In some patients, a disulfiram-like reaction may be produced by the ingestion of alcohol.", "arg1": {"span": [[20, 30]], "type": "drug", "id": "DDI-DrugBank.d245.s8.e0"}, "arg2": {"span": [[81, 88]], "type": "drug", "id": "DDI-DrugBank.d245.s8.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d245.s9-0", "sentence_id": "DDI-DrugBank.d245.s9", "sentence": "A potential interaction between oral miconazole and oral hypoglycemic agents leading to severe hypoglycemia has been reported.", "arg1": {"span": [[37, 47]], "type": "drug", "id": "DDI-DrugBank.d245.s9.e0"}, "arg2": {"span": [[57, 76]], "type": "group", "id": "DDI-DrugBank.d245.s9.e1"}, "ddi_label": 1, "ddi_type": "effect"}
{"id": "DDI-DrugBank.d120.s1-0", "sentence_id": "DDI-DrugBank.d120.s1", "sentence": "anticholinergics or other medications with anticholinergic activity - anticholinergic effects may be potentiated when these medications are used concurrently with diphenidol;", "arg1": {"span": [[0, 16]], "type": "group", "id": "DDI-DrugBank.d120.s1.e0"}, "arg2": {"span": [[163, 173]], "type": "drug", "id": "DDI-DrugBank.d120.s1.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d120.s2-0", "sentence_id": "DDI-DrugBank.d120.s2", "sentence": "apomorphine - prior ingestion of diphenidol may decrease the emetic response to apomorphine in the treatment of poisoning.", "arg1": {"span": [[0, 11]], "type": "drug", "id": "DDI-DrugBank.d120.s2.e0"}, "arg2": {"span": [[33, 43]], "type": "drug", "id": "DDI-DrugBank.d120.s2.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d120.s2-1", "sentence_id": "DDI-DrugBank.d120.s2", "sentence": "apomorphine - prior ingestion of diphenidol may decrease the emetic response to apomorphine in the treatment of poisoning.", "arg1": {"span": [[0, 11]], "type": "drug", "id": "DDI-DrugBank.d120.s2.e0"}, "arg2": {"span": [[61, 67]], "type": "group", "id": "DDI-DrugBank.d120.s2.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d120.s2-2", "sentence_id": "DDI-DrugBank.d120.s2", "sentence": "apomorphine - prior ingestion of diphenidol may decrease the emetic response to apomorphine in the treatment of poisoning.", "arg1": {"span": [[0, 11]], "type": "drug", "id": "DDI-DrugBank.d120.s2.e0"}, "arg2": {"span": [[80, 91]], "type": "drug", "id": "DDI-DrugBank.d120.s2.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d120.s2-3", "sentence_id": "DDI-DrugBank.d120.s2", "sentence": "apomorphine - prior ingestion of diphenidol may decrease the emetic response to apomorphine in the treatment of poisoning.", "arg1": {"span": [[33, 43]], "type": "drug", "id": "DDI-DrugBank.d120.s2.e1"}, "arg2": {"span": [[61, 67]], "type": "group", "id": "DDI-DrugBank.d120.s2.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d120.s2-4", "sentence_id": "DDI-DrugBank.d120.s2", "sentence": "apomorphine - prior ingestion of diphenidol may decrease the emetic response to apomorphine in the treatment of poisoning.", "arg1": {"span": [[33, 43]], "type": "drug", "id": "DDI-DrugBank.d120.s2.e1"}, "arg2": {"span": [[80, 91]], "type": "drug", "id": "DDI-DrugBank.d120.s2.e3"}, "ddi_label": 1, "ddi_type": "effect"}
{"id": "DDI-DrugBank.d120.s2-5", "sentence_id": "DDI-DrugBank.d120.s2", "sentence": "apomorphine - prior ingestion of diphenidol may decrease the emetic response to apomorphine in the treatment of poisoning.", "arg1": {"span": [[61, 67]], "type": "group", "id": "DDI-DrugBank.d120.s2.e2"}, "arg2": {"span": [[80, 91]], "type": "drug", "id": "DDI-DrugBank.d120.s2.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d419.s0-0", "sentence_id": "DDI-DrugBank.d419.s0", "sentence": "The concurrent administration of allopurinol and ampicillin increases substantially the incidence of rashes in patients receiving both drugs as compared to patients receiving ampicillin alone.", "arg1": {"span": [[33, 44]], "type": "drug", "id": "DDI-DrugBank.d419.s0.e0"}, "arg2": {"span": [[49, 59]], "type": "drug", "id": "DDI-DrugBank.d419.s0.e1"}, "ddi_label": 1, "ddi_type": "effect"}
{"id": "DDI-DrugBank.d419.s0-1", "sentence_id": "DDI-DrugBank.d419.s0", "sentence": "The concurrent administration of allopurinol and ampicillin increases substantially the incidence of rashes in patients receiving both drugs as compared to patients receiving ampicillin alone.", "arg1": {"span": [[33, 44]], "type": "drug", "id": "DDI-DrugBank.d419.s0.e0"}, "arg2": {"span": [[175, 185]], "type": "drug", "id": "DDI-DrugBank.d419.s0.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d419.s0-2", "sentence_id": "DDI-DrugBank.d419.s0", "sentence": "The concurrent administration of allopurinol and ampicillin increases substantially the incidence of rashes in patients receiving both drugs as compared to patients receiving ampicillin alone.", "arg1": {"span": [[49, 59]], "type": "drug", "id": "DDI-DrugBank.d419.s0.e1"}, "arg2": {"span": [[175, 185]], "type": "drug", "id": "DDI-DrugBank.d419.s0.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d419.s1-0", "sentence_id": "DDI-DrugBank.d419.s1", "sentence": "It is not known whether this potentiation of ampicillin rashes is due to allopurinol or the hyperuricemia present in these patients.", "arg1": {"span": [[45, 55]], "type": "drug", "id": "DDI-DrugBank.d419.s1.e0"}, "arg2": {"span": [[73, 84]], "type": "drug", "id": "DDI-DrugBank.d419.s1.e1"}, "ddi_label": 1, "ddi_type": "effect"}
{"id": "DDI-DrugBank.d419.s2-0", "sentence_id": "DDI-DrugBank.d419.s2", "sentence": "In controlled clinical trials of AUGMENTIN XR, 22 patients received concomitant allopurinol and AUGMENTIN XR.", "arg1": {"span": [[33, 45]], "type": "brand", "id": "DDI-DrugBank.d419.s2.e0"}, "arg2": {"span": [[80, 91]], "type": "drug", "id": "DDI-DrugBank.d419.s2.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d419.s2-1", "sentence_id": "DDI-DrugBank.d419.s2", "sentence": "In controlled clinical trials of AUGMENTIN XR, 22 patients received concomitant allopurinol and AUGMENTIN XR.", "arg1": {"span": [[33, 45]], "type": "brand", "id": "DDI-DrugBank.d419.s2.e0"}, "arg2": {"span": [[96, 108]], "type": "brand", "id": "DDI-DrugBank.d419.s2.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d419.s2-2", "sentence_id": "DDI-DrugBank.d419.s2", "sentence": "In controlled clinical trials of AUGMENTIN XR, 22 patients received concomitant allopurinol and AUGMENTIN XR.", "arg1": {"span": [[80, 91]], "type": "drug", "id": "DDI-DrugBank.d419.s2.e1"}, "arg2": {"span": [[96, 108]], "type": "brand", "id": "DDI-DrugBank.d419.s2.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d419.s4-0", "sentence_id": "DDI-DrugBank.d419.s4", "sentence": "However, this sample size is too small to allow for any conclusions to be drawn regarding the risk of rashes with concomitant AUGMENTIN XR and allopurinol use.", "arg1": {"span": [[126, 138]], "type": "brand", "id": "DDI-DrugBank.d419.s4.e0"}, "arg2": {"span": [[143, 154]], "type": "drug", "id": "DDI-DrugBank.d419.s4.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d419.s5-0", "sentence_id": "DDI-DrugBank.d419.s5", "sentence": "In common with other broad-spectrum antibiotics, AUGMENTIN XR may reduce the efficacy of oral contraceptives", "arg1": {"span": [[21, 47]], "type": "group", "id": "DDI-DrugBank.d419.s5.e0"}, "arg2": {"span": [[49, 61]], "type": "brand", "id": "DDI-DrugBank.d419.s5.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d419.s5-1", "sentence_id": "DDI-DrugBank.d419.s5", "sentence": "In common with other broad-spectrum antibiotics, AUGMENTIN XR may reduce the efficacy of oral contraceptives", "arg1": {"span": [[21, 47]], "type": "group", "id": "DDI-DrugBank.d419.s5.e0"}, "arg2": {"span": [[94, 108]], "type": "group", "id": "DDI-DrugBank.d419.s5.e2"}, "ddi_label": 1, "ddi_type": "effect"}
{"id": "DDI-DrugBank.d419.s5-2", "sentence_id": "DDI-DrugBank.d419.s5", "sentence": "In common with other broad-spectrum antibiotics, AUGMENTIN XR may reduce the efficacy of oral contraceptives", "arg1": {"span": [[49, 61]], "type": "brand", "id": "DDI-DrugBank.d419.s5.e1"}, "arg2": {"span": [[94, 108]], "type": "group", "id": "DDI-DrugBank.d419.s5.e2"}, "ddi_label": 1, "ddi_type": "effect"}
{"id": "DDI-DrugBank.d132.s0-0", "sentence_id": "DDI-DrugBank.d132.s0", "sentence": "Oral Anticoagulants: In some normal volunteers, the concomitant administration of diflunisal and warfarin, acenocoumarol, or phenprocoumon resulted in prolongation of prothrombin time.", "arg1": {"span": [[5, 19]], "type": "group", "id": "DDI-DrugBank.d132.s0.e0"}, "arg2": {"span": [[82, 92]], "type": "drug", "id": "DDI-DrugBank.d132.s0.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d132.s0-1", "sentence_id": "DDI-DrugBank.d132.s0", "sentence": "Oral Anticoagulants: In some normal volunteers, the concomitant administration of diflunisal and warfarin, acenocoumarol, or phenprocoumon resulted in prolongation of prothrombin time.", "arg1": {"span": [[5, 19]], "type": "group", "id": "DDI-DrugBank.d132.s0.e0"}, "arg2": {"span": [[97, 105]], "type": "drug", "id": "DDI-DrugBank.d132.s0.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d132.s0-2", "sentence_id": "DDI-DrugBank.d132.s0", "sentence": "Oral Anticoagulants: In some normal volunteers, the concomitant administration of diflunisal and warfarin, acenocoumarol, or phenprocoumon resulted in prolongation of prothrombin time.", "arg1": {"span": [[5, 19]], "type": "group", "id": "DDI-DrugBank.d132.s0.e0"}, "arg2": {"span": [[107, 120]], "type": "drug", "id": "DDI-DrugBank.d132.s0.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d132.s0-3", "sentence_id": "DDI-DrugBank.d132.s0", "sentence": "Oral Anticoagulants: In some normal volunteers, the concomitant administration of diflunisal and warfarin, acenocoumarol, or phenprocoumon resulted in prolongation of prothrombin time.", "arg1": {"span": [[5, 19]], "type": "group", "id": "DDI-DrugBank.d132.s0.e0"}, "arg2": {"span": [[125, 138]], "type": "drug", "id": "DDI-DrugBank.d132.s0.e4"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d132.s0-4", "sentence_id": "DDI-DrugBank.d132.s0", "sentence": "Oral Anticoagulants: In some normal volunteers, the concomitant administration of diflunisal and warfarin, acenocoumarol, or phenprocoumon resulted in prolongation of prothrombin time.", "arg1": {"span": [[82, 92]], "type": "drug", "id": "DDI-DrugBank.d132.s0.e1"}, "arg2": {"span": [[97, 105]], "type": "drug", "id": "DDI-DrugBank.d132.s0.e2"}, "ddi_label": 1, "ddi_type": "effect"}
{"id": "DDI-DrugBank.d132.s0-5", "sentence_id": "DDI-DrugBank.d132.s0", "sentence": "Oral Anticoagulants: In some normal volunteers, the concomitant administration of diflunisal and warfarin, acenocoumarol, or phenprocoumon resulted in prolongation of prothrombin time.", "arg1": {"span": [[82, 92]], "type": "drug", "id": "DDI-DrugBank.d132.s0.e1"}, "arg2": {"span": [[107, 120]], "type": "drug", "id": "DDI-DrugBank.d132.s0.e3"}, "ddi_label": 1, "ddi_type": "effect"}
{"id": "DDI-DrugBank.d132.s0-6", "sentence_id": "DDI-DrugBank.d132.s0", "sentence": "Oral Anticoagulants: In some normal volunteers, the concomitant administration of diflunisal and warfarin, acenocoumarol, or phenprocoumon resulted in prolongation of prothrombin time.", "arg1": {"span": [[82, 92]], "type": "drug", "id": "DDI-DrugBank.d132.s0.e1"}, "arg2": {"span": [[125, 138]], "type": "drug", "id": "DDI-DrugBank.d132.s0.e4"}, "ddi_label": 1, "ddi_type": "effect"}
{"id": "DDI-DrugBank.d132.s0-7", "sentence_id": "DDI-DrugBank.d132.s0", "sentence": "Oral Anticoagulants: In some normal volunteers, the concomitant administration of diflunisal and warfarin, acenocoumarol, or phenprocoumon resulted in prolongation of prothrombin time.", "arg1": {"span": [[97, 105]], "type": "drug", "id": "DDI-DrugBank.d132.s0.e2"}, "arg2": {"span": [[107, 120]], "type": "drug", "id": "DDI-DrugBank.d132.s0.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d132.s0-8", "sentence_id": "DDI-DrugBank.d132.s0", "sentence": "Oral Anticoagulants: In some normal volunteers, the concomitant administration of diflunisal and warfarin, acenocoumarol, or phenprocoumon resulted in prolongation of prothrombin time.", "arg1": {"span": [[97, 105]], "type": "drug", "id": "DDI-DrugBank.d132.s0.e2"}, "arg2": {"span": [[125, 138]], "type": "drug", "id": "DDI-DrugBank.d132.s0.e4"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d132.s0-9", "sentence_id": "DDI-DrugBank.d132.s0", "sentence": "Oral Anticoagulants: In some normal volunteers, the concomitant administration of diflunisal and warfarin, acenocoumarol, or phenprocoumon resulted in prolongation of prothrombin time.", "arg1": {"span": [[107, 120]], "type": "drug", "id": "DDI-DrugBank.d132.s0.e3"}, "arg2": {"span": [[125, 138]], "type": "drug", "id": "DDI-DrugBank.d132.s0.e4"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d132.s1-0", "sentence_id": "DDI-DrugBank.d132.s1", "sentence": "This may occur because diflunisal competitively displaces coumarins from protein binding sites.", "arg1": {"span": [[23, 33]], "type": "drug", "id": "DDI-DrugBank.d132.s1.e0"}, "arg2": {"span": [[58, 67]], "type": "group", "id": "DDI-DrugBank.d132.s1.e1"}, "ddi_label": 1, "ddi_type": "mechanism"}
{"id": "DDI-DrugBank.d132.s2-0", "sentence_id": "DDI-DrugBank.d132.s2", "sentence": "Accordingly, when diflunisal is administered with oral anticoagulants, the prothrombin time should be closely monitored during and for several days after concomitant drug administration.", "arg1": {"span": [[18, 28]], "type": "drug", "id": "DDI-DrugBank.d132.s2.e0"}, "arg2": {"span": [[55, 69]], "type": "group", "id": "DDI-DrugBank.d132.s2.e1"}, "ddi_label": 1, "ddi_type": "advise"}
{"id": "DDI-DrugBank.d132.s4-0", "sentence_id": "DDI-DrugBank.d132.s4", "sentence": "Tolbutamide: In diabetic patients receiving diflunisal and tolbutamide, no significant effects were seen on tolbutamide plasma levels or fasting blood glucose.", "arg1": {"span": [[0, 11]], "type": "drug", "id": "DDI-DrugBank.d132.s4.e0"}, "arg2": {"span": [[44, 54]], "type": "drug", "id": "DDI-DrugBank.d132.s4.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d132.s4-1", "sentence_id": "DDI-DrugBank.d132.s4", "sentence": "Tolbutamide: In diabetic patients receiving diflunisal and tolbutamide, no significant effects were seen on tolbutamide plasma levels or fasting blood glucose.", "arg1": {"span": [[0, 11]], "type": "drug", "id": "DDI-DrugBank.d132.s4.e0"}, "arg2": {"span": [[59, 70]], "type": "drug", "id": "DDI-DrugBank.d132.s4.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d132.s4-2", "sentence_id": "DDI-DrugBank.d132.s4", "sentence": "Tolbutamide: In diabetic patients receiving diflunisal and tolbutamide, no significant effects were seen on tolbutamide plasma levels or fasting blood glucose.", "arg1": {"span": [[0, 11]], "type": "drug", "id": "DDI-DrugBank.d132.s4.e0"}, "arg2": {"span": [[108, 119]], "type": "drug", "id": "DDI-DrugBank.d132.s4.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d132.s4-3", "sentence_id": "DDI-DrugBank.d132.s4", "sentence": "Tolbutamide: In diabetic patients receiving diflunisal and tolbutamide, no significant effects were seen on tolbutamide plasma levels or fasting blood glucose.", "arg1": {"span": [[44, 54]], "type": "drug", "id": "DDI-DrugBank.d132.s4.e1"}, "arg2": {"span": [[59, 70]], "type": "drug", "id": "DDI-DrugBank.d132.s4.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d132.s4-4", "sentence_id": "DDI-DrugBank.d132.s4", "sentence": "Tolbutamide: In diabetic patients receiving diflunisal and tolbutamide, no significant effects were seen on tolbutamide plasma levels or fasting blood glucose.", "arg1": {"span": [[44, 54]], "type": "drug", "id": "DDI-DrugBank.d132.s4.e1"}, "arg2": {"span": [[108, 119]], "type": "drug", "id": "DDI-DrugBank.d132.s4.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d132.s4-5", "sentence_id": "DDI-DrugBank.d132.s4", "sentence": "Tolbutamide: In diabetic patients receiving diflunisal and tolbutamide, no significant effects were seen on tolbutamide plasma levels or fasting blood glucose.", "arg1": {"span": [[59, 70]], "type": "drug", "id": "DDI-DrugBank.d132.s4.e2"}, "arg2": {"span": [[108, 119]], "type": "drug", "id": "DDI-DrugBank.d132.s4.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d132.s5-0", "sentence_id": "DDI-DrugBank.d132.s5", "sentence": "Hydrochlorothiazide: In normal volunteers, concomitant administration of diflunisal and hydrochlorothiazide resulted in significantly increased plasma levels of hydrochlorothiazide.", "arg1": {"span": [[0, 19]], "type": "drug", "id": "DDI-DrugBank.d132.s5.e0"}, "arg2": {"span": [[73, 83]], "type": "drug", "id": "DDI-DrugBank.d132.s5.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d132.s5-1", "sentence_id": "DDI-DrugBank.d132.s5", "sentence": "Hydrochlorothiazide: In normal volunteers, concomitant administration of diflunisal and hydrochlorothiazide resulted in significantly increased plasma levels of hydrochlorothiazide.", "arg1": {"span": [[0, 19]], "type": "drug", "id": "DDI-DrugBank.d132.s5.e0"}, "arg2": {"span": [[88, 107]], "type": "drug", "id": "DDI-DrugBank.d132.s5.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d132.s5-2", "sentence_id": "DDI-DrugBank.d132.s5", "sentence": "Hydrochlorothiazide: In normal volunteers, concomitant administration of diflunisal and hydrochlorothiazide resulted in significantly increased plasma levels of hydrochlorothiazide.", "arg1": {"span": [[0, 19]], "type": "drug", "id": "DDI-DrugBank.d132.s5.e0"}, "arg2": {"span": [[161, 180]], "type": "drug", "id": "DDI-DrugBank.d132.s5.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d132.s5-3", "sentence_id": "DDI-DrugBank.d132.s5", "sentence": "Hydrochlorothiazide: In normal volunteers, concomitant administration of diflunisal and hydrochlorothiazide resulted in significantly increased plasma levels of hydrochlorothiazide.", "arg1": {"span": [[73, 83]], "type": "drug", "id": "DDI-DrugBank.d132.s5.e1"}, "arg2": {"span": [[88, 107]], "type": "drug", "id": "DDI-DrugBank.d132.s5.e2"}, "ddi_label": 1, "ddi_type": "mechanism"}
{"id": "DDI-DrugBank.d132.s5-4", "sentence_id": "DDI-DrugBank.d132.s5", "sentence": "Hydrochlorothiazide: In normal volunteers, concomitant administration of diflunisal and hydrochlorothiazide resulted in significantly increased plasma levels of hydrochlorothiazide.", "arg1": {"span": [[73, 83]], "type": "drug", "id": "DDI-DrugBank.d132.s5.e1"}, "arg2": {"span": [[161, 180]], "type": "drug", "id": "DDI-DrugBank.d132.s5.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d132.s5-5", "sentence_id": "DDI-DrugBank.d132.s5", "sentence": "Hydrochlorothiazide: In normal volunteers, concomitant administration of diflunisal and hydrochlorothiazide resulted in significantly increased plasma levels of hydrochlorothiazide.", "arg1": {"span": [[88, 107]], "type": "drug", "id": "DDI-DrugBank.d132.s5.e2"}, "arg2": {"span": [[161, 180]], "type": "drug", "id": "DDI-DrugBank.d132.s5.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d132.s6-0", "sentence_id": "DDI-DrugBank.d132.s6", "sentence": "Diflunisal decreased the hyperuricemic effect of hydrochlorothiazide.", "arg1": {"span": [[0, 10]], "type": "drug", "id": "DDI-DrugBank.d132.s6.e0"}, "arg2": {"span": [[49, 68]], "type": "drug", "id": "DDI-DrugBank.d132.s6.e1"}, "ddi_label": 1, "ddi_type": "effect"}
{"id": "DDI-DrugBank.d132.s7-0", "sentence_id": "DDI-DrugBank.d132.s7", "sentence": "Furosemide: In normal volunteers, the concomitant administration of diflunisal and furosemide had no effect on the diuretic activity of furosemide.", "arg1": {"span": [[0, 10]], "type": "drug", "id": "DDI-DrugBank.d132.s7.e0"}, "arg2": {"span": [[68, 78]], "type": "drug", "id": "DDI-DrugBank.d132.s7.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d132.s7-1", "sentence_id": "DDI-DrugBank.d132.s7", "sentence": "Furosemide: In normal volunteers, the concomitant administration of diflunisal and furosemide had no effect on the diuretic activity of furosemide.", "arg1": {"span": [[0, 10]], "type": "drug", "id": "DDI-DrugBank.d132.s7.e0"}, "arg2": {"span": [[83, 93]], "type": "drug", "id": "DDI-DrugBank.d132.s7.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d132.s7-2", "sentence_id": "DDI-DrugBank.d132.s7", "sentence": "Furosemide: In normal volunteers, the concomitant administration of diflunisal and furosemide had no effect on the diuretic activity of furosemide.", "arg1": {"span": [[0, 10]], "type": "drug", "id": "DDI-DrugBank.d132.s7.e0"}, "arg2": {"span": [[136, 146]], "type": "drug", "id": "DDI-DrugBank.d132.s7.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d132.s7-3", "sentence_id": "DDI-DrugBank.d132.s7", "sentence": "Furosemide: In normal volunteers, the concomitant administration of diflunisal and furosemide had no effect on the diuretic activity of furosemide.", "arg1": {"span": [[68, 78]], "type": "drug", "id": "DDI-DrugBank.d132.s7.e1"}, "arg2": {"span": [[83, 93]], "type": "drug", "id": "DDI-DrugBank.d132.s7.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d132.s7-4", "sentence_id": "DDI-DrugBank.d132.s7", "sentence": "Furosemide: In normal volunteers, the concomitant administration of diflunisal and furosemide had no effect on the diuretic activity of furosemide.", "arg1": {"span": [[68, 78]], "type": "drug", "id": "DDI-DrugBank.d132.s7.e1"}, "arg2": {"span": [[136, 146]], "type": "drug", "id": "DDI-DrugBank.d132.s7.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d132.s7-5", "sentence_id": "DDI-DrugBank.d132.s7", "sentence": "Furosemide: In normal volunteers, the concomitant administration of diflunisal and furosemide had no effect on the diuretic activity of furosemide.", "arg1": {"span": [[83, 93]], "type": "drug", "id": "DDI-DrugBank.d132.s7.e2"}, "arg2": {"span": [[136, 146]], "type": "drug", "id": "DDI-DrugBank.d132.s7.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d132.s8-0", "sentence_id": "DDI-DrugBank.d132.s8", "sentence": "Diflunisal decreased the hyperuricemic effect of furosemide.", "arg1": {"span": [[0, 10]], "type": "drug", "id": "DDI-DrugBank.d132.s8.e0"}, "arg2": {"span": [[49, 59]], "type": "drug", "id": "DDI-DrugBank.d132.s8.e1"}, "ddi_label": 1, "ddi_type": "effect"}
{"id": "DDI-DrugBank.d132.s9-0", "sentence_id": "DDI-DrugBank.d132.s9", "sentence": "Antacids: Concomitant administration of antacids may reduce plasma levels of diflunisal.", "arg1": {"span": [[0, 8]], "type": "group", "id": "DDI-DrugBank.d132.s9.e0"}, "arg2": {"span": [[40, 48]], "type": "group", "id": "DDI-DrugBank.d132.s9.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d132.s9-1", "sentence_id": "DDI-DrugBank.d132.s9", "sentence": "Antacids: Concomitant administration of antacids may reduce plasma levels of diflunisal.", "arg1": {"span": [[0, 8]], "type": "group", "id": "DDI-DrugBank.d132.s9.e0"}, "arg2": {"span": [[77, 87]], "type": "drug", "id": "DDI-DrugBank.d132.s9.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d132.s9-2", "sentence_id": "DDI-DrugBank.d132.s9", "sentence": "Antacids: Concomitant administration of antacids may reduce plasma levels of diflunisal.", "arg1": {"span": [[40, 48]], "type": "group", "id": "DDI-DrugBank.d132.s9.e1"}, "arg2": {"span": [[77, 87]], "type": "drug", "id": "DDI-DrugBank.d132.s9.e2"}, "ddi_label": 1, "ddi_type": "mechanism"}
{"id": "DDI-DrugBank.d132.s10-0", "sentence_id": "DDI-DrugBank.d132.s10", "sentence": "This effect is small with occasional doses of antacids, but may be clinically significant when antacids are used on a continuous schedule.", "arg1": {"span": [[46, 54]], "type": "group", "id": "DDI-DrugBank.d132.s10.e0"}, "arg2": {"span": [[95, 103]], "type": "group", "id": "DDI-DrugBank.d132.s10.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d132.s11-0", "sentence_id": "DDI-DrugBank.d132.s11", "sentence": "Acetaminophen: In normal volunteers, concomitant administration of diflunisal and acetaminophen resulted in an approximate 50% increase in plasma levels of acetaminophen.", "arg1": {"span": [[0, 13]], "type": "drug", "id": "DDI-DrugBank.d132.s11.e0"}, "arg2": {"span": [[67, 77]], "type": "drug", "id": "DDI-DrugBank.d132.s11.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d132.s11-1", "sentence_id": "DDI-DrugBank.d132.s11", "sentence": "Acetaminophen: In normal volunteers, concomitant administration of diflunisal and acetaminophen resulted in an approximate 50% increase in plasma levels of acetaminophen.", "arg1": {"span": [[0, 13]], "type": "drug", "id": "DDI-DrugBank.d132.s11.e0"}, "arg2": {"span": [[82, 95]], "type": "drug", "id": "DDI-DrugBank.d132.s11.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d132.s11-2", "sentence_id": "DDI-DrugBank.d132.s11", "sentence": "Acetaminophen: In normal volunteers, concomitant administration of diflunisal and acetaminophen resulted in an approximate 50% increase in plasma levels of acetaminophen.", "arg1": {"span": [[0, 13]], "type": "drug", "id": "DDI-DrugBank.d132.s11.e0"}, "arg2": {"span": [[156, 169]], "type": "drug", "id": "DDI-DrugBank.d132.s11.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d132.s11-3", "sentence_id": "DDI-DrugBank.d132.s11", "sentence": "Acetaminophen: In normal volunteers, concomitant administration of diflunisal and acetaminophen resulted in an approximate 50% increase in plasma levels of acetaminophen.", "arg1": {"span": [[67, 77]], "type": "drug", "id": "DDI-DrugBank.d132.s11.e1"}, "arg2": {"span": [[82, 95]], "type": "drug", "id": "DDI-DrugBank.d132.s11.e2"}, "ddi_label": 1, "ddi_type": "mechanism"}
{"id": "DDI-DrugBank.d132.s11-4", "sentence_id": "DDI-DrugBank.d132.s11", "sentence": "Acetaminophen: In normal volunteers, concomitant administration of diflunisal and acetaminophen resulted in an approximate 50% increase in plasma levels of acetaminophen.", "arg1": {"span": [[67, 77]], "type": "drug", "id": "DDI-DrugBank.d132.s11.e1"}, "arg2": {"span": [[156, 169]], "type": "drug", "id": "DDI-DrugBank.d132.s11.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d132.s11-5", "sentence_id": "DDI-DrugBank.d132.s11", "sentence": "Acetaminophen: In normal volunteers, concomitant administration of diflunisal and acetaminophen resulted in an approximate 50% increase in plasma levels of acetaminophen.", "arg1": {"span": [[82, 95]], "type": "drug", "id": "DDI-DrugBank.d132.s11.e2"}, "arg2": {"span": [[156, 169]], "type": "drug", "id": "DDI-DrugBank.d132.s11.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d132.s12-0", "sentence_id": "DDI-DrugBank.d132.s12", "sentence": "Acetaminophen had no effect on plasma levels of diflunisal.", "arg1": {"span": [[0, 13]], "type": "drug", "id": "DDI-DrugBank.d132.s12.e0"}, "arg2": {"span": [[48, 58]], "type": "drug", "id": "DDI-DrugBank.d132.s12.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d132.s13-0", "sentence_id": "DDI-DrugBank.d132.s13", "sentence": "Since acetaminophen in high doses has been associated with hepatotoxicity, concomitant administration of diflunisal and acetaminophen should be used cautiously, with careful monitoring of patients.", "arg1": {"span": [[6, 19]], "type": "drug", "id": "DDI-DrugBank.d132.s13.e0"}, "arg2": {"span": [[105, 115]], "type": "drug", "id": "DDI-DrugBank.d132.s13.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d132.s13-1", "sentence_id": "DDI-DrugBank.d132.s13", "sentence": "Since acetaminophen in high doses has been associated with hepatotoxicity, concomitant administration of diflunisal and acetaminophen should be used cautiously, with careful monitoring of patients.", "arg1": {"span": [[6, 19]], "type": "drug", "id": "DDI-DrugBank.d132.s13.e0"}, "arg2": {"span": [[120, 133]], "type": "drug", "id": "DDI-DrugBank.d132.s13.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d132.s13-2", "sentence_id": "DDI-DrugBank.d132.s13", "sentence": "Since acetaminophen in high doses has been associated with hepatotoxicity, concomitant administration of diflunisal and acetaminophen should be used cautiously, with careful monitoring of patients.", "arg1": {"span": [[105, 115]], "type": "drug", "id": "DDI-DrugBank.d132.s13.e1"}, "arg2": {"span": [[120, 133]], "type": "drug", "id": "DDI-DrugBank.d132.s13.e2"}, "ddi_label": 1, "ddi_type": "advise"}
{"id": "DDI-DrugBank.d132.s14-0", "sentence_id": "DDI-DrugBank.d132.s14", "sentence": "Concomitant administration of diflunisal and acetaminophen in dogs, but not in rats, at approximately 2 times the recommended maximum human therapeutic dose of each (40 to 52 mg/kg/day of diflunisal/acetaminophen) resulted in greater gastrointestinal toxicity than when either drug was administered alone.", "arg1": {"span": [[30, 40]], "type": "drug", "id": "DDI-DrugBank.d132.s14.e0"}, "arg2": {"span": [[45, 58]], "type": "drug", "id": "DDI-DrugBank.d132.s14.e1"}, "ddi_label": 1, "ddi_type": "effect"}
{"id": "DDI-DrugBank.d132.s14-1", "sentence_id": "DDI-DrugBank.d132.s14", "sentence": "Concomitant administration of diflunisal and acetaminophen in dogs, but not in rats, at approximately 2 times the recommended maximum human therapeutic dose of each (40 to 52 mg/kg/day of diflunisal/acetaminophen) resulted in greater gastrointestinal toxicity than when either drug was administered alone.", "arg1": {"span": [[30, 40]], "type": "drug", "id": "DDI-DrugBank.d132.s14.e0"}, "arg2": {"span": [[188, 198]], "type": "drug", "id": "DDI-DrugBank.d132.s14.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d132.s14-2", "sentence_id": "DDI-DrugBank.d132.s14", "sentence": "Concomitant administration of diflunisal and acetaminophen in dogs, but not in rats, at approximately 2 times the recommended maximum human therapeutic dose of each (40 to 52 mg/kg/day of diflunisal/acetaminophen) resulted in greater gastrointestinal toxicity than when either drug was administered alone.", "arg1": {"span": [[30, 40]], "type": "drug", "id": "DDI-DrugBank.d132.s14.e0"}, "arg2": {"span": [[199, 212]], "type": "drug", "id": "DDI-DrugBank.d132.s14.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d132.s14-3", "sentence_id": "DDI-DrugBank.d132.s14", "sentence": "Concomitant administration of diflunisal and acetaminophen in dogs, but not in rats, at approximately 2 times the recommended maximum human therapeutic dose of each (40 to 52 mg/kg/day of diflunisal/acetaminophen) resulted in greater gastrointestinal toxicity than when either drug was administered alone.", "arg1": {"span": [[45, 58]], "type": "drug", "id": "DDI-DrugBank.d132.s14.e1"}, "arg2": {"span": [[188, 198]], "type": "drug", "id": "DDI-DrugBank.d132.s14.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d132.s14-4", "sentence_id": "DDI-DrugBank.d132.s14", "sentence": "Concomitant administration of diflunisal and acetaminophen in dogs, but not in rats, at approximately 2 times the recommended maximum human therapeutic dose of each (40 to 52 mg/kg/day of diflunisal/acetaminophen) resulted in greater gastrointestinal toxicity than when either drug was administered alone.", "arg1": {"span": [[45, 58]], "type": "drug", "id": "DDI-DrugBank.d132.s14.e1"}, "arg2": {"span": [[199, 212]], "type": "drug", "id": "DDI-DrugBank.d132.s14.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d132.s14-5", "sentence_id": "DDI-DrugBank.d132.s14", "sentence": "Concomitant administration of diflunisal and acetaminophen in dogs, but not in rats, at approximately 2 times the recommended maximum human therapeutic dose of each (40 to 52 mg/kg/day of diflunisal/acetaminophen) resulted in greater gastrointestinal toxicity than when either drug was administered alone.", "arg1": {"span": [[188, 198]], "type": "drug", "id": "DDI-DrugBank.d132.s14.e2"}, "arg2": {"span": [[199, 212]], "type": "drug", "id": "DDI-DrugBank.d132.s14.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d132.s16-0", "sentence_id": "DDI-DrugBank.d132.s16", "sentence": "Methotrexate: Caution should be used if diflunisal is administered concomitantly with methotrexate.", "arg1": {"span": [[0, 12]], "type": "drug", "id": "DDI-DrugBank.d132.s16.e0"}, "arg2": {"span": [[40, 50]], "type": "drug", "id": "DDI-DrugBank.d132.s16.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d132.s16-1", "sentence_id": "DDI-DrugBank.d132.s16", "sentence": "Methotrexate: Caution should be used if diflunisal is administered concomitantly with methotrexate.", "arg1": {"span": [[0, 12]], "type": "drug", "id": "DDI-DrugBank.d132.s16.e0"}, "arg2": {"span": [[86, 98]], "type": "drug", "id": "DDI-DrugBank.d132.s16.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d132.s16-2", "sentence_id": "DDI-DrugBank.d132.s16", "sentence": "Methotrexate: Caution should be used if diflunisal is administered concomitantly with methotrexate.", "arg1": {"span": [[40, 50]], "type": "drug", "id": "DDI-DrugBank.d132.s16.e1"}, "arg2": {"span": [[86, 98]], "type": "drug", "id": "DDI-DrugBank.d132.s16.e2"}, "ddi_label": 1, "ddi_type": "advise"}
{"id": "DDI-DrugBank.d132.s17-0", "sentence_id": "DDI-DrugBank.d132.s17", "sentence": "Nonsteroidal anti-inflammatory drugs have been reported to decrease the tubular secretion of methotrexate and to potentiate its toxicity.", "arg1": {"span": [[0, 36]], "type": "group", "id": "DDI-DrugBank.d132.s17.e0"}, "arg2": {"span": [[93, 105]], "type": "drug", "id": "DDI-DrugBank.d132.s17.e1"}, "ddi_label": 1, "ddi_type": "mechanism"}
{"id": "DDI-DrugBank.d132.s18-0", "sentence_id": "DDI-DrugBank.d132.s18", "sentence": "Cyclosporine: Administration of nonsteroial anti-inflammatory drugs concomitantly with cyclosporine has been associated with an increase in cyclosporine-induced toxicity, possibly due to decreased synthesis of renal prostacyclin.", "arg1": {"span": [[0, 12]], "type": "drug", "id": "DDI-DrugBank.d132.s18.e0"}, "arg2": {"span": [[32, 67]], "type": "group", "id": "DDI-DrugBank.d132.s18.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d132.s18-1", "sentence_id": "DDI-DrugBank.d132.s18", "sentence": "Cyclosporine: Administration of nonsteroial anti-inflammatory drugs concomitantly with cyclosporine has been associated with an increase in cyclosporine-induced toxicity, possibly due to decreased synthesis of renal prostacyclin.", "arg1": {"span": [[0, 12]], "type": "drug", "id": "DDI-DrugBank.d132.s18.e0"}, "arg2": {"span": [[87, 99]], "type": "drug", "id": "DDI-DrugBank.d132.s18.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d132.s18-2", "sentence_id": "DDI-DrugBank.d132.s18", "sentence": "Cyclosporine: Administration of nonsteroial anti-inflammatory drugs concomitantly with cyclosporine has been associated with an increase in cyclosporine-induced toxicity, possibly due to decreased synthesis of renal prostacyclin.", "arg1": {"span": [[0, 12]], "type": "drug", "id": "DDI-DrugBank.d132.s18.e0"}, "arg2": {"span": [[140, 152]], "type": "drug", "id": "DDI-DrugBank.d132.s18.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d132.s18-3", "sentence_id": "DDI-DrugBank.d132.s18", "sentence": "Cyclosporine: Administration of nonsteroial anti-inflammatory drugs concomitantly with cyclosporine has been associated with an increase in cyclosporine-induced toxicity, possibly due to decreased synthesis of renal prostacyclin.", "arg1": {"span": [[32, 67]], "type": "group", "id": "DDI-DrugBank.d132.s18.e1"}, "arg2": {"span": [[87, 99]], "type": "drug", "id": "DDI-DrugBank.d132.s18.e2"}, "ddi_label": 1, "ddi_type": "mechanism"}
{"id": "DDI-DrugBank.d132.s18-4", "sentence_id": "DDI-DrugBank.d132.s18", "sentence": "Cyclosporine: Administration of nonsteroial anti-inflammatory drugs concomitantly with cyclosporine has been associated with an increase in cyclosporine-induced toxicity, possibly due to decreased synthesis of renal prostacyclin.", "arg1": {"span": [[32, 67]], "type": "group", "id": "DDI-DrugBank.d132.s18.e1"}, "arg2": {"span": [[140, 152]], "type": "drug", "id": "DDI-DrugBank.d132.s18.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d132.s18-5", "sentence_id": "DDI-DrugBank.d132.s18", "sentence": "Cyclosporine: Administration of nonsteroial anti-inflammatory drugs concomitantly with cyclosporine has been associated with an increase in cyclosporine-induced toxicity, possibly due to decreased synthesis of renal prostacyclin.", "arg1": {"span": [[87, 99]], "type": "drug", "id": "DDI-DrugBank.d132.s18.e2"}, "arg2": {"span": [[140, 152]], "type": "drug", "id": "DDI-DrugBank.d132.s18.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d132.s19-0", "sentence_id": "DDI-DrugBank.d132.s19", "sentence": "NSAIDs should be used with caution in patients taking cyclosporine, and renal function should be carefully monitored.", "arg1": {"span": [[0, 6]], "type": "group", "id": "DDI-DrugBank.d132.s19.e0"}, "arg2": {"span": [[54, 66]], "type": "drug", "id": "DDI-DrugBank.d132.s19.e1"}, "ddi_label": 1, "ddi_type": "advise"}
{"id": "DDI-DrugBank.d132.s20-0", "sentence_id": "DDI-DrugBank.d132.s20", "sentence": "Nonsteroidal Anti-Inflammatory Drugs: The administration of diflunisal to normal volunteers receiving indomethacin decreased the renal clearance and significantly increased the plasma levels of indomethacin.", "arg1": {"span": [[0, 36]], "type": "group", "id": "DDI-DrugBank.d132.s20.e0"}, "arg2": {"span": [[60, 70]], "type": "drug", "id": "DDI-DrugBank.d132.s20.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d132.s20-1", "sentence_id": "DDI-DrugBank.d132.s20", "sentence": "Nonsteroidal Anti-Inflammatory Drugs: The administration of diflunisal to normal volunteers receiving indomethacin decreased the renal clearance and significantly increased the plasma levels of indomethacin.", "arg1": {"span": [[0, 36]], "type": "group", "id": "DDI-DrugBank.d132.s20.e0"}, "arg2": {"span": [[102, 114]], "type": "drug", "id": "DDI-DrugBank.d132.s20.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d132.s20-2", "sentence_id": "DDI-DrugBank.d132.s20", "sentence": "Nonsteroidal Anti-Inflammatory Drugs: The administration of diflunisal to normal volunteers receiving indomethacin decreased the renal clearance and significantly increased the plasma levels of indomethacin.", "arg1": {"span": [[0, 36]], "type": "group", "id": "DDI-DrugBank.d132.s20.e0"}, "arg2": {"span": [[194, 206]], "type": "drug", "id": "DDI-DrugBank.d132.s20.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d132.s20-3", "sentence_id": "DDI-DrugBank.d132.s20", "sentence": "Nonsteroidal Anti-Inflammatory Drugs: The administration of diflunisal to normal volunteers receiving indomethacin decreased the renal clearance and significantly increased the plasma levels of indomethacin.", "arg1": {"span": [[60, 70]], "type": "drug", "id": "DDI-DrugBank.d132.s20.e1"}, "arg2": {"span": [[102, 114]], "type": "drug", "id": "DDI-DrugBank.d132.s20.e2"}, "ddi_label": 1, "ddi_type": "mechanism"}
{"id": "DDI-DrugBank.d132.s20-4", "sentence_id": "DDI-DrugBank.d132.s20", "sentence": "Nonsteroidal Anti-Inflammatory Drugs: The administration of diflunisal to normal volunteers receiving indomethacin decreased the renal clearance and significantly increased the plasma levels of indomethacin.", "arg1": {"span": [[60, 70]], "type": "drug", "id": "DDI-DrugBank.d132.s20.e1"}, "arg2": {"span": [[194, 206]], "type": "drug", "id": "DDI-DrugBank.d132.s20.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d132.s20-5", "sentence_id": "DDI-DrugBank.d132.s20", "sentence": "Nonsteroidal Anti-Inflammatory Drugs: The administration of diflunisal to normal volunteers receiving indomethacin decreased the renal clearance and significantly increased the plasma levels of indomethacin.", "arg1": {"span": [[102, 114]], "type": "drug", "id": "DDI-DrugBank.d132.s20.e2"}, "arg2": {"span": [[194, 206]], "type": "drug", "id": "DDI-DrugBank.d132.s20.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d132.s21-0", "sentence_id": "DDI-DrugBank.d132.s21", "sentence": "In some patients the combined use of indomethacin and diflunisal has been associated with fatal gastrointestinal hemorrhage.", "arg1": {"span": [[37, 49]], "type": "drug", "id": "DDI-DrugBank.d132.s21.e0"}, "arg2": {"span": [[54, 64]], "type": "drug", "id": "DDI-DrugBank.d132.s21.e1"}, "ddi_label": 1, "ddi_type": "effect"}
{"id": "DDI-DrugBank.d132.s22-0", "sentence_id": "DDI-DrugBank.d132.s22", "sentence": "Therefore, indomethacin and diflunisal should not be used concomitantly.", "arg1": {"span": [[11, 23]], "type": "drug", "id": "DDI-DrugBank.d132.s22.e0"}, "arg2": {"span": [[28, 38]], "type": "drug", "id": "DDI-DrugBank.d132.s22.e1"}, "ddi_label": 1, "ddi_type": "advise"}
{"id": "DDI-DrugBank.d132.s23-0", "sentence_id": "DDI-DrugBank.d132.s23", "sentence": "The concomitant use of diflunisal tablets and other NSAIDs is not recommended due to the increased possibility of gastrointestinal toxicity, with little or no increase in efficacy.", "arg1": {"span": [[23, 33]], "type": "drug", "id": "DDI-DrugBank.d132.s23.e0"}, "arg2": {"span": [[52, 58]], "type": "group", "id": "DDI-DrugBank.d132.s23.e1"}, "ddi_label": 1, "ddi_type": "effect"}
{"id": "DDI-DrugBank.d132.s25-0", "sentence_id": "DDI-DrugBank.d132.s25", "sentence": "Aspirin: In normal volunteers, a small decrease in diflunisal levels was observed when multiple doses of diflunisal and aspirin were administered concomitantly.", "arg1": {"span": [[0, 7]], "type": "brand", "id": "DDI-DrugBank.d132.s25.e0"}, "arg2": {"span": [[51, 61]], "type": "drug", "id": "DDI-DrugBank.d132.s25.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d132.s25-1", "sentence_id": "DDI-DrugBank.d132.s25", "sentence": "Aspirin: In normal volunteers, a small decrease in diflunisal levels was observed when multiple doses of diflunisal and aspirin were administered concomitantly.", "arg1": {"span": [[0, 7]], "type": "brand", "id": "DDI-DrugBank.d132.s25.e0"}, "arg2": {"span": [[105, 115]], "type": "drug", "id": "DDI-DrugBank.d132.s25.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d132.s25-2", "sentence_id": "DDI-DrugBank.d132.s25", "sentence": "Aspirin: In normal volunteers, a small decrease in diflunisal levels was observed when multiple doses of diflunisal and aspirin were administered concomitantly.", "arg1": {"span": [[0, 7]], "type": "brand", "id": "DDI-DrugBank.d132.s25.e0"}, "arg2": {"span": [[120, 127]], "type": "brand", "id": "DDI-DrugBank.d132.s25.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d132.s25-3", "sentence_id": "DDI-DrugBank.d132.s25", "sentence": "Aspirin: In normal volunteers, a small decrease in diflunisal levels was observed when multiple doses of diflunisal and aspirin were administered concomitantly.", "arg1": {"span": [[51, 61]], "type": "drug", "id": "DDI-DrugBank.d132.s25.e1"}, "arg2": {"span": [[105, 115]], "type": "drug", "id": "DDI-DrugBank.d132.s25.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d132.s25-4", "sentence_id": "DDI-DrugBank.d132.s25", "sentence": "Aspirin: In normal volunteers, a small decrease in diflunisal levels was observed when multiple doses of diflunisal and aspirin were administered concomitantly.", "arg1": {"span": [[51, 61]], "type": "drug", "id": "DDI-DrugBank.d132.s25.e1"}, "arg2": {"span": [[120, 127]], "type": "brand", "id": "DDI-DrugBank.d132.s25.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d132.s25-5", "sentence_id": "DDI-DrugBank.d132.s25", "sentence": "Aspirin: In normal volunteers, a small decrease in diflunisal levels was observed when multiple doses of diflunisal and aspirin were administered concomitantly.", "arg1": {"span": [[105, 115]], "type": "drug", "id": "DDI-DrugBank.d132.s25.e2"}, "arg2": {"span": [[120, 127]], "type": "brand", "id": "DDI-DrugBank.d132.s25.e3"}, "ddi_label": 1, "ddi_type": "mechanism"}
{"id": "DDI-DrugBank.d132.s26-0", "sentence_id": "DDI-DrugBank.d132.s26", "sentence": "Sulindac: The concomitant administration of diflunisal and sulindac in normal volunteers resulted in lowering of the plasma levels of the active sulindac sulfide metabolite by approximately one-third.", "arg1": {"span": [[0, 8]], "type": "drug", "id": "DDI-DrugBank.d132.s26.e0"}, "arg2": {"span": [[44, 54]], "type": "drug", "id": "DDI-DrugBank.d132.s26.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d132.s26-1", "sentence_id": "DDI-DrugBank.d132.s26", "sentence": "Sulindac: The concomitant administration of diflunisal and sulindac in normal volunteers resulted in lowering of the plasma levels of the active sulindac sulfide metabolite by approximately one-third.", "arg1": {"span": [[0, 8]], "type": "drug", "id": "DDI-DrugBank.d132.s26.e0"}, "arg2": {"span": [[59, 67]], "type": "drug", "id": "DDI-DrugBank.d132.s26.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d132.s26-2", "sentence_id": "DDI-DrugBank.d132.s26", "sentence": "Sulindac: The concomitant administration of diflunisal and sulindac in normal volunteers resulted in lowering of the plasma levels of the active sulindac sulfide metabolite by approximately one-third.", "arg1": {"span": [[44, 54]], "type": "drug", "id": "DDI-DrugBank.d132.s26.e1"}, "arg2": {"span": [[59, 67]], "type": "drug", "id": "DDI-DrugBank.d132.s26.e2"}, "ddi_label": 1, "ddi_type": "mechanism"}
{"id": "DDI-DrugBank.d132.s27-0", "sentence_id": "DDI-DrugBank.d132.s27", "sentence": "Naproxen: The concomitant administration of diflunisal and naproxen in normal volunteers had no effect on the plasma levels of naproxen, but significantly decreased the urinary excretion of naproxen and its glucuronide metabolite.", "arg1": {"span": [[0, 8]], "type": "drug", "id": "DDI-DrugBank.d132.s27.e0"}, "arg2": {"span": [[44, 54]], "type": "drug", "id": "DDI-DrugBank.d132.s27.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d132.s27-1", "sentence_id": "DDI-DrugBank.d132.s27", "sentence": "Naproxen: The concomitant administration of diflunisal and naproxen in normal volunteers had no effect on the plasma levels of naproxen, but significantly decreased the urinary excretion of naproxen and its glucuronide metabolite.", "arg1": {"span": [[0, 8]], "type": "drug", "id": "DDI-DrugBank.d132.s27.e0"}, "arg2": {"span": [[59, 67]], "type": "drug", "id": "DDI-DrugBank.d132.s27.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d132.s27-2", "sentence_id": "DDI-DrugBank.d132.s27", "sentence": "Naproxen: The concomitant administration of diflunisal and naproxen in normal volunteers had no effect on the plasma levels of naproxen, but significantly decreased the urinary excretion of naproxen and its glucuronide metabolite.", "arg1": {"span": [[0, 8]], "type": "drug", "id": "DDI-DrugBank.d132.s27.e0"}, "arg2": {"span": [[127, 135]], "type": "drug", "id": "DDI-DrugBank.d132.s27.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d132.s27-3", "sentence_id": "DDI-DrugBank.d132.s27", "sentence": "Naproxen: The concomitant administration of diflunisal and naproxen in normal volunteers had no effect on the plasma levels of naproxen, but significantly decreased the urinary excretion of naproxen and its glucuronide metabolite.", "arg1": {"span": [[0, 8]], "type": "drug", "id": "DDI-DrugBank.d132.s27.e0"}, "arg2": {"span": [[190, 198]], "type": "drug", "id": "DDI-DrugBank.d132.s27.e4"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d132.s27-4", "sentence_id": "DDI-DrugBank.d132.s27", "sentence": "Naproxen: The concomitant administration of diflunisal and naproxen in normal volunteers had no effect on the plasma levels of naproxen, but significantly decreased the urinary excretion of naproxen and its glucuronide metabolite.", "arg1": {"span": [[44, 54]], "type": "drug", "id": "DDI-DrugBank.d132.s27.e1"}, "arg2": {"span": [[59, 67]], "type": "drug", "id": "DDI-DrugBank.d132.s27.e2"}, "ddi_label": 1, "ddi_type": "mechanism"}
{"id": "DDI-DrugBank.d132.s27-5", "sentence_id": "DDI-DrugBank.d132.s27", "sentence": "Naproxen: The concomitant administration of diflunisal and naproxen in normal volunteers had no effect on the plasma levels of naproxen, but significantly decreased the urinary excretion of naproxen and its glucuronide metabolite.", "arg1": {"span": [[44, 54]], "type": "drug", "id": "DDI-DrugBank.d132.s27.e1"}, "arg2": {"span": [[127, 135]], "type": "drug", "id": "DDI-DrugBank.d132.s27.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d132.s27-6", "sentence_id": "DDI-DrugBank.d132.s27", "sentence": "Naproxen: The concomitant administration of diflunisal and naproxen in normal volunteers had no effect on the plasma levels of naproxen, but significantly decreased the urinary excretion of naproxen and its glucuronide metabolite.", "arg1": {"span": [[44, 54]], "type": "drug", "id": "DDI-DrugBank.d132.s27.e1"}, "arg2": {"span": [[190, 198]], "type": "drug", "id": "DDI-DrugBank.d132.s27.e4"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d132.s27-7", "sentence_id": "DDI-DrugBank.d132.s27", "sentence": "Naproxen: The concomitant administration of diflunisal and naproxen in normal volunteers had no effect on the plasma levels of naproxen, but significantly decreased the urinary excretion of naproxen and its glucuronide metabolite.", "arg1": {"span": [[59, 67]], "type": "drug", "id": "DDI-DrugBank.d132.s27.e2"}, "arg2": {"span": [[127, 135]], "type": "drug", "id": "DDI-DrugBank.d132.s27.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d132.s27-8", "sentence_id": "DDI-DrugBank.d132.s27", "sentence": "Naproxen: The concomitant administration of diflunisal and naproxen in normal volunteers had no effect on the plasma levels of naproxen, but significantly decreased the urinary excretion of naproxen and its glucuronide metabolite.", "arg1": {"span": [[59, 67]], "type": "drug", "id": "DDI-DrugBank.d132.s27.e2"}, "arg2": {"span": [[190, 198]], "type": "drug", "id": "DDI-DrugBank.d132.s27.e4"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d132.s27-9", "sentence_id": "DDI-DrugBank.d132.s27", "sentence": "Naproxen: The concomitant administration of diflunisal and naproxen in normal volunteers had no effect on the plasma levels of naproxen, but significantly decreased the urinary excretion of naproxen and its glucuronide metabolite.", "arg1": {"span": [[127, 135]], "type": "drug", "id": "DDI-DrugBank.d132.s27.e3"}, "arg2": {"span": [[190, 198]], "type": "drug", "id": "DDI-DrugBank.d132.s27.e4"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d132.s28-0", "sentence_id": "DDI-DrugBank.d132.s28", "sentence": "Naproxen had no effect on plasma levels of diflunisal.", "arg1": {"span": [[0, 8]], "type": "drug", "id": "DDI-DrugBank.d132.s28.e0"}, "arg2": {"span": [[43, 53]], "type": "drug", "id": "DDI-DrugBank.d132.s28.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d30.s0-0", "sentence_id": "DDI-DrugBank.d30.s0", "sentence": "No significant drug-drug pharmacokinetic interactions have been found in interaction studies with hydrochlorothiazide, digoxin, warfarin, cimetidine and phenobarbital.", "arg1": {"span": [[98, 117]], "type": "drug", "id": "DDI-DrugBank.d30.s0.e0"}, "arg2": {"span": [[119, 126]], "type": "drug", "id": "DDI-DrugBank.d30.s0.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d30.s0-1", "sentence_id": "DDI-DrugBank.d30.s0", "sentence": "No significant drug-drug pharmacokinetic interactions have been found in interaction studies with hydrochlorothiazide, digoxin, warfarin, cimetidine and phenobarbital.", "arg1": {"span": [[98, 117]], "type": "drug", "id": "DDI-DrugBank.d30.s0.e0"}, "arg2": {"span": [[128, 136]], "type": "drug", "id": "DDI-DrugBank.d30.s0.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d30.s0-2", "sentence_id": "DDI-DrugBank.d30.s0", "sentence": "No significant drug-drug pharmacokinetic interactions have been found in interaction studies with hydrochlorothiazide, digoxin, warfarin, cimetidine and phenobarbital.", "arg1": {"span": [[98, 117]], "type": "drug", "id": "DDI-DrugBank.d30.s0.e0"}, "arg2": {"span": [[138, 148]], "type": "drug", "id": "DDI-DrugBank.d30.s0.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d30.s0-3", "sentence_id": "DDI-DrugBank.d30.s0", "sentence": "No significant drug-drug pharmacokinetic interactions have been found in interaction studies with hydrochlorothiazide, digoxin, warfarin, cimetidine and phenobarbital.", "arg1": {"span": [[98, 117]], "type": "drug", "id": "DDI-DrugBank.d30.s0.e0"}, "arg2": {"span": [[153, 166]], "type": "drug", "id": "DDI-DrugBank.d30.s0.e4"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d30.s0-4", "sentence_id": "DDI-DrugBank.d30.s0", "sentence": "No significant drug-drug pharmacokinetic interactions have been found in interaction studies with hydrochlorothiazide, digoxin, warfarin, cimetidine and phenobarbital.", "arg1": {"span": [[119, 126]], "type": "drug", "id": "DDI-DrugBank.d30.s0.e1"}, "arg2": {"span": [[128, 136]], "type": "drug", "id": "DDI-DrugBank.d30.s0.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d30.s0-5", "sentence_id": "DDI-DrugBank.d30.s0", "sentence": "No significant drug-drug pharmacokinetic interactions have been found in interaction studies with hydrochlorothiazide, digoxin, warfarin, cimetidine and phenobarbital.", "arg1": {"span": [[119, 126]], "type": "drug", "id": "DDI-DrugBank.d30.s0.e1"}, "arg2": {"span": [[138, 148]], "type": "drug", "id": "DDI-DrugBank.d30.s0.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d30.s0-6", "sentence_id": "DDI-DrugBank.d30.s0", "sentence": "No significant drug-drug pharmacokinetic interactions have been found in interaction studies with hydrochlorothiazide, digoxin, warfarin, cimetidine and phenobarbital.", "arg1": {"span": [[119, 126]], "type": "drug", "id": "DDI-DrugBank.d30.s0.e1"}, "arg2": {"span": [[153, 166]], "type": "drug", "id": "DDI-DrugBank.d30.s0.e4"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d30.s0-7", "sentence_id": "DDI-DrugBank.d30.s0", "sentence": "No significant drug-drug pharmacokinetic interactions have been found in interaction studies with hydrochlorothiazide, digoxin, warfarin, cimetidine and phenobarbital.", "arg1": {"span": [[128, 136]], "type": "drug", "id": "DDI-DrugBank.d30.s0.e2"}, "arg2": {"span": [[138, 148]], "type": "drug", "id": "DDI-DrugBank.d30.s0.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d30.s0-8", "sentence_id": "DDI-DrugBank.d30.s0", "sentence": "No significant drug-drug pharmacokinetic interactions have been found in interaction studies with hydrochlorothiazide, digoxin, warfarin, cimetidine and phenobarbital.", "arg1": {"span": [[128, 136]], "type": "drug", "id": "DDI-DrugBank.d30.s0.e2"}, "arg2": {"span": [[153, 166]], "type": "drug", "id": "DDI-DrugBank.d30.s0.e4"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d30.s0-9", "sentence_id": "DDI-DrugBank.d30.s0", "sentence": "No significant drug-drug pharmacokinetic interactions have been found in interaction studies with hydrochlorothiazide, digoxin, warfarin, cimetidine and phenobarbital.", "arg1": {"span": [[138, 148]], "type": "drug", "id": "DDI-DrugBank.d30.s0.e3"}, "arg2": {"span": [[153, 166]], "type": "drug", "id": "DDI-DrugBank.d30.s0.e4"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d30.s1-0", "sentence_id": "DDI-DrugBank.d30.s1", "sentence": "Rifampin, an inducer of drug metabolism, decreased the concentrations of losartan and its active metabolite.", "arg1": {"span": [[0, 8]], "type": "drug", "id": "DDI-DrugBank.d30.s1.e0"}, "arg2": {"span": [[73, 81]], "type": "drug", "id": "DDI-DrugBank.d30.s1.e1"}, "ddi_label": 1, "ddi_type": "mechanism"}
{"id": "DDI-DrugBank.d30.s3-0", "sentence_id": "DDI-DrugBank.d30.s3", "sentence": "Ketoconazole did not affect the conversion of losartan to the active metabolite after intravenous administration of losartan, and erythromycin had no clinically significant effect after oral administration.", "arg1": {"span": [[0, 12]], "type": "drug", "id": "DDI-DrugBank.d30.s3.e0"}, "arg2": {"span": [[46, 54]], "type": "drug", "id": "DDI-DrugBank.d30.s3.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d30.s3-1", "sentence_id": "DDI-DrugBank.d30.s3", "sentence": "Ketoconazole did not affect the conversion of losartan to the active metabolite after intravenous administration of losartan, and erythromycin had no clinically significant effect after oral administration.", "arg1": {"span": [[0, 12]], "type": "drug", "id": "DDI-DrugBank.d30.s3.e0"}, "arg2": {"span": [[116, 124]], "type": "drug", "id": "DDI-DrugBank.d30.s3.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d30.s3-2", "sentence_id": "DDI-DrugBank.d30.s3", "sentence": "Ketoconazole did not affect the conversion of losartan to the active metabolite after intravenous administration of losartan, and erythromycin had no clinically significant effect after oral administration.", "arg1": {"span": [[0, 12]], "type": "drug", "id": "DDI-DrugBank.d30.s3.e0"}, "arg2": {"span": [[130, 142]], "type": "drug", "id": "DDI-DrugBank.d30.s3.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d30.s3-3", "sentence_id": "DDI-DrugBank.d30.s3", "sentence": "Ketoconazole did not affect the conversion of losartan to the active metabolite after intravenous administration of losartan, and erythromycin had no clinically significant effect after oral administration.", "arg1": {"span": [[46, 54]], "type": "drug", "id": "DDI-DrugBank.d30.s3.e1"}, "arg2": {"span": [[116, 124]], "type": "drug", "id": "DDI-DrugBank.d30.s3.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d30.s3-4", "sentence_id": "DDI-DrugBank.d30.s3", "sentence": "Ketoconazole did not affect the conversion of losartan to the active metabolite after intravenous administration of losartan, and erythromycin had no clinically significant effect after oral administration.", "arg1": {"span": [[46, 54]], "type": "drug", "id": "DDI-DrugBank.d30.s3.e1"}, "arg2": {"span": [[130, 142]], "type": "drug", "id": "DDI-DrugBank.d30.s3.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d30.s3-5", "sentence_id": "DDI-DrugBank.d30.s3", "sentence": "Ketoconazole did not affect the conversion of losartan to the active metabolite after intravenous administration of losartan, and erythromycin had no clinically significant effect after oral administration.", "arg1": {"span": [[116, 124]], "type": "drug", "id": "DDI-DrugBank.d30.s3.e2"}, "arg2": {"span": [[130, 142]], "type": "drug", "id": "DDI-DrugBank.d30.s3.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d30.s4-0", "sentence_id": "DDI-DrugBank.d30.s4", "sentence": "Fluconazole, an inhibitor of P450 2C9, decreased active metabolite concentration and increased losartan concentration.", "arg1": {"span": [[0, 11]], "type": "drug", "id": "DDI-DrugBank.d30.s4.e0"}, "arg2": {"span": [[95, 103]], "type": "drug", "id": "DDI-DrugBank.d30.s4.e1"}, "ddi_label": 1, "ddi_type": "mechanism"}
{"id": "DDI-DrugBank.d30.s8-0", "sentence_id": "DDI-DrugBank.d30.s8", "sentence": "As with other drugs that block angiotensin II or its effects, concomitant use of potassium-sparing diuretics (e.g., spironolactone, triamterene, amiloride), potassium supplements, or salt substitutes containing potassium may lead to increases in serum potassium.", "arg1": {"span": [[81, 108]], "type": "group", "id": "DDI-DrugBank.d30.s8.e0"}, "arg2": {"span": [[116, 130]], "type": "drug", "id": "DDI-DrugBank.d30.s8.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d30.s8-1", "sentence_id": "DDI-DrugBank.d30.s8", "sentence": "As with other drugs that block angiotensin II or its effects, concomitant use of potassium-sparing diuretics (e.g., spironolactone, triamterene, amiloride), potassium supplements, or salt substitutes containing potassium may lead to increases in serum potassium.", "arg1": {"span": [[81, 108]], "type": "group", "id": "DDI-DrugBank.d30.s8.e0"}, "arg2": {"span": [[132, 143]], "type": "drug", "id": "DDI-DrugBank.d30.s8.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d30.s8-2", "sentence_id": "DDI-DrugBank.d30.s8", "sentence": "As with other drugs that block angiotensin II or its effects, concomitant use of potassium-sparing diuretics (e.g., spironolactone, triamterene, amiloride), potassium supplements, or salt substitutes containing potassium may lead to increases in serum potassium.", "arg1": {"span": [[81, 108]], "type": "group", "id": "DDI-DrugBank.d30.s8.e0"}, "arg2": {"span": [[145, 154]], "type": "drug", "id": "DDI-DrugBank.d30.s8.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d30.s8-3", "sentence_id": "DDI-DrugBank.d30.s8", "sentence": "As with other drugs that block angiotensin II or its effects, concomitant use of potassium-sparing diuretics (e.g., spironolactone, triamterene, amiloride), potassium supplements, or salt substitutes containing potassium may lead to increases in serum potassium.", "arg1": {"span": [[81, 108]], "type": "group", "id": "DDI-DrugBank.d30.s8.e0"}, "arg2": {"span": [[157, 166]], "type": "drug", "id": "DDI-DrugBank.d30.s8.e4"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d30.s8-4", "sentence_id": "DDI-DrugBank.d30.s8", "sentence": "As with other drugs that block angiotensin II or its effects, concomitant use of potassium-sparing diuretics (e.g., spironolactone, triamterene, amiloride), potassium supplements, or salt substitutes containing potassium may lead to increases in serum potassium.", "arg1": {"span": [[116, 130]], "type": "drug", "id": "DDI-DrugBank.d30.s8.e1"}, "arg2": {"span": [[132, 143]], "type": "drug", "id": "DDI-DrugBank.d30.s8.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d30.s8-5", "sentence_id": "DDI-DrugBank.d30.s8", "sentence": "As with other drugs that block angiotensin II or its effects, concomitant use of potassium-sparing diuretics (e.g., spironolactone, triamterene, amiloride), potassium supplements, or salt substitutes containing potassium may lead to increases in serum potassium.", "arg1": {"span": [[116, 130]], "type": "drug", "id": "DDI-DrugBank.d30.s8.e1"}, "arg2": {"span": [[145, 154]], "type": "drug", "id": "DDI-DrugBank.d30.s8.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d30.s8-6", "sentence_id": "DDI-DrugBank.d30.s8", "sentence": "As with other drugs that block angiotensin II or its effects, concomitant use of potassium-sparing diuretics (e.g., spironolactone, triamterene, amiloride), potassium supplements, or salt substitutes containing potassium may lead to increases in serum potassium.", "arg1": {"span": [[116, 130]], "type": "drug", "id": "DDI-DrugBank.d30.s8.e1"}, "arg2": {"span": [[157, 166]], "type": "drug", "id": "DDI-DrugBank.d30.s8.e4"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d30.s8-7", "sentence_id": "DDI-DrugBank.d30.s8", "sentence": "As with other drugs that block angiotensin II or its effects, concomitant use of potassium-sparing diuretics (e.g., spironolactone, triamterene, amiloride), potassium supplements, or salt substitutes containing potassium may lead to increases in serum potassium.", "arg1": {"span": [[132, 143]], "type": "drug", "id": "DDI-DrugBank.d30.s8.e2"}, "arg2": {"span": [[145, 154]], "type": "drug", "id": "DDI-DrugBank.d30.s8.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d30.s8-8", "sentence_id": "DDI-DrugBank.d30.s8", "sentence": "As with other drugs that block angiotensin II or its effects, concomitant use of potassium-sparing diuretics (e.g., spironolactone, triamterene, amiloride), potassium supplements, or salt substitutes containing potassium may lead to increases in serum potassium.", "arg1": {"span": [[132, 143]], "type": "drug", "id": "DDI-DrugBank.d30.s8.e2"}, "arg2": {"span": [[157, 166]], "type": "drug", "id": "DDI-DrugBank.d30.s8.e4"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d30.s8-9", "sentence_id": "DDI-DrugBank.d30.s8", "sentence": "As with other drugs that block angiotensin II or its effects, concomitant use of potassium-sparing diuretics (e.g., spironolactone, triamterene, amiloride), potassium supplements, or salt substitutes containing potassium may lead to increases in serum potassium.", "arg1": {"span": [[145, 154]], "type": "drug", "id": "DDI-DrugBank.d30.s8.e3"}, "arg2": {"span": [[157, 166]], "type": "drug", "id": "DDI-DrugBank.d30.s8.e4"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d30.s9-0", "sentence_id": "DDI-DrugBank.d30.s9", "sentence": "As with other antihypertensive agents, the antihypertensive effect of losartan may be blunted by the non-steroidal anti-inflammatory drug indomethacin", "arg1": {"span": [[14, 37]], "type": "group", "id": "DDI-DrugBank.d30.s9.e0"}, "arg2": {"span": [[70, 78]], "type": "drug", "id": "DDI-DrugBank.d30.s9.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d30.s9-1", "sentence_id": "DDI-DrugBank.d30.s9", "sentence": "As with other antihypertensive agents, the antihypertensive effect of losartan may be blunted by the non-steroidal anti-inflammatory drug indomethacin", "arg1": {"span": [[14, 37]], "type": "group", "id": "DDI-DrugBank.d30.s9.e0"}, "arg2": {"span": [[101, 137]], "type": "group", "id": "DDI-DrugBank.d30.s9.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d30.s9-2", "sentence_id": "DDI-DrugBank.d30.s9", "sentence": "As with other antihypertensive agents, the antihypertensive effect of losartan may be blunted by the non-steroidal anti-inflammatory drug indomethacin", "arg1": {"span": [[14, 37]], "type": "group", "id": "DDI-DrugBank.d30.s9.e0"}, "arg2": {"span": [[138, 150]], "type": "drug", "id": "DDI-DrugBank.d30.s9.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d30.s9-3", "sentence_id": "DDI-DrugBank.d30.s9", "sentence": "As with other antihypertensive agents, the antihypertensive effect of losartan may be blunted by the non-steroidal anti-inflammatory drug indomethacin", "arg1": {"span": [[70, 78]], "type": "drug", "id": "DDI-DrugBank.d30.s9.e1"}, "arg2": {"span": [[101, 137]], "type": "group", "id": "DDI-DrugBank.d30.s9.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d30.s9-4", "sentence_id": "DDI-DrugBank.d30.s9", "sentence": "As with other antihypertensive agents, the antihypertensive effect of losartan may be blunted by the non-steroidal anti-inflammatory drug indomethacin", "arg1": {"span": [[70, 78]], "type": "drug", "id": "DDI-DrugBank.d30.s9.e1"}, "arg2": {"span": [[138, 150]], "type": "drug", "id": "DDI-DrugBank.d30.s9.e3"}, "ddi_label": 1, "ddi_type": "effect"}
{"id": "DDI-DrugBank.d30.s9-5", "sentence_id": "DDI-DrugBank.d30.s9", "sentence": "As with other antihypertensive agents, the antihypertensive effect of losartan may be blunted by the non-steroidal anti-inflammatory drug indomethacin", "arg1": {"span": [[101, 137]], "type": "group", "id": "DDI-DrugBank.d30.s9.e2"}, "arg2": {"span": [[138, 150]], "type": "drug", "id": "DDI-DrugBank.d30.s9.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d393.s2-0", "sentence_id": "DDI-DrugBank.d393.s2", "sentence": "In a multiple dose study of theophylline (400 mg once daily for 3 days) and cetirizine (20 mg once daily for 3 days), a 16% decrease in the clearance of cetirizine was observed.", "arg1": {"span": [[28, 40]], "type": "drug", "id": "DDI-DrugBank.d393.s2.e0"}, "arg2": {"span": [[76, 86]], "type": "drug", "id": "DDI-DrugBank.d393.s2.e1"}, "ddi_label": 1, "ddi_type": "mechanism"}
{"id": "DDI-DrugBank.d393.s2-1", "sentence_id": "DDI-DrugBank.d393.s2", "sentence": "In a multiple dose study of theophylline (400 mg once daily for 3 days) and cetirizine (20 mg once daily for 3 days), a 16% decrease in the clearance of cetirizine was observed.", "arg1": {"span": [[28, 40]], "type": "drug", "id": "DDI-DrugBank.d393.s2.e0"}, "arg2": {"span": [[153, 163]], "type": "drug", "id": "DDI-DrugBank.d393.s2.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d393.s2-2", "sentence_id": "DDI-DrugBank.d393.s2", "sentence": "In a multiple dose study of theophylline (400 mg once daily for 3 days) and cetirizine (20 mg once daily for 3 days), a 16% decrease in the clearance of cetirizine was observed.", "arg1": {"span": [[76, 86]], "type": "drug", "id": "DDI-DrugBank.d393.s2.e1"}, "arg2": {"span": [[153, 163]], "type": "drug", "id": "DDI-DrugBank.d393.s2.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d393.s3-0", "sentence_id": "DDI-DrugBank.d393.s3", "sentence": "The disposition of theophylline was not altered by concomitant cetirizine administration.", "arg1": {"span": [[19, 31]], "type": "drug", "id": "DDI-DrugBank.d393.s3.e0"}, "arg2": {"span": [[63, 73]], "type": "drug", "id": "DDI-DrugBank.d393.s3.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d393.s4-0", "sentence_id": "DDI-DrugBank.d393.s4", "sentence": "Drug-Drug Interactions: No clinically significant drug interactions have been found with theophylline at a low dose, azithromycin, pseudoephedrine, ketoconazole, or erythromycin.", "arg1": {"span": [[89, 101]], "type": "drug", "id": "DDI-DrugBank.d393.s4.e0"}, "arg2": {"span": [[117, 129]], "type": "drug", "id": "DDI-DrugBank.d393.s4.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d393.s4-1", "sentence_id": "DDI-DrugBank.d393.s4", "sentence": "Drug-Drug Interactions: No clinically significant drug interactions have been found with theophylline at a low dose, azithromycin, pseudoephedrine, ketoconazole, or erythromycin.", "arg1": {"span": [[89, 101]], "type": "drug", "id": "DDI-DrugBank.d393.s4.e0"}, "arg2": {"span": [[131, 146]], "type": "drug", "id": "DDI-DrugBank.d393.s4.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d393.s4-2", "sentence_id": "DDI-DrugBank.d393.s4", "sentence": "Drug-Drug Interactions: No clinically significant drug interactions have been found with theophylline at a low dose, azithromycin, pseudoephedrine, ketoconazole, or erythromycin.", "arg1": {"span": [[89, 101]], "type": "drug", "id": "DDI-DrugBank.d393.s4.e0"}, "arg2": {"span": [[148, 160]], "type": "drug", "id": "DDI-DrugBank.d393.s4.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d393.s4-3", "sentence_id": "DDI-DrugBank.d393.s4", "sentence": "Drug-Drug Interactions: No clinically significant drug interactions have been found with theophylline at a low dose, azithromycin, pseudoephedrine, ketoconazole, or erythromycin.", "arg1": {"span": [[89, 101]], "type": "drug", "id": "DDI-DrugBank.d393.s4.e0"}, "arg2": {"span": [[165, 177]], "type": "drug", "id": "DDI-DrugBank.d393.s4.e4"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d393.s4-4", "sentence_id": "DDI-DrugBank.d393.s4", "sentence": "Drug-Drug Interactions: No clinically significant drug interactions have been found with theophylline at a low dose, azithromycin, pseudoephedrine, ketoconazole, or erythromycin.", "arg1": {"span": [[117, 129]], "type": "drug", "id": "DDI-DrugBank.d393.s4.e1"}, "arg2": {"span": [[131, 146]], "type": "drug", "id": "DDI-DrugBank.d393.s4.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d393.s4-5", "sentence_id": "DDI-DrugBank.d393.s4", "sentence": "Drug-Drug Interactions: No clinically significant drug interactions have been found with theophylline at a low dose, azithromycin, pseudoephedrine, ketoconazole, or erythromycin.", "arg1": {"span": [[117, 129]], "type": "drug", "id": "DDI-DrugBank.d393.s4.e1"}, "arg2": {"span": [[148, 160]], "type": "drug", "id": "DDI-DrugBank.d393.s4.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d393.s4-6", "sentence_id": "DDI-DrugBank.d393.s4", "sentence": "Drug-Drug Interactions: No clinically significant drug interactions have been found with theophylline at a low dose, azithromycin, pseudoephedrine, ketoconazole, or erythromycin.", "arg1": {"span": [[117, 129]], "type": "drug", "id": "DDI-DrugBank.d393.s4.e1"}, "arg2": {"span": [[165, 177]], "type": "drug", "id": "DDI-DrugBank.d393.s4.e4"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d393.s4-7", "sentence_id": "DDI-DrugBank.d393.s4", "sentence": "Drug-Drug Interactions: No clinically significant drug interactions have been found with theophylline at a low dose, azithromycin, pseudoephedrine, ketoconazole, or erythromycin.", "arg1": {"span": [[131, 146]], "type": "drug", "id": "DDI-DrugBank.d393.s4.e2"}, "arg2": {"span": [[148, 160]], "type": "drug", "id": "DDI-DrugBank.d393.s4.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d393.s4-8", "sentence_id": "DDI-DrugBank.d393.s4", "sentence": "Drug-Drug Interactions: No clinically significant drug interactions have been found with theophylline at a low dose, azithromycin, pseudoephedrine, ketoconazole, or erythromycin.", "arg1": {"span": [[131, 146]], "type": "drug", "id": "DDI-DrugBank.d393.s4.e2"}, "arg2": {"span": [[165, 177]], "type": "drug", "id": "DDI-DrugBank.d393.s4.e4"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d393.s4-9", "sentence_id": "DDI-DrugBank.d393.s4", "sentence": "Drug-Drug Interactions: No clinically significant drug interactions have been found with theophylline at a low dose, azithromycin, pseudoephedrine, ketoconazole, or erythromycin.", "arg1": {"span": [[148, 160]], "type": "drug", "id": "DDI-DrugBank.d393.s4.e3"}, "arg2": {"span": [[165, 177]], "type": "drug", "id": "DDI-DrugBank.d393.s4.e4"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d393.s5-0", "sentence_id": "DDI-DrugBank.d393.s5", "sentence": "There was a small decrease in the clearance of cetirizine caused by a 400-mg dose of theophylline;", "arg1": {"span": [[47, 57]], "type": "drug", "id": "DDI-DrugBank.d393.s5.e0"}, "arg2": {"span": [[85, 97]], "type": "drug", "id": "DDI-DrugBank.d393.s5.e1"}, "ddi_label": 1, "ddi_type": "mechanism"}
{"id": "DDI-DrugBank.d420.s0-0", "sentence_id": "DDI-DrugBank.d420.s0", "sentence": "Antacids (aluminum- or magnesium-containing): Concomitant administration of 300-mg cefdinir capsules with 30 mL Maalox TC suspension reduces the rate (Cmax) and extent (AUC) of absorption by approximately 40%.", "arg1": {"span": [[0, 8]], "type": "group", "id": "DDI-DrugBank.d420.s0.e0"}, "arg2": {"span": [[10, 18]], "type": "drug", "id": "DDI-DrugBank.d420.s0.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d420.s0-1", "sentence_id": "DDI-DrugBank.d420.s0", "sentence": "Antacids (aluminum- or magnesium-containing): Concomitant administration of 300-mg cefdinir capsules with 30 mL Maalox TC suspension reduces the rate (Cmax) and extent (AUC) of absorption by approximately 40%.", "arg1": {"span": [[0, 8]], "type": "group", "id": "DDI-DrugBank.d420.s0.e0"}, "arg2": {"span": [[23, 32]], "type": "drug", "id": "DDI-DrugBank.d420.s0.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d420.s0-2", "sentence_id": "DDI-DrugBank.d420.s0", "sentence": "Antacids (aluminum- or magnesium-containing): Concomitant administration of 300-mg cefdinir capsules with 30 mL Maalox TC suspension reduces the rate (Cmax) and extent (AUC) of absorption by approximately 40%.", "arg1": {"span": [[0, 8]], "type": "group", "id": "DDI-DrugBank.d420.s0.e0"}, "arg2": {"span": [[83, 91]], "type": "drug", "id": "DDI-DrugBank.d420.s0.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d420.s0-3", "sentence_id": "DDI-DrugBank.d420.s0", "sentence": "Antacids (aluminum- or magnesium-containing): Concomitant administration of 300-mg cefdinir capsules with 30 mL Maalox TC suspension reduces the rate (Cmax) and extent (AUC) of absorption by approximately 40%.", "arg1": {"span": [[0, 8]], "type": "group", "id": "DDI-DrugBank.d420.s0.e0"}, "arg2": {"span": [[112, 121]], "type": "brand", "id": "DDI-DrugBank.d420.s0.e4"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d420.s0-4", "sentence_id": "DDI-DrugBank.d420.s0", "sentence": "Antacids (aluminum- or magnesium-containing): Concomitant administration of 300-mg cefdinir capsules with 30 mL Maalox TC suspension reduces the rate (Cmax) and extent (AUC) of absorption by approximately 40%.", "arg1": {"span": [[10, 18]], "type": "drug", "id": "DDI-DrugBank.d420.s0.e1"}, "arg2": {"span": [[23, 32]], "type": "drug", "id": "DDI-DrugBank.d420.s0.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d420.s0-5", "sentence_id": "DDI-DrugBank.d420.s0", "sentence": "Antacids (aluminum- or magnesium-containing): Concomitant administration of 300-mg cefdinir capsules with 30 mL Maalox TC suspension reduces the rate (Cmax) and extent (AUC) of absorption by approximately 40%.", "arg1": {"span": [[10, 18]], "type": "drug", "id": "DDI-DrugBank.d420.s0.e1"}, "arg2": {"span": [[83, 91]], "type": "drug", "id": "DDI-DrugBank.d420.s0.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d420.s0-6", "sentence_id": "DDI-DrugBank.d420.s0", "sentence": "Antacids (aluminum- or magnesium-containing): Concomitant administration of 300-mg cefdinir capsules with 30 mL Maalox TC suspension reduces the rate (Cmax) and extent (AUC) of absorption by approximately 40%.", "arg1": {"span": [[10, 18]], "type": "drug", "id": "DDI-DrugBank.d420.s0.e1"}, "arg2": {"span": [[112, 121]], "type": "brand", "id": "DDI-DrugBank.d420.s0.e4"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d420.s0-7", "sentence_id": "DDI-DrugBank.d420.s0", "sentence": "Antacids (aluminum- or magnesium-containing): Concomitant administration of 300-mg cefdinir capsules with 30 mL Maalox TC suspension reduces the rate (Cmax) and extent (AUC) of absorption by approximately 40%.", "arg1": {"span": [[23, 32]], "type": "drug", "id": "DDI-DrugBank.d420.s0.e2"}, "arg2": {"span": [[83, 91]], "type": "drug", "id": "DDI-DrugBank.d420.s0.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d420.s0-8", "sentence_id": "DDI-DrugBank.d420.s0", "sentence": "Antacids (aluminum- or magnesium-containing): Concomitant administration of 300-mg cefdinir capsules with 30 mL Maalox TC suspension reduces the rate (Cmax) and extent (AUC) of absorption by approximately 40%.", "arg1": {"span": [[23, 32]], "type": "drug", "id": "DDI-DrugBank.d420.s0.e2"}, "arg2": {"span": [[112, 121]], "type": "brand", "id": "DDI-DrugBank.d420.s0.e4"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d420.s0-9", "sentence_id": "DDI-DrugBank.d420.s0", "sentence": "Antacids (aluminum- or magnesium-containing): Concomitant administration of 300-mg cefdinir capsules with 30 mL Maalox TC suspension reduces the rate (Cmax) and extent (AUC) of absorption by approximately 40%.", "arg1": {"span": [[83, 91]], "type": "drug", "id": "DDI-DrugBank.d420.s0.e3"}, "arg2": {"span": [[112, 121]], "type": "brand", "id": "DDI-DrugBank.d420.s0.e4"}, "ddi_label": 1, "ddi_type": "mechanism"}
{"id": "DDI-DrugBank.d420.s2-0", "sentence_id": "DDI-DrugBank.d420.s2", "sentence": "There are no significant effects on cefdinir pharmacokinetics if the antacid is administered 2 hours before or 2 hours after cefdinir.", "arg1": {"span": [[36, 44]], "type": "drug", "id": "DDI-DrugBank.d420.s2.e0"}, "arg2": {"span": [[69, 76]], "type": "group", "id": "DDI-DrugBank.d420.s2.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d420.s2-1", "sentence_id": "DDI-DrugBank.d420.s2", "sentence": "There are no significant effects on cefdinir pharmacokinetics if the antacid is administered 2 hours before or 2 hours after cefdinir.", "arg1": {"span": [[36, 44]], "type": "drug", "id": "DDI-DrugBank.d420.s2.e0"}, "arg2": {"span": [[125, 133]], "type": "drug", "id": "DDI-DrugBank.d420.s2.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d420.s2-2", "sentence_id": "DDI-DrugBank.d420.s2", "sentence": "There are no significant effects on cefdinir pharmacokinetics if the antacid is administered 2 hours before or 2 hours after cefdinir.", "arg1": {"span": [[69, 76]], "type": "group", "id": "DDI-DrugBank.d420.s2.e1"}, "arg2": {"span": [[125, 133]], "type": "drug", "id": "DDI-DrugBank.d420.s2.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d420.s3-0", "sentence_id": "DDI-DrugBank.d420.s3", "sentence": "If antacids are required during OMNICEF therapy, OMNICEF should be taken at least 2 hours before or after the antacid.", "arg1": {"span": [[3, 11]], "type": "group", "id": "DDI-DrugBank.d420.s3.e0"}, "arg2": {"span": [[32, 39]], "type": "brand", "id": "DDI-DrugBank.d420.s3.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d420.s3-1", "sentence_id": "DDI-DrugBank.d420.s3", "sentence": "If antacids are required during OMNICEF therapy, OMNICEF should be taken at least 2 hours before or after the antacid.", "arg1": {"span": [[3, 11]], "type": "group", "id": "DDI-DrugBank.d420.s3.e0"}, "arg2": {"span": [[49, 56]], "type": "brand", "id": "DDI-DrugBank.d420.s3.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d420.s3-2", "sentence_id": "DDI-DrugBank.d420.s3", "sentence": "If antacids are required during OMNICEF therapy, OMNICEF should be taken at least 2 hours before or after the antacid.", "arg1": {"span": [[3, 11]], "type": "group", "id": "DDI-DrugBank.d420.s3.e0"}, "arg2": {"span": [[110, 117]], "type": "group", "id": "DDI-DrugBank.d420.s3.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d420.s3-3", "sentence_id": "DDI-DrugBank.d420.s3", "sentence": "If antacids are required during OMNICEF therapy, OMNICEF should be taken at least 2 hours before or after the antacid.", "arg1": {"span": [[32, 39]], "type": "brand", "id": "DDI-DrugBank.d420.s3.e1"}, "arg2": {"span": [[49, 56]], "type": "brand", "id": "DDI-DrugBank.d420.s3.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d420.s3-4", "sentence_id": "DDI-DrugBank.d420.s3", "sentence": "If antacids are required during OMNICEF therapy, OMNICEF should be taken at least 2 hours before or after the antacid.", "arg1": {"span": [[32, 39]], "type": "brand", "id": "DDI-DrugBank.d420.s3.e1"}, "arg2": {"span": [[110, 117]], "type": "group", "id": "DDI-DrugBank.d420.s3.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d420.s3-5", "sentence_id": "DDI-DrugBank.d420.s3", "sentence": "If antacids are required during OMNICEF therapy, OMNICEF should be taken at least 2 hours before or after the antacid.", "arg1": {"span": [[49, 56]], "type": "brand", "id": "DDI-DrugBank.d420.s3.e2"}, "arg2": {"span": [[110, 117]], "type": "group", "id": "DDI-DrugBank.d420.s3.e3"}, "ddi_label": 1, "ddi_type": "advise"}
{"id": "DDI-DrugBank.d420.s4-0", "sentence_id": "DDI-DrugBank.d420.s4", "sentence": "Probenecid: As with other b-lactam antibiotics, probenecid inhibits the renal excretion of cefdinir, resulting in an approximate doubling in A.C. a 54% increase in peak cefdinir plasma levels, and a 50% prolongation in the apparent elimination half-life.", "arg1": {"span": [[0, 10]], "type": "drug", "id": "DDI-DrugBank.d420.s4.e0"}, "arg2": {"span": [[26, 46]], "type": "group", "id": "DDI-DrugBank.d420.s4.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d420.s4-1", "sentence_id": "DDI-DrugBank.d420.s4", "sentence": "Probenecid: As with other b-lactam antibiotics, probenecid inhibits the renal excretion of cefdinir, resulting in an approximate doubling in A.C. a 54% increase in peak cefdinir plasma levels, and a 50% prolongation in the apparent elimination half-life.", "arg1": {"span": [[0, 10]], "type": "drug", "id": "DDI-DrugBank.d420.s4.e0"}, "arg2": {"span": [[48, 58]], "type": "drug", "id": "DDI-DrugBank.d420.s4.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d420.s4-2", "sentence_id": "DDI-DrugBank.d420.s4", "sentence": "Probenecid: As with other b-lactam antibiotics, probenecid inhibits the renal excretion of cefdinir, resulting in an approximate doubling in A.C. a 54% increase in peak cefdinir plasma levels, and a 50% prolongation in the apparent elimination half-life.", "arg1": {"span": [[0, 10]], "type": "drug", "id": "DDI-DrugBank.d420.s4.e0"}, "arg2": {"span": [[91, 99]], "type": "drug", "id": "DDI-DrugBank.d420.s4.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d420.s4-3", "sentence_id": "DDI-DrugBank.d420.s4", "sentence": "Probenecid: As with other b-lactam antibiotics, probenecid inhibits the renal excretion of cefdinir, resulting in an approximate doubling in A.C. a 54% increase in peak cefdinir plasma levels, and a 50% prolongation in the apparent elimination half-life.", "arg1": {"span": [[0, 10]], "type": "drug", "id": "DDI-DrugBank.d420.s4.e0"}, "arg2": {"span": [[169, 177]], "type": "drug", "id": "DDI-DrugBank.d420.s4.e4"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d420.s4-4", "sentence_id": "DDI-DrugBank.d420.s4", "sentence": "Probenecid: As with other b-lactam antibiotics, probenecid inhibits the renal excretion of cefdinir, resulting in an approximate doubling in A.C. a 54% increase in peak cefdinir plasma levels, and a 50% prolongation in the apparent elimination half-life.", "arg1": {"span": [[26, 46]], "type": "group", "id": "DDI-DrugBank.d420.s4.e1"}, "arg2": {"span": [[48, 58]], "type": "drug", "id": "DDI-DrugBank.d420.s4.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d420.s4-5", "sentence_id": "DDI-DrugBank.d420.s4", "sentence": "Probenecid: As with other b-lactam antibiotics, probenecid inhibits the renal excretion of cefdinir, resulting in an approximate doubling in A.C. a 54% increase in peak cefdinir plasma levels, and a 50% prolongation in the apparent elimination half-life.", "arg1": {"span": [[26, 46]], "type": "group", "id": "DDI-DrugBank.d420.s4.e1"}, "arg2": {"span": [[91, 99]], "type": "drug", "id": "DDI-DrugBank.d420.s4.e3"}, "ddi_label": 1, "ddi_type": "mechanism"}
{"id": "DDI-DrugBank.d420.s4-6", "sentence_id": "DDI-DrugBank.d420.s4", "sentence": "Probenecid: As with other b-lactam antibiotics, probenecid inhibits the renal excretion of cefdinir, resulting in an approximate doubling in A.C. a 54% increase in peak cefdinir plasma levels, and a 50% prolongation in the apparent elimination half-life.", "arg1": {"span": [[26, 46]], "type": "group", "id": "DDI-DrugBank.d420.s4.e1"}, "arg2": {"span": [[169, 177]], "type": "drug", "id": "DDI-DrugBank.d420.s4.e4"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d420.s4-7", "sentence_id": "DDI-DrugBank.d420.s4", "sentence": "Probenecid: As with other b-lactam antibiotics, probenecid inhibits the renal excretion of cefdinir, resulting in an approximate doubling in A.C. a 54% increase in peak cefdinir plasma levels, and a 50% prolongation in the apparent elimination half-life.", "arg1": {"span": [[48, 58]], "type": "drug", "id": "DDI-DrugBank.d420.s4.e2"}, "arg2": {"span": [[91, 99]], "type": "drug", "id": "DDI-DrugBank.d420.s4.e3"}, "ddi_label": 1, "ddi_type": "mechanism"}
{"id": "DDI-DrugBank.d420.s4-8", "sentence_id": "DDI-DrugBank.d420.s4", "sentence": "Probenecid: As with other b-lactam antibiotics, probenecid inhibits the renal excretion of cefdinir, resulting in an approximate doubling in A.C. a 54% increase in peak cefdinir plasma levels, and a 50% prolongation in the apparent elimination half-life.", "arg1": {"span": [[48, 58]], "type": "drug", "id": "DDI-DrugBank.d420.s4.e2"}, "arg2": {"span": [[169, 177]], "type": "drug", "id": "DDI-DrugBank.d420.s4.e4"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d420.s4-9", "sentence_id": "DDI-DrugBank.d420.s4", "sentence": "Probenecid: As with other b-lactam antibiotics, probenecid inhibits the renal excretion of cefdinir, resulting in an approximate doubling in A.C. a 54% increase in peak cefdinir plasma levels, and a 50% prolongation in the apparent elimination half-life.", "arg1": {"span": [[91, 99]], "type": "drug", "id": "DDI-DrugBank.d420.s4.e3"}, "arg2": {"span": [[169, 177]], "type": "drug", "id": "DDI-DrugBank.d420.s4.e4"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d420.s6-0", "sentence_id": "DDI-DrugBank.d420.s6", "sentence": "If iron supplements are required during OMNICEF therapy, OMNICEF should be taken at least 2 hours before or after the supplement.", "arg1": {"span": [[3, 19]], "type": "group", "id": "DDI-DrugBank.d420.s6.e0"}, "arg2": {"span": [[40, 47]], "type": "brand", "id": "DDI-DrugBank.d420.s6.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d420.s6-1", "sentence_id": "DDI-DrugBank.d420.s6", "sentence": "If iron supplements are required during OMNICEF therapy, OMNICEF should be taken at least 2 hours before or after the supplement.", "arg1": {"span": [[3, 19]], "type": "group", "id": "DDI-DrugBank.d420.s6.e0"}, "arg2": {"span": [[57, 64]], "type": "brand", "id": "DDI-DrugBank.d420.s6.e2"}, "ddi_label": 1, "ddi_type": "advise"}
{"id": "DDI-DrugBank.d420.s6-2", "sentence_id": "DDI-DrugBank.d420.s6", "sentence": "If iron supplements are required during OMNICEF therapy, OMNICEF should be taken at least 2 hours before or after the supplement.", "arg1": {"span": [[40, 47]], "type": "brand", "id": "DDI-DrugBank.d420.s6.e1"}, "arg2": {"span": [[57, 64]], "type": "brand", "id": "DDI-DrugBank.d420.s6.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d420.s7-0", "sentence_id": "DDI-DrugBank.d420.s7", "sentence": "The effect of foods highly fortified with elemental iron (primarily iron-fortified breakfast cereals) on cefdinir absorption has not been studied.", "arg1": {"span": [[52, 56]], "type": "drug_n", "id": "DDI-DrugBank.d420.s7.e0"}, "arg2": {"span": [[68, 72]], "type": "drug_n", "id": "DDI-DrugBank.d420.s7.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d420.s7-1", "sentence_id": "DDI-DrugBank.d420.s7", "sentence": "The effect of foods highly fortified with elemental iron (primarily iron-fortified breakfast cereals) on cefdinir absorption has not been studied.", "arg1": {"span": [[52, 56]], "type": "drug_n", "id": "DDI-DrugBank.d420.s7.e0"}, "arg2": {"span": [[105, 113]], "type": "drug", "id": "DDI-DrugBank.d420.s7.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d420.s7-2", "sentence_id": "DDI-DrugBank.d420.s7", "sentence": "The effect of foods highly fortified with elemental iron (primarily iron-fortified breakfast cereals) on cefdinir absorption has not been studied.", "arg1": {"span": [[68, 72]], "type": "drug_n", "id": "DDI-DrugBank.d420.s7.e1"}, "arg2": {"span": [[105, 113]], "type": "drug", "id": "DDI-DrugBank.d420.s7.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d420.s8-0", "sentence_id": "DDI-DrugBank.d420.s8", "sentence": "Concomitantly administered iron-fortified infant formula (2.2 mg elemental iron/6 oz) has no significant effect on cefdinir pharmacokinetics.", "arg1": {"span": [[27, 31]], "type": "drug_n", "id": "DDI-DrugBank.d420.s8.e0"}, "arg2": {"span": [[75, 79]], "type": "drug_n", "id": "DDI-DrugBank.d420.s8.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d420.s8-1", "sentence_id": "DDI-DrugBank.d420.s8", "sentence": "Concomitantly administered iron-fortified infant formula (2.2 mg elemental iron/6 oz) has no significant effect on cefdinir pharmacokinetics.", "arg1": {"span": [[27, 31]], "type": "drug_n", "id": "DDI-DrugBank.d420.s8.e0"}, "arg2": {"span": [[115, 123]], "type": "drug", "id": "DDI-DrugBank.d420.s8.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d420.s8-2", "sentence_id": "DDI-DrugBank.d420.s8", "sentence": "Concomitantly administered iron-fortified infant formula (2.2 mg elemental iron/6 oz) has no significant effect on cefdinir pharmacokinetics.", "arg1": {"span": [[75, 79]], "type": "drug_n", "id": "DDI-DrugBank.d420.s8.e1"}, "arg2": {"span": [[115, 123]], "type": "drug", "id": "DDI-DrugBank.d420.s8.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d420.s9-0", "sentence_id": "DDI-DrugBank.d420.s9", "sentence": "Therefore, OMNICEF for Oral Suspension can be administered with iron-fortified infant formula.", "arg1": {"span": [[11, 18]], "type": "brand", "id": "DDI-DrugBank.d420.s9.e0"}, "arg2": {"span": [[64, 68]], "type": "drug_n", "id": "DDI-DrugBank.d420.s9.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d420.s11-0", "sentence_id": "DDI-DrugBank.d420.s11", "sentence": "The reddish color is due to the formation of a nonabsorbable complex between cefdinir or its breakdown products and iron in the gastrointestinal tract.", "arg1": {"span": [[77, 85]], "type": "drug", "id": "DDI-DrugBank.d420.s11.e0"}, "arg2": {"span": [[116, 120]], "type": "drug", "id": "DDI-DrugBank.d420.s11.e1"}, "ddi_label": 1, "ddi_type": "mechanism"}
{"id": "DDI-DrugBank.d420.s12-0", "sentence_id": "DDI-DrugBank.d420.s12", "sentence": "Drug/Laboratory Test Interactions A false-positive reaction for ketones in the urine may occur with tests using nitroprusside, but not with those using nitroferricyanide.", "arg1": {"span": [[112, 125]], "type": "drug", "id": "DDI-DrugBank.d420.s12.e0"}, "arg2": {"span": [[152, 169]], "type": "drug", "id": "DDI-DrugBank.d420.s12.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d174.s1-0", "sentence_id": "DDI-DrugBank.d174.s1", "sentence": "Caution should be exercised when administering nabumetone with warfarin since interactions have been seen with other NSAIDs.", "arg1": {"span": [[47, 57]], "type": "drug", "id": "DDI-DrugBank.d174.s1.e0"}, "arg2": {"span": [[63, 71]], "type": "drug", "id": "DDI-DrugBank.d174.s1.e1"}, "ddi_label": 1, "ddi_type": "advise"}
{"id": "DDI-DrugBank.d174.s1-1", "sentence_id": "DDI-DrugBank.d174.s1", "sentence": "Caution should be exercised when administering nabumetone with warfarin since interactions have been seen with other NSAIDs.", "arg1": {"span": [[47, 57]], "type": "drug", "id": "DDI-DrugBank.d174.s1.e0"}, "arg2": {"span": [[117, 123]], "type": "group", "id": "DDI-DrugBank.d174.s1.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d174.s1-2", "sentence_id": "DDI-DrugBank.d174.s1", "sentence": "Caution should be exercised when administering nabumetone with warfarin since interactions have been seen with other NSAIDs.", "arg1": {"span": [[63, 71]], "type": "drug", "id": "DDI-DrugBank.d174.s1.e1"}, "arg2": {"span": [[117, 123]], "type": "group", "id": "DDI-DrugBank.d174.s1.e2"}, "ddi_label": 1, "ddi_type": "int"}
{"id": "DDI-DrugBank.d174.s2-0", "sentence_id": "DDI-DrugBank.d174.s2", "sentence": "Concomitant administration of an aluminum-containing antacid had no significant effect in the bioavailability of 6MNA.", "arg1": {"span": [[33, 41]], "type": "drug", "id": "DDI-DrugBank.d174.s2.e0"}, "arg2": {"span": [[53, 60]], "type": "group", "id": "DDI-DrugBank.d174.s2.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d174.s2-1", "sentence_id": "DDI-DrugBank.d174.s2", "sentence": "Concomitant administration of an aluminum-containing antacid had no significant effect in the bioavailability of 6MNA.", "arg1": {"span": [[33, 41]], "type": "drug", "id": "DDI-DrugBank.d174.s2.e0"}, "arg2": {"span": [[113, 117]], "type": "drug_n", "id": "DDI-DrugBank.d174.s2.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d174.s2-2", "sentence_id": "DDI-DrugBank.d174.s2", "sentence": "Concomitant administration of an aluminum-containing antacid had no significant effect in the bioavailability of 6MNA.", "arg1": {"span": [[53, 60]], "type": "group", "id": "DDI-DrugBank.d174.s2.e1"}, "arg2": {"span": [[113, 117]], "type": "drug_n", "id": "DDI-DrugBank.d174.s2.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d237.s1-0", "sentence_id": "DDI-DrugBank.d237.s1", "sentence": "In some cases where serious ventricular arrhythmias, QT prolongation, and torsades de pointes have occurred when cisapride was taken in conjunction with one of the cytochrome P450 3A4 inhibitors, elevated blood cisapride levels were noted at the time of the QT prolongation.", "arg1": {"span": [[113, 122]], "type": "drug", "id": "DDI-DrugBank.d237.s1.e0"}, "arg2": {"span": [[211, 220]], "type": "drug", "id": "DDI-DrugBank.d237.s1.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d237.s3-0", "sentence_id": "DDI-DrugBank.d237.s3", "sentence": "Anticholinergics: Concurrent administration of certain anticholinergic compounds, such as belladonna alkaloids and dicyclomine, would be expected to compromise the beneficial effects of cisapride.", "arg1": {"span": [[0, 16]], "type": "group", "id": "DDI-DrugBank.d237.s3.e0"}, "arg2": {"span": [[55, 80]], "type": "group", "id": "DDI-DrugBank.d237.s3.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d237.s3-1", "sentence_id": "DDI-DrugBank.d237.s3", "sentence": "Anticholinergics: Concurrent administration of certain anticholinergic compounds, such as belladonna alkaloids and dicyclomine, would be expected to compromise the beneficial effects of cisapride.", "arg1": {"span": [[0, 16]], "type": "group", "id": "DDI-DrugBank.d237.s3.e0"}, "arg2": {"span": [[90, 110]], "type": "group", "id": "DDI-DrugBank.d237.s3.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d237.s3-2", "sentence_id": "DDI-DrugBank.d237.s3", "sentence": "Anticholinergics: Concurrent administration of certain anticholinergic compounds, such as belladonna alkaloids and dicyclomine, would be expected to compromise the beneficial effects of cisapride.", "arg1": {"span": [[0, 16]], "type": "group", "id": "DDI-DrugBank.d237.s3.e0"}, "arg2": {"span": [[115, 126]], "type": "drug", "id": "DDI-DrugBank.d237.s3.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d237.s3-3", "sentence_id": "DDI-DrugBank.d237.s3", "sentence": "Anticholinergics: Concurrent administration of certain anticholinergic compounds, such as belladonna alkaloids and dicyclomine, would be expected to compromise the beneficial effects of cisapride.", "arg1": {"span": [[0, 16]], "type": "group", "id": "DDI-DrugBank.d237.s3.e0"}, "arg2": {"span": [[186, 195]], "type": "drug", "id": "DDI-DrugBank.d237.s3.e4"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d237.s3-4", "sentence_id": "DDI-DrugBank.d237.s3", "sentence": "Anticholinergics: Concurrent administration of certain anticholinergic compounds, such as belladonna alkaloids and dicyclomine, would be expected to compromise the beneficial effects of cisapride.", "arg1": {"span": [[55, 80]], "type": "group", "id": "DDI-DrugBank.d237.s3.e1"}, "arg2": {"span": [[90, 110]], "type": "group", "id": "DDI-DrugBank.d237.s3.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d237.s3-5", "sentence_id": "DDI-DrugBank.d237.s3", "sentence": "Anticholinergics: Concurrent administration of certain anticholinergic compounds, such as belladonna alkaloids and dicyclomine, would be expected to compromise the beneficial effects of cisapride.", "arg1": {"span": [[55, 80]], "type": "group", "id": "DDI-DrugBank.d237.s3.e1"}, "arg2": {"span": [[115, 126]], "type": "drug", "id": "DDI-DrugBank.d237.s3.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d237.s3-6", "sentence_id": "DDI-DrugBank.d237.s3", "sentence": "Anticholinergics: Concurrent administration of certain anticholinergic compounds, such as belladonna alkaloids and dicyclomine, would be expected to compromise the beneficial effects of cisapride.", "arg1": {"span": [[55, 80]], "type": "group", "id": "DDI-DrugBank.d237.s3.e1"}, "arg2": {"span": [[186, 195]], "type": "drug", "id": "DDI-DrugBank.d237.s3.e4"}, "ddi_label": 1, "ddi_type": "effect"}
{"id": "DDI-DrugBank.d237.s3-7", "sentence_id": "DDI-DrugBank.d237.s3", "sentence": "Anticholinergics: Concurrent administration of certain anticholinergic compounds, such as belladonna alkaloids and dicyclomine, would be expected to compromise the beneficial effects of cisapride.", "arg1": {"span": [[90, 110]], "type": "group", "id": "DDI-DrugBank.d237.s3.e2"}, "arg2": {"span": [[115, 126]], "type": "drug", "id": "DDI-DrugBank.d237.s3.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d237.s3-8", "sentence_id": "DDI-DrugBank.d237.s3", "sentence": "Anticholinergics: Concurrent administration of certain anticholinergic compounds, such as belladonna alkaloids and dicyclomine, would be expected to compromise the beneficial effects of cisapride.", "arg1": {"span": [[90, 110]], "type": "group", "id": "DDI-DrugBank.d237.s3.e2"}, "arg2": {"span": [[186, 195]], "type": "drug", "id": "DDI-DrugBank.d237.s3.e4"}, "ddi_label": 1, "ddi_type": "effect"}
{"id": "DDI-DrugBank.d237.s3-9", "sentence_id": "DDI-DrugBank.d237.s3", "sentence": "Anticholinergics: Concurrent administration of certain anticholinergic compounds, such as belladonna alkaloids and dicyclomine, would be expected to compromise the beneficial effects of cisapride.", "arg1": {"span": [[115, 126]], "type": "drug", "id": "DDI-DrugBank.d237.s3.e3"}, "arg2": {"span": [[186, 195]], "type": "drug", "id": "DDI-DrugBank.d237.s3.e4"}, "ddi_label": 1, "ddi_type": "effect"}
{"id": "DDI-DrugBank.d237.s4-0", "sentence_id": "DDI-DrugBank.d237.s4", "sentence": "Anticoagulants (Oral): In patients receiving oral anticoagulants, the coagulation times were increased in some cases.", "arg1": {"span": [[0, 14]], "type": "group", "id": "DDI-DrugBank.d237.s4.e0"}, "arg2": {"span": [[50, 64]], "type": "group", "id": "DDI-DrugBank.d237.s4.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d237.s5-0", "sentence_id": "DDI-DrugBank.d237.s5", "sentence": "It is advisable to check coagulation time within the first few days after the start and discontinuation of cisapride therapy, with an appropriate adjustment of the anticoagulant dose, if necessary.", "arg1": {"span": [[107, 116]], "type": "drug", "id": "DDI-DrugBank.d237.s5.e0"}, "arg2": {"span": [[164, 177]], "type": "group", "id": "DDI-DrugBank.d237.s5.e1"}, "ddi_label": 1, "ddi_type": "advise"}
{"id": "DDI-DrugBank.d237.s6-0", "sentence_id": "DDI-DrugBank.d237.s6", "sentence": "Antidepressants: In vitro data indicate that nefazodone inhibits the metabolism of cisapride, which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.", "arg1": {"span": [[0, 15]], "type": "group", "id": "DDI-DrugBank.d237.s6.e0"}, "arg2": {"span": [[45, 55]], "type": "drug", "id": "DDI-DrugBank.d237.s6.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d237.s6-1", "sentence_id": "DDI-DrugBank.d237.s6", "sentence": "Antidepressants: In vitro data indicate that nefazodone inhibits the metabolism of cisapride, which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.", "arg1": {"span": [[0, 15]], "type": "group", "id": "DDI-DrugBank.d237.s6.e0"}, "arg2": {"span": [[83, 92]], "type": "drug", "id": "DDI-DrugBank.d237.s6.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d237.s6-2", "sentence_id": "DDI-DrugBank.d237.s6", "sentence": "Antidepressants: In vitro data indicate that nefazodone inhibits the metabolism of cisapride, which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.", "arg1": {"span": [[0, 15]], "type": "group", "id": "DDI-DrugBank.d237.s6.e0"}, "arg2": {"span": [[136, 145]], "type": "drug", "id": "DDI-DrugBank.d237.s6.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d237.s6-3", "sentence_id": "DDI-DrugBank.d237.s6", "sentence": "Antidepressants: In vitro data indicate that nefazodone inhibits the metabolism of cisapride, which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.", "arg1": {"span": [[45, 55]], "type": "drug", "id": "DDI-DrugBank.d237.s6.e1"}, "arg2": {"span": [[83, 92]], "type": "drug", "id": "DDI-DrugBank.d237.s6.e2"}, "ddi_label": 1, "ddi_type": "mechanism"}
{"id": "DDI-DrugBank.d237.s6-4", "sentence_id": "DDI-DrugBank.d237.s6", "sentence": "Antidepressants: In vitro data indicate that nefazodone inhibits the metabolism of cisapride, which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.", "arg1": {"span": [[45, 55]], "type": "drug", "id": "DDI-DrugBank.d237.s6.e1"}, "arg2": {"span": [[136, 145]], "type": "drug", "id": "DDI-DrugBank.d237.s6.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d237.s6-5", "sentence_id": "DDI-DrugBank.d237.s6", "sentence": "Antidepressants: In vitro data indicate that nefazodone inhibits the metabolism of cisapride, which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.", "arg1": {"span": [[83, 92]], "type": "drug", "id": "DDI-DrugBank.d237.s6.e2"}, "arg2": {"span": [[136, 145]], "type": "drug", "id": "DDI-DrugBank.d237.s6.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d237.s8-0", "sentence_id": "DDI-DrugBank.d237.s8", "sentence": "Human pharmacokinetic data indicate that oral ketoconazole markedly inhibits the metabolism of cisapride, resulting in a mean eight-fold increase in AUC of cisapride.", "arg1": {"span": [[46, 58]], "type": "drug", "id": "DDI-DrugBank.d237.s8.e0"}, "arg2": {"span": [[95, 104]], "type": "drug", "id": "DDI-DrugBank.d237.s8.e1"}, "ddi_label": 1, "ddi_type": "mechanism"}
{"id": "DDI-DrugBank.d237.s8-1", "sentence_id": "DDI-DrugBank.d237.s8", "sentence": "Human pharmacokinetic data indicate that oral ketoconazole markedly inhibits the metabolism of cisapride, resulting in a mean eight-fold increase in AUC of cisapride.", "arg1": {"span": [[46, 58]], "type": "drug", "id": "DDI-DrugBank.d237.s8.e0"}, "arg2": {"span": [[156, 165]], "type": "drug", "id": "DDI-DrugBank.d237.s8.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d237.s8-2", "sentence_id": "DDI-DrugBank.d237.s8", "sentence": "Human pharmacokinetic data indicate that oral ketoconazole markedly inhibits the metabolism of cisapride, resulting in a mean eight-fold increase in AUC of cisapride.", "arg1": {"span": [[95, 104]], "type": "drug", "id": "DDI-DrugBank.d237.s8.e1"}, "arg2": {"span": [[156, 165]], "type": "drug", "id": "DDI-DrugBank.d237.s8.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d237.s9-0", "sentence_id": "DDI-DrugBank.d237.s9", "sentence": "A study in 14 normal male and female volunteers suggests that coadministration of cisapride and ketoconazole can result in prolongation of the QT interval on the ECG.", "arg1": {"span": [[82, 91]], "type": "drug", "id": "DDI-DrugBank.d237.s9.e0"}, "arg2": {"span": [[96, 108]], "type": "drug", "id": "DDI-DrugBank.d237.s9.e1"}, "ddi_label": 1, "ddi_type": "effect"}
{"id": "DDI-DrugBank.d237.s10-0", "sentence_id": "DDI-DrugBank.d237.s10", "sentence": "H2 Receptor Antagonists: Cimetidine coadministration leads to an increased peak plasma concentration and AUC of cisapride, there is no effect on cisapride absorption when it is coadministered with ranitidine.", "arg1": {"span": [[0, 23]], "type": "group", "id": "DDI-DrugBank.d237.s10.e0"}, "arg2": {"span": [[25, 35]], "type": "drug", "id": "DDI-DrugBank.d237.s10.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d237.s10-1", "sentence_id": "DDI-DrugBank.d237.s10", "sentence": "H2 Receptor Antagonists: Cimetidine coadministration leads to an increased peak plasma concentration and AUC of cisapride, there is no effect on cisapride absorption when it is coadministered with ranitidine.", "arg1": {"span": [[0, 23]], "type": "group", "id": "DDI-DrugBank.d237.s10.e0"}, "arg2": {"span": [[112, 121]], "type": "drug", "id": "DDI-DrugBank.d237.s10.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d237.s10-2", "sentence_id": "DDI-DrugBank.d237.s10", "sentence": "H2 Receptor Antagonists: Cimetidine coadministration leads to an increased peak plasma concentration and AUC of cisapride, there is no effect on cisapride absorption when it is coadministered with ranitidine.", "arg1": {"span": [[0, 23]], "type": "group", "id": "DDI-DrugBank.d237.s10.e0"}, "arg2": {"span": [[145, 154]], "type": "drug", "id": "DDI-DrugBank.d237.s10.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d237.s10-3", "sentence_id": "DDI-DrugBank.d237.s10", "sentence": "H2 Receptor Antagonists: Cimetidine coadministration leads to an increased peak plasma concentration and AUC of cisapride, there is no effect on cisapride absorption when it is coadministered with ranitidine.", "arg1": {"span": [[0, 23]], "type": "group", "id": "DDI-DrugBank.d237.s10.e0"}, "arg2": {"span": [[197, 207]], "type": "drug", "id": "DDI-DrugBank.d237.s10.e4"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d237.s10-4", "sentence_id": "DDI-DrugBank.d237.s10", "sentence": "H2 Receptor Antagonists: Cimetidine coadministration leads to an increased peak plasma concentration and AUC of cisapride, there is no effect on cisapride absorption when it is coadministered with ranitidine.", "arg1": {"span": [[25, 35]], "type": "drug", "id": "DDI-DrugBank.d237.s10.e1"}, "arg2": {"span": [[112, 121]], "type": "drug", "id": "DDI-DrugBank.d237.s10.e2"}, "ddi_label": 1, "ddi_type": "mechanism"}
{"id": "DDI-DrugBank.d237.s10-5", "sentence_id": "DDI-DrugBank.d237.s10", "sentence": "H2 Receptor Antagonists: Cimetidine coadministration leads to an increased peak plasma concentration and AUC of cisapride, there is no effect on cisapride absorption when it is coadministered with ranitidine.", "arg1": {"span": [[25, 35]], "type": "drug", "id": "DDI-DrugBank.d237.s10.e1"}, "arg2": {"span": [[145, 154]], "type": "drug", "id": "DDI-DrugBank.d237.s10.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d237.s10-6", "sentence_id": "DDI-DrugBank.d237.s10", "sentence": "H2 Receptor Antagonists: Cimetidine coadministration leads to an increased peak plasma concentration and AUC of cisapride, there is no effect on cisapride absorption when it is coadministered with ranitidine.", "arg1": {"span": [[25, 35]], "type": "drug", "id": "DDI-DrugBank.d237.s10.e1"}, "arg2": {"span": [[197, 207]], "type": "drug", "id": "DDI-DrugBank.d237.s10.e4"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d237.s10-7", "sentence_id": "DDI-DrugBank.d237.s10", "sentence": "H2 Receptor Antagonists: Cimetidine coadministration leads to an increased peak plasma concentration and AUC of cisapride, there is no effect on cisapride absorption when it is coadministered with ranitidine.", "arg1": {"span": [[112, 121]], "type": "drug", "id": "DDI-DrugBank.d237.s10.e2"}, "arg2": {"span": [[145, 154]], "type": "drug", "id": "DDI-DrugBank.d237.s10.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d237.s10-8", "sentence_id": "DDI-DrugBank.d237.s10", "sentence": "H2 Receptor Antagonists: Cimetidine coadministration leads to an increased peak plasma concentration and AUC of cisapride, there is no effect on cisapride absorption when it is coadministered with ranitidine.", "arg1": {"span": [[112, 121]], "type": "drug", "id": "DDI-DrugBank.d237.s10.e2"}, "arg2": {"span": [[197, 207]], "type": "drug", "id": "DDI-DrugBank.d237.s10.e4"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d237.s10-9", "sentence_id": "DDI-DrugBank.d237.s10", "sentence": "H2 Receptor Antagonists: Cimetidine coadministration leads to an increased peak plasma concentration and AUC of cisapride, there is no effect on cisapride absorption when it is coadministered with ranitidine.", "arg1": {"span": [[145, 154]], "type": "drug", "id": "DDI-DrugBank.d237.s10.e3"}, "arg2": {"span": [[197, 207]], "type": "drug", "id": "DDI-DrugBank.d237.s10.e4"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d237.s11-0", "sentence_id": "DDI-DrugBank.d237.s11", "sentence": "The gastrointestinal absorption of cimetidine and ranitidine is accelerated when they are coadministered with cisapride.", "arg1": {"span": [[35, 45]], "type": "drug", "id": "DDI-DrugBank.d237.s11.e0"}, "arg2": {"span": [[50, 60]], "type": "drug", "id": "DDI-DrugBank.d237.s11.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d237.s11-1", "sentence_id": "DDI-DrugBank.d237.s11", "sentence": "The gastrointestinal absorption of cimetidine and ranitidine is accelerated when they are coadministered with cisapride.", "arg1": {"span": [[35, 45]], "type": "drug", "id": "DDI-DrugBank.d237.s11.e0"}, "arg2": {"span": [[110, 119]], "type": "drug", "id": "DDI-DrugBank.d237.s11.e2"}, "ddi_label": 1, "ddi_type": "mechanism"}
{"id": "DDI-DrugBank.d237.s11-2", "sentence_id": "DDI-DrugBank.d237.s11", "sentence": "The gastrointestinal absorption of cimetidine and ranitidine is accelerated when they are coadministered with cisapride.", "arg1": {"span": [[50, 60]], "type": "drug", "id": "DDI-DrugBank.d237.s11.e1"}, "arg2": {"span": [[110, 119]], "type": "drug", "id": "DDI-DrugBank.d237.s11.e2"}, "ddi_label": 1, "ddi_type": "mechanism"}
{"id": "DDI-DrugBank.d237.s12-0", "sentence_id": "DDI-DrugBank.d237.s12", "sentence": "Protease Inhibitors: In vitro data indicate that indinavir and ritonavir markedly inhibit the metabolism of cisapride which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.", "arg1": {"span": [[0, 19]], "type": "group", "id": "DDI-DrugBank.d237.s12.e0"}, "arg2": {"span": [[49, 58]], "type": "drug", "id": "DDI-DrugBank.d237.s12.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d237.s12-1", "sentence_id": "DDI-DrugBank.d237.s12", "sentence": "Protease Inhibitors: In vitro data indicate that indinavir and ritonavir markedly inhibit the metabolism of cisapride which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.", "arg1": {"span": [[0, 19]], "type": "group", "id": "DDI-DrugBank.d237.s12.e0"}, "arg2": {"span": [[63, 72]], "type": "drug", "id": "DDI-DrugBank.d237.s12.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d237.s12-2", "sentence_id": "DDI-DrugBank.d237.s12", "sentence": "Protease Inhibitors: In vitro data indicate that indinavir and ritonavir markedly inhibit the metabolism of cisapride which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.", "arg1": {"span": [[0, 19]], "type": "group", "id": "DDI-DrugBank.d237.s12.e0"}, "arg2": {"span": [[108, 117]], "type": "drug", "id": "DDI-DrugBank.d237.s12.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d237.s12-3", "sentence_id": "DDI-DrugBank.d237.s12", "sentence": "Protease Inhibitors: In vitro data indicate that indinavir and ritonavir markedly inhibit the metabolism of cisapride which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.", "arg1": {"span": [[0, 19]], "type": "group", "id": "DDI-DrugBank.d237.s12.e0"}, "arg2": {"span": [[160, 169]], "type": "drug", "id": "DDI-DrugBank.d237.s12.e4"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d237.s12-4", "sentence_id": "DDI-DrugBank.d237.s12", "sentence": "Protease Inhibitors: In vitro data indicate that indinavir and ritonavir markedly inhibit the metabolism of cisapride which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.", "arg1": {"span": [[49, 58]], "type": "drug", "id": "DDI-DrugBank.d237.s12.e1"}, "arg2": {"span": [[63, 72]], "type": "drug", "id": "DDI-DrugBank.d237.s12.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d237.s12-5", "sentence_id": "DDI-DrugBank.d237.s12", "sentence": "Protease Inhibitors: In vitro data indicate that indinavir and ritonavir markedly inhibit the metabolism of cisapride which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.", "arg1": {"span": [[49, 58]], "type": "drug", "id": "DDI-DrugBank.d237.s12.e1"}, "arg2": {"span": [[108, 117]], "type": "drug", "id": "DDI-DrugBank.d237.s12.e3"}, "ddi_label": 1, "ddi_type": "mechanism"}
{"id": "DDI-DrugBank.d237.s12-6", "sentence_id": "DDI-DrugBank.d237.s12", "sentence": "Protease Inhibitors: In vitro data indicate that indinavir and ritonavir markedly inhibit the metabolism of cisapride which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.", "arg1": {"span": [[49, 58]], "type": "drug", "id": "DDI-DrugBank.d237.s12.e1"}, "arg2": {"span": [[160, 169]], "type": "drug", "id": "DDI-DrugBank.d237.s12.e4"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d237.s12-7", "sentence_id": "DDI-DrugBank.d237.s12", "sentence": "Protease Inhibitors: In vitro data indicate that indinavir and ritonavir markedly inhibit the metabolism of cisapride which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.", "arg1": {"span": [[63, 72]], "type": "drug", "id": "DDI-DrugBank.d237.s12.e2"}, "arg2": {"span": [[108, 117]], "type": "drug", "id": "DDI-DrugBank.d237.s12.e3"}, "ddi_label": 1, "ddi_type": "mechanism"}
{"id": "DDI-DrugBank.d237.s12-8", "sentence_id": "DDI-DrugBank.d237.s12", "sentence": "Protease Inhibitors: In vitro data indicate that indinavir and ritonavir markedly inhibit the metabolism of cisapride which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.", "arg1": {"span": [[63, 72]], "type": "drug", "id": "DDI-DrugBank.d237.s12.e2"}, "arg2": {"span": [[160, 169]], "type": "drug", "id": "DDI-DrugBank.d237.s12.e4"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d237.s12-9", "sentence_id": "DDI-DrugBank.d237.s12", "sentence": "Protease Inhibitors: In vitro data indicate that indinavir and ritonavir markedly inhibit the metabolism of cisapride which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.", "arg1": {"span": [[108, 117]], "type": "drug", "id": "DDI-DrugBank.d237.s12.e3"}, "arg2": {"span": [[160, 169]], "type": "drug", "id": "DDI-DrugBank.d237.s12.e4"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d237.s13-0", "sentence_id": "DDI-DrugBank.d237.s13", "sentence": "Other: Coadministration of grapefruit juice with cisapride increases the bioavailability of cisapride and concomitant use should be avoided.", "arg1": {"span": [[49, 58]], "type": "drug", "id": "DDI-DrugBank.d237.s13.e0"}, "arg2": {"span": [[92, 101]], "type": "drug", "id": "DDI-DrugBank.d237.s13.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d237.s14-0", "sentence_id": "DDI-DrugBank.d237.s14", "sentence": "Cisapride should not be used concomitantly with other drugs known to prolong the QT interval: certain antiarrhythmics, including those of Class IA (such as quinidine and procainamide) and Class III (such as sotalol);", "arg1": {"span": [[0, 9]], "type": "drug", "id": "DDI-DrugBank.d237.s14.e0"}, "arg2": {"span": [[102, 117]], "type": "group", "id": "DDI-DrugBank.d237.s14.e1"}, "ddi_label": 1, "ddi_type": "advise"}
{"id": "DDI-DrugBank.d237.s14-1", "sentence_id": "DDI-DrugBank.d237.s14", "sentence": "Cisapride should not be used concomitantly with other drugs known to prolong the QT interval: certain antiarrhythmics, including those of Class IA (such as quinidine and procainamide) and Class III (such as sotalol);", "arg1": {"span": [[0, 9]], "type": "drug", "id": "DDI-DrugBank.d237.s14.e0"}, "arg2": {"span": [[156, 165]], "type": "drug", "id": "DDI-DrugBank.d237.s14.e2"}, "ddi_label": 1, "ddi_type": "advise"}
{"id": "DDI-DrugBank.d237.s14-2", "sentence_id": "DDI-DrugBank.d237.s14", "sentence": "Cisapride should not be used concomitantly with other drugs known to prolong the QT interval: certain antiarrhythmics, including those of Class IA (such as quinidine and procainamide) and Class III (such as sotalol);", "arg1": {"span": [[0, 9]], "type": "drug", "id": "DDI-DrugBank.d237.s14.e0"}, "arg2": {"span": [[170, 182]], "type": "drug", "id": "DDI-DrugBank.d237.s14.e3"}, "ddi_label": 1, "ddi_type": "advise"}
{"id": "DDI-DrugBank.d237.s14-3", "sentence_id": "DDI-DrugBank.d237.s14", "sentence": "Cisapride should not be used concomitantly with other drugs known to prolong the QT interval: certain antiarrhythmics, including those of Class IA (such as quinidine and procainamide) and Class III (such as sotalol);", "arg1": {"span": [[0, 9]], "type": "drug", "id": "DDI-DrugBank.d237.s14.e0"}, "arg2": {"span": [[207, 214]], "type": "drug", "id": "DDI-DrugBank.d237.s14.e4"}, "ddi_label": 1, "ddi_type": "advise"}
{"id": "DDI-DrugBank.d237.s14-4", "sentence_id": "DDI-DrugBank.d237.s14", "sentence": "Cisapride should not be used concomitantly with other drugs known to prolong the QT interval: certain antiarrhythmics, including those of Class IA (such as quinidine and procainamide) and Class III (such as sotalol);", "arg1": {"span": [[102, 117]], "type": "group", "id": "DDI-DrugBank.d237.s14.e1"}, "arg2": {"span": [[156, 165]], "type": "drug", "id": "DDI-DrugBank.d237.s14.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d237.s14-5", "sentence_id": "DDI-DrugBank.d237.s14", "sentence": "Cisapride should not be used concomitantly with other drugs known to prolong the QT interval: certain antiarrhythmics, including those of Class IA (such as quinidine and procainamide) and Class III (such as sotalol);", "arg1": {"span": [[102, 117]], "type": "group", "id": "DDI-DrugBank.d237.s14.e1"}, "arg2": {"span": [[170, 182]], "type": "drug", "id": "DDI-DrugBank.d237.s14.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d237.s14-6", "sentence_id": "DDI-DrugBank.d237.s14", "sentence": "Cisapride should not be used concomitantly with other drugs known to prolong the QT interval: certain antiarrhythmics, including those of Class IA (such as quinidine and procainamide) and Class III (such as sotalol);", "arg1": {"span": [[102, 117]], "type": "group", "id": "DDI-DrugBank.d237.s14.e1"}, "arg2": {"span": [[207, 214]], "type": "drug", "id": "DDI-DrugBank.d237.s14.e4"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d237.s14-7", "sentence_id": "DDI-DrugBank.d237.s14", "sentence": "Cisapride should not be used concomitantly with other drugs known to prolong the QT interval: certain antiarrhythmics, including those of Class IA (such as quinidine and procainamide) and Class III (such as sotalol);", "arg1": {"span": [[156, 165]], "type": "drug", "id": "DDI-DrugBank.d237.s14.e2"}, "arg2": {"span": [[170, 182]], "type": "drug", "id": "DDI-DrugBank.d237.s14.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d237.s14-8", "sentence_id": "DDI-DrugBank.d237.s14", "sentence": "Cisapride should not be used concomitantly with other drugs known to prolong the QT interval: certain antiarrhythmics, including those of Class IA (such as quinidine and procainamide) and Class III (such as sotalol);", "arg1": {"span": [[156, 165]], "type": "drug", "id": "DDI-DrugBank.d237.s14.e2"}, "arg2": {"span": [[207, 214]], "type": "drug", "id": "DDI-DrugBank.d237.s14.e4"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d237.s14-9", "sentence_id": "DDI-DrugBank.d237.s14", "sentence": "Cisapride should not be used concomitantly with other drugs known to prolong the QT interval: certain antiarrhythmics, including those of Class IA (such as quinidine and procainamide) and Class III (such as sotalol);", "arg1": {"span": [[170, 182]], "type": "drug", "id": "DDI-DrugBank.d237.s14.e3"}, "arg2": {"span": [[207, 214]], "type": "drug", "id": "DDI-DrugBank.d237.s14.e4"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d237.s15-0", "sentence_id": "DDI-DrugBank.d237.s15", "sentence": "tricyclic antidepressants (such as amitriptyline);", "arg1": {"span": [[0, 25]], "type": "group", "id": "DDI-DrugBank.d237.s15.e0"}, "arg2": {"span": [[35, 48]], "type": "drug", "id": "DDI-DrugBank.d237.s15.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d237.s16-0", "sentence_id": "DDI-DrugBank.d237.s16", "sentence": "certain tetracyclic antidepressants (such as maprotiline);", "arg1": {"span": [[8, 35]], "type": "group", "id": "DDI-DrugBank.d237.s16.e0"}, "arg2": {"span": [[45, 56]], "type": "drug", "id": "DDI-DrugBank.d237.s16.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d237.s17-0", "sentence_id": "DDI-DrugBank.d237.s17", "sentence": "certain antipsychotic medications (such as sertindole);", "arg1": {"span": [[8, 33]], "type": "group", "id": "DDI-DrugBank.d237.s17.e0"}, "arg2": {"span": [[43, 53]], "type": "drug", "id": "DDI-DrugBank.d237.s17.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d237.s18-0", "sentence_id": "DDI-DrugBank.d237.s18", "sentence": "astemizole, bepridil, sparfloxacin, and terodiline.", "arg1": {"span": [[0, 10]], "type": "drug", "id": "DDI-DrugBank.d237.s18.e0"}, "arg2": {"span": [[12, 20]], "type": "drug", "id": "DDI-DrugBank.d237.s18.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d237.s18-1", "sentence_id": "DDI-DrugBank.d237.s18", "sentence": "astemizole, bepridil, sparfloxacin, and terodiline.", "arg1": {"span": [[0, 10]], "type": "drug", "id": "DDI-DrugBank.d237.s18.e0"}, "arg2": {"span": [[22, 34]], "type": "drug", "id": "DDI-DrugBank.d237.s18.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d237.s18-2", "sentence_id": "DDI-DrugBank.d237.s18", "sentence": "astemizole, bepridil, sparfloxacin, and terodiline.", "arg1": {"span": [[0, 10]], "type": "drug", "id": "DDI-DrugBank.d237.s18.e0"}, "arg2": {"span": [[40, 50]], "type": "drug", "id": "DDI-DrugBank.d237.s18.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d237.s18-3", "sentence_id": "DDI-DrugBank.d237.s18", "sentence": "astemizole, bepridil, sparfloxacin, and terodiline.", "arg1": {"span": [[12, 20]], "type": "drug", "id": "DDI-DrugBank.d237.s18.e1"}, "arg2": {"span": [[22, 34]], "type": "drug", "id": "DDI-DrugBank.d237.s18.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d237.s18-4", "sentence_id": "DDI-DrugBank.d237.s18", "sentence": "astemizole, bepridil, sparfloxacin, and terodiline.", "arg1": {"span": [[12, 20]], "type": "drug", "id": "DDI-DrugBank.d237.s18.e1"}, "arg2": {"span": [[40, 50]], "type": "drug", "id": "DDI-DrugBank.d237.s18.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d237.s18-5", "sentence_id": "DDI-DrugBank.d237.s18", "sentence": "astemizole, bepridil, sparfloxacin, and terodiline.", "arg1": {"span": [[22, 34]], "type": "drug", "id": "DDI-DrugBank.d237.s18.e2"}, "arg2": {"span": [[40, 50]], "type": "drug", "id": "DDI-DrugBank.d237.s18.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-MedLine.d48.s3-0", "sentence_id": "DDI-MedLine.d48.s3", "sentence": "Diethyl pyrocarbonate, at pH 7.0, was used to chemically modify exposed histidine residues on toxin A. ", "arg1": {"span": [[0, 21]], "type": "drug_n", "id": "DDI-MedLine.d48.s3.e0"}, "arg2": {"span": [[94, 101]], "type": "drug_n", "id": "DDI-MedLine.d48.s3.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-MedLine.d48.s4-0", "sentence_id": "DDI-MedLine.d48.s4", "sentence": "Modification of toxin A with diethyl pyrocarbonate abolished both its cytotoxic activity and the ability of the toxin to bind Zn-Sepharose gel. ", "arg1": {"span": [[16, 23]], "type": "drug_n", "id": "DDI-MedLine.d48.s4.e0"}, "arg2": {"span": [[29, 50]], "type": "drug_n", "id": "DDI-MedLine.d48.s4.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-MedLine.d48.s5-0", "sentence_id": "DDI-MedLine.d48.s5", "sentence": "Treatment of toxin A with [(14)C]-diethyl pyrocarbonate revealed concentration dependent labelling of histidine residues on the toxin molecules. ", "arg1": {"span": [[13, 20]], "type": "drug_n", "id": "DDI-MedLine.d48.s5.e0"}, "arg2": {"span": [[34, 55]], "type": "drug_n", "id": "DDI-MedLine.d48.s5.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-MedLine.d48.s6-0", "sentence_id": "DDI-MedLine.d48.s6", "sentence": "The effects of diethyl pyrocarbonate could be reversed by hydroxylamine treatment. ", "arg1": {"span": [[15, 36]], "type": "drug_n", "id": "DDI-MedLine.d48.s6.e0"}, "arg2": {"span": [[58, 71]], "type": "drug_n", "id": "DDI-MedLine.d48.s6.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-MedLine.d48.s11-0", "sentence_id": "DDI-MedLine.d48.s11", "sentence": "Exposed histidines on toxin A are available for zinc chelation, and these have been exploited in the development of a novel purification protocol for toxin A using zinc-chelating chromatography.", "arg1": {"span": [[22, 29]], "type": "drug_n", "id": "DDI-MedLine.d48.s11.e0"}, "arg2": {"span": [[48, 52]], "type": "drug", "id": "DDI-MedLine.d48.s11.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-MedLine.d48.s11-1", "sentence_id": "DDI-MedLine.d48.s11", "sentence": "Exposed histidines on toxin A are available for zinc chelation, and these have been exploited in the development of a novel purification protocol for toxin A using zinc-chelating chromatography.", "arg1": {"span": [[22, 29]], "type": "drug_n", "id": "DDI-MedLine.d48.s11.e0"}, "arg2": {"span": [[150, 157]], "type": "drug_n", "id": "DDI-MedLine.d48.s11.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-MedLine.d48.s11-2", "sentence_id": "DDI-MedLine.d48.s11", "sentence": "Exposed histidines on toxin A are available for zinc chelation, and these have been exploited in the development of a novel purification protocol for toxin A using zinc-chelating chromatography.", "arg1": {"span": [[22, 29]], "type": "drug_n", "id": "DDI-MedLine.d48.s11.e0"}, "arg2": {"span": [[164, 168]], "type": "drug", "id": "DDI-MedLine.d48.s11.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-MedLine.d48.s11-3", "sentence_id": "DDI-MedLine.d48.s11", "sentence": "Exposed histidines on toxin A are available for zinc chelation, and these have been exploited in the development of a novel purification protocol for toxin A using zinc-chelating chromatography.", "arg1": {"span": [[48, 52]], "type": "drug", "id": "DDI-MedLine.d48.s11.e1"}, "arg2": {"span": [[150, 157]], "type": "drug_n", "id": "DDI-MedLine.d48.s11.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-MedLine.d48.s11-4", "sentence_id": "DDI-MedLine.d48.s11", "sentence": "Exposed histidines on toxin A are available for zinc chelation, and these have been exploited in the development of a novel purification protocol for toxin A using zinc-chelating chromatography.", "arg1": {"span": [[48, 52]], "type": "drug", "id": "DDI-MedLine.d48.s11.e1"}, "arg2": {"span": [[164, 168]], "type": "drug", "id": "DDI-MedLine.d48.s11.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-MedLine.d48.s11-5", "sentence_id": "DDI-MedLine.d48.s11", "sentence": "Exposed histidines on toxin A are available for zinc chelation, and these have been exploited in the development of a novel purification protocol for toxin A using zinc-chelating chromatography.", "arg1": {"span": [[150, 157]], "type": "drug_n", "id": "DDI-MedLine.d48.s11.e2"}, "arg2": {"span": [[164, 168]], "type": "drug", "id": "DDI-MedLine.d48.s11.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-MedLine.d95.s4-0", "sentence_id": "DDI-MedLine.d95.s4", "sentence": "Resveratrol (5-35 micromol/l) induced concentration-dependent relaxation of mesenteric arteries preconstricted with noradrenaline (8 micromol/l) or KCl (125 mmol/l) from both lean and dietary-obese rats. ", "arg1": {"span": [[0, 11]], "type": "drug_n", "id": "DDI-MedLine.d95.s4.e0"}, "arg2": {"span": [[116, 129]], "type": "drug", "id": "DDI-MedLine.d95.s4.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-MedLine.d95.s4-1", "sentence_id": "DDI-MedLine.d95.s4", "sentence": "Resveratrol (5-35 micromol/l) induced concentration-dependent relaxation of mesenteric arteries preconstricted with noradrenaline (8 micromol/l) or KCl (125 mmol/l) from both lean and dietary-obese rats. ", "arg1": {"span": [[0, 11]], "type": "drug_n", "id": "DDI-MedLine.d95.s4.e0"}, "arg2": {"span": [[148, 151]], "type": "drug", "id": "DDI-MedLine.d95.s4.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-MedLine.d95.s4-2", "sentence_id": "DDI-MedLine.d95.s4", "sentence": "Resveratrol (5-35 micromol/l) induced concentration-dependent relaxation of mesenteric arteries preconstricted with noradrenaline (8 micromol/l) or KCl (125 mmol/l) from both lean and dietary-obese rats. ", "arg1": {"span": [[116, 129]], "type": "drug", "id": "DDI-MedLine.d95.s4.e1"}, "arg2": {"span": [[148, 151]], "type": "drug", "id": "DDI-MedLine.d95.s4.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-MedLine.d95.s6-0", "sentence_id": "DDI-MedLine.d95.s6", "sentence": "However, L-NAME (100 and 300 micromol/l) did not alter the effects of reseveratrol on arteries from dietary-obese rats, giving superimposed concentration-responses curves. ", "arg1": {"span": [[9, 15]], "type": "drug_n", "id": "DDI-MedLine.d95.s6.e0"}, "arg2": {"span": [[70, 82]], "type": "drug_n", "id": "DDI-MedLine.d95.s6.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-MedLine.d95.s7-0", "sentence_id": "DDI-MedLine.d95.s7", "sentence": "Indomethacin was also ineffective in altering resveratrol activity in arteries from both lean and dietary-obese rats. ", "arg1": {"span": [[0, 12]], "type": "drug", "id": "DDI-MedLine.d95.s7.e0"}, "arg2": {"span": [[46, 57]], "type": "drug_n", "id": "DDI-MedLine.d95.s7.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-MedLine.d95.s8-0", "sentence_id": "DDI-MedLine.d95.s8", "sentence": "In noradrenaline-precontracted arteries from dietary-obese rats, responses to resveratrol were not attenuated by endothelial denudation, indicating an action independent of the endothelium. ", "arg1": {"span": [[3, 16]], "type": "drug", "id": "DDI-MedLine.d95.s8.e0"}, "arg2": {"span": [[78, 89]], "type": "drug_n", "id": "DDI-MedLine.d95.s8.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-MedLine.d95.s9-0", "sentence_id": "DDI-MedLine.d95.s9", "sentence": "This study indicates that: (a) the maximal effects of resveratrol on resistance arteries from lean and dietary-obese rats are not effected by endothelial dysfunction, and (b) the effects of resveratrol in lean animals (where endothelial function is not impaired), but not in dietary-obese rats, are mediated via NO.", "arg1": {"span": [[54, 65]], "type": "drug_n", "id": "DDI-MedLine.d95.s9.e0"}, "arg2": {"span": [[190, 201]], "type": "drug_n", "id": "DDI-MedLine.d95.s9.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-MedLine.d112.s0-0", "sentence_id": "DDI-MedLine.d112.s0", "sentence": "Effect of dofetillide on the pharmacokinetics of digoxin.\r\n", "arg1": {"span": [[10, 21]], "type": "drug", "id": "DDI-MedLine.d112.s0.e0"}, "arg2": {"span": [[49, 56]], "type": "drug", "id": "DDI-MedLine.d112.s0.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-MedLine.d112.s1-0", "sentence_id": "DDI-MedLine.d112.s1", "sentence": "The effect of dofetilide on the steady-state pharmacokinetics of digoxin was evaluated in a randomized, double-blind study. ", "arg1": {"span": [[14, 24]], "type": "drug", "id": "DDI-MedLine.d112.s1.e0"}, "arg2": {"span": [[65, 72]], "type": "drug", "id": "DDI-MedLine.d112.s1.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-MedLine.d112.s2-0", "sentence_id": "DDI-MedLine.d112.s2", "sentence": "Five days of dofetilide treatment did not significantly affect steady-state pharmacokinetic variables of digoxin compared with placebo; ", "arg1": {"span": [[13, 23]], "type": "drug", "id": "DDI-MedLine.d112.s2.e0"}, "arg2": {"span": [[105, 112]], "type": "drug", "id": "DDI-MedLine.d112.s2.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-MedLine.d112.s3-0", "sentence_id": "DDI-MedLine.d112.s3", "sentence": "therefore, the use of dofetilide does not necessitate an adjustment in digoxin dose to maintain therapeutic digoxin levels.", "arg1": {"span": [[22, 32]], "type": "drug", "id": "DDI-MedLine.d112.s3.e0"}, "arg2": {"span": [[71, 78]], "type": "drug", "id": "DDI-MedLine.d112.s3.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-MedLine.d116.s0-0", "sentence_id": "DDI-MedLine.d116.s0", "sentence": "Rifampin and warfarin: a drug interaction.\r\n", "arg1": {"span": [[0, 8]], "type": "drug", "id": "DDI-MedLine.d116.s0.e0"}, "arg2": {"span": [[13, 21]], "type": "drug", "id": "DDI-MedLine.d116.s0.e1"}, "ddi_label": 1, "ddi_type": "int"}
{"id": "DDI-MedLine.d116.s1-0", "sentence_id": "DDI-MedLine.d116.s1", "sentence": "The drug interaction between warfarin and rifampin is not well known. ", "arg1": {"span": [[29, 37]], "type": "drug", "id": "DDI-MedLine.d116.s1.e0"}, "arg2": {"span": [[42, 50]], "type": "drug", "id": "DDI-MedLine.d116.s1.e1"}, "ddi_label": 1, "ddi_type": "int"}
{"id": "DDI-MedLine.d116.s2-0", "sentence_id": "DDI-MedLine.d116.s2", "sentence": "Rifampin has been reported to increase the warfarin requirements in human subjects ingesting these agents simultaneously. ", "arg1": {"span": [[0, 8]], "type": "drug", "id": "DDI-MedLine.d116.s2.e0"}, "arg2": {"span": [[43, 51]], "type": "drug", "id": "DDI-MedLine.d116.s2.e1"}, "ddi_label": 1, "ddi_type": "mechanism"}
{"id": "DDI-MedLine.d116.s3-0", "sentence_id": "DDI-MedLine.d116.s3", "sentence": "The concomitant administration of rifampin and warfarin resulted in the need for an unusually high maintenance dose of warfarin (20 mg per day) in order to produce a therapeutic effect. ", "arg1": {"span": [[34, 42]], "type": "drug", "id": "DDI-MedLine.d116.s3.e0"}, "arg2": {"span": [[47, 55]], "type": "drug", "id": "DDI-MedLine.d116.s3.e1"}, "ddi_label": 1, "ddi_type": "mechanism"}
{"id": "DDI-MedLine.d116.s3-1", "sentence_id": "DDI-MedLine.d116.s3", "sentence": "The concomitant administration of rifampin and warfarin resulted in the need for an unusually high maintenance dose of warfarin (20 mg per day) in order to produce a therapeutic effect. ", "arg1": {"span": [[34, 42]], "type": "drug", "id": "DDI-MedLine.d116.s3.e0"}, "arg2": {"span": [[119, 127]], "type": "drug", "id": "DDI-MedLine.d116.s3.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-MedLine.d116.s3-2", "sentence_id": "DDI-MedLine.d116.s3", "sentence": "The concomitant administration of rifampin and warfarin resulted in the need for an unusually high maintenance dose of warfarin (20 mg per day) in order to produce a therapeutic effect. ", "arg1": {"span": [[47, 55]], "type": "drug", "id": "DDI-MedLine.d116.s3.e1"}, "arg2": {"span": [[119, 127]], "type": "drug", "id": "DDI-MedLine.d116.s3.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-MedLine.d116.s4-0", "sentence_id": "DDI-MedLine.d116.s4", "sentence": "Withdrawal of rifampin decreased the warfarin requirement by 50%. ", "arg1": {"span": [[14, 22]], "type": "drug", "id": "DDI-MedLine.d116.s4.e0"}, "arg2": {"span": [[37, 45]], "type": "drug", "id": "DDI-MedLine.d116.s4.e1"}, "ddi_label": 1, "ddi_type": "mechanism"}
{"id": "DDI-MedLine.d116.s5-0", "sentence_id": "DDI-MedLine.d116.s5", "sentence": "This effect may be mediated by the ability of rifampin to induce microsomal enzymes and, thus, the catabolism of warfarin. ", "arg1": {"span": [[46, 54]], "type": "drug", "id": "DDI-MedLine.d116.s5.e0"}, "arg2": {"span": [[113, 121]], "type": "drug", "id": "DDI-MedLine.d116.s5.e1"}, "ddi_label": 1, "ddi_type": "mechanism"}
{"id": "DDI-MedLine.d116.s6-0", "sentence_id": "DDI-MedLine.d116.s6", "sentence": "The effect of rifampin on the warfarin requirement of our patient appeared to be maximal 5 to 7 days after the initiation of rifampin and extended a similar length of time after rifampin withdrawal. ", "arg1": {"span": [[14, 22]], "type": "drug", "id": "DDI-MedLine.d116.s6.e0"}, "arg2": {"span": [[30, 38]], "type": "drug", "id": "DDI-MedLine.d116.s6.e1"}, "ddi_label": 1, "ddi_type": "effect"}
{"id": "DDI-MedLine.d116.s6-1", "sentence_id": "DDI-MedLine.d116.s6", "sentence": "The effect of rifampin on the warfarin requirement of our patient appeared to be maximal 5 to 7 days after the initiation of rifampin and extended a similar length of time after rifampin withdrawal. ", "arg1": {"span": [[14, 22]], "type": "drug", "id": "DDI-MedLine.d116.s6.e0"}, "arg2": {"span": [[125, 133]], "type": "drug", "id": "DDI-MedLine.d116.s6.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-MedLine.d116.s6-2", "sentence_id": "DDI-MedLine.d116.s6", "sentence": "The effect of rifampin on the warfarin requirement of our patient appeared to be maximal 5 to 7 days after the initiation of rifampin and extended a similar length of time after rifampin withdrawal. ", "arg1": {"span": [[14, 22]], "type": "drug", "id": "DDI-MedLine.d116.s6.e0"}, "arg2": {"span": [[178, 186]], "type": "drug", "id": "DDI-MedLine.d116.s6.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-MedLine.d116.s6-3", "sentence_id": "DDI-MedLine.d116.s6", "sentence": "The effect of rifampin on the warfarin requirement of our patient appeared to be maximal 5 to 7 days after the initiation of rifampin and extended a similar length of time after rifampin withdrawal. ", "arg1": {"span": [[30, 38]], "type": "drug", "id": "DDI-MedLine.d116.s6.e1"}, "arg2": {"span": [[125, 133]], "type": "drug", "id": "DDI-MedLine.d116.s6.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-MedLine.d116.s6-4", "sentence_id": "DDI-MedLine.d116.s6", "sentence": "The effect of rifampin on the warfarin requirement of our patient appeared to be maximal 5 to 7 days after the initiation of rifampin and extended a similar length of time after rifampin withdrawal. ", "arg1": {"span": [[30, 38]], "type": "drug", "id": "DDI-MedLine.d116.s6.e1"}, "arg2": {"span": [[178, 186]], "type": "drug", "id": "DDI-MedLine.d116.s6.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-MedLine.d116.s6-5", "sentence_id": "DDI-MedLine.d116.s6", "sentence": "The effect of rifampin on the warfarin requirement of our patient appeared to be maximal 5 to 7 days after the initiation of rifampin and extended a similar length of time after rifampin withdrawal. ", "arg1": {"span": [[125, 133]], "type": "drug", "id": "DDI-MedLine.d116.s6.e2"}, "arg2": {"span": [[178, 186]], "type": "drug", "id": "DDI-MedLine.d116.s6.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-MedLine.d28.s7-0", "sentence_id": "DDI-MedLine.d28.s7", "sentence": "The thiazolidinediones (rosiglitazone and pioglitazone), a new class of oral antidiabetic agents, are \"insulin sensitizers\" ", "arg1": {"span": [[4, 22]], "type": "group", "id": "DDI-MedLine.d28.s7.e0"}, "arg2": {"span": [[24, 37]], "type": "drug", "id": "DDI-MedLine.d28.s7.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-MedLine.d28.s7-1", "sentence_id": "DDI-MedLine.d28.s7", "sentence": "The thiazolidinediones (rosiglitazone and pioglitazone), a new class of oral antidiabetic agents, are \"insulin sensitizers\" ", "arg1": {"span": [[4, 22]], "type": "group", "id": "DDI-MedLine.d28.s7.e0"}, "arg2": {"span": [[42, 54]], "type": "drug", "id": "DDI-MedLine.d28.s7.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-MedLine.d28.s7-2", "sentence_id": "DDI-MedLine.d28.s7", "sentence": "The thiazolidinediones (rosiglitazone and pioglitazone), a new class of oral antidiabetic agents, are \"insulin sensitizers\" ", "arg1": {"span": [[4, 22]], "type": "group", "id": "DDI-MedLine.d28.s7.e0"}, "arg2": {"span": [[77, 96]], "type": "group", "id": "DDI-MedLine.d28.s7.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-MedLine.d28.s7-3", "sentence_id": "DDI-MedLine.d28.s7", "sentence": "The thiazolidinediones (rosiglitazone and pioglitazone), a new class of oral antidiabetic agents, are \"insulin sensitizers\" ", "arg1": {"span": [[24, 37]], "type": "drug", "id": "DDI-MedLine.d28.s7.e1"}, "arg2": {"span": [[42, 54]], "type": "drug", "id": "DDI-MedLine.d28.s7.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-MedLine.d28.s7-4", "sentence_id": "DDI-MedLine.d28.s7", "sentence": "The thiazolidinediones (rosiglitazone and pioglitazone), a new class of oral antidiabetic agents, are \"insulin sensitizers\" ", "arg1": {"span": [[24, 37]], "type": "drug", "id": "DDI-MedLine.d28.s7.e1"}, "arg2": {"span": [[77, 96]], "type": "group", "id": "DDI-MedLine.d28.s7.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-MedLine.d28.s7-5", "sentence_id": "DDI-MedLine.d28.s7", "sentence": "The thiazolidinediones (rosiglitazone and pioglitazone), a new class of oral antidiabetic agents, are \"insulin sensitizers\" ", "arg1": {"span": [[42, 54]], "type": "drug", "id": "DDI-MedLine.d28.s7.e2"}, "arg2": {"span": [[77, 96]], "type": "group", "id": "DDI-MedLine.d28.s7.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-MedLine.d102.s0-0", "sentence_id": "DDI-MedLine.d102.s0", "sentence": "Influence of estradiol and progesterone on the sensitivity of rat thoracic aorta to noradrenaline.\r\n", "arg1": {"span": [[13, 22]], "type": "drug", "id": "DDI-MedLine.d102.s0.e0"}, "arg2": {"span": [[27, 39]], "type": "drug", "id": "DDI-MedLine.d102.s0.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-MedLine.d102.s0-1", "sentence_id": "DDI-MedLine.d102.s0", "sentence": "Influence of estradiol and progesterone on the sensitivity of rat thoracic aorta to noradrenaline.\r\n", "arg1": {"span": [[13, 22]], "type": "drug", "id": "DDI-MedLine.d102.s0.e0"}, "arg2": {"span": [[84, 97]], "type": "drug", "id": "DDI-MedLine.d102.s0.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-MedLine.d102.s0-2", "sentence_id": "DDI-MedLine.d102.s0", "sentence": "Influence of estradiol and progesterone on the sensitivity of rat thoracic aorta to noradrenaline.\r\n", "arg1": {"span": [[27, 39]], "type": "drug", "id": "DDI-MedLine.d102.s0.e1"}, "arg2": {"span": [[84, 97]], "type": "drug", "id": "DDI-MedLine.d102.s0.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-MedLine.d102.s1-0", "sentence_id": "DDI-MedLine.d102.s1", "sentence": "The aim of this study was to investigate the effects of low and high doses of estradiol, and of progesterone on the response to noradrenaline in rat thoracic aorta. ", "arg1": {"span": [[78, 87]], "type": "drug", "id": "DDI-MedLine.d102.s1.e0"}, "arg2": {"span": [[96, 108]], "type": "drug", "id": "DDI-MedLine.d102.s1.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-MedLine.d102.s1-1", "sentence_id": "DDI-MedLine.d102.s1", "sentence": "The aim of this study was to investigate the effects of low and high doses of estradiol, and of progesterone on the response to noradrenaline in rat thoracic aorta. ", "arg1": {"span": [[78, 87]], "type": "drug", "id": "DDI-MedLine.d102.s1.e0"}, "arg2": {"span": [[128, 141]], "type": "drug", "id": "DDI-MedLine.d102.s1.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-MedLine.d102.s1-2", "sentence_id": "DDI-MedLine.d102.s1", "sentence": "The aim of this study was to investigate the effects of low and high doses of estradiol, and of progesterone on the response to noradrenaline in rat thoracic aorta. ", "arg1": {"span": [[96, 108]], "type": "drug", "id": "DDI-MedLine.d102.s1.e1"}, "arg2": {"span": [[128, 141]], "type": "drug", "id": "DDI-MedLine.d102.s1.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-MedLine.d102.s3-0", "sentence_id": "DDI-MedLine.d102.s3", "sentence": "injection of vehicle (corn oil, 0.1 mL/day), estradiol (10 microg/kg/day or 4 mg/kg/day) and/or progesterone (20 mg/kg/day), for eight days. ", "arg1": {"span": [[45, 54]], "type": "drug", "id": "DDI-MedLine.d102.s3.e0"}, "arg2": {"span": [[96, 108]], "type": "drug", "id": "DDI-MedLine.d102.s3.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-MedLine.d102.s5-0", "sentence_id": "DDI-MedLine.d102.s5", "sentence": "Aortic rings with intact endothelium from the high-dose (4 mg/kg/day) estradiol group were supersensitive to noradrenaline compared to the vehicle or low-dose (10 microg/kg/day) estradiol groups (pD2 values = 7.86+/-0.09, 7.30+/-0.11 and 7.35+/-0.04, respectively). ", "arg1": {"span": [[70, 79]], "type": "drug", "id": "DDI-MedLine.d102.s5.e0"}, "arg2": {"span": [[109, 122]], "type": "drug", "id": "DDI-MedLine.d102.s5.e1"}, "ddi_label": 1, "ddi_type": "effect"}
{"id": "DDI-MedLine.d102.s6-0", "sentence_id": "DDI-MedLine.d102.s6", "sentence": "Endothelium-intact aortic rings from high-estradiol rats were supersensitive to noradrenaline when compared to vehicle-, progesterone- and progesterone + high-estradiol-treated rats (pD2 values = 7.77+/-0.12, 7.21+/-0.13, 6.93+/-0.04 and 7.22+/-0.18, respectively). ", "arg1": {"span": [[42, 51]], "type": "drug", "id": "DDI-MedLine.d102.s6.e0"}, "arg2": {"span": [[80, 93]], "type": "drug", "id": "DDI-MedLine.d102.s6.e1"}, "ddi_label": 1, "ddi_type": "effect"}
{"id": "DDI-MedLine.d102.s6-1", "sentence_id": "DDI-MedLine.d102.s6", "sentence": "Endothelium-intact aortic rings from high-estradiol rats were supersensitive to noradrenaline when compared to vehicle-, progesterone- and progesterone + high-estradiol-treated rats (pD2 values = 7.77+/-0.12, 7.21+/-0.13, 6.93+/-0.04 and 7.22+/-0.18, respectively). ", "arg1": {"span": [[42, 51]], "type": "drug", "id": "DDI-MedLine.d102.s6.e0"}, "arg2": {"span": [[121, 133]], "type": "drug", "id": "DDI-MedLine.d102.s6.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-MedLine.d102.s6-2", "sentence_id": "DDI-MedLine.d102.s6", "sentence": "Endothelium-intact aortic rings from high-estradiol rats were supersensitive to noradrenaline when compared to vehicle-, progesterone- and progesterone + high-estradiol-treated rats (pD2 values = 7.77+/-0.12, 7.21+/-0.13, 6.93+/-0.04 and 7.22+/-0.18, respectively). ", "arg1": {"span": [[42, 51]], "type": "drug", "id": "DDI-MedLine.d102.s6.e0"}, "arg2": {"span": [[139, 151]], "type": "drug", "id": "DDI-MedLine.d102.s6.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-MedLine.d102.s6-3", "sentence_id": "DDI-MedLine.d102.s6", "sentence": "Endothelium-intact aortic rings from high-estradiol rats were supersensitive to noradrenaline when compared to vehicle-, progesterone- and progesterone + high-estradiol-treated rats (pD2 values = 7.77+/-0.12, 7.21+/-0.13, 6.93+/-0.04 and 7.22+/-0.18, respectively). ", "arg1": {"span": [[42, 51]], "type": "drug", "id": "DDI-MedLine.d102.s6.e0"}, "arg2": {"span": [[159, 168]], "type": "drug", "id": "DDI-MedLine.d102.s6.e4"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-MedLine.d102.s6-4", "sentence_id": "DDI-MedLine.d102.s6", "sentence": "Endothelium-intact aortic rings from high-estradiol rats were supersensitive to noradrenaline when compared to vehicle-, progesterone- and progesterone + high-estradiol-treated rats (pD2 values = 7.77+/-0.12, 7.21+/-0.13, 6.93+/-0.04 and 7.22+/-0.18, respectively). ", "arg1": {"span": [[80, 93]], "type": "drug", "id": "DDI-MedLine.d102.s6.e1"}, "arg2": {"span": [[121, 133]], "type": "drug", "id": "DDI-MedLine.d102.s6.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-MedLine.d102.s6-5", "sentence_id": "DDI-MedLine.d102.s6", "sentence": "Endothelium-intact aortic rings from high-estradiol rats were supersensitive to noradrenaline when compared to vehicle-, progesterone- and progesterone + high-estradiol-treated rats (pD2 values = 7.77+/-0.12, 7.21+/-0.13, 6.93+/-0.04 and 7.22+/-0.18, respectively). ", "arg1": {"span": [[80, 93]], "type": "drug", "id": "DDI-MedLine.d102.s6.e1"}, "arg2": {"span": [[139, 151]], "type": "drug", "id": "DDI-MedLine.d102.s6.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-MedLine.d102.s6-6", "sentence_id": "DDI-MedLine.d102.s6", "sentence": "Endothelium-intact aortic rings from high-estradiol rats were supersensitive to noradrenaline when compared to vehicle-, progesterone- and progesterone + high-estradiol-treated rats (pD2 values = 7.77+/-0.12, 7.21+/-0.13, 6.93+/-0.04 and 7.22+/-0.18, respectively). ", "arg1": {"span": [[80, 93]], "type": "drug", "id": "DDI-MedLine.d102.s6.e1"}, "arg2": {"span": [[159, 168]], "type": "drug", "id": "DDI-MedLine.d102.s6.e4"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-MedLine.d102.s6-7", "sentence_id": "DDI-MedLine.d102.s6", "sentence": "Endothelium-intact aortic rings from high-estradiol rats were supersensitive to noradrenaline when compared to vehicle-, progesterone- and progesterone + high-estradiol-treated rats (pD2 values = 7.77+/-0.12, 7.21+/-0.13, 6.93+/-0.04 and 7.22+/-0.18, respectively). ", "arg1": {"span": [[121, 133]], "type": "drug", "id": "DDI-MedLine.d102.s6.e2"}, "arg2": {"span": [[139, 151]], "type": "drug", "id": "DDI-MedLine.d102.s6.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-MedLine.d102.s6-8", "sentence_id": "DDI-MedLine.d102.s6", "sentence": "Endothelium-intact aortic rings from high-estradiol rats were supersensitive to noradrenaline when compared to vehicle-, progesterone- and progesterone + high-estradiol-treated rats (pD2 values = 7.77+/-0.12, 7.21+/-0.13, 6.93+/-0.04 and 7.22+/-0.18, respectively). ", "arg1": {"span": [[121, 133]], "type": "drug", "id": "DDI-MedLine.d102.s6.e2"}, "arg2": {"span": [[159, 168]], "type": "drug", "id": "DDI-MedLine.d102.s6.e4"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-MedLine.d102.s6-9", "sentence_id": "DDI-MedLine.d102.s6", "sentence": "Endothelium-intact aortic rings from high-estradiol rats were supersensitive to noradrenaline when compared to vehicle-, progesterone- and progesterone + high-estradiol-treated rats (pD2 values = 7.77+/-0.12, 7.21+/-0.13, 6.93+/-0.04 and 7.22+/-0.18, respectively). ", "arg1": {"span": [[139, 151]], "type": "drug", "id": "DDI-MedLine.d102.s6.e3"}, "arg2": {"span": [[159, 168]], "type": "drug", "id": "DDI-MedLine.d102.s6.e4"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-MedLine.d83.s1-0", "sentence_id": "DDI-MedLine.d83.s1", "sentence": "Olanzapine, a thienobenzodiazepine derivative, is a second generation (atypical) antipsychotic agent which has proven efficacy against the positive and negative symptoms of schizophrenia. ", "arg1": {"span": [[0, 10]], "type": "drug", "id": "DDI-MedLine.d83.s1.e0"}, "arg2": {"span": [[14, 45]], "type": "group", "id": "DDI-MedLine.d83.s1.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-MedLine.d83.s1-1", "sentence_id": "DDI-MedLine.d83.s1", "sentence": "Olanzapine, a thienobenzodiazepine derivative, is a second generation (atypical) antipsychotic agent which has proven efficacy against the positive and negative symptoms of schizophrenia. ", "arg1": {"span": [[0, 10]], "type": "drug", "id": "DDI-MedLine.d83.s1.e0"}, "arg2": {"span": [[52, 100]], "type": "group", "id": "DDI-MedLine.d83.s1.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-MedLine.d83.s1-2", "sentence_id": "DDI-MedLine.d83.s1", "sentence": "Olanzapine, a thienobenzodiazepine derivative, is a second generation (atypical) antipsychotic agent which has proven efficacy against the positive and negative symptoms of schizophrenia. ", "arg1": {"span": [[14, 45]], "type": "group", "id": "DDI-MedLine.d83.s1.e1"}, "arg2": {"span": [[52, 100]], "type": "group", "id": "DDI-MedLine.d83.s1.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-MedLine.d83.s3-0", "sentence_id": "DDI-MedLine.d83.s3", "sentence": "In large, well controlled trials in patients with schizophrenia or related psychoses, olanzapine 5 to 20 mg/day was significantly superior to haloperidol 5 to 20 mg/day in overall improvements in psychopathology rating scales and in the treatment of depressive and negative symptoms, and was comparable in effects on positive psychotic symptoms. ", "arg1": {"span": [[86, 96]], "type": "drug", "id": "DDI-MedLine.d83.s3.e0"}, "arg2": {"span": [[142, 153]], "type": "drug", "id": "DDI-MedLine.d83.s3.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-MedLine.d83.s4-0", "sentence_id": "DDI-MedLine.d83.s4", "sentence": "The 1-year risk of relapse (rehospitalisation) was significantly lower with olanzapine than with haloperidol treatment. ", "arg1": {"span": [[76, 86]], "type": "drug", "id": "DDI-MedLine.d83.s4.e0"}, "arg2": {"span": [[97, 108]], "type": "drug", "id": "DDI-MedLine.d83.s4.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-MedLine.d83.s5-0", "sentence_id": "DDI-MedLine.d83.s5", "sentence": "In the first double-blind comparative study (28-week) of olanzapine and risperidone, olanzapine 10 to 20 mg/day proved to be significantly more effective than risperidone 4 to 12 mg/day in the treatment of negative and depressive symptoms but not on overall psychopathology symptoms. ", "arg1": {"span": [[57, 67]], "type": "drug", "id": "DDI-MedLine.d83.s5.e0"}, "arg2": {"span": [[72, 83]], "type": "drug", "id": "DDI-MedLine.d83.s5.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-MedLine.d83.s5-1", "sentence_id": "DDI-MedLine.d83.s5", "sentence": "In the first double-blind comparative study (28-week) of olanzapine and risperidone, olanzapine 10 to 20 mg/day proved to be significantly more effective than risperidone 4 to 12 mg/day in the treatment of negative and depressive symptoms but not on overall psychopathology symptoms. ", "arg1": {"span": [[57, 67]], "type": "drug", "id": "DDI-MedLine.d83.s5.e0"}, "arg2": {"span": [[85, 95]], "type": "drug", "id": "DDI-MedLine.d83.s5.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-MedLine.d83.s5-2", "sentence_id": "DDI-MedLine.d83.s5", "sentence": "In the first double-blind comparative study (28-week) of olanzapine and risperidone, olanzapine 10 to 20 mg/day proved to be significantly more effective than risperidone 4 to 12 mg/day in the treatment of negative and depressive symptoms but not on overall psychopathology symptoms. ", "arg1": {"span": [[57, 67]], "type": "drug", "id": "DDI-MedLine.d83.s5.e0"}, "arg2": {"span": [[159, 170]], "type": "drug", "id": "DDI-MedLine.d83.s5.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-MedLine.d83.s5-3", "sentence_id": "DDI-MedLine.d83.s5", "sentence": "In the first double-blind comparative study (28-week) of olanzapine and risperidone, olanzapine 10 to 20 mg/day proved to be significantly more effective than risperidone 4 to 12 mg/day in the treatment of negative and depressive symptoms but not on overall psychopathology symptoms. ", "arg1": {"span": [[72, 83]], "type": "drug", "id": "DDI-MedLine.d83.s5.e1"}, "arg2": {"span": [[85, 95]], "type": "drug", "id": "DDI-MedLine.d83.s5.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-MedLine.d83.s5-4", "sentence_id": "DDI-MedLine.d83.s5", "sentence": "In the first double-blind comparative study (28-week) of olanzapine and risperidone, olanzapine 10 to 20 mg/day proved to be significantly more effective than risperidone 4 to 12 mg/day in the treatment of negative and depressive symptoms but not on overall psychopathology symptoms. ", "arg1": {"span": [[72, 83]], "type": "drug", "id": "DDI-MedLine.d83.s5.e1"}, "arg2": {"span": [[159, 170]], "type": "drug", "id": "DDI-MedLine.d83.s5.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-MedLine.d83.s5-5", "sentence_id": "DDI-MedLine.d83.s5", "sentence": "In the first double-blind comparative study (28-week) of olanzapine and risperidone, olanzapine 10 to 20 mg/day proved to be significantly more effective than risperidone 4 to 12 mg/day in the treatment of negative and depressive symptoms but not on overall psychopathology symptoms. ", "arg1": {"span": [[85, 95]], "type": "drug", "id": "DDI-MedLine.d83.s5.e2"}, "arg2": {"span": [[159, 170]], "type": "drug", "id": "DDI-MedLine.d83.s5.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-MedLine.d83.s6-0", "sentence_id": "DDI-MedLine.d83.s6", "sentence": "In contrast, preliminary results from an 8-week controlled study suggested risperidone 2 to 6 mg/day was superior to olanzapine 5 to 20 mg/day against positive and anxiety/depressive symptoms (p < 0.05), although consistent with the first study, both agents demonstrated similar efficacy on measures of overall psychopathology. ", "arg1": {"span": [[75, 86]], "type": "drug", "id": "DDI-MedLine.d83.s6.e0"}, "arg2": {"span": [[117, 127]], "type": "drug", "id": "DDI-MedLine.d83.s6.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-MedLine.d83.s7-0", "sentence_id": "DDI-MedLine.d83.s7", "sentence": "Improvements in general cognitive function seen with olanzapine treatment in a 1-year controlled study of patients with early-phase schizophrenia, were significantly greater than changes seen with either risperidone or haloperidol. ", "arg1": {"span": [[53, 63]], "type": "drug", "id": "DDI-MedLine.d83.s7.e0"}, "arg2": {"span": [[204, 215]], "type": "drug", "id": "DDI-MedLine.d83.s7.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-MedLine.d83.s7-1", "sentence_id": "DDI-MedLine.d83.s7", "sentence": "Improvements in general cognitive function seen with olanzapine treatment in a 1-year controlled study of patients with early-phase schizophrenia, were significantly greater than changes seen with either risperidone or haloperidol. ", "arg1": {"span": [[53, 63]], "type": "drug", "id": "DDI-MedLine.d83.s7.e0"}, "arg2": {"span": [[219, 230]], "type": "drug", "id": "DDI-MedLine.d83.s7.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-MedLine.d83.s7-2", "sentence_id": "DDI-MedLine.d83.s7", "sentence": "Improvements in general cognitive function seen with olanzapine treatment in a 1-year controlled study of patients with early-phase schizophrenia, were significantly greater than changes seen with either risperidone or haloperidol. ", "arg1": {"span": [[204, 215]], "type": "drug", "id": "DDI-MedLine.d83.s7.e1"}, "arg2": {"span": [[219, 230]], "type": "drug", "id": "DDI-MedLine.d83.s7.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-MedLine.d83.s8-0", "sentence_id": "DDI-MedLine.d83.s8", "sentence": "However, preliminary results from an 8-week trial showed comparable cognitive enhancing effects of olanzapine and risperidone treatment in patients with schizophrenia or schizoaffective disorder. ", "arg1": {"span": [[99, 109]], "type": "drug", "id": "DDI-MedLine.d83.s8.e0"}, "arg2": {"span": [[114, 125]], "type": "drug", "id": "DDI-MedLine.d83.s8.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-MedLine.d83.s9-0", "sentence_id": "DDI-MedLine.d83.s9", "sentence": "Several studies indicate that olanzapine has benefits against symptoms of aggression and agitation, while other studies strongly support the effectiveness of olanzapine in the treatment of depressive symptomatology. ", "arg1": {"span": [[30, 40]], "type": "drug", "id": "DDI-MedLine.d83.s9.e0"}, "arg2": {"span": [[158, 168]], "type": "drug", "id": "DDI-MedLine.d83.s9.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-MedLine.d83.s10-0", "sentence_id": "DDI-MedLine.d83.s10", "sentence": "Olanzapine is associated with significantly fewer extrapyramidal symptoms than haloperidol and risperidone. ", "arg1": {"span": [[0, 10]], "type": "drug", "id": "DDI-MedLine.d83.s10.e0"}, "arg2": {"span": [[79, 90]], "type": "drug", "id": "DDI-MedLine.d83.s10.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-MedLine.d83.s10-1", "sentence_id": "DDI-MedLine.d83.s10", "sentence": "Olanzapine is associated with significantly fewer extrapyramidal symptoms than haloperidol and risperidone. ", "arg1": {"span": [[0, 10]], "type": "drug", "id": "DDI-MedLine.d83.s10.e0"}, "arg2": {"span": [[95, 106]], "type": "drug", "id": "DDI-MedLine.d83.s10.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-MedLine.d83.s10-2", "sentence_id": "DDI-MedLine.d83.s10", "sentence": "Olanzapine is associated with significantly fewer extrapyramidal symptoms than haloperidol and risperidone. ", "arg1": {"span": [[79, 90]], "type": "drug", "id": "DDI-MedLine.d83.s10.e1"}, "arg2": {"span": [[95, 106]], "type": "drug", "id": "DDI-MedLine.d83.s10.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-MedLine.d83.s11-0", "sentence_id": "DDI-MedLine.d83.s11", "sentence": "In addition, olanzapine is not associated with a risk of agranulocytosis as seen with clozapine or clinically significant hyperprolactinaemia as seen with risperidone or prolongation of the QT interval. ", "arg1": {"span": [[13, 23]], "type": "drug", "id": "DDI-MedLine.d83.s11.e0"}, "arg2": {"span": [[86, 95]], "type": "drug", "id": "DDI-MedLine.d83.s11.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-MedLine.d83.s11-1", "sentence_id": "DDI-MedLine.d83.s11", "sentence": "In addition, olanzapine is not associated with a risk of agranulocytosis as seen with clozapine or clinically significant hyperprolactinaemia as seen with risperidone or prolongation of the QT interval. ", "arg1": {"span": [[13, 23]], "type": "drug", "id": "DDI-MedLine.d83.s11.e0"}, "arg2": {"span": [[155, 166]], "type": "drug", "id": "DDI-MedLine.d83.s11.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-MedLine.d83.s11-2", "sentence_id": "DDI-MedLine.d83.s11", "sentence": "In addition, olanzapine is not associated with a risk of agranulocytosis as seen with clozapine or clinically significant hyperprolactinaemia as seen with risperidone or prolongation of the QT interval. ", "arg1": {"span": [[86, 95]], "type": "drug", "id": "DDI-MedLine.d83.s11.e1"}, "arg2": {"span": [[155, 166]], "type": "drug", "id": "DDI-MedLine.d83.s11.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-MedLine.d83.s13-0", "sentence_id": "DDI-MedLine.d83.s13", "sentence": "In comparison with haloperidol, the adverse events reported significantly more frequently with olanzapine in > or = 3.5% of patients were dry mouth, bodyweight gain and increased appetite and compared with risperidone, only bodyweight gain occurred significantly more frequently with olanzapine. ", "arg1": {"span": [[19, 30]], "type": "drug", "id": "DDI-MedLine.d83.s13.e0"}, "arg2": {"span": [[95, 105]], "type": "drug", "id": "DDI-MedLine.d83.s13.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-MedLine.d83.s13-1", "sentence_id": "DDI-MedLine.d83.s13", "sentence": "In comparison with haloperidol, the adverse events reported significantly more frequently with olanzapine in > or = 3.5% of patients were dry mouth, bodyweight gain and increased appetite and compared with risperidone, only bodyweight gain occurred significantly more frequently with olanzapine. ", "arg1": {"span": [[19, 30]], "type": "drug", "id": "DDI-MedLine.d83.s13.e0"}, "arg2": {"span": [[206, 217]], "type": "drug", "id": "DDI-MedLine.d83.s13.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-MedLine.d83.s13-2", "sentence_id": "DDI-MedLine.d83.s13", "sentence": "In comparison with haloperidol, the adverse events reported significantly more frequently with olanzapine in > or = 3.5% of patients were dry mouth, bodyweight gain and increased appetite and compared with risperidone, only bodyweight gain occurred significantly more frequently with olanzapine. ", "arg1": {"span": [[19, 30]], "type": "drug", "id": "DDI-MedLine.d83.s13.e0"}, "arg2": {"span": [[284, 294]], "type": "drug", "id": "DDI-MedLine.d83.s13.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-MedLine.d83.s13-3", "sentence_id": "DDI-MedLine.d83.s13", "sentence": "In comparison with haloperidol, the adverse events reported significantly more frequently with olanzapine in > or = 3.5% of patients were dry mouth, bodyweight gain and increased appetite and compared with risperidone, only bodyweight gain occurred significantly more frequently with olanzapine. ", "arg1": {"span": [[95, 105]], "type": "drug", "id": "DDI-MedLine.d83.s13.e1"}, "arg2": {"span": [[206, 217]], "type": "drug", "id": "DDI-MedLine.d83.s13.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-MedLine.d83.s13-4", "sentence_id": "DDI-MedLine.d83.s13", "sentence": "In comparison with haloperidol, the adverse events reported significantly more frequently with olanzapine in > or = 3.5% of patients were dry mouth, bodyweight gain and increased appetite and compared with risperidone, only bodyweight gain occurred significantly more frequently with olanzapine. ", "arg1": {"span": [[95, 105]], "type": "drug", "id": "DDI-MedLine.d83.s13.e1"}, "arg2": {"span": [[284, 294]], "type": "drug", "id": "DDI-MedLine.d83.s13.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-MedLine.d83.s13-5", "sentence_id": "DDI-MedLine.d83.s13", "sentence": "In comparison with haloperidol, the adverse events reported significantly more frequently with olanzapine in > or = 3.5% of patients were dry mouth, bodyweight gain and increased appetite and compared with risperidone, only bodyweight gain occurred significantly more frequently with olanzapine. ", "arg1": {"span": [[206, 217]], "type": "drug", "id": "DDI-MedLine.d83.s13.e2"}, "arg2": {"span": [[284, 294]], "type": "drug", "id": "DDI-MedLine.d83.s13.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-MedLine.d83.s15-0", "sentence_id": "DDI-MedLine.d83.s15", "sentence": "Pharmacoeconomic analyses indicate that olanzapine does not significantly increase, and may even decrease, the overall direct treatment costs of schizophrenia, compared with haloperidol. ", "arg1": {"span": [[40, 50]], "type": "drug", "id": "DDI-MedLine.d83.s15.e0"}, "arg2": {"span": [[174, 185]], "type": "drug", "id": "DDI-MedLine.d83.s15.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-MedLine.d83.s16-0", "sentence_id": "DDI-MedLine.d83.s16", "sentence": "Compared with risperidone, olanzapine has also been reported to decrease overall treatment costs, despite the several-fold higher daily acquisition cost of the drug. ", "arg1": {"span": [[14, 25]], "type": "drug", "id": "DDI-MedLine.d83.s16.e0"}, "arg2": {"span": [[27, 37]], "type": "drug", "id": "DDI-MedLine.d83.s16.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-MedLine.d83.s17-0", "sentence_id": "DDI-MedLine.d83.s17", "sentence": "Olanzapine treatment improves quality of life in patients with schizophrenia and related psychoses to a greater extent than haloperidol, and to broadly the same extent as risperidone. ", "arg1": {"span": [[0, 10]], "type": "drug", "id": "DDI-MedLine.d83.s17.e0"}, "arg2": {"span": [[124, 135]], "type": "drug", "id": "DDI-MedLine.d83.s17.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-MedLine.d83.s17-1", "sentence_id": "DDI-MedLine.d83.s17", "sentence": "Olanzapine treatment improves quality of life in patients with schizophrenia and related psychoses to a greater extent than haloperidol, and to broadly the same extent as risperidone. ", "arg1": {"span": [[0, 10]], "type": "drug", "id": "DDI-MedLine.d83.s17.e0"}, "arg2": {"span": [[171, 182]], "type": "drug", "id": "DDI-MedLine.d83.s17.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-MedLine.d83.s17-2", "sentence_id": "DDI-MedLine.d83.s17", "sentence": "Olanzapine treatment improves quality of life in patients with schizophrenia and related psychoses to a greater extent than haloperidol, and to broadly the same extent as risperidone. ", "arg1": {"span": [[124, 135]], "type": "drug", "id": "DDI-MedLine.d83.s17.e1"}, "arg2": {"span": [[171, 182]], "type": "drug", "id": "DDI-MedLine.d83.s17.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-MedLine.d83.s18-0", "sentence_id": "DDI-MedLine.d83.s18", "sentence": "CONCLUSIONS: Olanzapine demonstrated superior antipsychotic efficacy compared with haloperidol in the treatment of acute phase schizophrenia, and in the treatment of some patients with first-episode or treatment-resistant schizophrenia. ", "arg1": {"span": [[13, 23]], "type": "drug", "id": "DDI-MedLine.d83.s18.e0"}, "arg2": {"span": [[83, 94]], "type": "drug", "id": "DDI-MedLine.d83.s18.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-MedLine.d83.s19-0", "sentence_id": "DDI-MedLine.d83.s19", "sentence": "The reduced risk of adverse events and therapeutic superiority compared with haloperidol and risperidone in the treatment of negative and depressive symptoms support the choice of olanzapine as a first-line option in the management of schizophrenia in the acute phase and for the maintenance of treatment response.", "arg1": {"span": [[77, 88]], "type": "drug", "id": "DDI-MedLine.d83.s19.e0"}, "arg2": {"span": [[93, 104]], "type": "drug", "id": "DDI-MedLine.d83.s19.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-MedLine.d83.s19-1", "sentence_id": "DDI-MedLine.d83.s19", "sentence": "The reduced risk of adverse events and therapeutic superiority compared with haloperidol and risperidone in the treatment of negative and depressive symptoms support the choice of olanzapine as a first-line option in the management of schizophrenia in the acute phase and for the maintenance of treatment response.", "arg1": {"span": [[77, 88]], "type": "drug", "id": "DDI-MedLine.d83.s19.e0"}, "arg2": {"span": [[180, 190]], "type": "drug", "id": "DDI-MedLine.d83.s19.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-MedLine.d83.s19-2", "sentence_id": "DDI-MedLine.d83.s19", "sentence": "The reduced risk of adverse events and therapeutic superiority compared with haloperidol and risperidone in the treatment of negative and depressive symptoms support the choice of olanzapine as a first-line option in the management of schizophrenia in the acute phase and for the maintenance of treatment response.", "arg1": {"span": [[93, 104]], "type": "drug", "id": "DDI-MedLine.d83.s19.e1"}, "arg2": {"span": [[180, 190]], "type": "drug", "id": "DDI-MedLine.d83.s19.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-MedLine.d120.s0-0", "sentence_id": "DDI-MedLine.d120.s0", "sentence": "Molecular basis for the selective toxicity of amphotericin B for yeast and filipin for animal cells.", "arg1": {"span": [[46, 60]], "type": "drug", "id": "DDI-MedLine.d120.s0.e0"}, "arg2": {"span": [[75, 82]], "type": "drug_n", "id": "DDI-MedLine.d120.s0.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-MedLine.d120.s1-0", "sentence_id": "DDI-MedLine.d120.s1", "sentence": "Among the polyene antibiotics, many, like filipin, cannot be used clinically because they are toxic; ", "arg1": {"span": [[10, 29]], "type": "group", "id": "DDI-MedLine.d120.s1.e0"}, "arg2": {"span": [[42, 49]], "type": "drug_n", "id": "DDI-MedLine.d120.s1.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-MedLine.d120.s3-0", "sentence_id": "DDI-MedLine.d120.s3", "sentence": "Both the toxicity of filipin and the therapeutic value of amphotericin B can be rationalized at the cellular and molecular level by the following observations: (i) these polyene antibiotics showed differential effects on cells; ", "arg1": {"span": [[21, 28]], "type": "drug_n", "id": "DDI-MedLine.d120.s3.e0"}, "arg2": {"span": [[58, 72]], "type": "drug", "id": "DDI-MedLine.d120.s3.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-MedLine.d120.s3-1", "sentence_id": "DDI-MedLine.d120.s3", "sentence": "Both the toxicity of filipin and the therapeutic value of amphotericin B can be rationalized at the cellular and molecular level by the following observations: (i) these polyene antibiotics showed differential effects on cells; ", "arg1": {"span": [[21, 28]], "type": "drug_n", "id": "DDI-MedLine.d120.s3.e0"}, "arg2": {"span": [[170, 189]], "type": "group", "id": "DDI-MedLine.d120.s3.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-MedLine.d120.s3-2", "sentence_id": "DDI-MedLine.d120.s3", "sentence": "Both the toxicity of filipin and the therapeutic value of amphotericin B can be rationalized at the cellular and molecular level by the following observations: (i) these polyene antibiotics showed differential effects on cells; ", "arg1": {"span": [[58, 72]], "type": "drug", "id": "DDI-MedLine.d120.s3.e1"}, "arg2": {"span": [[170, 189]], "type": "group", "id": "DDI-MedLine.d120.s3.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-MedLine.d120.s4-0", "sentence_id": "DDI-MedLine.d120.s4", "sentence": "filipin was more potent in lysing human red blood cells, whereas amphotericin B was more potent in inhibiting yeast cell growth; ", "arg1": {"span": [[0, 7]], "type": "drug_n", "id": "DDI-MedLine.d120.s4.e0"}, "arg2": {"span": [[65, 79]], "type": "drug", "id": "DDI-MedLine.d120.s4.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-MedLine.d120.s5-0", "sentence_id": "DDI-MedLine.d120.s5", "sentence": "and (ii) the effects of filipin were more efficiently inhibited by added cholesterol, the major membrane sterol in human cells, whereas the effects of amphotericin B were more efficiently inhibited by ergosterol, the major membrane sterol in yeast. ", "arg1": {"span": [[24, 31]], "type": "drug_n", "id": "DDI-MedLine.d120.s5.e0"}, "arg2": {"span": [[151, 165]], "type": "drug", "id": "DDI-MedLine.d120.s5.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-MedLine.d85.s0-0", "sentence_id": "DDI-MedLine.d85.s0", "sentence": "Misonidazole protects mouse tumour and normal tissues from the toxicity of oral CCNU.\r\n", "arg1": {"span": [[0, 12]], "type": "drug_n", "id": "DDI-MedLine.d85.s0.e0"}, "arg2": {"span": [[80, 84]], "type": "drug", "id": "DDI-MedLine.d85.s0.e1"}, "ddi_label": 1, "ddi_type": "effect"}
{"id": "DDI-MedLine.d85.s1-0", "sentence_id": "DDI-MedLine.d85.s1", "sentence": "Because the nitrosourea CCNU is given exclusively by the oral route in man, we have carried out studies in mice on the antitumour activity, acute toxicity and pharmacokinetics of oral CCNU, either alone or in combination with the chemosensitizer misonidazole. ", "arg1": {"span": [[12, 23]], "type": "group", "id": "DDI-MedLine.d85.s1.e0"}, "arg2": {"span": [[24, 28]], "type": "drug", "id": "DDI-MedLine.d85.s1.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-MedLine.d85.s1-1", "sentence_id": "DDI-MedLine.d85.s1", "sentence": "Because the nitrosourea CCNU is given exclusively by the oral route in man, we have carried out studies in mice on the antitumour activity, acute toxicity and pharmacokinetics of oral CCNU, either alone or in combination with the chemosensitizer misonidazole. ", "arg1": {"span": [[12, 23]], "type": "group", "id": "DDI-MedLine.d85.s1.e0"}, "arg2": {"span": [[184, 188]], "type": "drug", "id": "DDI-MedLine.d85.s1.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-MedLine.d85.s1-2", "sentence_id": "DDI-MedLine.d85.s1", "sentence": "Because the nitrosourea CCNU is given exclusively by the oral route in man, we have carried out studies in mice on the antitumour activity, acute toxicity and pharmacokinetics of oral CCNU, either alone or in combination with the chemosensitizer misonidazole. ", "arg1": {"span": [[12, 23]], "type": "group", "id": "DDI-MedLine.d85.s1.e0"}, "arg2": {"span": [[246, 258]], "type": "drug_n", "id": "DDI-MedLine.d85.s1.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-MedLine.d85.s1-3", "sentence_id": "DDI-MedLine.d85.s1", "sentence": "Because the nitrosourea CCNU is given exclusively by the oral route in man, we have carried out studies in mice on the antitumour activity, acute toxicity and pharmacokinetics of oral CCNU, either alone or in combination with the chemosensitizer misonidazole. ", "arg1": {"span": [[24, 28]], "type": "drug", "id": "DDI-MedLine.d85.s1.e1"}, "arg2": {"span": [[184, 188]], "type": "drug", "id": "DDI-MedLine.d85.s1.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-MedLine.d85.s1-4", "sentence_id": "DDI-MedLine.d85.s1", "sentence": "Because the nitrosourea CCNU is given exclusively by the oral route in man, we have carried out studies in mice on the antitumour activity, acute toxicity and pharmacokinetics of oral CCNU, either alone or in combination with the chemosensitizer misonidazole. ", "arg1": {"span": [[24, 28]], "type": "drug", "id": "DDI-MedLine.d85.s1.e1"}, "arg2": {"span": [[246, 258]], "type": "drug_n", "id": "DDI-MedLine.d85.s1.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-MedLine.d85.s1-5", "sentence_id": "DDI-MedLine.d85.s1", "sentence": "Because the nitrosourea CCNU is given exclusively by the oral route in man, we have carried out studies in mice on the antitumour activity, acute toxicity and pharmacokinetics of oral CCNU, either alone or in combination with the chemosensitizer misonidazole. ", "arg1": {"span": [[184, 188]], "type": "drug", "id": "DDI-MedLine.d85.s1.e2"}, "arg2": {"span": [[246, 258]], "type": "drug_n", "id": "DDI-MedLine.d85.s1.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-MedLine.d85.s7-0", "sentence_id": "DDI-MedLine.d85.s7", "sentence": "Misonidazole reduced the antitumour activity of oral CCNU by dose modifying factors (DMF) of 0.58-0.71. ", "arg1": {"span": [[0, 12]], "type": "drug_n", "id": "DDI-MedLine.d85.s7.e0"}, "arg2": {"span": [[53, 57]], "type": "drug", "id": "DDI-MedLine.d85.s7.e1"}, "ddi_label": 1, "ddi_type": "effect"}
{"id": "DDI-MedLine.d85.s9-0", "sentence_id": "DDI-MedLine.d85.s9", "sentence": "Misonidazole has a complex effect on oral CCNU pharmacokinetics. ", "arg1": {"span": [[0, 12]], "type": "drug_n", "id": "DDI-MedLine.d85.s9.e0"}, "arg2": {"span": [[42, 46]], "type": "drug", "id": "DDI-MedLine.d85.s9.e1"}, "ddi_label": 1, "ddi_type": "mechanism"}
{"id": "DDI-MedLine.d85.s14-0", "sentence_id": "DDI-MedLine.d85.s14", "sentence": "We propose these pharmacokinetic changes to be the underlying mechanism for the reduction of oral CCNU cytotoxicity by misonidazole. ", "arg1": {"span": [[98, 102]], "type": "drug", "id": "DDI-MedLine.d85.s14.e0"}, "arg2": {"span": [[119, 131]], "type": "drug_n", "id": "DDI-MedLine.d85.s14.e1"}, "ddi_label": 1, "ddi_type": "mechanism"}
{"id": "DDI-MedLine.d55.s0-0", "sentence_id": "DDI-MedLine.d55.s0", "sentence": "Increased hepatotoxicity of acetaminophen by concomitant administration of caffeine in the rat.", "arg1": {"span": [[28, 41]], "type": "drug", "id": "DDI-MedLine.d55.s0.e0"}, "arg2": {"span": [[75, 83]], "type": "drug", "id": "DDI-MedLine.d55.s0.e1"}, "ddi_label": 1, "ddi_type": "effect"}
{"id": "DDI-MedLine.d55.s1-0", "sentence_id": "DDI-MedLine.d55.s1", "sentence": "Since caffeine is frequently co-administered with acetaminophen, it is of clinical interest to study the effect of caffeine on the hepatotoxicity of acetaminophen. ", "arg1": {"span": [[6, 14]], "type": "drug", "id": "DDI-MedLine.d55.s1.e0"}, "arg2": {"span": [[50, 63]], "type": "drug", "id": "DDI-MedLine.d55.s1.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-MedLine.d55.s1-1", "sentence_id": "DDI-MedLine.d55.s1", "sentence": "Since caffeine is frequently co-administered with acetaminophen, it is of clinical interest to study the effect of caffeine on the hepatotoxicity of acetaminophen. ", "arg1": {"span": [[6, 14]], "type": "drug", "id": "DDI-MedLine.d55.s1.e0"}, "arg2": {"span": [[115, 123]], "type": "drug", "id": "DDI-MedLine.d55.s1.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-MedLine.d55.s1-2", "sentence_id": "DDI-MedLine.d55.s1", "sentence": "Since caffeine is frequently co-administered with acetaminophen, it is of clinical interest to study the effect of caffeine on the hepatotoxicity of acetaminophen. ", "arg1": {"span": [[6, 14]], "type": "drug", "id": "DDI-MedLine.d55.s1.e0"}, "arg2": {"span": [[149, 162]], "type": "drug", "id": "DDI-MedLine.d55.s1.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-MedLine.d55.s1-3", "sentence_id": "DDI-MedLine.d55.s1", "sentence": "Since caffeine is frequently co-administered with acetaminophen, it is of clinical interest to study the effect of caffeine on the hepatotoxicity of acetaminophen. ", "arg1": {"span": [[50, 63]], "type": "drug", "id": "DDI-MedLine.d55.s1.e1"}, "arg2": {"span": [[115, 123]], "type": "drug", "id": "DDI-MedLine.d55.s1.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-MedLine.d55.s1-4", "sentence_id": "DDI-MedLine.d55.s1", "sentence": "Since caffeine is frequently co-administered with acetaminophen, it is of clinical interest to study the effect of caffeine on the hepatotoxicity of acetaminophen. ", "arg1": {"span": [[50, 63]], "type": "drug", "id": "DDI-MedLine.d55.s1.e1"}, "arg2": {"span": [[149, 162]], "type": "drug", "id": "DDI-MedLine.d55.s1.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-MedLine.d55.s1-5", "sentence_id": "DDI-MedLine.d55.s1", "sentence": "Since caffeine is frequently co-administered with acetaminophen, it is of clinical interest to study the effect of caffeine on the hepatotoxicity of acetaminophen. ", "arg1": {"span": [[115, 123]], "type": "drug", "id": "DDI-MedLine.d55.s1.e2"}, "arg2": {"span": [[149, 162]], "type": "drug", "id": "DDI-MedLine.d55.s1.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-MedLine.d55.s4-0", "sentence_id": "DDI-MedLine.d55.s4", "sentence": "Careful observations on hepatotoxicity are suggested when acetaminophen is prescribed with caffeine.", "arg1": {"span": [[58, 71]], "type": "drug", "id": "DDI-MedLine.d55.s4.e0"}, "arg2": {"span": [[91, 99]], "type": "drug", "id": "DDI-MedLine.d55.s4.e1"}, "ddi_label": 1, "ddi_type": "effect"}
{"id": "DDI-MedLine.d4.s0-0", "sentence_id": "DDI-MedLine.d4.s0", "sentence": "[The effect of sandimmune on the activity of mixed-function mono-oxidases in the liver microsomes] The effects of the immunodepressant--the drug sandimmune--on hepatic microsomal monooxygenase activities were studied. ", "arg1": {"span": [[15, 25]], "type": "brand", "id": "DDI-MedLine.d4.s0.e0"}, "arg2": {"span": [[118, 134]], "type": "group", "id": "DDI-MedLine.d4.s0.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-MedLine.d4.s0-1", "sentence_id": "DDI-MedLine.d4.s0", "sentence": "[The effect of sandimmune on the activity of mixed-function mono-oxidases in the liver microsomes] The effects of the immunodepressant--the drug sandimmune--on hepatic microsomal monooxygenase activities were studied. ", "arg1": {"span": [[15, 25]], "type": "brand", "id": "DDI-MedLine.d4.s0.e0"}, "arg2": {"span": [[145, 155]], "type": "brand", "id": "DDI-MedLine.d4.s0.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-MedLine.d4.s0-2", "sentence_id": "DDI-MedLine.d4.s0", "sentence": "[The effect of sandimmune on the activity of mixed-function mono-oxidases in the liver microsomes] The effects of the immunodepressant--the drug sandimmune--on hepatic microsomal monooxygenase activities were studied. ", "arg1": {"span": [[118, 134]], "type": "group", "id": "DDI-MedLine.d4.s0.e1"}, "arg2": {"span": [[145, 155]], "type": "brand", "id": "DDI-MedLine.d4.s0.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-MedLine.d14.s0-0", "sentence_id": "DDI-MedLine.d14.s0", "sentence": "[A pharmacological analysis of the effect of angiotensin on stimulated gastric secretion] Chronic experiments on dogs with gastric fistulas were carried out to study the influence of angiotensin 1 and angiotensin 2 on pentagastrin- and histamine-induced gastric acid secretion. ", "arg1": {"span": [[45, 56]], "type": "drug_n", "id": "DDI-MedLine.d14.s0.e0"}, "arg2": {"span": [[183, 196]], "type": "drug_n", "id": "DDI-MedLine.d14.s0.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-MedLine.d14.s0-1", "sentence_id": "DDI-MedLine.d14.s0", "sentence": "[A pharmacological analysis of the effect of angiotensin on stimulated gastric secretion] Chronic experiments on dogs with gastric fistulas were carried out to study the influence of angiotensin 1 and angiotensin 2 on pentagastrin- and histamine-induced gastric acid secretion. ", "arg1": {"span": [[45, 56]], "type": "drug_n", "id": "DDI-MedLine.d14.s0.e0"}, "arg2": {"span": [[201, 214]], "type": "drug_n", "id": "DDI-MedLine.d14.s0.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-MedLine.d14.s0-2", "sentence_id": "DDI-MedLine.d14.s0", "sentence": "[A pharmacological analysis of the effect of angiotensin on stimulated gastric secretion] Chronic experiments on dogs with gastric fistulas were carried out to study the influence of angiotensin 1 and angiotensin 2 on pentagastrin- and histamine-induced gastric acid secretion. ", "arg1": {"span": [[45, 56]], "type": "drug_n", "id": "DDI-MedLine.d14.s0.e0"}, "arg2": {"span": [[218, 230]], "type": "drug", "id": "DDI-MedLine.d14.s0.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-MedLine.d14.s0-3", "sentence_id": "DDI-MedLine.d14.s0", "sentence": "[A pharmacological analysis of the effect of angiotensin on stimulated gastric secretion] Chronic experiments on dogs with gastric fistulas were carried out to study the influence of angiotensin 1 and angiotensin 2 on pentagastrin- and histamine-induced gastric acid secretion. ", "arg1": {"span": [[45, 56]], "type": "drug_n", "id": "DDI-MedLine.d14.s0.e0"}, "arg2": {"span": [[236, 245]], "type": "drug", "id": "DDI-MedLine.d14.s0.e4"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-MedLine.d14.s0-4", "sentence_id": "DDI-MedLine.d14.s0", "sentence": "[A pharmacological analysis of the effect of angiotensin on stimulated gastric secretion] Chronic experiments on dogs with gastric fistulas were carried out to study the influence of angiotensin 1 and angiotensin 2 on pentagastrin- and histamine-induced gastric acid secretion. ", "arg1": {"span": [[183, 196]], "type": "drug_n", "id": "DDI-MedLine.d14.s0.e1"}, "arg2": {"span": [[201, 214]], "type": "drug_n", "id": "DDI-MedLine.d14.s0.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-MedLine.d14.s0-5", "sentence_id": "DDI-MedLine.d14.s0", "sentence": "[A pharmacological analysis of the effect of angiotensin on stimulated gastric secretion] Chronic experiments on dogs with gastric fistulas were carried out to study the influence of angiotensin 1 and angiotensin 2 on pentagastrin- and histamine-induced gastric acid secretion. ", "arg1": {"span": [[183, 196]], "type": "drug_n", "id": "DDI-MedLine.d14.s0.e1"}, "arg2": {"span": [[218, 230]], "type": "drug", "id": "DDI-MedLine.d14.s0.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-MedLine.d14.s0-6", "sentence_id": "DDI-MedLine.d14.s0", "sentence": "[A pharmacological analysis of the effect of angiotensin on stimulated gastric secretion] Chronic experiments on dogs with gastric fistulas were carried out to study the influence of angiotensin 1 and angiotensin 2 on pentagastrin- and histamine-induced gastric acid secretion. ", "arg1": {"span": [[183, 196]], "type": "drug_n", "id": "DDI-MedLine.d14.s0.e1"}, "arg2": {"span": [[236, 245]], "type": "drug", "id": "DDI-MedLine.d14.s0.e4"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-MedLine.d14.s0-7", "sentence_id": "DDI-MedLine.d14.s0", "sentence": "[A pharmacological analysis of the effect of angiotensin on stimulated gastric secretion] Chronic experiments on dogs with gastric fistulas were carried out to study the influence of angiotensin 1 and angiotensin 2 on pentagastrin- and histamine-induced gastric acid secretion. ", "arg1": {"span": [[201, 214]], "type": "drug_n", "id": "DDI-MedLine.d14.s0.e2"}, "arg2": {"span": [[218, 230]], "type": "drug", "id": "DDI-MedLine.d14.s0.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-MedLine.d14.s0-8", "sentence_id": "DDI-MedLine.d14.s0", "sentence": "[A pharmacological analysis of the effect of angiotensin on stimulated gastric secretion] Chronic experiments on dogs with gastric fistulas were carried out to study the influence of angiotensin 1 and angiotensin 2 on pentagastrin- and histamine-induced gastric acid secretion. ", "arg1": {"span": [[201, 214]], "type": "drug_n", "id": "DDI-MedLine.d14.s0.e2"}, "arg2": {"span": [[236, 245]], "type": "drug", "id": "DDI-MedLine.d14.s0.e4"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-MedLine.d14.s0-9", "sentence_id": "DDI-MedLine.d14.s0", "sentence": "[A pharmacological analysis of the effect of angiotensin on stimulated gastric secretion] Chronic experiments on dogs with gastric fistulas were carried out to study the influence of angiotensin 1 and angiotensin 2 on pentagastrin- and histamine-induced gastric acid secretion. ", "arg1": {"span": [[218, 230]], "type": "drug", "id": "DDI-MedLine.d14.s0.e3"}, "arg2": {"span": [[236, 245]], "type": "drug", "id": "DDI-MedLine.d14.s0.e4"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-MedLine.d14.s1-0", "sentence_id": "DDI-MedLine.d14.s1", "sentence": "It was established that both angiotensins inhibited gastric acid secretion stimulated by pentagastrin but not by histamine. ", "arg1": {"span": [[89, 101]], "type": "drug", "id": "DDI-MedLine.d14.s1.e0"}, "arg2": {"span": [[113, 122]], "type": "drug", "id": "DDI-MedLine.d14.s1.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-MedLine.d14.s2-0", "sentence_id": "DDI-MedLine.d14.s2", "sentence": "Comparative analysis of the effects of stimulation and inhibition of cholino- and adrenoreceptors on this inhibitory action of angiotensins suggested the mediation of angiotensin influence through the modulation of cholinergic reactions of parietal cells in the stomach.", "arg1": {"span": [[127, 139]], "type": "drug_n", "id": "DDI-MedLine.d14.s2.e0"}, "arg2": {"span": [[167, 178]], "type": "drug_n", "id": "DDI-MedLine.d14.s2.e1"}, "ddi_label": 0, "ddi_type": ""}
